text,chunk_id,title,publication_date,authors,disease
"Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments Huntington disease (HD) is a rare, inherited, neurodegenerative disorder characterized by progressive motor symptoms including involuntary choreatic movements as well as cognitive, behavioral, and psychiatric changes.<sup><xref rid=""R1"" ref-type=""bibr"">1</xref>,<xref rid=""R2"" ref-type=""bibr"">2</xref></sup> The disease is caused by an increase in the number of CAG repeats in the DNA sequence of exon 1 of the",0_0,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"CAG repeats in the DNA sequence of exon 1 of the <italic toggle=""yes"">HTT</italic> gene.<sup><xref rid=""R3"" ref-type=""bibr"">3</xref></sup> The overall prevalence of HD is increasing,<sup><xref rid=""R4"" ref-type=""bibr"">4</xref></sup> and the economic and humanistic burden associated with the condition is substantial.<sup><xref rid=""R5"" ref-type=""bibr"">5</xref>,<xref rid=""R6"" ref-type=""bibr"">6</xref></sup> Recent research estimates that annual costs associated with HD in the United States ranges from $6,600",0_1,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"with HD in the United States ranges from $6,600 to $30,300 per year depending on the stage of progression.<sup><xref rid=""R5"" ref-type=""bibr"">5</xref></sup> Furthermore, there is limited evidence available providing a comprehensive assessment of the clinical, economic, and humanistic burden of HD by disease stage and on a large scale. Currently, there is no cure for HD, and available treatments do not alter the course of disease progression. Medications such as tetrabenazine (Xenazine) and deutetrabenazine",0_2,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"as tetrabenazine (Xenazine) and deutetrabenazine (Austedo) may lessen movement disorder (chorea) symptoms<sup><xref rid=""R7"" ref-type=""bibr"">7</xref></sup> while antidepressants and antipsychotic drugs can be used in tandem but may also have an effect on chorea.<sup><xref rid=""R8"" ref-type=""bibr"">8</xref></sup> Treatments typically evolve over the course of the disease, depending on individual individuals' overall treatment goals. Potential disease-modifying treatments (DMTs) such as gene therapy (GTx),",0_3,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"treatments (DMTs) such as gene therapy (GTx), antisense oligonucleotides (ASOs), and small molecule–based therapeutic approaches aim to provide long-term health benefits for people with HD by slowing down, arresting, or even reverting disease progression.<sup><xref rid=""R9"" ref-type=""bibr"">9</xref></sup> Once clinical trial evidence becomes available, health economic research will be necessary to quantify the long-term costs and health outcomes for health care decision makers. In anticipation of future",0_4,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"care decision makers. In anticipation of future DMTs for HD, we aimed to estimate the long-term natural history of HD progression and explore the efficacy and potential value of hypothetical DMTs to treat HD using a decision-analytic modeling framework.   We developed a decision model to track the natural history of HD progression and associated costs, survival, and quality of life of 3 40-year-old HD populations over their remaining lifetime. Our results support previous HD burden-of-illness study",0_5,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"support previous HD burden-of-illness study findings that people with HD incur substantial cost and quality-of-life burdens that increase as HD progresses. It is important to note that our model can be used to explore these relationships and to target stages of disease where the health impacts of future DMTs are most likely to be cost effective. In time, the model can be adapted to incorporate clinical trial findings for future DMTs. Our natural history results for the 3 modeled HD populations expectedly",0_6,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"for the 3 modeled HD populations expectedly showed that people with HD who are at earlier stages of disease have a longer life expectancy and greater quality of life but lower lifetime cost compared with later stages of disease, although all modeled individuals who do not die from other causes (background mortality) would eventually progress through each expensive stage of HD before death. This finding was due to the annualized 3% discount applied to direct and indirect costs and health outcomes over time,",0_7,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"and indirect costs and health outcomes over time, a standard health economics method that applies greater weight to values nearesr to the present than to the future.<sup><xref rid=""R11"" ref-type=""bibr"">11</xref></sup> In essence, each population's quality of life was greatest at the outset of the model when it was time-weighted the most and declined as time progressed but was time-weighted progressively less. The opposite is true for cost in that it is time-weighted the most at its lowest values and",0_8,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"time-weighted the most at its lowest values and time-weighted the least at its highest values. To address potential confusion, we presented both discounted and undiscounted natural history results, with the latter showing greater cost and QALY parity among the modeled patient populations, given later-stage outcomes were not time-weighted and thus equivalent. Our exploratory analysis of hypothetical HD treatments that slow and/or arrest HD progression demonstrates that cost savings and QALY gains may be",0_9,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"that cost savings and QALY gains may be procured from increased survival time in less progressed health states, but that prolonging survival within expensive, low quality-of-life stages of late disease may lead to overall increases in cost. A previous HD-modeling analysis by Albin and Burke reached similar conclusions compared with our study.<sup><xref rid=""R31"" ref-type=""bibr"">31</xref></sup> They used a Markov chain Monte Carlo approach to simulate the effects of potential therapies with effects on time",0_10,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"of potential therapies with effects on time to onset of HD and survival with HD and found that a delay in symptom onset (0.7–8.1 years depending on patient age and CGG repeat length) was associated with a 5.2-5.3-year increase in life years spent with HD. Our model indicated that the hypothetical treatment effect with the greatest potential to derail potential cost savings was the rate ratio parameter applied to the constant rate of progression once onset began, which did result in overall QALY gains for",0_11,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"began, which did result in overall QALY gains for all 3 patient populations but became more costly in populations initiating treatment when at lower TFC scores. The combination of these results seems to indicate that treating people with HD with active functional decline likely achieves good value up to a point followed by diminishing returns, a finding that may affect treatment discontinuation decisions and the eventual shift from DMT to supportive and palliative care. Of note, the hypothetical DMT",0_12,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"palliative care. Of note, the hypothetical DMT efficacies used in our exploratory analysis are highly speculative. Furthermore, the DMTs currently under development vary in mechanism of action (small molecule, ASO, gene therapy), route of administration (oral, intrathecal, intraparenchymal), and once vs recurrent therapy; these contingencies make it difficult at this time to assign a DMT price in our exploratory analysis. Future cost-effectiveness models based on settled regimens and clinical trial",0_13,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"based on settled regimens and clinical trial efficacy data should estimate the value-based price of each DMT under accepted willingness to pay per QALY threshold for a given country. Our analysis had several limitations. First, our projections for TFC progression are uncertain, given follow-up data from TRACK-HD are limited to 3 years<sup><xref rid=""R17"" ref-type=""bibr"">17</xref></sup> and our assumption that declines in TFC score progress at a constant rate thereafter. We addressed this limitation by",0_14,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"rate thereafter. We addressed this limitation by varying the 12-month and 36-month TFC outcomes in sensitivity analyses, which provides a range of potential progression trajectories, and by applying variable rate ratios to the rate of progression in our exploratory analyses. We also validated our assumption of a constant progression rate through comparison with the Enroll-HD database.<sup><xref rid=""R18"" ref-type=""bibr"">18</xref>,<xref rid=""R19"" ref-type=""bibr"">19</xref></sup> Nonetheless, future research",0_15,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"Nonetheless, future research with longer-term follow-up of people may identify distinct progression trajectories that do not follow a linear path. Second, our analysis focused on the TFC score because it is commonly used to assess an individual's ability to function in daily life, the availability of longitudinal data, and the availability of cost and utility values estimated within the broader TFC-based Shoulson and Fahn categories. However, the TFC score is limited in that it does not capture the",0_16,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"score is limited in that it does not capture the emotional, relational, or psychological stressors associated with HD, including in individuals who have yet to experience motor symptom onset, and has been shown to be insensitive to quality of life, particularly neuropsychiatric symptoms.<sup><xref rid=""R32"" ref-type=""bibr"">32</xref>,<xref rid=""R33"" ref-type=""bibr"">33</xref></sup> Based on the new HD Integrated Staging System, brain deterioration precedes cognitive and motor manifestation, which precedes",0_17,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"cognitive and motor manifestation, which precedes functional decline.<sup><xref rid=""R21"" ref-type=""bibr"">21</xref></sup> The first functional decline tends to be a modification at one's occupation because of a disease effect (motor and/or cognitive). Neuropsychiatric symptoms can have a profound impact on both the person with HD and caregivers, especially when characterized by aggression.<sup><xref rid=""R34"" ref-type=""bibr"">34</xref></sup> These same burdens are particularly consequential to the families",0_18,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"are particularly consequential to the families and children of individuals with HD.<sup><xref rid=""R32"" ref-type=""bibr"">32</xref>,<xref rid=""R35"" ref-type=""bibr"">35</xref></sup> Such problems can also affect activities of daily living that are indexed by the TFC; however, the TFC does not consider specifically how neuropsychiatric symptoms might affect daily functioning. Thus, the role of neuropsychiatric symptoms in progression is complicated because there is not a clear tracking with progression in other",0_19,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"is not a clear tracking with progression in other domains, such as motor. Furthermore, neuropsychiatric symptoms such as anxiety and depression can be treated with antipsychotics, whereas cognitive decline (for example) cannot. Future iterations of our modeling framework should include these considerations as relevant data become available. Third, the estimates for costs and utilities were derived from a burden-of-illness (BOI) study with increasingly smaller sample sizes of individuals with lower TFC",0_20,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"sample sizes of individuals with lower TFC scores. This was particularly true for societal costs, those of which for the Shoulson and Fahn III and IV health states were obtained from a sample of only 2 individuals. Relatedly, professional caregiving (i.e., nursing home) services were included in the direct medical cost category; however, the cost data were only available for a subgroup of participants who responded to the BOI's patient survey; therefore, our direct medical costs may be underestimated",0_21,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"our direct medical costs may be underestimated because they fail to capture the cost of professional caregiving services for a subgroup of the population. We accounted for these parameter uncertainties by modeling the full ranges of possible values, derived from each estimates' standard deviation, in sensitivity analyses. Fourth, we did not consider safety impacts of DMTs because they are currently unknown; we assume that any DMT that eventually makes it to market will have a favorable risk-benefit profile",0_22,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"market will have a favorable risk-benefit profile appropriate for the indicated population; however, trial-observed major adverse events may have important impacts on cost-effectiveness estimates. Last, our results focused on a 40-year-old population only. Younger people with HD who may be years away from presenting signs and symptoms of disease may benefit from future DMTs; however, the ethical considerations<sup><xref rid=""R36"" ref-type=""bibr"">36</xref></sup> and risk-benefit profile of treating these",0_23,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"and risk-benefit profile of treating these individuals is beyond the current scope of this exploratory analysis. Ultimately, our model could be adapted by future researchers to consider treatment prioritization of different age groups, CAG repeats, and other factors. In conclusion, our novel HD-modeling framework estimates HD progression over a lifetime and the lifetime costs and QALYs. We showed that the health benefits and value of a novel DMT increase as the DMT efficacy increases; however, the",0_24,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"as the DMT efficacy increases; however, the tradeoffs between longer life expectancy and greater cost and prolonged time spent with a lower quality of life should be considered in future health economic evaluations of forthcoming treatments. Our framework can be used for future HD cost-effectiveness models as clinical trial evidence becomes available.<boxed-text id=""B1"" position=""float""><sec><title>TAKE-HOME POINTS</title><p><list list-type=""simple""><list-item><p>→ Huntington disease (HD) is a rare,",0_25,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"Huntington disease (HD) is a rare, inherited, neurodegenerative disorder characterized by progressive motor symptoms including involuntary choreatic movements as well as cognitive, behavioral, and psychiatric changes.</p></list-item><list-item><p>→ Potential disease-modifying treatments (DMTs) are in development, but no clinical trial data are currently available.</p></list-item><list-item><p>→ In anticipation of future DMTs for HD, we aimed to estimate the long-term natural history of HD progression and",0_26,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"long-term natural history of HD progression and explore the efficacy and potential value of hypothetical DMTs to treat HD using a decision-analytic modeling framework.</p></list-item><list-item><p>→ We estimated that the health benefits and value of a novel DMT increase as the DMT efficacy increases; however, the tradeoffs between longer life expectancy and greater cost and prolonged time spent with a lower quality of life should be considered in future health economic evaluations of forthcoming",0_27,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
future health economic evaluations of forthcoming treatments.</p></list-item><list-item><p>→ Our framework can be used for future HD cost-effectiveness models as clinical trial evidence becomes available.</p></list-item></list></p></sec></boxed-text>,0_28,Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments,10 2024,,Huntington_Disease
"Age‐ and disease‐related autophagy impairment in Huntington disease: New insights from direct neuronal reprogramming Autophagy impairment in Huntington disease (HD) has been reported for almost two decades. However, the molecular mechanisms underlying this phenomenon are still unclear. This is partially because it is challenging to model the impact of the disease‐causing mutation, aging, as well as the selective vulnerability of neurons in a single model. Recently developed direct neuronal reprogramming",1_0,Age‐ and disease‐related autophagy impairment in Huntington disease: New insights from direct neuronal reprogramming,23 7 2024,,Huntington_Disease
Recently developed direct neuronal reprogramming that allows researchers to induce neurons‐of‐interest retaining biological aging information made it possible to establish HD cellular models to study more relevant age‐ and disease‐related molecular changes in neurons. We here summarized the findings from a few latest studies utilizing directly reprogrammed HD neurons and discussed the new insights they brought to the understanding of the age‐ and disease‐related autophagy impairment in HD. It is,1_1,Age‐ and disease‐related autophagy impairment in Huntington disease: New insights from direct neuronal reprogramming,23 7 2024,,Huntington_Disease
disease‐related autophagy impairment in HD. It is challenging to model the impact of aging in age‐related disease like Huntington disease (HD). Recently developed direct neuronal reprogramming allows researchers to induce neurons‐of‐interest retaining biological aging information. We here summarized the findings from a few latest studies utilizing directly reprogrammed HD neurons and discussed the new insights they brought to the understanding of the age‐ and disease‐related autophagy impairment in,1_2,Age‐ and disease‐related autophagy impairment in Huntington disease: New insights from direct neuronal reprogramming,23 7 2024,,Huntington_Disease
"age‐ and disease‐related autophagy impairment in HD.<boxed-text position=""anchor"" content-type=""graphic"" id=""acel14285-blkfxd-0001""><graphic http://www.w3.org/1999/xlink href=""ACEL-23-e14285-g001.jpg"" position=""anchor"" id=""jats-graphic-1""></graphic></boxed-text>",1_3,Age‐ and disease‐related autophagy impairment in Huntington disease: New insights from direct neuronal reprogramming,23 7 2024,,Huntington_Disease
CL and JY discussed the idea of this manuscript; CL prepared the initial draft; JY finalized the draft and made the figure. The authors declare no competing interests.,1_4,Age‐ and disease‐related autophagy impairment in Huntington disease: New insights from direct neuronal reprogramming,23 7 2024,,Huntington_Disease
"Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease Huntington disease (HD) is a dominantly inherited neurodegenerative disorder caused by a CAG expansion on the huntingtin (<italic toggle=""yes"">HTT</italic>) gene and is characterized by progressive motor, cognitive, and neuropsychiatric decline. Recently, new genetic factors besides CAG repeats have been implicated in the disease pathogenesis. Most genetic modifiers are involved in DNA repair pathways and, as the cause of the loss",2_0,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"DNA repair pathways and, as the cause of the loss of CAA interruption in the <italic toggle=""yes"">HTT</italic> gene, they exert their main influence through somatic expansion. However, this mechanism might not be the only driver of HD pathogenesis, and future studies are warranted in this field. The aim of the present review is to dissect the many faces of genetics in HD pathogenesis, from cis- and trans-acting genetic modifiers to RNA toxicity, mitochondrial DNA mutations, and epigenetics factors.",2_1,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"DNA mutations, and epigenetics factors. Exploring genetic modifiers of HD onset and progression appears crucial to elucidate not only disease pathogenesis, but also to improve disease prediction and prevention, develop biomarkers of disease progression and response to therapies, and recognize new therapeutic opportunities. Since the same genetic mechanisms are also described in other repeat expansion diseases, their implications might encompass the whole spectrum of these disorders. Huntington disease (HD)",2_2,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"of these disorders. Huntington disease (HD) is a dominantly inherited neurodegenerative disorder characterized by motor, cognitive, and neuropsychiatric features [<xref rid=""B1-genes-15-00807"" ref-type=""bibr"">1</xref>]. It is caused by an expanded CAG repeat in exon 1 of the huntingtin (<italic toggle=""yes"">HTT</italic>) gene [<xref rid=""B2-genes-15-00807"" ref-type=""bibr"">2</xref>]. The CAG repeat length explains around 50–70% of the variability in the age at onset (AAO) of HD [<xref",2_3,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"in the age at onset (AAO) of HD [<xref rid=""B3-genes-15-00807"" ref-type=""bibr"">3</xref>,<xref rid=""B4-genes-15-00807"" ref-type=""bibr"">4</xref>]. In fact, two individuals with an identical CAG repeat length can develop HD symptoms decades apart [<xref rid=""B5-genes-15-00807"" ref-type=""bibr"">5</xref>]. This is particularly evident in individuals carrying reduced penetrance alleles ranging from 36 to 39 CAG, who might develop HD at very late ages [<xref rid=""B6-genes-15-00807"" ref-type=""bibr"">6</xref>]. The",2_4,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"ref-type=""bibr"">6</xref>]. The unexplained variability in HD onset and pathogenesis underscores the presence of additional genetic factors that exert a crucial influence [<xref rid=""B7-genes-15-00807"" ref-type=""bibr"">7</xref>,<xref rid=""B8-genes-15-00807"" ref-type=""bibr"">8</xref>,<xref rid=""B9-genes-15-00807"" ref-type=""bibr"">9</xref>]. This highlights the necessity for further investigation into the intricate genetic landscape contributing to HD. In the last few years, dramatic advances in sequencing",2_5,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"last few years, dramatic advances in sequencing technology and the availability of larger patient cohorts have moved the HD genetic field forward, identifying modifiers on chromosomes 8 and 15 mainly involved in the DNA mismatch repair pathway [<xref rid=""B10-genes-15-00807"" ref-type=""bibr"">10</xref>,<xref rid=""B11-genes-15-00807"" ref-type=""bibr"">11</xref>,<xref rid=""B12-genes-15-00807"" ref-type=""bibr"">12</xref>]. In addition, cis-acting factors in the <italic toggle=""yes"">HTT</italic> locus have also been",2_6,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"toggle=""yes"">HTT</italic> locus have also been discovered [<xref rid=""B13-genes-15-00807"" ref-type=""bibr"">13</xref>] which can modulate disease frequency [<xref rid=""B14-genes-15-00807"" ref-type=""bibr"">14</xref>,<xref rid=""B15-genes-15-00807"" ref-type=""bibr"">15</xref>] and expressivity [<xref rid=""B16-genes-15-00807"" ref-type=""bibr"">16</xref>,<xref rid=""B17-genes-15-00807"" ref-type=""bibr"">17</xref>]: particularly, the loss of the CAA interruption variant has raised great interest, especially in carriers of",2_7,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"raised great interest, especially in carriers of reduced penetrance alleles [<xref rid=""B18-genes-15-00807"" ref-type=""bibr"">18</xref>,<xref rid=""B19-genes-15-00807"" ref-type=""bibr"">19</xref>,<xref rid=""B20-genes-15-00807"" ref-type=""bibr"">20</xref>,<xref rid=""B21-genes-15-00807"" ref-type=""bibr"">21</xref>,<xref rid=""B22-genes-15-00807"" ref-type=""bibr"">22</xref>]. Genetic modifiers exert their main effect through somatic expansions of the CAG triplet, which appears to be a key driver of HD pathogenesis.",2_8,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"appears to be a key driver of HD pathogenesis. Indeed, the <italic toggle=""yes"">HTT</italic> CAG displays somatic instability, which is greater in the brain and in areas most affected by HD (i.e., particularly the caudate) [<xref rid=""B8-genes-15-00807"" ref-type=""bibr"">8</xref>,<xref rid=""B23-genes-15-00807"" ref-type=""bibr"">23</xref>,<xref rid=""B24-genes-15-00807"" ref-type=""bibr"">24</xref>,<xref rid=""B25-genes-15-00807"" ref-type=""bibr"">25</xref>,<xref rid=""B26-genes-15-00807"" ref-type=""bibr"">26</xref>].",2_9,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"ref-type=""bibr"">26</xref>]. Research of surrogates of somatic expansion in peripheral tissues is mandatory, as it has been demonstrated that higher blood DNA CAG somatic expansions are associated with worse outcomes [<xref rid=""B27-genes-15-00807"" ref-type=""bibr"">27</xref>]. RNA-related pathology, mitochondrial DNA mutations, and epigenetic alterations are emerging aspects in HD genetics research that might contribute to the disentangling of the disease pathogenesis, as well as the identification of",2_10,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"pathogenesis, as well as the identification of potential biomarkers of early disease stages and disease progression, and therapeutic targets [<xref rid=""B28-genes-15-00807"" ref-type=""bibr"">28</xref>,<xref rid=""B29-genes-15-00807"" ref-type=""bibr"">29</xref>]. In this review, we first provide an overview of the complex role of genetics in HD, in addition to the expanded CAG repeat mutation. We describe gene modifiers including cis- and trans-acting candidate genetic alterations that are thought to have a",2_11,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"genetic alterations that are thought to have a relevant role in HD AAO and progression. As the ultimate objective to further improve knowledge in this field, we focus on targets for therapeutic interventions. The contribution of genetics to the development of therapies is fundamental if we consider that drug trials supported by genetics can potentially double clinical success rates [<xref rid=""B30-genes-15-00807"" ref-type=""bibr"">30</xref>,<xref rid=""B31-genes-15-00807"" ref-type=""bibr"">31</xref>] and",2_12,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"ref-type=""bibr"">31</xref>] and two-thirds of 2021 FDA-approved drugs are supported by human genetics evidence [<xref rid=""B32-genes-15-00807"" ref-type=""bibr"">32</xref>]. Finally, the implications of pharmaceutical research into genetic modifiers of HD can be extrapolated to encompass other CAG/polyglutamine expansion disorders that share genetic similarities with HD, as will also be elucidated in this review. The typical sequence of the <italic toggle=""yes"">HTT</italic> repeat tract accounts for a number",2_13,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"repeat tract accounts for a number of CAG repeats, followed downstream by a 12-base-pair interrupting sequence (CAA-CAG-CCG-CCA) and a subsequent CCG tract. According to the traditional view of the disease, HD pathogenesis has always been related to the toxic effect of the protein through the Poly-Q tract in the huntingtin protein. Since both CAG and CAA encode glutamine, a change in the final CAG-CAA sequence in the <italic toggle=""yes"">HTT</italic> locus was assumed to be irrelevant. Notwithstanding",2_14,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"was assumed to be irrelevant. Notwithstanding this, three concurrent genetic studies supported that CAG length is more predictive than polyglutamine length for HD AAO [<xref rid=""B12-genes-15-00807"" ref-type=""bibr"">12</xref>,<xref rid=""B18-genes-15-00807"" ref-type=""bibr"">18</xref>,<xref rid=""B19-genes-15-00807"" ref-type=""bibr"">19</xref>]. The Genome Wide Association Study (GWAS) on genetic modifiers from the GeM-HD consortium detected two association signals at the <italic toggle=""yes"">HTT</italic> locus",2_15,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"at the <italic toggle=""yes"">HTT</italic> locus influencing AAO [<xref rid=""B12-genes-15-00807"" ref-type=""bibr"">12</xref>]. The other two studies identified a variant characterized by the loss of the CAA-CAG sequence at the end of the <italic toggle=""yes"">HTT</italic> locus, thus extending the uninterrupted CAG length, leaving the polyglutamine length unchanged [<xref rid=""B12-genes-15-00807"" ref-type=""bibr"">12</xref>,<xref rid=""B18-genes-15-00807"" ref-type=""bibr"">18</xref>,<xref rid=""B19-genes-15-00807""",2_16,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"rid=""B19-genes-15-00807"" ref-type=""bibr"">19</xref>]. This variant was defined as the loss of interruption (LOI) and was associated with a hastened age of onset of approximately 9 years [<xref rid=""B19-genes-15-00807"" ref-type=""bibr"">19</xref>] Conversely, a duplication of the interruption was associated with the opposite effect, delaying the AAO. Somatic repeat instability is the most probable mechanism mediating the LOI effect in low penetrance alleles since they were associated with increased somatic",2_17,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"since they were associated with increased somatic expansions in the blood and in the germline [<xref rid=""B19-genes-15-00807"" ref-type=""bibr"">19</xref>]. However, somatic instability might not be the only driver of the LOI. Indeed, possible alternative pathogenic processes have been suggested, such as repeat-associated non-AUG-dependent translation, CAG RNA toxicity (which will be described later in the text), and spliceosome dysregulation [<xref rid=""B33-genes-15-00807"" ref-type=""bibr"">33</xref>,<xref",2_18,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"ref-type=""bibr"">33</xref>,<xref rid=""B34-genes-15-00807"" ref-type=""bibr"">34</xref>,<xref rid=""B35-genes-15-00807"" ref-type=""bibr"">35</xref>,<xref rid=""B36-genes-15-00807"" ref-type=""bibr"">36</xref>]. LOI has implications at different levels. From a clinical point of view, although rare (0.9% to 2.5% in fully penetrant alleles [<xref rid=""B19-genes-15-00807"" ref-type=""bibr"">19</xref>], LOI is especially important to certain patient sub-populations, in particular in reduced penetrance allele carriers (i.e.,",2_19,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"in reduced penetrance allele carriers (i.e., CAG 36-39) [<xref rid=""B37-genes-15-00807"" ref-type=""bibr"">37</xref>,<xref rid=""B38-genes-15-00807"" ref-type=""bibr"">38</xref>]. Approximately a third of symptomatic carriers of low penetrance alleles harbor this variant [<xref rid=""B19-genes-15-00807"" ref-type=""bibr"">19</xref>,<xref rid=""B20-genes-15-00807"" ref-type=""bibr"">20</xref>]. As a consequence, LOI influence could be taken into account by genetic counseling guidelines in the future when patients carry",2_20,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"guidelines in the future when patients carry low penetrance alleles [<xref rid=""B39-genes-15-00807"" ref-type=""bibr"">39</xref>]. At a diagnostic level, it should be considered that current diagnostic tests do not recognize them, since they only assess the length of amplified products and do not take DNA sequence into account [<xref rid=""B40-genes-15-00807"" ref-type=""bibr"">40</xref>]. Thus, developing an LOI-specific PCR assay may complement genetic testing in the future. Finally, interruptions represent a",2_21,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"in the future. Finally, interruptions represent a potential therapeutic target, not only in HD but also for other repeat expansion disorders [<xref rid=""B41-genes-15-00807"" ref-type=""bibr"">41</xref>,<xref rid=""B42-genes-15-00807"" ref-type=""bibr"">42</xref>,<xref rid=""B43-genes-15-00807"" ref-type=""bibr"">43</xref>]. At present, different therapeutic approaches are under investigation to interfere with somatic repeat instability in preclinical studies; the CRISPR-Cas9 technique might be used to introduce",2_22,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"CRISPR-Cas9 technique might be used to introduce additional interruptions into the CAG tract [<xref rid=""B44-genes-15-00807"" ref-type=""bibr"">44</xref>,<xref rid=""B45-genes-15-00807"" ref-type=""bibr"">45</xref>]. Future aims in this research field might be the investigation of LOI in different population groups other than Caucasians, such as individuals from Africa and Asia. The importance of studying genetically diverse populations in the context of the disease has been recently highlighted in people of",2_23,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"has been recently highlighted in people of African ancestry [<xref rid=""B15-genes-15-00807"" ref-type=""bibr"">15</xref>,<xref rid=""B17-genes-15-00807"" ref-type=""bibr"">17</xref>]. More in detail, atypical allele structures characterized by either a CCG-CCA proline loss downstream to the CAG repeat [<xref rid=""B17-genes-15-00807"" ref-type=""bibr"">17</xref>] or by a rare haplotype recombination [<xref rid=""B15-genes-15-00807"" ref-type=""bibr"">15</xref>] were observed in African disease alleles, whereas they were",2_24,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"in African disease alleles, whereas they were rare or missing in people with European ancestries. In these cases an association with an anticipation of an expected AAO of approximately 7.1 years in both African and European populations [<xref rid=""B17-genes-15-00807"" ref-type=""bibr"">17</xref>] and an increased frequency of juvenile cases in Middle East populations of African ancestries were observed [<xref rid=""B15-genes-15-00807"" ref-type=""bibr"">15</xref>,<xref rid=""B46-genes-15-00807""",2_25,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"rid=""B46-genes-15-00807"" ref-type=""bibr"">46</xref>]. Moreover, a linkage disequilibrium between the number of CAA and the number of CCA variants was reported, and a double loss was associated with a much earlier AAO. CCG-CCA loss seemed to act through a mechanism different from somatic instability since it was associated with reduced somatic expansion in blood DNA [<xref rid=""B17-genes-15-00807"" ref-type=""bibr"">17</xref>]. These recent findings demonstrate that not only the number of CAG repeats and the",2_26,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"that not only the number of CAG repeats and the polyglutamine are involved in HD pathogenesis, but there might be also other factors, such as the downstream polyproline sequence which might affect the mRNA and the encoded protein. These alternative alleles warrant further investigation since they might influence the AAO, and analyzing them in parallel with CAG length will have a great impact on genetic counseling [<xref rid=""B17-genes-15-00807"" ref-type=""bibr"">17</xref>]. Several GWAS conducted in the last",2_27,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"Several GWAS conducted in the last years on large international cohorts allowed the identification of other genetic factors influencing HD AAO besides CAG length (<xref rid=""genes-15-00807-t001"" ref-type=""table"">Table 1</xref>, <xref rid=""genes-15-00807-f001"" ref-type=""fig"">Figure 1</xref>). Many of them fall under the umbrella of DNA repair genes, and more specifically are involved in the mismatch repair pathway. The Genetic Modifiers of Huntington’s Disease (GeM-HD) consortium’s GWAS conducted on 4082 HD",2_28,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"(GeM-HD) consortium’s GWAS conducted on 4082 HD patients identified three significant modifying signals at two loci, one on chromosome 8 and the others on chromosome 15, associated with the AAO [<xref rid=""B10-genes-15-00807"" ref-type=""bibr"">10</xref>]. Two independent signals on chromosome 15 corresponded to the gene encoding <italic toggle=""yes"">FAN1</italic>, which is an endo- and exonuclease involved in interstrand DNA crosslink repair [<xref rid=""B47-genes-15-00807"" ref-type=""bibr"">47</xref>]. <italic",2_29,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"ref-type=""bibr"">47</xref>]. <italic toggle=""yes"">FAN1</italic> seems to be protective in HD: <italic toggle=""yes"">FAN1</italic> depletion in the neurons of animal models and in HD patients accelerates repeat expansion [<xref rid=""B48-genes-15-00807"" ref-type=""bibr"">48</xref>]. In fact, <italic toggle=""yes"">FAN1</italic> variants that cause protein decreases hastened the disease onset by more than 6 years earlier than would be expected from CAG length alone, and the others that increase <italic",2_30,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"alone, and the others that increase <italic toggle=""yes"">FAN1</italic> expression delayed the disease onset by 1.4 years [<xref rid=""B48-genes-15-00807"" ref-type=""bibr"">48</xref>]. The current thinking is that <italic toggle=""yes"">FAN1</italic> suppresses somatic expansion at the <italic toggle=""yes"">HTT</italic> locus [<xref rid=""B49-genes-15-00807"" ref-type=""bibr"">49</xref>,<xref rid=""B50-genes-15-00807"" ref-type=""bibr"">50</xref>]. Two mechanisms have been shown to mediate somatic stability in <italic",2_31,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"shown to mediate somatic stability in <italic toggle=""yes"">HTT</italic>. The first is mediated by MLH1 binding [<xref rid=""B48-genes-15-00807"" ref-type=""bibr"">48</xref>,<xref rid=""B50-genes-15-00807"" ref-type=""bibr"">50</xref>,<xref rid=""B51-genes-15-00807"" ref-type=""bibr"">51</xref>]; indeed, FAN1 binds to MLH1, preventing its recruitment in the mismatch repair complex, thus stabilizing CAG repeat expansion [<xref rid=""B51-genes-15-00807"" ref-type=""bibr"">51</xref>]. The interaction between FAN1 and MLH1 is",2_32,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"The interaction between FAN1 and MLH1 is negatively regulated by phosphorylation of FAN1’s S126 residue [<xref rid=""B48-genes-15-00807"" ref-type=""bibr"">48</xref>]. The second is related to FAN1’s nuclease activity [<xref rid=""B52-genes-15-00807"" ref-type=""bibr"">52</xref>,<xref rid=""B53-genes-15-00807"" ref-type=""bibr"">53</xref>] which is activated by PCNA and RFC on DNA harboring triplet repeat extrusions [<xref rid=""B54-genes-15-00807"" ref-type=""bibr"">54</xref>]. McAllister and colleagues described <italic",2_33,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"McAllister and colleagues described <italic toggle=""yes"">FAN1</italic> mutations to be associated with a worse HD onset and a more severe phenotype. In particular, AAO-hastening SNPs (Single Nucleotide Polymorphisms) demonstrated reduced nuclease activity [<xref rid=""B53-genes-15-00807"" ref-type=""bibr"">53</xref>]. <italic toggle=""yes"">FAN1</italic> is also involved in other neurogenerative diseases caused by repeat expansion, such as certain hereditary spinocerebellar ataxias and X fragile syndrome [<xref",2_34,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"ataxias and X fragile syndrome [<xref rid=""B55-genes-15-00807"" ref-type=""bibr"">55</xref>,<xref rid=""B56-genes-15-00807"" ref-type=""bibr"">56</xref>,<xref rid=""B57-genes-15-00807"" ref-type=""bibr"">57</xref>]. Therefore, the DNA repair pathway represents a common genetic mechanism underlying repeat expansion disorders with potential broader therapeutic implications [<xref rid=""B58-genes-15-00807"" ref-type=""bibr"">58</xref>]. Moreover, there is also evidence of the involvement of <italic",2_35,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"is also evidence of the involvement of <italic toggle=""yes"">FAN1</italic> in epilepsy, bipolar disorder, schizophrenia, and autism [<xref rid=""B58-genes-15-00807"" ref-type=""bibr"">58</xref>]. Future works are needed to assess the therapeutic tractability of <italic toggle=""yes"">FAN1</italic> in attenuating <italic toggle=""yes"">HTT</italic> somatic expansion. A possible therapeutic target under current investigation might be the aforementioned phosphorylation of FAN1-S126. The chromosome 8 signal observed in",2_36,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"of FAN1-S126. The chromosome 8 signal observed in GeM-HD GWAS was associated with an anticipated AAO of 1.6 years earlier than expected and could correspond to <italic toggle=""yes"">RRM2B</italic> or <italic toggle=""yes"">UBR5</italic> loci. These genes are involved in the following functions implicated in HD pathogenesis: mitochondrial regulation, DNA maintenance, oxidative stress, and proteostasis. Another study [<xref rid=""B59-genes-15-00807"" ref-type=""bibr"">59</xref>] confirmed the signals identified on",2_37,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"confirmed the signals identified on chromosomes 8 and 15 and also found a locus at <italic toggle=""yes"">MLH1</italic> on chromosome 3, associated with a delay in disease onset of 0.7 years. Dominant loss of function mutations of <italic toggle=""yes"">MLH1</italic> are associated with Lynch syndrome [<xref rid=""B60-genes-15-00807"" ref-type=""bibr"">60</xref>], the most common cause of hereditary colorectal cancer; moreover, the <italic toggle=""yes"">MLH1</italic> gene is associated with brain CAG instability in",2_38,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"gene is associated with brain CAG instability in the <italic toggle=""yes"">Htt</italic> knock-in mouse [<xref rid=""B61-genes-15-00807"" ref-type=""bibr"">61</xref>]. The GWAS study conducted on 216 and 1773 participants from the TRACK-HD and REGISTRY studies, respectively, identified an association at chromosome 5, which corresponds to <italic toggle=""yes"">MSH3</italic>, associated with slower disease progression [<xref rid=""B11-genes-15-00807"" ref-type=""bibr"">11</xref>]. As with <italic",2_39,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"ref-type=""bibr"">11</xref>]. As with <italic toggle=""yes"">FAN1</italic> and <italic toggle=""yes"">MLH1</italic>, <italic toggle=""yes"">MSH3</italic> is also involved in the DNA mismatch repair pathway [<xref rid=""B62-genes-15-00807"" ref-type=""bibr"">62</xref>,<xref rid=""B63-genes-15-00807"" ref-type=""bibr"">63</xref>,<xref rid=""B64-genes-15-00807"" ref-type=""bibr"">64</xref>] and is the first identified genetic modifier of the rate of progression in HD. In particular, Moss and colleagues demonstrated that each",2_40,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"Moss and colleagues demonstrated that each copy of the minor allele at the lead SNP in <italic toggle=""yes"">MHS3</italic> was associated with a reduction in the change in the Unified Huntington’s Disease Rating Scale (UHDRS) Total Motor Score and Total Functional Capacity (0.4 and 0.12 units per year, respectively). <italic toggle=""yes"">MSH3</italic> involvement has been demonstrated also in myotonic dystrophy type 1 [<xref rid=""B65-genes-15-00807"" ref-type=""bibr"">65</xref>], further underlying the common",2_41,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"further underlying the common genetic background of triplet diseases. O’Reilly and collaborators have recently characterized a fully chemically modified short interfering RNA (siRNA) capable of silencing <italic toggle=""yes"">MSH3</italic> in both in vitro and in vivo models [<xref rid=""B66-genes-15-00807"" ref-type=""bibr"">66</xref>]. The application of siRNA to downregulate <italic toggle=""yes"">MSH3</italic> proved highly effective in inhibiting the expansion of CAG repeats within the striatum in two",2_42,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"of CAG repeats within the striatum in two distinct HD murine models. This discovery presents a promising therapeutic avenue for individuals afflicted by HD and other disorders characterized by repeat expansion mutations. Interestingly, Lee and colleagues suggested that genetic modifiers might preferentially affect motor or cognitive functions [<xref rid=""B67-genes-15-00807"" ref-type=""bibr"">67</xref>]. For instance, <italic toggle=""yes"">MSH3</italic> could mainly impact the cognitive domain, whereas <italic",2_43,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"impact the cognitive domain, whereas <italic toggle=""yes"">FAN1</italic> could impact motor function. As a consequence, these genetic modifiers might act differentially on the neuronal networks underlying diverse clinical outcomes. In 2019, an extended GWAS study involving over 9000 HD patients from the REGISTRY and Enroll-HD cohorts confirmed the findings of the previous GeM-HD GWAS and also identified new HD onset-associated loci, corresponding to other DNA repair genes <italic toggle=""yes"">PMS1</italic>,",2_44,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"repair genes <italic toggle=""yes"">PMS1</italic>, <italic toggle=""yes"">MSH3</italic>/<italic toggle=""yes"">DHFR</italic>, <italic toggle=""yes"">PMS2,</italic> and <italic toggle=""yes"">LIG1</italic>, as well as <italic toggle=""yes"">TCERG1</italic> and <italic toggle=""yes"">CCDC82</italic> [<xref rid=""B12-genes-15-00807"" ref-type=""bibr"">12</xref>]. Interestingly, <italic toggle=""yes"">PMS1</italic> has been found to be a target of splice modulators, small molecules that are being investigated in HD clinical",2_45,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"that are being investigated in HD clinical trials to reduce HTT levels, providing alternative targets to prevent CAG somatic expansion [<xref rid=""B68-genes-15-00807"" ref-type=""bibr"">68</xref>]. The results of these genetic studies point out the central role of the mismatch DNA repair pathway in HD pathogenesis (<xref rid=""genes-15-00807-f001"" ref-type=""fig"">Figure 1</xref>). Expanded repeat sequences can form secondary structures, such as hairpins and large loops, that might induce the mismatch repair",2_46,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"loops, that might induce the mismatch repair complex to act erroneously, leading to somatic expansions. In more detail, MutSβ (MSH2-MSH3) recognizes these structures and recruits MutLα (MLH1-PMS2) or MutLγ (MLH1-MLH3), endonucleases that co-ordinate excision [<xref rid=""B69-genes-15-00807"" ref-type=""bibr"">69</xref>]. The MutL complex erroneously creates a break in the strand opposite the loop. The polymerase then uses the strand with the loop as the template strand, thus determining the elongation of the",2_47,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"strand, thus determining the elongation of the repeat sequence. On the contrary, MutSα (MHS2-MSH3) seems not to be involved in CAG instability, since it recognizes small DNA loops, rather than the longer loops targeted by MutSβ. MSH2, MSH6, or MLH1 depletion may cause cancer in humans, while MSH3 loss of function does not affect lifespan or cause cancer in mice [<xref rid=""B70-genes-15-00807"" ref-type=""bibr"">70</xref>]. Therefore, small molecules or ASOs against MSH3 might represent fruitful strategies for",2_48,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"MSH3 might represent fruitful strategies for potential therapies for HD [<xref rid=""B71-genes-15-00807"" ref-type=""bibr"">71</xref>]. DNA-repair genes represent promising candidates for future therapies, and in preclinical development, MSH3 is the most encouraging target [<xref rid=""B62-genes-15-00807"" ref-type=""bibr"">62</xref>,<xref rid=""B72-genes-15-00807"" ref-type=""bibr"">72</xref>]. Moreover, since slipped DNAs occur during somatic repeat expansions, small molecules that specifically bind to these",2_49,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"small molecules that specifically bind to these structures are under development [<xref rid=""B36-genes-15-00807"" ref-type=""bibr"">36</xref>]. Whereas inherited mutations are transmitted across generations, somatic mutations occur post-zygotically. They can develop throughout the entire life of an individual, leading to somatic mosaicism, a condition in which only some cells of an individual harbor the mutation [<xref rid=""B73-genes-15-00807"" ref-type=""bibr"">73</xref>,<xref rid=""B74-genes-15-00807""",2_50,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"rid=""B74-genes-15-00807"" ref-type=""bibr"">74</xref>]. Their role in contributing to disease pathogenesis has been first described in cancer. Recently, thanks to technical improvements such as single-cell and whole-genome sequencing, growing evidence has supported their involvement also in neurodevelopmental disorders [<xref rid=""B75-genes-15-00807"" ref-type=""bibr"">75</xref>,<xref rid=""B76-genes-15-00807"" ref-type=""bibr"">76</xref>], such as in brain malformations associated with epilepsy and intellectual",2_51,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"associated with epilepsy and intellectual disabilities [<xref rid=""B77-genes-15-00807"" ref-type=""bibr"">77</xref>]. Besides these conditions, it has been demonstrated that somatic mutations are involved also in normal brain aging [<xref rid=""B78-genes-15-00807"" ref-type=""bibr"">78</xref>] and neurodegenerative disorders [<xref rid=""B79-genes-15-00807"" ref-type=""bibr"">79</xref>]. The CAG repeat causing HD shows great meiotic instability and frequently increases in length across generations [<xref",2_52,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"increases in length across generations [<xref rid=""B80-genes-15-00807"" ref-type=""bibr"">80</xref>,<xref rid=""B81-genes-15-00807"" ref-type=""bibr"">81</xref>]. The risk of expansion is higher in spermatogenesis than in oogenesis. This may contribute to partially explain pediatric-onset HD cases inherited by affected fathers [<xref rid=""B81-genes-15-00807"" ref-type=""bibr"">81</xref>,<xref rid=""B82-genes-15-00807"" ref-type=""bibr"">82</xref>], and the occurrence of de novo mutations from paternal intermediate",2_53,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"of de novo mutations from paternal intermediate alleles [<xref rid=""B83-genes-15-00807"" ref-type=""bibr"">83</xref>]. CAG repeat expansion is highly unstable not only in germline but also in somatic cells, thus determining somatic mosaicism. The tissue specificity of somatic repeat instability has been described in both mice models and in humans, with the striatum and cerebral cortex displaying the highest levels of somatic expansions [<xref rid=""B84-genes-15-00807"" ref-type=""bibr"">84</xref>,<xref",2_54,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"ref-type=""bibr"">84</xref>,<xref rid=""B85-genes-15-00807"" ref-type=""bibr"">85</xref>,<xref rid=""B86-genes-15-00807"" ref-type=""bibr"">86</xref>,<xref rid=""B87-genes-15-00807"" ref-type=""bibr"">87</xref>,<xref rid=""B88-genes-15-00807"" ref-type=""bibr"">88</xref>,<xref rid=""B89-genes-15-00807"" ref-type=""bibr"">89</xref>,<xref rid=""B90-genes-15-00807"" ref-type=""bibr"">90</xref>]. Brain somatic CAG instability is associated with an earlier age at onset [<xref rid=""B90-genes-15-00807"" ref-type=""bibr"">90</xref>] and",2_55,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"ref-type=""bibr"">90</xref>] and mounting evidence suggests that the degree of somatic repeat length in undifferentiated neurons better explains the AAO than the germline repeat [<xref rid=""B72-genes-15-00807"" ref-type=""bibr"">72</xref>]. Somatic instability can be investigated in peripheral tissues [<xref rid=""B27-genes-15-00807"" ref-type=""bibr"">27</xref>] whose alterations might mirror what happens in the brain. In a large study of nearly 750 HD mutation carriers, somatic expansions in the blood correlated",2_56,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"somatic expansions in the blood correlated with worse clinical outcomes, encompassing an earlier AAO, worse baseline motor scores, and higher disease progression scores [<xref rid=""B18-genes-15-00807"" ref-type=""bibr"">18</xref>]. Variants in several DNA repair genes are associated with somatic expansion, both in HD animal models [<xref rid=""B61-genes-15-00807"" ref-type=""bibr"">61</xref>,<xref rid=""B62-genes-15-00807"" ref-type=""bibr"">62</xref>,<xref rid=""B91-genes-15-00807"" ref-type=""bibr"">91</xref>] and HD",2_57,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"ref-type=""bibr"">91</xref>] and HD patients [<xref rid=""B12-genes-15-00807"" ref-type=""bibr"">12</xref>,<xref rid=""B18-genes-15-00807"" ref-type=""bibr"">18</xref>,<xref rid=""B64-genes-15-00807"" ref-type=""bibr"">64</xref>]. Therefore, it seems reasonable that their effect might be mediated through somatic expansion of the CAG repeat. However, other factors might also contribute to drive somatic instability. A possible candidate is oxidative stress since it could modify instability rates [<xref",2_58,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"since it could modify instability rates [<xref rid=""B92-genes-15-00807"" ref-type=""bibr"">92</xref>]. Somatic expansions in blood samples increase with age, whereas they are minimal in fetal mutation carriers [<xref rid=""B93-genes-15-00807"" ref-type=""bibr"">93</xref>]. As a consequence, these findings support a computational, simulational approach proposed by Kaplan et al. to explain the onset and progression of HD [<xref rid=""B94-genes-15-00807"" ref-type=""bibr"">94</xref>]. According to this view, disease",2_59,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"According to this view, disease onset occurs once the repeat sequence has increased in length beyond a cell type-specific pathological threshold in a critical proportion of vulnerable cells to trigger toxicity and dysfunction, leading eventually to cell death [<xref rid=""B94-genes-15-00807"" ref-type=""bibr"">94</xref>,<xref rid=""B95-genes-15-00807"" ref-type=""bibr"">95</xref>]. The threshold for each specific cell type is yet to be determined. By performing quantitative analyses of CAG instability across",2_60,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"quantitative analyses of CAG instability across several central nervous system (CNS) regions and peripheral post mortem tissues of HD individuals, Pinto et al. demonstrated that <italic toggle=""yes"">HTT</italic> CAG repeat expansion indeed occurs in all tissues analyzed, though to different extents [<xref rid=""B25-genes-15-00807"" ref-type=""bibr"">25</xref>]. The greatest instability was found in multiple cortical regions and neostriatum in the CNS, and liver in the periphery, the latter of which indeed",2_61,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"in the periphery, the latter of which indeed affected children with highly expanded and unstable mutations [<xref rid=""B96-genes-15-00807"" ref-type=""bibr"">96</xref>]. The presence of CAG instability also in peripheral cells opens new ways to further investigate triplet mosaicism. Furthermore, given the central role of somatic expansions in disease progression, targeting repeat instability might have extremely relevant, even though challenging, therapeutic implications in triplet disorders [<xref",2_62,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"implications in triplet disorders [<xref rid=""B97-genes-15-00807"" ref-type=""bibr"">97</xref>]. Altogether, the above considerations lend support to the following hypotheses: (1) the inherited expanded <italic toggle=""yes"">HTT</italic>-CAG repeats undergo further expansion somatically toward a critical threshold length in vulnerable cell types [<xref rid=""B91-genes-15-00807"" ref-type=""bibr"">91</xref>], thus extensively and progressively affecting HD biology in a length-dependent manner [<xref",2_63,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"HD biology in a length-dependent manner [<xref rid=""B98-genes-15-00807"" ref-type=""bibr"">98</xref>]; (2) when the expanded CAG threshold length is reached, a mechanism is triggered that affects HD progression [<xref rid=""B94-genes-15-00807"" ref-type=""bibr"">94</xref>,<xref rid=""B98-genes-15-00807"" ref-type=""bibr"">98</xref>]; (3) in cis haplotypes may affect HD frequency and toxicity of mutant HTT in axons [<xref rid=""B13-genes-15-00807"" ref-type=""bibr"">13</xref>,<xref rid=""B14-genes-15-00807""",2_64,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"rid=""B14-genes-15-00807"" ref-type=""bibr"">14</xref>,<xref rid=""B15-genes-15-00807"" ref-type=""bibr"">15</xref>]; (4) factors in trans to expanded <italic toggle=""yes"">HTT</italic>-CAG repeats may act as disease modifiers [<xref rid=""B9-genes-15-00807"" ref-type=""bibr"">9</xref>,<xref rid=""B10-genes-15-00807"" ref-type=""bibr"">10</xref>,<xref rid=""B11-genes-15-00807"" ref-type=""bibr"">11</xref>,<xref rid=""B12-genes-15-00807"" ref-type=""bibr"">12</xref>]. Although a great number of works demonstrated that the mHTT",2_65,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"great number of works demonstrated that the mHTT protein affects many cellular functions, leading to cell death and neurodegeneration, an increasing body of evidence indicates that also the mHTT RNA may contribute to toxicity [<xref rid=""B34-genes-15-00807"" ref-type=""bibr"">34</xref>]. Normally, two alternatively spliced transcripts emanate from the <italic toggle=""yes"">HTT</italic> gene. These transcripts vary in the length of their 3′ untranslated region (UTR) by 3 kilobases (kb), producing an identical",2_66,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"(UTR) by 3 kilobases (kb), producing an identical HTT protein. The extended transcript is primarily observed in the brain, whereas the other variant has a broader expression throughout various tissues [<xref rid=""B99-genes-15-00807"" ref-type=""bibr"">99</xref>]. However, a well-documented feature of HD is that HTT pre-mRNA splicing can be altered, leading to the production of different isoforms of the huntingtin protein [<xref rid=""B100-genes-15-00807"" ref-type=""bibr"">100</xref>,<xref",2_67,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"ref-type=""bibr"">100</xref>,<xref rid=""B101-genes-15-00807"" ref-type=""bibr"">101</xref>]. Among the multiple shorter versions of the HTT, exon 1 is the most toxic N-terminal fragment [<xref rid=""B102-genes-15-00807"" ref-type=""bibr"">102</xref>,<xref rid=""B103-genes-15-00807"" ref-type=""bibr"">103</xref>]. This short exon 1 transcript (HTT1a) was described in mice models and post mortem brains of subjects with HD [<xref rid=""B104-genes-15-00807"" ref-type=""bibr"">104</xref>]; its level is proportional to the CAG",2_68,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"its level is proportional to the CAG repeat length, it is only seen in mutant alleles, and it produces the pathogenic and highly aggregation-prone exon 1 huntingtin protein [<xref rid=""B105-genes-15-00807"" ref-type=""bibr"">105</xref>]. In mice models expressing the human <italic toggle=""yes"">HTT</italic> gene (YAC128 mice), HTT1a was found both in large nuclear RNA clusters and as single transcripts in the cytoplasm [<xref rid=""B106-genes-15-00807"" ref-type=""bibr"">106</xref>]. The levels of exon 1 HTT in",2_69,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"The levels of exon 1 HTT in YAS128 mice correlated with HTT aggregation, suggesting the hypothesis that exon 1 HTT initiates the aggregation process. These findings might have profound therapeutic implications, underlying the importance of specifically targeting the exon 1 protein instead of the full-length HTT mRNA. Another characteristic of RNA pathology in HD is related to the production of toxic RNA species. Indeed, repeat-containing RNAs may agglomerate in the nucleus as foci or undergo aberrant",2_70,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"in the nucleus as foci or undergo aberrant repeat-associated non-AUG (RAN) translation. RAN translation refers to a phenomenon in which RNA sequences containing repetitive elements are translated into proteins without the requirement of a traditional start codon (ATG) that usually initiates protein translation. As a result, short, abnormal proteins with repeated amino acid sequences are produced. This process was documented in certain genetic disorders associated with repeat expansion, such as HD, myotonic",2_71,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"with repeat expansion, such as HD, myotonic dystrophy, and amyotrophic lateral sclerosis [<xref rid=""B33-genes-15-00807"" ref-type=""bibr"">33</xref>,<xref rid=""B107-genes-15-00807"" ref-type=""bibr"">107</xref>,<xref rid=""B108-genes-15-00807"" ref-type=""bibr"">108</xref>]. In HD, these elements accumulate most abundantly in regions associated with HD pathology, such as the striatum, the white matter, and the cerebellum in juvenile HD [<xref rid=""B108-genes-15-00807"" ref-type=""bibr"">108</xref>]. RNA translation",2_72,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"ref-type=""bibr"">108</xref>]. RNA translation adds a further layer of complexity to the molecular mechanisms underlying HD and other neurodegenerative diseases. The abnormal proteins generated through RAN translation might contribute to cellular dysfunction and toxicity, ultimately contributing to neurodegeneration [<xref rid=""B109-genes-15-00807"" ref-type=""bibr"">109</xref>,<xref rid=""B110-genes-15-00807"" ref-type=""bibr"">110</xref>]. However, another study showed that HD knock-in mice lack RAN-mediated",2_73,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"showed that HD knock-in mice lack RAN-mediated toxicity [<xref rid=""B111-genes-15-00807"" ref-type=""bibr"">111</xref>]; thus, the role of this form of translation in HD pathogenesis requires further confirmation. In summary, RNA plays a critical role in the development and progression of HD. The expanded CAG repeat within the <italic toggle=""yes"">HTT</italic> gene leads to various RNA-related abnormalities, including altered transcription, RNA processing, and the generation of toxic RNA species. Harnessing",2_74,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"the generation of toxic RNA species. Harnessing the understanding of these RNA-related mechanisms has led to the development of potential therapeutic strategies aimed at mitigating the effects of the disease. For instance, pharmaceutical companies have been developing <italic toggle=""yes"">HTT</italic>-lowering therapies, aiming at specifically targeting and leading to HTT mRNA degradation including small interfering RNA molecules (siRNAs) and antisense oligonucleotides (ASOs). These therapies aim to",2_75,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"oligonucleotides (ASOs). These therapies aim to finally reduce the production of the toxic proteins, potentially slowing down or halting the progression of the disease [<xref rid=""B1-genes-15-00807"" ref-type=""bibr"">1</xref>,<xref rid=""B71-genes-15-00807"" ref-type=""bibr"">71</xref>]. Robust evidence demonstrates that mitochondrial dysfunction plays a central role in normal aging and neurodegenerative diseases [<xref rid=""B112-genes-15-00807"" ref-type=""bibr"">112</xref>,<xref rid=""B113-genes-15-00807""",2_76,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"rid=""B113-genes-15-00807"" ref-type=""bibr"">113</xref>]. Mitochondrial DNA (mtDNA), compared to nuclear DNA (nDNA), is 10 times more susceptible to mutations and plays a key role in the development and progression of neurodegenerative disorders, including HD [<xref rid=""B114-genes-15-00807"" ref-type=""bibr"">114</xref>]. Additionally, it is worth noting that the repair mechanisms for mtDNA and nDNA differ [<xref rid=""B115-genes-15-00807"" ref-type=""bibr"">115</xref>] and there is still a dearth of studies",2_77,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"and there is still a dearth of studies focusing on the assessment of mtDNA repair machinery [<xref rid=""B116-genes-15-00807"" ref-type=""bibr"">116</xref>]. Mitochondrial alterations are well documented in HD [<xref rid=""B117-genes-15-00807"" ref-type=""bibr"">117</xref>,<xref rid=""B118-genes-15-00807"" ref-type=""bibr"">118</xref>] and several molecular mechanisms have been hypothesized to connect mHTT to mitochondrial dysfunction [<xref rid=""B119-genes-15-00807"" ref-type=""bibr"">119</xref>]. Disentangling these",2_78,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"ref-type=""bibr"">119</xref>]. Disentangling these mechanisms is of particular interest since promoting mitochondrial function might represent a complementary approach to target the causative gene mutation in HD. Mitochondria are crucial for energy metabolism and their proteins are encoded by both nDNA and mtDNA. mtDNA damage has been described in the brain of HD mouse models [<xref rid=""B120-genes-15-00807"" ref-type=""bibr"">120</xref>,<xref rid=""B121-genes-15-00807"" ref-type=""bibr"">121</xref>], adult HD",2_79,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"ref-type=""bibr"">121</xref>], adult HD [<xref rid=""B122-genes-15-00807"" ref-type=""bibr"">122</xref>,<xref rid=""B123-genes-15-00807"" ref-type=""bibr"">123</xref>], and pediatric HD patients [<xref rid=""B124-genes-15-00807"" ref-type=""bibr"">124</xref>]. Moreover, nDNA and mtDNA alterations have been reported also in peripheral tissues, suggesting a possible role as easily accessible biomarkers of disease progression and therapeutic monitoring. In this field, several open issues should be addressed, namely which",2_80,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"open issues should be addressed, namely which kind of peripheral cell is the most promising (e.g., different subpopulations of leukocytes), the different roles as potential biomarkers of nDNA and mtDNA, and the correlation with scores of disease severity and disease progression. Different works have described alterations in mtDNA amounts in leukocytes of HD patients [<xref rid=""B125-genes-15-00807"" ref-type=""bibr"">125</xref>,<xref rid=""B126-genes-15-00807"" ref-type=""bibr"">126</xref>,<xref",2_81,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"ref-type=""bibr"">126</xref>,<xref rid=""B127-genes-15-00807"" ref-type=""bibr"">127</xref>,<xref rid=""B128-genes-15-00807"" ref-type=""bibr"">128</xref>]. However, the results of the first studies were not conclusive, showing both a depletion [<xref rid=""B125-genes-15-00807"" ref-type=""bibr"">125</xref>,<xref rid=""B127-genes-15-00807"" ref-type=""bibr"">127</xref>,<xref rid=""B128-genes-15-00807"" ref-type=""bibr"">128</xref>] and an increase in the mtDNA copy number [<xref rid=""B126-genes-15-00807""",2_82,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"copy number [<xref rid=""B126-genes-15-00807"" ref-type=""bibr"">126</xref>,<xref rid=""B129-genes-15-00807"" ref-type=""bibr"">129</xref>]. An opposed alteration in mtDNA amount between leukocytes and fibroblasts in the same patients was reported [<xref rid=""B129-genes-15-00807"" ref-type=""bibr"">129</xref>]. These discrepancies could have been due to differences in the size of populations, techniques, or type of cells considered. Moreover, an association between mtDNA alterations and disease severity was not",2_83,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"mtDNA alterations and disease severity was not clearly defined. On the other hand, results from another study conducted on peripheral blood mononuclear cells (PBMC) of 36 HD patients were further in contrast to the works aforementioned [<xref rid=""B130-genes-15-00807"" ref-type=""bibr"">130</xref>]. Askeland and colleagues found a reduction in genes associated with aerobic metabolism in PBMC of HD patients, thus suggesting mitochondrial dysfunction. However, they showed reduced mtDNA damage in HD patients",2_84,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"they showed reduced mtDNA damage in HD patients compared to healthy controls, whereas nDNA was severely damaged in patients. An inverse correlation between nDNA damage and total functional capacity (TFC) was described. A study conducted on a large population of 1549 HD patients shed more light on this research field [<xref rid=""B28-genes-15-00807"" ref-type=""bibr"">28</xref>]. A significant increase in mtDNA heteroplasmies of predicted pathogenicity was found in the lymphoblast of HD patients, which",2_85,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"found in the lymphoblast of HD patients, which correlated with HD stage and disease severity, determined by motor and cognitive scores and TFC. Moreover, with a 6-year longitudinal follow-up of a subgroup of 169 HD patients, the authors found that the expansion of pathogenic mtDNA heteroplasmies was correlated with disease progression, evaluated by means of decline in TFC, motor score, and symbol digit modality test results. In conclusion, mtDNA alterations in peripheral tissues could provide an accessible",2_86,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"in peripheral tissues could provide an accessible biomarker of disease progression in HD. The implications might be even broader in the field of triplet disorders since the observations have been extended also to other polyglutamine diseases [<xref rid=""B127-genes-15-00807"" ref-type=""bibr"">127</xref>]. Epigenetics describes heritable modifications that alter the accessibility of DNA and regulate gene transcription without changing the underlying DNA sequence. Methylation is the most studied epigenetic",2_87,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"Methylation is the most studied epigenetic alteration and consists of the binding of a methyl group to CpG dinucleotide in the promoter region of a gene, thus reducing its transcription. Various DNA methylation alterations in neurological diseases are associated with disease activity, disease progression, and clinical outcomes, and may have a prognostic or diagnostic value [<xref rid=""B131-genes-15-00807"" ref-type=""bibr"">131</xref>]. Different works underlined the potential role of methylation in HD, both",2_88,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"the potential role of methylation in HD, both in animal models and in humans. Through the analysis of the cortex DNA methylation profiles in HD patients, De Souza and colleagues found an association between DNA methylation and the age of disease onset [<xref rid=""B132-genes-15-00807"" ref-type=""bibr"">132</xref>]. However, they failed to identify any HD-associated DNA methylation changes at probe sites. Transcriptional dysregulation is a major characteristic of early HD, preceding neuronal death,",2_89,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"of early HD, preceding neuronal death, demonstrated both in human post mortem tissues and mouse models [<xref rid=""B23-genes-15-00807"" ref-type=""bibr"">23</xref>,<xref rid=""B133-genes-15-00807"" ref-type=""bibr"">133</xref>]. The polyglutamine-expanded <italic toggle=""yes"">HTT</italic> might be directly involved in these expression changes. Indeed, in cell lines derived from mouse striatal neurons, the presence of mutant HTT was associated with significant changes in DNA methylation, with the downregulation of",2_90,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"in DNA methylation, with the downregulation of the expression of genes associated with neurogenesis, and neuronal differentiation, such as SOX2, PAX6, and NES [<xref rid=""B134-genes-15-00807"" ref-type=""bibr"">134</xref>]. mHTT might be involved in the regulation of DNA methyltransferases [<xref rid=""B134-genes-15-00807"" ref-type=""bibr"">134</xref>,<xref rid=""B135-genes-15-00807"" ref-type=""bibr"">135</xref>] and it could also bind directly to DNA, thus driving the recruitment of epigenetic modifiers [<xref",2_91,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"the recruitment of epigenetic modifiers [<xref rid=""B136-genes-15-00807"" ref-type=""bibr"">136</xref>]. In primary neuronal models of HD, mHTT increased the levels of DNA methylation in the promoters of BDNF, an essential neurotrophic factor [<xref rid=""B137-genes-15-00807"" ref-type=""bibr"">137</xref>]. Conversely, pharmacological inhibition of DNA methyltransferase decreased methylation, thus restoring BDNF transcription. If on one hand there is evidence that polyglutamine-expanded HTT is associated with",2_92,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"polyglutamine-expanded HTT is associated with transcription regulation of key genes, on the other hand, the epigenetic status in and around the CAG repeat also plays a relevant role. To the best of our knowledge, at present, the largest study on DNA methylation in HD was conducted by Lu and colleagues in seven DNA sources from three species, namely human, mouse, and sheep models [<xref rid=""B29-genes-15-00807"" ref-type=""bibr"">29</xref>]. First of all, they demonstrated that manifest HD, but not",2_93,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"all, they demonstrated that manifest HD, but not premanifest, was associated with increased epigenetic age in human blood DNA. This is in line with previous evidence from human brain samples [<xref rid=""B138-genes-15-00807"" ref-type=""bibr"">138</xref>]. Secondly, epigenome-wide association studies found that HTT is the main locus involved in all three species. This finding might help to explore disease pathogenesis. Moreover, investigating whether methylation at this locus contributes to drive somatic",2_94,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"at this locus contributes to drive somatic expansion would be of great interest in research. Finally, methylation levels at three loci (PEX14, GRIK4, and COX4I2) were significantly associated with motor progression in manifest HD. Post-translational histone modifications (e.g., acetylation) are also epigenetic events that have been well studied in HD. For instance, a reduction in histone acetylation and in specific loci has been documented in several HD models and human HD biosamples [<xref",2_95,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"several HD models and human HD biosamples [<xref rid=""B24-genes-15-00807"" ref-type=""bibr"">24</xref>]. In addition, there is also evidence that many RNA species can contribute to HD pathogenesis which has been described elsewhere [<xref rid=""B139-genes-15-00807"" ref-type=""bibr"">139</xref>,<xref rid=""B140-genes-15-00807"" ref-type=""bibr"">140</xref>]. One of these species, i.e., lncRNAs, RNA molecules exceeding 200 nucleotides in length, have been observed to exhibit notably higher expression in the brain,",2_96,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"exhibit notably higher expression in the brain, playing intricate roles in a multitude of cellular processes, including functions pertaining to transcriptional regulation and chromatin modulation. In conclusion, assessing the diagnostic relevance of epigenetic regulations in HD through DNA methylation and RNA species might represent an attractive target for future therapeutic intervention. The field of genetic modification research has expanded enormously in the last years, significantly enhancing our",2_97,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"in the last years, significantly enhancing our comprehension of somatic instability as the pivotal driver of HD pathogenesis. This newfound knowledge not only holds profound implications for advancing our understanding of other repeat expansion disorders but also offers a wide range of therapeutic prospects for these diseases. In the near future, it is imperative to delve into alternative pathways of pathogenesis that extend beyond somatic instability and to explore the involvement of other genetic factors",2_98,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"explore the involvement of other genetic factors such as the ones discussed in this review. These avenues of investigation not only promise to disentangle HD pathogenesis but also present opportunities for the development of disease progression biomarkers and innovative therapeutic targets. The multifaceted nature of HD genetics demands a comprehensive approach, and continued extensive research on genetic modifiers holds the key to unlocking new horizons in our quest to cure this devastating disorder.",2_99,Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease,19 6 2024,,Huntington_Disease
"Deep behavioural phenotyping of the Q175 Huntington disease mouse model: effects of age, sex, and weight Huntington disease (HD) is a progressive neurodegenerative disorder characterized by motor, cognitive, and psychiatric disturbances [<xref ref-type=""bibr"" rid=""CR1"">1</xref>, <xref ref-type=""bibr"" rid=""CR2"">2</xref>]. It is caused by an autosomal dominant CAG repeat expansion in the Huntingtin (Htt) gene, resulting in aberrant forms of the Htt protein [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. Many",3_0,"Deep behavioural phenotyping of the Q175 Huntington disease mouse model: effects of age, sex, and weight",23 5 2024,,Huntington_Disease
"[<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. Many direct and indirect effects of the mutant Htt (mHtt) protein have been identified in humans and animal models, including changes to gene expression, synaptic transmission, and intracellular signaling [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. On the macroscopic scale, HD causes extensive degeneration of the dorsal striatum, in addition to progressive degeneration of other brain regions including cortex [<xref ref-type=""bibr"" rid=""CR2"">2</xref>]. Due to the",3_1,"Deep behavioural phenotyping of the Q175 Huntington disease mouse model: effects of age, sex, and weight",23 5 2024,,Huntington_Disease
"ref-type=""bibr"" rid=""CR2"">2</xref>]. Due to the monogenic nature of HD, many animal models have been created, contributing to discoveries in HD research. Among these, genetic mouse models are the most developed and commonly used (reviewed in [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]). These mouse models vary in the severity of phenotype, including the alterations in brain structural and electrophysiological measures, as well as behavioural changes they exhibit. Although none of the mouse models",3_2,"Deep behavioural phenotyping of the Q175 Huntington disease mouse model: effects of age, sex, and weight",23 5 2024,,Huntington_Disease
"they exhibit. Although none of the mouse models recapitulate all the brain and behavioural changes seen in human HD, especially the cortical atrophy and profound striatal volume loss, most of these models show progressive motor and cognitive deficits, such as impaired rotarod learning, changes to spontaneous behaviour patterns, and impaired learning in T-maze tasks [<xref ref-type=""bibr"" rid=""CR4"">4</xref>–<xref ref-type=""bibr"" rid=""CR6"">6</xref>]. These impairments mimic changes that occur in humans,",3_3,"Deep behavioural phenotyping of the Q175 Huntington disease mouse model: effects of age, sex, and weight",23 5 2024,,Huntington_Disease
"impairments mimic changes that occur in humans, including altered motor learning and coordination, and cognitive deficits, although the timing and degree of impairment in these mice varies widely between models. Knock-in mouse models have CAG repeat expansions of various lengths expressed in the mouse Htt locus [<xref ref-type=""bibr"" rid=""CR3"">3</xref>, <xref ref-type=""bibr"" rid=""CR6"">6</xref>–<xref ref-type=""bibr"" rid=""CR8"">8</xref>], and have gained popularity due to their accuracy in replicating the",3_4,"Deep behavioural phenotyping of the Q175 Huntington disease mouse model: effects of age, sex, and weight",23 5 2024,,Huntington_Disease
"due to their accuracy in replicating the genetic context that occurs in HD patients [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. The zQ175 model contains a knock-in of 175 CAG repeats into the mouse Htt allele on a C57BL/6 J background [<xref ref-type=""bibr"" rid=""CR6"">6</xref>, <xref ref-type=""bibr"" rid=""CR9"">9</xref>] and was derived from a spontaneous CAG expansion in the CAG140 knock-in colony [<xref ref-type=""bibr"" rid=""CR8"">8</xref>]. To further improve the phenotype of this model, newer versions of",3_5,"Deep behavioural phenotyping of the Q175 Huntington disease mouse model: effects of age, sex, and weight",23 5 2024,,Huntington_Disease
"the phenotype of this model, newer versions of zQ175 mice have been developed in which a floxed neomycin selection cassette is excised (zQ175dn), resulting in increased expression of the mHtt transgene [<xref ref-type=""bibr"" rid=""CR10"">10</xref>, <xref ref-type=""bibr"" rid=""CR11"">11</xref>]. Studies have characterized physiological and behavioural changes in zQ175dn mice that progress with age; however, these are often subtle, vary by sex and background strain, and are more apparent in homozygous than",3_6,"Deep behavioural phenotyping of the Q175 Huntington disease mouse model: effects of age, sex, and weight",23 5 2024,,Huntington_Disease
"strain, and are more apparent in homozygous than heterozygous mice [<xref ref-type=""bibr"" rid=""CR6"">6</xref>, <xref ref-type=""bibr"" rid=""CR9"">9</xref>, <xref ref-type=""bibr"" rid=""CR10"">10</xref>]. Given that the vast majority of HD-affected individuals carry a single copy of the mutant gene [<xref ref-type=""bibr"" rid=""CR12"">12</xref>], it is crucial to use heterozygous mice when employing knock-in models to accurately reflect the genetic environment in which HD develops. In this study, we investigate the",3_7,"Deep behavioural phenotyping of the Q175 Huntington disease mouse model: effects of age, sex, and weight",23 5 2024,,Huntington_Disease
"HD develops. In this study, we investigate the behaviour of heterozygous male and female zQ175dn mice at two ages: 2–3-month-old (“premanifest”) mice and 9–12-month-old (“manifest”) mice. Recent work from our group has revealed interesting behavioural deficits in the YAC128 mouse model, such as altered paw kinematics on the accelerating rotarod, even in mice that were performing normally on the task according to traditional measures [<xref ref-type=""bibr"" rid=""CR13"">13</xref>]. In this study, we have",3_8,"Deep behavioural phenotyping of the Q175 Huntington disease mouse model: effects of age, sex, and weight",23 5 2024,,Huntington_Disease
"rid=""CR13"">13</xref>]. In this study, we have combined machine learning-based analysis approaches [<xref ref-type=""bibr"" rid=""CR14"">14</xref>, <xref ref-type=""bibr"" rid=""CR15"">15</xref>] to characterize behaviour on the rotarod, open field, water T-maze, and a home cage-based lever pulling assay in the zQ175dn mouse model. We compare and contrast behaviour at premanifest and manifest disease stages, between males and females, as well as to open field behaviour of the Q175FDN model, which differs in",3_9,"Deep behavioural phenotyping of the Q175 Huntington disease mouse model: effects of age, sex, and weight",23 5 2024,,Huntington_Disease
"behaviour of the Q175FDN model, which differs in background strain. We also present electrophysiological measures for select experiments. Our work highlights new ways that behaviour can be characterized in mice that is particularly useful in identifying subtle behavioural changes and provides a comprehensive report of how these behaviours are affected in the zQ175dn model.  Mouse models of HD have contributed significantly to elucidating mechanisms of mutant Htt toxicity and development of therapeutic",3_10,"Deep behavioural phenotyping of the Q175 Huntington disease mouse model: effects of age, sex, and weight",23 5 2024,,Huntington_Disease
"Htt toxicity and development of therapeutic approaches to mitigate pathophysiology [<xref ref-type=""bibr"" rid=""CR3"">3</xref>, <xref ref-type=""bibr"" rid=""CR4"">4</xref>]. Of these models, Q175 heterozygous knock-in mice have been widely used because of their genetic construct validity; however, a better understanding of their stage-dependent behavioural deficits is key to translating molecular-cellular mechanisms towards therapeutic interventions. We identified a variety of behavioural deficits in the Q175",3_11,"Deep behavioural phenotyping of the Q175 Huntington disease mouse model: effects of age, sex, and weight",23 5 2024,,Huntington_Disease
"a variety of behavioural deficits in the Q175 model influenced by age, sex, and mouse background strain. We also determined that differences in the animals’ weight between genotypes can have a considerable effect on behavioural results and describe a way to correct for this. Finally, we used state-of-the-art analysis methods to dissect behavioural phenotypes beyond traditional measures, revealing interesting differences in Q175 mice compared to WT littermates. In addition to exploring behaviour in Q175",3_12,"Deep behavioural phenotyping of the Q175 Huntington disease mouse model: effects of age, sex, and weight",23 5 2024,,Huntington_Disease
"In addition to exploring behaviour in Q175 knock-in mice, this work has provided key insights for research in general. Firstly, animal weight should be accounted for when analyzing or interpreting results. In addition, the protocol used can greatly impact learning and the ability to detect differences between groups. The phase of the light/dark cycle is also important, as we were not able to replicate some behavioural results found during the dark cycle in previous studies, when conducting our experiments",3_13,"Deep behavioural phenotyping of the Q175 Huntington disease mouse model: effects of age, sex, and weight",23 5 2024,,Huntington_Disease
"previous studies, when conducting our experiments in the light cycle. Our results emphasize the power of using machine learning tools to analyze behaviour, which we used to investigate behaviour in the open field, accelerating rotarod, and water T-maze in deeper ways than traditional methods allow. Researchers in this field are not only interested in how behaviour is affected in HD, but the underlying neural mechanisms as well. By combining the advanced behaviour analysis tools used in this study with in",3_14,"Deep behavioural phenotyping of the Q175 Huntington disease mouse model: effects of age, sex, and weight",23 5 2024,,Huntington_Disease
"analysis tools used in this study with in vivo imaging, we can gain a deeper understanding of HD neuropathology and provide a platform to test therapeutic interventions on both behavioural and neurological phenotypes.",3_15,"Deep behavioural phenotyping of the Q175 Huntington disease mouse model: effects of age, sex, and weight",23 5 2024,,Huntington_Disease
"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease The pathological huntingtin (<italic toggle=""yes"">HTT</italic>) trinucleotide repeat underlying Huntington disease (HD) continues to expand throughout life. Repeat length correlates both with earlier age at onset (AaO) and faster progression, making slowing its expansion an attractive therapeutic approach. Genome-wide association studies have identified candidate variants",4_0,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"studies have identified candidate variants associated with altered AaO and progression, with many found in DNA mismatch repair (MMR)-associated genes. We examine whether lowering expression of these genes affects the rate of repeat expansion in human <italic toggle=""yes"">ex vivo</italic> models using HD iPSCs and HD iPSC-derived striatal medium spiny neuron-enriched cultures. We have generated a stable CRISPR interference HD iPSC line in which we can specifically and efficiently lower gene expression from",4_1,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"and efficiently lower gene expression from a donor carrying over 125 CAG repeats. Lowering expression of each member of the MMR complexes MutS (MSH2, MSH3, and MSH6), MutL (MLH1, PMS1, PMS2, and MLH3), and LIG1 resulted in characteristic MMR deficiencies. Reduced MSH2, MSH3, and MLH1 slowed repeat expansion to the largest degree, while lowering either PMS1, PMS2, or MLH3 slowed it to a lesser degree. These effects were recapitulated in iPSC-derived striatal cultures where MutL factor expression was",4_2,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
cultures where MutL factor expression was lowered. CRISPRi-mediated lowering of key MMR factor expression to levels feasibly achievable by current therapeutic approaches was able to effectively slow the expansion of the HTT CAG tract. We highlight members of the MutL family as potential targets to slow pathogenic repeat expansion with the aim to delay onset and progression of HD and potentially other repeat expansion disorders exhibiting somatic instability.  The expanded trinucleotide repeat underlying,4_3,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"The expanded trinucleotide repeat underlying Huntington disease (HD) continues to lengthen across the carrier’s lifetime and correlates with disease onset. A core of DNA mismatch repair factors has been identified as onset modifiers, and we show that lowering expression of these factors slows repeat expansion in striatal neurons derived from HD iPSCs. Huntington disease (HD [MIM: <ext-link ext-link-type=""omim"" http://www.w3.org/1999/xlink href=""143100"" id=""intref0010"">143100</ext-link>]) is a dominantly",4_4,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"is a dominantly inherited fully penetrant neurodegenerative disease characterized by motor, cognitive, and psychiatric symptoms with progression to death typically 15–20 years from onset. The mean age of onset is ∼43 years old, and we currently have no disease-modifying therapeutics. The onset and neurodegenerative pathophysiology of HD are driven by the inexorable increase in length of the expanded CAG repeat tract in exon 1 of the <italic toggle=""yes"">huntingtin</italic> gene (<italic",4_5,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"toggle=""yes"">huntingtin</italic> gene (<italic toggle=""yes"">HTT</italic> [MIM: <ext-link ext-link-type=""omim"" http://www.w3.org/1999/xlink href=""613004"" id=""intref0015"">613004</ext-link>]) throughout the lifetime of the individuals carrying the pathogenic allele.<xref rid=""bib1"" ref-type=""bibr""><sup>1</sup></xref><sup>,</sup><xref rid=""bib2"" ref-type=""bibr""><sup>2</sup></xref><sup>,</sup><xref rid=""bib3"" ref-type=""bibr""><sup>3</sup></xref><sup>,</sup><xref rid=""bib4""",4_6,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"rid=""bib4"" ref-type=""bibr""><sup>4</sup></xref><sup>,</sup><xref rid=""bib5"" ref-type=""bibr""><sup>5</sup></xref> Here, we examine candidate HD modifier genes identified through genetic studies to validate targets to pursue in slowing repeat expansion rates, with the hope to delay disease onset and slow progression. Expansion of the CAG repeat beyond a pathological threshold leads to progressive neurodegeneration.<xref rid=""bib6"" ref-type=""bibr""><sup>6</sup></xref> Striatal medium spiny neurons (MSNs) show",4_7,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"Striatal medium spiny neurons (MSNs) show particular vulnerability, and degeneration is detectable well before onset.<xref rid=""bib7"" ref-type=""bibr""><sup>7</sup></xref><sup>,</sup><xref rid=""bib8"" ref-type=""bibr""><sup>8</sup></xref><sup>,</sup><xref rid=""bib9"" ref-type=""bibr""><sup>9</sup></xref><sup>,</sup><xref rid=""bib10"" ref-type=""bibr""><sup>10</sup></xref><sup>,</sup><xref rid=""bib11"" ref-type=""bibr""><sup>11</sup></xref><sup>,</sup><xref rid=""bib12"" ref-type=""bibr""><sup>12</sup></xref> Striatal MSNs",4_8,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"Striatal MSNs and layer V cortical pyramidal cells more frequently carry high repeat length burdens than other neuron sub-types in both mouse and human,<xref rid=""bib8"" ref-type=""bibr""><sup>8</sup></xref><sup>,</sup><xref rid=""bib10"" ref-type=""bibr""><sup>10</sup></xref><sup>,</sup><xref rid=""bib13"" ref-type=""bibr""><sup>13</sup></xref><sup>,</sup><xref rid=""bib14"" ref-type=""bibr""><sup>14</sup></xref> suggesting that increased repeat expansion is a significant driver of vulnerability in these neurons.",4_9,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"driver of vulnerability in these neurons. Although CAG repeat length correlates with its expansion rate, additional cell-type-dependent modifiers that drive somatic CAG repeat mosaicism within an individual are not understood.<xref rid=""bib14"" ref-type=""bibr""><sup>14</sup></xref><sup>,</sup><xref rid=""bib15"" ref-type=""bibr""><sup>15</sup></xref><sup>,</sup><xref rid=""bib16"" ref-type=""bibr""><sup>16</sup></xref> Increasing length of the <italic toggle=""yes"">HTT</italic> CAG repeat robustly correlates with",4_10,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"CAG repeat robustly correlates with earlier age at onset (AaO) and disease progression; however, substantial variation exists between HD carriers with similar repeat lengths.<xref rid=""bib1"" ref-type=""bibr""><sup>1</sup></xref><sup>,</sup><xref rid=""bib2"" ref-type=""bibr""><sup>2</sup></xref><sup>,</sup><xref rid=""bib17"" ref-type=""bibr""><sup>17</sup></xref>. Genome-wide association studies (GWASs) have identified variants associated with altered AaO and progression in HD cohorts controlled for repeat",4_11,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"progression in HD cohorts controlled for repeat length.<xref rid=""bib1"" ref-type=""bibr""><sup>1</sup></xref><sup>,</sup><xref rid=""bib2"" ref-type=""bibr""><sup>2</sup></xref><sup>,</sup><xref rid=""bib18"" ref-type=""bibr""><sup>18</sup></xref><sup>,</sup><xref rid=""bib19"" ref-type=""bibr""><sup>19</sup></xref><sup>,</sup><xref rid=""bib20"" ref-type=""bibr""><sup>20</sup></xref> Many variants are located in DNA damage response (DDR) genes. Variants in the Fanconi-anaemia pathway-associated protein FAN1 (MIM: <ext-link",4_12,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"pathway-associated protein FAN1 (MIM: <ext-link ext-link-type=""omim"" http://www.w3.org/1999/xlink href=""613534"" id=""intref0020"">613534</ext-link>) strongly associated with altered AaO, and FAN1 has been convincingly shown to significantly alter repeat expansion in multiple models.<xref rid=""bib21"" ref-type=""bibr""><sup>21</sup></xref><sup>,</sup><xref rid=""bib22"" ref-type=""bibr""><sup>22</sup></xref><sup>,</sup><xref rid=""bib23"" ref-type=""bibr""><sup>23</sup></xref> Disease-modifying variants in multiple",4_13,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"Disease-modifying variants in multiple members of the mismatch repair (MMR) pathway were also identified, including MSH3 (MIM: <ext-link ext-link-type=""omim"" http://www.w3.org/1999/xlink href=""604395"" id=""intref0025"">604395</ext-link>), MLH1 (MIM: <ext-link ext-link-type=""omim"" http://www.w3.org/1999/xlink href=""120436"" id=""intref0030"">120436</ext-link>), PMS1 (MIM: <ext-link ext-link-type=""omim"" http://www.w3.org/1999/xlink href=""600258"" id=""intref0035"">600258</ext-link>), PMS2 (MIM: <ext-link",4_14,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"PMS2 (MIM: <ext-link ext-link-type=""omim"" http://www.w3.org/1999/xlink href=""600259"" id=""intref0040"">600259</ext-link>), and LIG1 (MIM: <ext-link ext-link-type=""omim"" http://www.w3.org/1999/xlink href=""126391"" id=""intref0045"">126391</ext-link>). MMR has long been implicated in instability at the <italic toggle=""yes"">HTT</italic> CAG repeat.<xref rid=""bib24"" ref-type=""bibr""><sup>24</sup></xref> Effective MMR in mammalian cells relies on the MutS heterodimer complexes—either MSH2 (MIM: <ext-link",4_15,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"heterodimer complexes—either MSH2 (MIM: <ext-link ext-link-type=""omim"" http://www.w3.org/1999/xlink href=""609309"" id=""intref0050"">609309</ext-link>) and MSH6 (MIM: <ext-link ext-link-type=""omim"" http://www.w3.org/1999/xlink href=""600678"" id=""intref0055"">600678</ext-link>) (MutSα) or MSH2 and MSH3 (MutSβ). While MutSα primarily engages 1–2 base mismatches, MutSβ recognizes larger extra-helical extrusions, though with some overlap.<xref rid=""bib25"" ref-type=""bibr""><sup>25</sup></xref><sup>,</sup><xref",4_16,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"rid=""bib26"" ref-type=""bibr""><sup>26</sup></xref>",4_17,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"<italic toggle=""yes"">In vitro</italic> studies propose that MutSβ associates with extra-helical DNA structures similar to those that occur at highly repetitive sequences like the <italic toggle=""yes"">HTT</italic> CAG repeat.<xref rid=""bib27"" ref-type=""bibr""><sup>27</sup></xref> Engagement of a lesion by either MutS complex recruits MutL protein heterodimers to form ternary complexes. MLH1 serves as the common component in each MutL heterodimer, partnering with either PMS2 (MutLα), PMS1 (MutLβ), or MLH3",4_18,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"with either PMS2 (MutLα), PMS1 (MutLβ), or MLH3 (MIM: <ext-link ext-link-type=""omim"" http://www.w3.org/1999/xlink href=""604395"" id=""intref0060"">604395</ext-link>; MutLγ).<xref rid=""bib28"" ref-type=""bibr""><sup>28</sup></xref> Upon activation by MutS and PCNA (MIM: <ext-link ext-link-type=""omim"" http://www.w3.org/1999/xlink href=""176740"" id=""intref0065"">176740</ext-link>), MutLα incises DNA flanking the mismatch,<xref rid=""bib29"" ref-type=""bibr""><sup>29</sup></xref> while MutLγ nicks in the opposing",4_19,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"while MutLγ nicks in the opposing strand.<xref rid=""bib30"" ref-type=""bibr""><sup>30</sup></xref> Unlike PMS2 and MLH3, PMS1 lacks a nuclease domain, so MutLβ function in MMR is unknown. At conventional MMR substrates, exonuclease EXO1 resects the lesion-containing strand, which then undergoes resynthesis and ligation facilitated by DNA polymerase δ and LIG1.<xref rid=""bib28"" ref-type=""bibr""><sup>28</sup></xref> Substrate, kinetics, ternary complex formation, and the co-factors present at unstable repeats",4_20,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"and the co-factors present at unstable repeats are not well understood in comparison to non-repeat MMR lesions, yet additional repeats are inevitably incorporated. Loss of individual MMR proteins in mouse models significantly affects repeat expansion: loss of MSH3 arrests repeat expansion in HD and in myotonic dystrophy (MIM: <ext-link ext-link-type=""omim"" http://www.w3.org/1999/xlink href=""160900"" id=""intref0070"">160900</ext-link>) mouse and cell models,<xref rid=""bib22""",4_21,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"mouse and cell models,<xref rid=""bib22"" ref-type=""bibr""><sup>22</sup></xref><sup>,</sup><xref rid=""bib24"" ref-type=""bibr""><sup>24</sup></xref><sup>,</sup><xref rid=""bib31"" ref-type=""bibr""><sup>31</sup></xref><sup>,</sup><xref rid=""bib32"" ref-type=""bibr""><sup>32</sup></xref><sup>,</sup><xref rid=""bib33"" ref-type=""bibr""><sup>33</sup></xref><sup>,</sup><xref rid=""bib34"" ref-type=""bibr""><sup>34</sup></xref><sup>,</sup><xref rid=""bib35"" ref-type=""bibr""><sup>35</sup></xref> while MSH6 loss has minor variable",4_22,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"while MSH6 loss has minor variable effects.<xref rid=""bib36"" ref-type=""bibr""><sup>36</sup></xref><sup>,</sup><xref rid=""bib37"" ref-type=""bibr""><sup>37</sup></xref> Likewise, loss of MLH1, PMS1, and MLH3 slows repeat expansion in HD and Friedrich’s ataxia (FRDA [MIM: <ext-link ext-link-type=""omim"" http://www.w3.org/1999/xlink href=""229300"" id=""intref0075"">229300</ext-link>]) models,<xref rid=""bib38"" ref-type=""bibr""><sup>38</sup></xref><sup>,</sup><xref rid=""bib39"" ref-type=""bibr""><sup>39</sup></xref> while",4_23,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"ref-type=""bibr""><sup>39</sup></xref> while PMS2 both promotes and suppresses expansion in different models.<xref rid=""bib38"" ref-type=""bibr""><sup>38</sup></xref><sup>,</sup><xref rid=""bib40"" ref-type=""bibr""><sup>40</sup></xref><sup>,</sup><xref rid=""bib41"" ref-type=""bibr""><sup>41</sup></xref><sup>,</sup><xref rid=""bib42"" ref-type=""bibr""><sup>42</sup></xref> The process of somatic repeat expansion in the brain appears to be a major factor in driving disease progression, leading to production of toxic HTT",4_24,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"progression, leading to production of toxic HTT protein species. Rather than a continuum of repeat length-dependent toxicity, it has been suggested that there is a critical threshold beyond which severe dysfunction occurs in vulnerable cells.<xref rid=""bib43"" ref-type=""bibr""><sup>43</sup></xref> Slowing the rate of expansion is clearly an attractive target for therapeutic intervention in HD and other repeat expansion disorders that exhibit somatic instability, but first it is necessary to confirm which",4_25,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"but first it is necessary to confirm which disease-modifying candidates actually play a role in the expansion process. The occurrence of gene function-modifying variants within the population, as identified by GWASs, suggests their effects are tolerated to some degree. Therefore, targeted expression modulation of these genes could also likely be tolerated in individuals. For example, functionally deleterious polymorphisms in <italic toggle=""yes"">MSH3</italic> slow repeat expansion and HD progression,<xref",4_26,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"slow repeat expansion and HD progression,<xref rid=""bib44"" ref-type=""bibr""><sup>44</sup></xref> and lowering MSH3 expression is currently being pursued therapeutically.<xref rid=""bib45"" ref-type=""bibr""><sup>45</sup></xref> Here, we have asked whether lowering expression of candidate MMR genes to levels achievable by current therapeutics can affect the rate of repeat expansion in a human <italic toggle=""yes"">ex vivo</italic> model of HD. We investigated HD modifier MMR genes and their cognate heterodimer",4_27,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"modifier MMR genes and their cognate heterodimer partners by targeting MutS (MSH2, MSH3, and MSH6), MutL (MLH1, PMS1, PMS2, and MLH3), and LIG1 expression using a CRISPR interference system in HD induced pluripotent stem cells (iPSCs). This lowers expression by targeting a catalytically inactive Cas9 fused to a transcriptional repressor to the transcriptional start site of each gene. The effects of lowering each target on repeat expansion were then assayed both in dividing HD iPSCs and HD iPSC-derived",4_28,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"both in dividing HD iPSCs and HD iPSC-derived post-mitotic striatal neurons.   Genetic studies to identify disease modifiers in human populations also offer valuable insight into the therapeutically exploitable tolerability of reduced gene function. Using disease-relevant cell types, we have shown that MMR-associated modifiers of HD onset and progression play a role in repeat expansion dynamics at the expanded <italic toggle=""yes"">HTT</italic> CAG repeat, as do MMR-associated factors not highlighted in",4_29,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"as do MMR-associated factors not highlighted in GWASs. We also show that lowering rather than complete ablation of gene expression is sufficient to attenuate repeat expansion in these models. MutSβ has been shown to be an almost essential driver of somatic expansion in multiple models across multiple repeat expansion-associated disorders including HD, and MSH3 locus modifiers are associated with delayed onset and progression.<xref rid=""bib20"" ref-type=""bibr""><sup>20</sup></xref><sup>,</sup><xref",4_30,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"rid=""bib44"" ref-type=""bibr""><sup>44</sup></xref> We confirm this also occurs in our human <italic toggle=""yes"">ex vivo</italic> models where lowering either MSH2 or MSH3 has a dramatic effect on repeat expansion in our HD iPSCs. In contrast, MSH6 (and so MutSα) has not been shown to affect somatic expansion in HD mouse models, though it has been implicated in preventing intergenerational contractions in CAG repeat length.<xref rid=""bib78"" ref-type=""bibr""><sup>78</sup></xref> In a mouse models of myotonic",4_31,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"In a mouse models of myotonic dystrophy type 1 (DM1), loss of MSH6 led to increased expansion in non-neuronal tissue.<xref rid=""bib36"" ref-type=""bibr""><sup>36</sup></xref> Here, we found no significant change in repeat expansion upon lowering MSH6. Although we were able to detect a significant MMR defect, we cannot discount the possibility that MSH6 levels simply weren’t lowered sufficiently for a change in repeat expansion rate to become detectable. The same may be the case for LIG1, which also showed no",4_32,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"may be the case for LIG1, which also showed no significant effect upon lowering, and functional redundancy may occur for LIG1 through other ligases.<xref rid=""bib79"" ref-type=""bibr""><sup>79</sup></xref><sup>,</sup><xref rid=""bib80"" ref-type=""bibr""><sup>80</sup></xref> Data from <italic toggle=""yes"">Lig1</italic> mouse models suggest this redundancy is more effective where protein levels are reduced in comparison to deleterious LIG1 variants as <italic toggle=""yes"">Lig1</italic> null mice fare better than",4_33,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"null mice fare better than <italic toggle=""yes"">Lig1</italic> mutant mice.<xref rid=""bib81"" ref-type=""bibr""><sup>81</sup></xref> This is consistent with an onset-delaying modifier haplotype in LIG1 resulting in a deleterious missense mutation while another is associated with increased expression.<xref rid=""bib82"" ref-type=""bibr""><sup>82</sup></xref> The missense MLH1 mutation I219V identified by GWASs is classed as benign, and no evidence for changes in transcript levels was found,<xref rid=""bib2""",4_34,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"in transcript levels was found,<xref rid=""bib2"" ref-type=""bibr""><sup>2</sup></xref> nor does it appear to affect protein stability.<xref rid=""bib75"" ref-type=""bibr""><sup>75</sup></xref> Despite this, the effect we observe upon lowering MLH1 expression is concordant with the reduced repeat expansion reported in multiple Mlh1 null mouse models of HD<xref rid=""bib23"" ref-type=""bibr""><sup>23</sup></xref><sup>,</sup><xref rid=""bib39"" ref-type=""bibr""><sup>39</sup></xref> and our previous work in a U2OS cell",4_35,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"and our previous work in a U2OS cell system.<xref rid=""bib22"" ref-type=""bibr""><sup>22</sup></xref> The same effect has also been seen on expansion of the GAA repeat in FRDA models.<xref rid=""bib42"" ref-type=""bibr""><sup>42</sup></xref><sup>,</sup><xref rid=""bib83"" ref-type=""bibr""><sup>83</sup></xref> One could ascribe this effect entirely to depletion of the total MutL pool in the absence of MLH1; however, we found that independently lowering each MutL co-factor, PMS1, PMS2, and MLH3, also slowed repeat",4_36,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"PMS1, PMS2, and MLH3, also slowed repeat expansion to a lesser degree despite their reported functional differences. Individually, each of the MutL complexes has been shown to be required for expansion of the Fmr1 CGG-tract in a mouse embryonic stem cell (mESC) model of fragile X-related disorders (FXDs [MIM: <ext-link ext-link-type=""omim"" http://www.w3.org/1999/xlink href=""309550"" id=""intref0090"">309550</ext-link>])<xref rid=""bib38"" ref-type=""bibr""><sup>38</sup></xref>; however, the consistency of effect",4_37,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"however, the consistency of effect between different cell and repeat types is not well characterized. A role for PMS1 in repeat expansion has not been previously examined either at the HD CAG repeat tract or in human models. Onset hastening and delaying modifier haplotypes were identified, though their effect on PMS1 function are unclear.<xref rid=""bib2"" ref-type=""bibr""><sup>2</sup></xref><sup>,</sup><xref rid=""bib82"" ref-type=""bibr""><sup>82</sup></xref> Variants that are predicted to be deleterious to",4_38,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"Variants that are predicted to be deleterious to PMS1 function have been associated with a later AaO and reduced disease severity in HD cohorts through exome sequencing.<xref rid=""bib84"" ref-type=""bibr""><sup>84</sup></xref> Here, we show lowering PMS1 levels slows CAG repeat expansion in human HD iPSC-derived striatal neurons. In keeping with each MutL complex being required for repeat expansion, we found that lowering MLH3 expression was also sufficient to slow expansion despite MLH3 abundance (and so",4_39,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"to slow expansion despite MLH3 abundance (and so MutLγ) being substantially lower than both MutLα and MutLβ here and in other somatic cell types.<xref rid=""bib85"" ref-type=""bibr""><sup>85</sup></xref> In FRDA and HD carrier fibroblasts, an HD mouse model and an FRDA model cell line, endonuclease-dead MLH3 variants result in the abrogation of the relevant repeat expansion to the same degree as a complete knockout.<xref rid=""bib42"" ref-type=""bibr""><sup>42</sup></xref><sup>,</sup><xref rid=""bib86""",4_40,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"rid=""bib86"" ref-type=""bibr""><sup>86</sup></xref><sup>,</sup><xref rid=""bib87"" ref-type=""bibr""><sup>87</sup></xref> Despite its clear role in repeat expansion, no modifier haplotypes are reported to associate with MLH3 in the Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium GWASs.<xref rid=""bib2"" ref-type=""bibr""><sup>2</sup></xref> MLH3 variants are, however, associated with somatic instability in blood in HD populations.<xref rid=""bib1"" ref-type=""bibr""><sup>1</sup></xref> The lack of",4_41,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"ref-type=""bibr""><sup>1</sup></xref> The lack of significance in the GWASs could be due to a low tolerance for reduced function MLH3 variants in germ cells during meiosis.<xref rid=""bib88"" ref-type=""bibr""><sup>88</sup></xref><sup>,</sup><xref rid=""bib89"" ref-type=""bibr""><sup>89</sup></xref> We also show here that lowering PMS2 slows expansion of the <italic toggle=""yes"">HTT</italic> CAG repeat tract in both dividing iPSCs and mixed striatal neuron cultures. Again, modifier haplotypes have been associated",4_42,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"Again, modifier haplotypes have been associated both with early or delayed onset,<xref rid=""bib2"" ref-type=""bibr""><sup>2</sup></xref> and previous characterizations of PMS2 have reported roles in both suppression and promotion of expansion. These observations have been made primarily for the mouse ortholog <italic toggle=""yes"">Pms2</italic> in the context of non-HD trinucleotide repeat tracts. Loss of <italic toggle=""yes"">Pms2</italic> slowed expansion of the CTG repeat in the brain of a DM1 mouse model",4_43,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"the CTG repeat in the brain of a DM1 mouse model and was accompanied by rare large contractions.<xref rid=""bib41"" ref-type=""bibr""><sup>41</sup></xref> Here, we found that lowering PMS2 slowed expansion by around 21% in line with previous reports, which showed a 50% reduction in Pms2 null mice.<xref rid=""bib41"" ref-type=""bibr""><sup>41</sup></xref> A more dramatic effect was seen on the <italic toggle=""yes"">Fmr1</italic> CGG repeat where loss of Pms2 completely halted expansion in FXD mESCs.<xref rid=""bib38""",4_44,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"halted expansion in FXD mESCs.<xref rid=""bib38"" ref-type=""bibr""><sup>38</sup></xref> Conversely, no significant change was seen in the expansion rate of a construct carrying the FRDA GAA repeat in HEK cells where PMS2 levels were lowered by shRNA.<xref rid=""bib42"" ref-type=""bibr""><sup>42</sup></xref> Bourn et al.<xref rid=""bib40"" ref-type=""bibr""><sup>40</sup></xref> found that PMS2 supresses expansion in the brain of an FRDA mouse model—loss of PMS2 resulted in increased frequency of large expansions. This",4_45,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"in increased frequency of large expansions. This apparent plasticity of PMS2’s role in somatic instability could be due to cell type, repeat structure, or MutL abundance. One potential explanation is the competition model<xref rid=""bib90"" ref-type=""bibr""><sup>90</sup></xref> where it’s suggested that changes in repeat substrate length and MutLα/β/γ stoichiometry result in favoring either expansion, contraction, or maintenance. Within this model, the loss of PMS2 and so MutLα supresses expansion at",4_46,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"loss of PMS2 and so MutLα supresses expansion at increased repeat lengths, and the reduced levels here in our system may be sufficient to reach this theoretical threshold. The implications of each MutL complex influencing repeat expansion rates are interesting mechanistically. PMS2 and MLH3, complexed with MLH1 as part of MutLα and MutLγ, are both independently capable of mediating repair in cell extracts otherwise lacking endogenous MutL.<xref rid=""bib30""",4_47,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"lacking endogenous MutL.<xref rid=""bib30"" ref-type=""bibr""><sup>30</sup></xref><sup>,</sup><xref rid=""bib91"" ref-type=""bibr""><sup>91</sup></xref> While this appears to suggest redundancy between them, PMS1 is unable to mediate repair in MutL-deficient extracts.<xref rid=""bib92"" ref-type=""bibr""><sup>92</sup></xref> Loss of either PMS2 or MLH3 in mouse leads to high tumor burdens despite MLH3 being substantially less abundant than either PMS1 or PMS2.<xref rid=""bib85""",4_48,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"than either PMS1 or PMS2.<xref rid=""bib85"" ref-type=""bibr""><sup>85</sup></xref><sup>,</sup><xref rid=""bib93"" ref-type=""bibr""><sup>93</sup></xref> Altering the relative levels of the different MutL complexes could affect the stoichiometry of MutS:MutL and MutLα:β:γ binding to DNA lesions.<xref rid=""bib94"" ref-type=""bibr""><sup>94</sup></xref><sup>,</sup><xref rid=""bib95"" ref-type=""bibr""><sup>95</sup></xref> The role each of the different MMR complexes play at repeat structures is not well understood. Recent",4_49,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"repeat structures is not well understood. Recent work characterized the effects of each on genome instability in a large panel of isogenic knockout hPSCs using whole-genome sequencing.<xref rid=""bib96"" ref-type=""bibr""><sup>96</sup></xref> In this system, loss of MSH2, MSH6, MLH1, and PMS1, to a lesser degree, results in very similar insertion/deletion (indel) signatures with deletions frequently found at long repetitive sequences. In contrast, PMS2 favors both insertions and deletions at the same class of",4_50,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"insertions and deletions at the same class of sequence. How this data correlates with effect at locus-specific expansions was not examined, but these repair signatures highlight the distinct effect of losing PMS2 in comparison to the other MMR factors. Interpreting the loss of any individual MutS or MutL target is mechanistically difficult due to differential secondary effects on the levels of their heterodimer partners. Where MSH2 levels are reduced by CRISPRi, we observed a loss of a larger proportion of",4_51,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"we observed a loss of a larger proportion of MSH6 than MSH3, as previously described in yeast and human cells.<xref rid=""bib76"" ref-type=""bibr""><sup>76</sup></xref><sup>,</sup><xref rid=""bib97"" ref-type=""bibr""><sup>97</sup></xref> While MSH3 has been reported to function outside of MMR in other DDR pathways, it is always as part of MutSβ.<xref rid=""bib98"" ref-type=""bibr""><sup>98</sup></xref><sup>,</sup><xref rid=""bib99"" ref-type=""bibr""><sup>99</sup></xref> This may suggest MSH3 has a higher affinity than",4_52,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"This may suggest MSH3 has a higher affinity than MSH6 for MSH2, resulting in a bias toward MutSβ formation where MSH2 is lowered. Regardless, the net reduction in MutSβ here is still sufficient to attenuate expansion rates, as seen in heterozygous <italic toggle=""yes"">Msh3</italic> knockout or <italic toggle=""yes"">Msh3</italic> small interfering RNA (siRNA)-treated mice.<xref rid=""bib45"" ref-type=""bibr""><sup>45</sup></xref><sup>,</sup><xref rid=""bib78"" ref-type=""bibr""><sup>78</sup></xref> The reciprocal",4_53,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"The reciprocal effect was seen upon lowering either MSH3 or MSH6; however, MSH2 levels were more substantially reduced where MSH6 levels were targeted, fitting with the higher abundance of MutSα than MutSβ.<xref rid=""bib100"" ref-type=""bibr""><sup>100</sup></xref> Similarly, where MLH1 levels are lowered, it is intuitive to assume proportional lowering of the function of MLH1-containing MutL complexes. This is supported by the MMR deficiency observed in response to MNNG. However, it is complicated by MLH3",4_54,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"to MNNG. However, it is complicated by MLH3 stability being independent of MLH1 abundance (here, and in Cannavo et al.<xref rid=""bib85"" ref-type=""bibr""><sup>85</sup></xref>), particularly in neurons as MutLγ (MLH1:MLH3) does not absolutely require PCNA for loading onto DNA for activity in cell-free systems.<xref rid=""bib30"" ref-type=""bibr""><sup>30</sup></xref> This draws parallels to the stability of MSH3 upon lowering MSH2. However, unlike MSH3, MLH3 (and PMS2) has been reported to function independently",4_55,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"PMS2) has been reported to function independently of the MLH1 complexes.<xref rid=""bib101"" ref-type=""bibr""><sup>101</sup></xref> These effects could be dissected by lowering multiple targets at once. As lowering each non-MLH1 MutL component slowed expansion to some degree, it also raises the question as to whether these effects are synergistic and whether we would see additive expansion rate slowing by targeting multiple components. Single-cell transcriptomic and repeat sizing in postmortem striatal tissue",4_56,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"and repeat sizing in postmortem striatal tissue from HD and SCA3 (MIM: <ext-link ext-link-type=""omim"" http://www.w3.org/1999/xlink href=""109150"" id=""intref0095"">109150</ext-link>) donors have clearly shown MSNs are exquisitely vulnerable to CAG repeat expansion in both the mutant <italic toggle=""yes"">HTT</italic> and <italic toggle=""yes"">ATXN3</italic> (MIM: <ext-link ext-link-type=""omim"" http://www.w3.org/1999/xlink href=""607047"" id=""intref0100"">607047</ext-link>) allele.<xref rid=""bib8""",4_57,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"allele.<xref rid=""bib8"" ref-type=""bibr""><sup>8</sup></xref> MSN-specific increases in MSH2 and MSH3 protein and transcript levels were also reported. Here, we found expression of MMR factors to be at lower levels in differentiated striatal neurons in comparison to levels in undifferentiated iPSCs and non-neuronal cells present within the differentiated cultures. The same effect has been described in hESC models of HD and DM1 upon differentiation to osteoprogenitor-like cells.<xref rid=""bib102""",4_58,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"to osteoprogenitor-like cells.<xref rid=""bib102"" ref-type=""bibr""><sup>102</sup></xref> Reduced MMR gene expression was accompanied by reduced repeat instability in the differentiated cells compared to their parent hESC. One corollary of hPSC-derived models is the juvenile nature of neurons generated. Transcriptomics have shown iPSC-derived neurons to be comparable to mid-gestational identities <italic toggle=""yes"">in vivo.</italic><xref rid=""bib103"" ref-type=""bibr""><sup>103</sup></xref><sup>,</sup><xref",4_59,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"rid=""bib104"" ref-type=""bibr""><sup>104</sup></xref> The high metabolic rate of neurons and associated increase of genotoxic byproducts leaves neurons particularly vulnerable to DNA damage.<xref rid=""bib105"" ref-type=""bibr""><sup>105</sup></xref> DDR gene expression is increased in response to damage,<xref rid=""bib106"" ref-type=""bibr""><sup>106</sup></xref><sup>,</sup><xref rid=""bib107"" ref-type=""bibr""><sup>107</sup></xref> and this increases alongside the accumulation of DNA damage in aging brains.<xref",4_60,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"accumulation of DNA damage in aging brains.<xref rid=""bib108"" ref-type=""bibr""><sup>108</sup></xref><sup>,</sup><xref rid=""bib109"" ref-type=""bibr""><sup>109</sup></xref> Oxidative stress has been linked to repeat expansion in R6/1 mESCs with impaired double-stranded break (DSB) repair.<xref rid=""bib110"" ref-type=""bibr""><sup>110</sup></xref> Perhaps transient increases in MMR factor expression in response to DNA damage act to briefly licence expansion, a window that widens with aging. Similarly, if PCNA is",4_61,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"that widens with aging. Similarly, if PCNA is present in MSNs in our cultures, it is at very low levels; however, increased PCNA expression in neurons has been reported in response to DNA damage, age, and neurodegeneration.<xref rid=""bib111"" ref-type=""bibr""><sup>111</sup></xref> We do not yet know what minimal levels of any of these factors are required to permit repeat expansion in post-mitotic neurons. As such, the low levels of PCNA or MMR proteins we observe in striatal neurons by immunofluorescence do",4_62,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"in striatal neurons by immunofluorescence do not preclude their involvement in the repeat expansion process. However, the contrast between the lower-level expression in the neuronal majority and higher expression in the non-neuronal minority confounds dissection of this process, warranting further careful analysis using single-cell or highly enriching methods that are currently out of the scope of this manuscript. Regardless of the mechanism, MSH3, PMS1, PMS2, and LIG1 are all tolerant of LoF over a",4_63,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"PMS2, and LIG1 are all tolerant of LoF over a predicted 2-fold range, and their variants are not readily removed from the population by selective pressures.<xref rid=""bib112"" ref-type=""bibr""><sup>112</sup></xref><sup>,</sup><xref rid=""bib113"" ref-type=""bibr""><sup>113</sup></xref> MSH2 and MLH1 are unlikely to be good therapeutic targets in the CNS as their loss is associated with significantly increased risk of CNS cancers, as is the loss of PMS2 to a lesser degree.<xref rid=""bib114""",4_64,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"of PMS2 to a lesser degree.<xref rid=""bib114"" ref-type=""bibr""><sup>114</sup></xref><sup>,</sup><xref rid=""bib115"" ref-type=""bibr""><sup>115</sup></xref> In addition to this, targeting the apparently flexible influence of PMS2 on repeat expansion could prove to be a double-edged sword without further investigation. We further highlight PMS1 as a potential therapeutic target for slowing repeat expansion. In this report, we have shown that lowering expression of MMR factors identified as HD-onset modifiers to",4_65,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"MMR factors identified as HD-onset modifiers to levels regularly achieved by current therapeutic modalities was sufficient to slow the pathogenic expansion of the <italic toggle=""yes"">HTT</italic> CAG repeat tract. This further lends support to the search for an intervention that could potentially delay onset and progression in HD and other repeat expansion disorders that demonstrate somatic instability. This study did not generate any datasets. Code for repeat sizing by fragment analysis is available from",4_66,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
sizing by fragment analysis is available from the corresponding author on request.,4_67,"Therapeutic validation of MMR-associated genetic modifiers in a human <italic toggle=""yes"">ex vivo</italic> model of Huntington disease",14 5 2024,,Huntington_Disease
"Atypical Presentations of Huntington Disease‐like 2 in South African Individuals This case series was conducted at a large state hospital in Cape Town between January 2006 and September 2021. Eight adults with genetically confirmed HDL2 were included; retrospective data were collected for half of the study participants, as they were deceased. The Unified Huntington's Disease Rating Scale (UHDRS) and the Montreal Cognitive Assessment (MoCA) tool were used for clinical assessment. In two deceased patients,",5_0,Atypical Presentations of Huntington Disease‐like 2 in South African Individuals,09 5 2024,,Huntington_Disease
"clinical assessment. In two deceased patients, Mini‐Mental State Exam (MMSE) scores were used (noting that the MMSE and MOCA lack normal controls in this population). All participants with genetically confirmed HDL2 (ie, CTG repeat lengths of 40 or more) had their DNA analyzed using polymerase chain reaction and capillary electrophoresis, and GeneMapper Software 5 (Applied Biosystems, Foster City, CA) was used for fragment analysis and sizing. Genetic counseling was provided by trained genetic counselors",5_1,Atypical Presentations of Huntington Disease‐like 2 in South African Individuals,09 5 2024,,Huntington_Disease
"was provided by trained genetic counselors to all participants. The UHDRS (Table <xref rid=""mdc314052-tbl-0001"" ref-type=""table"">1</xref>) was carried out by two movement disorder experts (J.C., R.v.C.), and where a numerical difference of ≥2 between raters was identified, video material was further reviewed by a rater with specific experience in the UHDRS (M.G.) Median repeat values between the patients reported here and those previously published from Gauteng were analyzed with a Mann–Whitney",5_2,Atypical Presentations of Huntington Disease‐like 2 in South African Individuals,09 5 2024,,Huntington_Disease
"from Gauteng were analyzed with a Mann–Whitney test<sup>2</sup>.  HDL2 is increasingly recognized as having a range of clinical presentations.<xref rid=""mdc314052-bib-0002"" ref-type=""bibr"">",5_3,Atypical Presentations of Huntington Disease‐like 2 in South African Individuals,09 5 2024,,Huntington_Disease
"<sup>2</sup>
</xref>, <xref rid=""mdc314052-bib-0003"" ref-type=""bibr"">
<sup>3</sup>
</xref>, <xref rid=""mdc314052-bib-0005"" ref-type=""bibr"">
<sup>5</sup>
</xref>, <xref rid=""mdc314052-bib-0006"" ref-type=""bibr"">
<sup>6</sup>",5_4,Atypical Presentations of Huntington Disease‐like 2 in South African Individuals,09 5 2024,,Huntington_Disease
"</xref> We report a predominantly cognitive and behavioral presentation, with less pronounced, or even absent, chorea. Albeit speculative, this may represent the effect of large repeat sizes. The notable clinical findings of this study were that affected individuals presented with cognitive and behavioral symptoms at onset, and in those with concurrent motor symptoms, the cognitive and behavioral features were more significant. Scores from the MMSE and MOCA ranged from 1 to 23, with all but a single",5_5,Atypical Presentations of Huntington Disease‐like 2 in South African Individuals,09 5 2024,,Huntington_Disease
"MOCA ranged from 1 to 23, with all but a single participant having a score <15. Patients displayed impaired executive function, with impairment in psychomotor speed.<xref rid=""mdc314052-bib-0007"" ref-type=""bibr"">",5_6,Atypical Presentations of Huntington Disease‐like 2 in South African Individuals,09 5 2024,,Huntington_Disease
"<sup>7</sup>
</xref> Early psychiatric symptoms ranged from depression to frank psychosis, and behavioral change was common. Chorea was infrequent and mild. Gait and speech abnormalities were insignificant. Eye movement abnormalities were common, confirming a recent report from South Africa.<xref rid=""mdc314052-bib-0002"" ref-type=""bibr"">
<sup>2</sup>
</xref>",5_7,Atypical Presentations of Huntington Disease‐like 2 in South African Individuals,09 5 2024,,Huntington_Disease
"<sup>2</sup>
</xref>
 Repeat length was inversely correlated with AAO (correlation coefficient of −0.8144), and this study consequently adds to existing evidence that there is a negative correlation between AAO and repeat length in HDL2.<xref rid=""mdc314052-bib-0003"" ref-type=""bibr"">
<sup>3</sup>
</xref> Moreover, we speculate that higher repeat lengths may result in atypical clinical presentations and greater severity of disease, as has been reported in HD.<xref rid=""mdc314052-bib-0008"" ref-type=""bibr"">",5_8,Atypical Presentations of Huntington Disease‐like 2 in South African Individuals,09 5 2024,,Huntington_Disease
"<sup>8</sup>
</xref> The population studied included an individual with, to our knowledge, the largest ever reported repeat length (14/63).<xref rid=""mdc314052-bib-0004"" ref-type=""bibr"">
<sup>4</sup>
</xref> In addition, the median repeat length (52) of the study population is significantly larger than the median of 46, which has previously been recorded from a group of patients from Northern Southern Africa who had typical features of HDL2.<xref rid=""mdc314052-bib-0002"" ref-type=""bibr"">
<sup>2</sup>",5_9,Atypical Presentations of Huntington Disease‐like 2 in South African Individuals,09 5 2024,,Huntington_Disease
"<sup>2</sup>
</xref> The average AAO in this study was 34 years, considerably lower than the 41 years recently reported as being the typical age at onset of motor symptoms.<xref rid=""mdc314052-bib-0004"" ref-type=""bibr"">
<sup>4</sup>",5_10,Atypical Presentations of Huntington Disease‐like 2 in South African Individuals,09 5 2024,,Huntington_Disease
"<sup>4</sup>
</xref> Furthermore, we report two unique cases of juvenile onset HDL2 (ages 18 and 19), noting that an AAO younger than 20 years has not been previously documented. The participants in this study had dystonia and rigidity as their predominant motor features, noting that presentations of HDL2 with parkinsonism have been reported from Brazil, the West Indies, and the United States.<xref rid=""mdc314052-bib-0009"" ref-type=""bibr"">
<sup>9</sup>",5_11,Atypical Presentations of Huntington Disease‐like 2 in South African Individuals,09 5 2024,,Huntington_Disease
"<sup>9</sup>
</xref>, <xref rid=""mdc314052-bib-0010"" ref-type=""bibr"">
<sup>10</sup>
</xref>, <xref rid=""mdc314052-bib-0011"" ref-type=""bibr"">
<sup>11</sup>
</xref> The Westphal variant of HD (juvenile HD), may present with dementia and parkinsonism,<xref rid=""mdc314052-bib-0011"" ref-type=""bibr"">
<sup>11</sup>
</xref>, <xref rid=""mdc314052-bib-0013"" ref-type=""bibr"">
<sup>13</sup>",5_12,Atypical Presentations of Huntington Disease‐like 2 in South African Individuals,09 5 2024,,Huntington_Disease
"<sup>13</sup>
</xref> and the two cases of juvenile HDL2 reported in our study presented similarly with dementia, dystonia, and rigidity, associated with large repeat expansions (14/63 and 14/59). It is established in HD that individuals with larger repeat lengths manifest symptoms at an earlier age, and those with 60 or more CAG repeats invariably manifest at age 20 or younger.<xref rid=""mdc314052-bib-0012"" ref-type=""bibr"">
<sup>12</sup>",5_13,Atypical Presentations of Huntington Disease‐like 2 in South African Individuals,09 5 2024,,Huntington_Disease
"<sup>12</sup>
</xref> The pathogenesis of HD is complex, and it is likely that CAG repeat length is the main driver of disease onset and progression. Somatic expansions because of genetic modifiers may increase the CAG repeat length, and both the rate of expansion, as well as the threshold repeat length, is implicated in disease onset and progression.<xref rid=""mdc314052-bib-0013"" ref-type=""bibr"">
<sup>13</sup>
</xref>, <xref rid=""mdc314052-bib-0014"" ref-type=""bibr"">
<sup>14</sup>",5_14,Atypical Presentations of Huntington Disease‐like 2 in South African Individuals,09 5 2024,,Huntington_Disease
"<sup>14</sup>
</xref> In addition, genetic modifiers have been identified that influence AAO in HD,<xref rid=""mdc314052-bib-0015"" ref-type=""bibr"">
<sup>15</sup>
</xref> and these may have contributed to variable clinical presentations in the South African patients studied. Haplotype studies have found multiple origins for the HD mutation in ethnically distinct subpopulations of South Africa.<xref rid=""mdc314052-bib-0016"" ref-type=""bibr"">
<sup>16</sup>",5_15,Atypical Presentations of Huntington Disease‐like 2 in South African Individuals,09 5 2024,,Huntington_Disease
"</xref> In conclusion, it is important for clinicians to be aware that individuals with HDL2 may present with severe and rapidly progressive cognitive and behavioral impairments, with a variable degree of motor deficit. (1) Research Project: A. Conception, B. Organization, C. Execution; (2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique; (3) Manuscript: A. Writing of the First Draft, B. Review and Critique. H.N.J.: 1B, 1C, 2A, 2B, 2C, 3A M.G.: 1A, 1C L.v.H.: 1A, 1B, 1C R.v.C.: 1A, 1C",5_16,Atypical Presentations of Huntington Disease‐like 2 in South African Individuals,09 5 2024,,Huntington_Disease
"3A M.G.: 1A, 1C L.v.H.: 1A, 1B, 1C R.v.C.: 1A, 1C A.K.: 1A, 1C, 3B J.C.: 1A, 1B, 1C, 3A, 3B",5_17,Atypical Presentations of Huntington Disease‐like 2 in South African Individuals,09 5 2024,,Huntington_Disease
<bold>Ethical Compliance Statement</bold>: This study was granted ethics approval from the Health Research Ethics Committee (HREC) of the University of Stellenbosch (S20/09/258). All participants provided informed consent. The authors confirm that they have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.,5_18,Atypical Presentations of Huntington Disease‐like 2 in South African Individuals,09 5 2024,,Huntington_Disease
"<bold>Funding Sources and Conflicts of Interest</bold>: No specific funding was received for this work; the authors declare that there are no conflicts of interest relevant to this work. 
<bold>Financial Disclosures for Previous 12 Months</bold>: M.G. is a consultant to CHDI Foundation, DSMB Board Chair for AskBio and SOM Therapeutics. J.C. has received grants from The Michael J. Fox Foundation.",5_19,Atypical Presentations of Huntington Disease‐like 2 in South African Individuals,09 5 2024,,Huntington_Disease
Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease  Unintended movements are often the first sign of Huntington disease. This type of unintended movement is called chorea in Huntington disease. Tardive dyskinesia causes unintended body movements. Deutetrabenazine is a medicine used to treat both types of movements. This report summarizes deutetrabenazine safety across five clinical studies. Safety was assessed via adverse events (side effects).,6_0,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"was assessed via adverse events (side effects). Adverse events were compared between deutetrabenazine and inactive treatment (placebo). Serious adverse events were also compared. Serious adverse events cause substantial impairment or disruption. In tardive dyskinesia and chorea in Huntington disease studies, most patients kept taking deutetrabenazine. Adverse events were not a common reason to stop treatment. For tardive dyskinesia, adverse event rates were similar between deutetrabenazine (≤ 60%) and",6_1,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"were similar between deutetrabenazine (≤ 60%) and placebo (54%). Serious adverse event rates were also similar for deutetrabenazine (≤ 8%) and placebo (7%). Adverse events tended to be reported earlier in treatment. Common adverse events were headache, sleepiness, nausea, anxiety, fatigue, dry mouth, and diarrhea. For chorea in Huntington disease, adverse event rates were similar for deutetrabenazine (64%) and placebo (60%). Serious adverse event rates were also similar for deutetrabenazine (2%) and",6_2,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"were also similar for deutetrabenazine (2%) and placebo (2%). Irritability, fall, depression, dry mouth, and fatigue were common adverse events. Adverse events were similar between deutetrabenazine and placebo in both conditions. Deutetrabenazine was well tolerated for patients with either tardive dyskinesia or chorea in Huntington disease.",6_3,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"<table-wrap id=""Taba""><table frame=""hsides"" rules=""groups""><tbody><tr><td align=""left"">
<bold><italic toggle=""yes"">Why carry out this study?</italic></bold>",6_4,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"</td></tr><tr><td align=""left"">Hyperkinetic movement from tardive dyskinesia (TD) and chorea associated with Huntington disease (HD) can have a severely negative impact on patient quality of life; deutetrabenazine is approved for the treatment of adults with these conditions.</td></tr><tr><td align=""left"">An integrated safety assessment from multiple pooled trials investigating deutetrabenazine in patients with TD or chorea in HD was conducted to gain additional insight into its adverse event (AE)",6_5,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"additional insight into its adverse event (AE) profile.</td></tr><tr><td align=""left"">",6_6,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"<bold><italic toggle=""yes"">What has been learned from this study?</italic></bold>",6_7,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"</td></tr><tr><td align=""left"">Deutetrabenazine was well tolerated in adults with TD or chorea associated with HD.</td></tr><tr><td align=""left"">Although AEs may be initially reported for a higher proportion of patients during deutetrabenazine dose optimization (compared with placebo), proportions tended to decrease as patients continued treatment on a stable dose up to week 15.</td></tr><tr><td align=""left"">This integrated analysis of AEs provides additional information to help guide treatment decisions",6_8,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
information to help guide treatment decisions and discussions between physicians and their patients with TD or chorea associated with HD.</td></tr></tbody></table></table-wrap>,6_9,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"Tardive dyskinesia (TD) and Huntington disease (HD) are hyperkinetic movement disorders that negatively impact quality of life and can be socially stigmatizing [<xref ref-type=""bibr"" rid=""CR1"">1</xref>–<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. TD is caused by dopamine receptor antagonists (DRAs). The estimated frequency of TD is approximately 20–30% for patients who use DRAs, but treatment and risk factors influence the development of TD [<xref ref-type=""bibr"" rid=""CR4"">4</xref>–<xref ref-type=""bibr""",6_10,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"rid=""CR4"">4</xref>–<xref ref-type=""bibr"" rid=""CR7"">7</xref>]. TD is characterized clinically by varied types of involuntary movements, such as stereotypic or choreiform movements of the tongue, lower face, jaw, and extremities, although sometimes the pharyngeal, diaphragmatic, or trunk muscles are involved [<xref ref-type=""bibr"" rid=""CR1"">1</xref>, <xref ref-type=""bibr"" rid=""CR4"">4</xref>, <xref ref-type=""bibr"" rid=""CR8"">8</xref>]. HD is a progressive disorder characterized by a triad of motor, cognitive,",6_11,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"characterized by a triad of motor, cognitive, and psychiatric symptoms that impair a person’s activities and interactions [<xref ref-type=""bibr"" rid=""CR9"">9</xref>, <xref ref-type=""bibr"" rid=""CR10"">10</xref>]. Chorea is a common motor manifestation of HD, affecting approximately 90% of patients [<xref ref-type=""bibr"" rid=""CR11"">11</xref>]. Deutetrabenazine is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor used for the treatment of TD and chorea associated with HD in adults [<xref",6_12,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"TD and chorea associated with HD in adults [<xref ref-type=""bibr"" rid=""CR12"">12</xref>]. The pivotal studies included two 12-week, double-blind, randomized, placebo-controlled trials of patients with TD (ARM-TD and AIM-TD) [<xref ref-type=""bibr"" rid=""CR13"">13</xref>, <xref ref-type=""bibr"" rid=""CR14"">14</xref>] and a 12-week, double-blind, randomized, placebo-controlled trial of patients with HD (First-HD) [<xref ref-type=""bibr"" rid=""CR15"">15</xref>]. Open-label extension (OLE) studies in TD (RIM-TD) and HD",6_13,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"extension (OLE) studies in TD (RIM-TD) and HD (ARC-HD) were also conducted to evaluate the long-term safety and efficacy of deutetrabenazine treatment [<xref ref-type=""bibr"" rid=""CR16"">16</xref>, <xref ref-type=""bibr"" rid=""CR17"">17</xref>]. As individual clinical trials enroll relatively small samples of patients, some safety signals may not be readily apparent. By pooling and analyzing data from multiple trials, an integrated safety analysis can supplement individual trials to help uncover rare adverse",6_14,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"individual trials to help uncover rare adverse events (AEs) or unexpected safety trends. This study is an integrated safety analysis of deutetrabenazine combining data across separate studies in TD (3 studies, 514 patients included) and HD (2 studies, 129 patients included) to further assess the safety of deutetrabenazine and identify any potentially emerging safety signals within the first 12–15 weeks of exposure. Safety data beyond week 15 from the OLE studies have been published previously [<xref",6_15,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"OLE studies have been published previously [<xref ref-type=""bibr"" rid=""CR16"">16</xref>, <xref ref-type=""bibr"" rid=""CR17"">17</xref>] and were not included in these integrated safety analyses. Because of differences between patients with HD and patients with TD, data from each indication were analyzed separately but presented side by side, because physicians may find it informative when considering potential risks of treatment. Ethics approval and informed consent were not required for this integrated",6_16,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"consent were not required for this integrated analysis as they were obtained for the original clinical studies previously published [<xref ref-type=""bibr"" rid=""CR13"">13</xref>–<xref ref-type=""bibr"" rid=""CR17"">17</xref>], which were in accordance with the Declaration of Helsinki.  Treatment options previously available to manage hyperkinetic movement disorders, including TD and HD, were limited, and some have undesirable side effects that may make them less appealing. It is important for clinicians to be",6_17,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"appealing. It is important for clinicians to be aware of the safety and tolerability profiles of deutetrabenazine in both TD and HD; however, non-specialists may be less aware of the safety profile of deutetrabenazine and how it compares with other agents. These integrated safety analyses used multiple studies to provide a collective perspective on safety upon first exposure to deutetrabenazine in TD and HD within the first 12–15 weeks of exposure to deutetrabenazine, when AEs are most likely to occur.",6_18,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"when AEs are most likely to occur. Analysis of complete long-term safety data has been previously published [<xref ref-type=""bibr"" rid=""CR16"">16</xref>, <xref ref-type=""bibr"" rid=""CR17"">17</xref>]. In these analyses, treatment with deutetrabenazine was shown to be generally well tolerated across studies for both indications. In the separate analyses of patients with TD or HD, the incidence rates of any AE, serious AEs, and AEs leading to discontinuation were generally comparable between deutetrabenazine",6_19,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"generally comparable between deutetrabenazine treatment arms and placebo. Patients with TD in the response-driven deutetrabenazine group had a numerically higher incidence of any AE and treatment-related AEs compared with the fixed-dose deutetrabenazine and placebo groups, but there was no meaningful increase in study drug discontinuation in the response-driven deutetrabenazine group. In patients with HD, the incidence of treatment-related AEs was numerically higher among patients receiving",6_20,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"was numerically higher among patients receiving deutetrabenazine than placebo, but there was no increase in study drug discontinuation attributable to AEs. The lack of increase in study discontinuation despite the increase in AEs with higher doses can be interpreted as the benefit seen with improved motor control in a response-driven manner outweighing the adverse experience in patients who experienced AEs. A potential concern for patients and clinicians is whether certain AEs emerge after a stable dose of",6_21,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"whether certain AEs emerge after a stable dose of deutetrabenazine is achieved. Analysis of AEs during titration and maintenance periods in both TD and HD demonstrated that deutetrabenazine was generally well tolerated, with AE rates similar to placebo during both phases. Furthermore, AE rates were generally higher during titration and decreased during maintenance. These data demonstrate that AEs occurring early after treatment initiation tend to resolve after achieving a stable dose, which may be related",6_22,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"achieving a stable dose, which may be related to dose adjustments. These data provide important context for the dosing schedule to providers and patients and reassurance that most initial AEs are transient in nature. The incidences of AEs of interest (analyzed by SMQs or selected preferred terms) were generally low across groups for both TD and HD. In particular, Parkinson-like events (per the SMQ that included preferred terms bradykinesia, cogwheel rigidity, drooling, gait disturbance, hypokinesia,",6_23,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"drooling, gait disturbance, hypokinesia, musculoskeletal stiffness, parkinsonian gait, parkinsonism, and tremor) were reported for higher proportions of patients in the higher-dose deutetrabenazine groups vs placebo or low-dose deutetrabenazine groups for patients with TD, and was higher in deutetrabenazine vs placebo for patients with HD. Additionally, UPDRS motor score improvements tapered off with higher doses of deutetrabenazine among patients with TD; UHDRS parkinsonism subscale scores were similar",6_24,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"UHDRS parkinsonism subscale scores were similar among patients with HD treated with deutetrabenazine and placebo. However, Parkinson-like events are a class-wide AE for VMAT2 inhibitors, as VMAT2 inhibition results in dopamine depletion in the nerve terminal [<xref ref-type=""bibr"" rid=""CR19"">19</xref>, <xref ref-type=""bibr"" rid=""CR20"">20</xref>]. Treatment decisions should use a patient-first, holistic approach that considers the risks and the benefits of available treatments. Data from this analysis show",6_25,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"treatments. Data from this analysis show no difference in the change in QTcF between deutetrabenazine and placebo in patients with TD, which supports that the degree of QT prolongation is not clinically meaningful for the recommended dosage range. Importantly, there were no reports of preferred-term AEs of Torsade de pointes in patients with TD despite most patients receiving concomitant DRAs. In patients with TD, the incidence of depression defined by the SMQ was numerically higher in patients receiving",6_26,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"SMQ was numerically higher in patients receiving deutetrabenazine than placebo, but there were no notable differences in HADS depression subscale scores across groups. Separately, AEs in the SMQ of suicidality/self-injury were generally low across groups. In addition, C-SSRS data indicated that suicidal ideation was generally low but comparable across groups and suicidal and self-injurious behavior was infrequent. The incidence of depression commonly associated with HD was low with treatment during the",6_27,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"with HD was low with treatment during the study time frame; there were no notable differences between groups in patients with HD. AEs were passively collected (without a prompt), while assessments such as C-SSRS and HADS actively collect data on these symptoms, and therefore may be more sensitive. This analysis of the safety of deutetrabenazine treatment and a cross-sectional study of the Enroll-HD database [<xref ref-type=""bibr"" rid=""CR21"">21</xref>] suggest AEs of depression and suicidality are not",6_28,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"suggest AEs of depression and suicidality are not common with either agent, despite the boxed warnings for both tetrabenazine [<xref ref-type=""bibr"" rid=""CR20"">20</xref>] and deutetrabenazine [<xref ref-type=""bibr"" rid=""CR12"">12</xref>] products. Deutetrabenazine treatment did not appear to substantially affect BMI or other metabolic parameters. Notably, BMI changes in both patient populations were modest compared to those seen with other medications commonly used in these populations (e.g.,",6_29,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"commonly used in these populations (e.g., antipsychotics), and these changes did not appear to affect other indicators of metabolic health, such as cholesterol, glucose, or triglycerides in patients with TD. Importantly, patients with HD often experience weight loss [<xref ref-type=""bibr"" rid=""CR22"">22</xref>], and, in this regard, weight gain may be desirable in patients with HD. Therefore, a modest amount of weight gain, as observed in this analysis, should not be perceived as an adverse safety outcome",6_30,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"not be perceived as an adverse safety outcome for these patients. Overall, the safety of deutetrabenazine treatment was demonstrated in patients with TD and HD taking a broad range of concomitant medications and with underlying health conditions. Although some antipsychotics have been developed to reduce the risk, TD continues to develop in some patients. Modification of the antipsychotic agent or dose may reduce TD symptoms; however, VMAT2 inhibitor treatment may allow for uninterrupted use of concomitant",6_31,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"may allow for uninterrupted use of concomitant DRAs for underlying psychiatric conditions. Furthermore, the benefits of treatment appear to be meaningful to patients who may experience initial AEs while optimizing deutetrabenazine dose, as patients who continued treatment on a stable dose up to week 15 tend to report fewer side effects. By integrating safety data across separate studies in patients with TD and HD, this study provides important evidence for clinicians and patients that may inform treatment",6_32,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"clinicians and patients that may inform treatment decisions and help anticipate potential safety concerns upon first exposure to deutetrabenazine and throughout the course of treatment. In particular, integrating safety data across separate studies provides data from more patients and presents a more robust summary of safety regarding treating two unique hyperkinetic movement disorders with deutetrabenazine over the first 12–15 weeks of therapy. Taken together, these data may aid conversations around",6_33,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"together, these data may aid conversations around treatment selection between clinicians and patients with these movement disorders and may improve patient outcomes. Below is the link to the electronic supplementary material.<supplementary-material content-type=""local-data"" id=""MOESM1""><media http://www.w3.org/1999/xlink href=""40120_2024_600_MOESM1_ESM.pdf""><caption><p>Supplementary file1 (PDF 426 KB)</p></caption></media></supplementary-material>",6_34,Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease,1 4 2024,,Huntington_Disease
"Postmortem neuropathology in early Huntington disease Two aspects of the neuropathology of early Huntington disease (HD) are examined. Neurons of the neostriatum are counted to determine relative loss in striosomes versus matrix at early stages, including for the first time in preclinical cases. An immunohistochemical procedure is described that tentatively distinguishes early HD from HD mimic disorders in postmortem brains. Counts of striatal projection neurons (SPNs) in striosomes defined by calbindin",7_0,Postmortem neuropathology in early Huntington disease,5 2024,,Huntington_Disease
"neurons (SPNs) in striosomes defined by calbindin immunohistochemistry versus counts in the surrounding matrix are reported for 8 Vonsattel grade 0 (including 5 premanifest), 8 grade 1, 2 grade 2 HD, and for 8 control postmortem brains. Mean counts of striosome and matrix SPNs were significantly lower in premanifest grade 0 versus controls, with striosome counts significantly lower than matrix. In 8 grade 1 and 2 grade 2 brains, no striosomes with higher SPN counts than in the surrounding matrix were",7_1,Postmortem neuropathology in early Huntington disease,5 2024,,Huntington_Disease
"SPN counts than in the surrounding matrix were observed. Comparing dorsal versus ventral neostriatum, SPNs in dorsal striosomes and matrix declined more than ventral, making clear the importance of the dorsoventral site of tissue selection for research studies. A characteristic pattern of expanded polyglutamine-immunopositive inclusions was seen in all HD cases. Inclusions were always present in some SPNs and some pontine nucleus neurons and were absent in Purkinje cells, which showed no obvious cell loss.",7_2,Postmortem neuropathology in early Huntington disease,5 2024,,Huntington_Disease
"cells, which showed no obvious cell loss. Huntington disease (HD) is a progressive disorder with clinical motor, behavioral, and cognitive manifestations (<xref rid=""nlae022-B1"" ref-type=""bibr"">1–3</xref>). HD is caused by an expanded CAG tract in the <italic toggle=""yes"">HTT</italic> gene, which is expressed as an expanded polyglutamine tract in huntingtin protein (<xref rid=""nlae022-B4"" ref-type=""bibr"">4</xref>). The pathogenetic mechanism is incompletely understood (<xref rid=""nlae022-B5""",7_3,Postmortem neuropathology in early Huntington disease,5 2024,,Huntington_Disease
"incompletely understood (<xref rid=""nlae022-B5"" ref-type=""bibr"">5</xref>). Neurons of the human neostriatum have several different morphologies and transmitters. Approximately 96% are medium spiny neurons (<xref rid=""nlae022-B6"" ref-type=""bibr"">6</xref>, <xref rid=""nlae022-B7"" ref-type=""bibr"">7</xref>), which have GABAergic inhibitory axonal terminals (<xref rid=""nlae022-B8"" ref-type=""bibr"">8</xref>). These neurons are the most sensitive to the pathophysiological process in HD. They are the output neurons",7_4,Postmortem neuropathology in early Huntington disease,5 2024,,Huntington_Disease
"process in HD. They are the output neurons of the neostriatum, termed striatal projection neurons (SPNs), with axons going to both segments of the globus pallidus (GP), to the substantia nigra (SN) compacta (SNc), and SN reticulata (SNr). The other 4% comprise several neuron types that show a lesser tendency to degenerate in HD. At postmortem examination of HD brains, loss of SPNs starts in the superior putamen and superior and medial caudate nucleus and progresses basally in putamen and basally and",7_5,Postmortem neuropathology in early Huntington disease,5 2024,,Huntington_Disease
"and progresses basally in putamen and basally and mediolaterally in the caudate, with relative preservation of basal neostriatum including nucleus accumbens neurons; there is also caudal to rostral progression (<xref rid=""nlae022-B9"" ref-type=""bibr"">9–11</xref>). Vonsattel et al devised a grading system for postmortem evaluation of brains with clinical HD, based on the progression of neostriatal SPN loss and neostriatal atrophy; the grades roughly correlate with years of clinical disease duration (<xref",7_6,Postmortem neuropathology in early Huntington disease,5 2024,,Huntington_Disease
"with years of clinical disease duration (<xref rid=""nlae022-B10"" ref-type=""bibr"">10</xref>). This grading system has been highly useful in research studies using postmortem HD brain tissue. They described 5 grades, designated 0 through 4. The Vonsattel grades were later found to correlate with measures of clinical decline (<xref rid=""nlae022-B12"" ref-type=""bibr"">12</xref>). Remarkably, despite the presence of a clear-cut clinical HD syndrome, Vonsattel et al saw little or no differences in gross or",7_7,Postmortem neuropathology in early Huntington disease,5 2024,,Huntington_Disease
"et al saw little or no differences in gross or microscopic examination between grade 0 brains and controls. Only by cell counts across a medial-lateral strip of the head of the caudate nucleus in grade 0 brains could loss of SPNs be demonstrated (<xref rid=""nlae022-B10"" ref-type=""bibr"">10</xref>, <xref rid=""nlae022-B13"" ref-type=""bibr"">13</xref>). The term “grade 0” later came to include postmortem brains of premanifest individuals known to have the HD mutation but not yet exhibiting chorea (<xref",7_8,Postmortem neuropathology in early Huntington disease,5 2024,,Huntington_Disease
"HD mutation but not yet exhibiting chorea (<xref rid=""nlae022-B14"" ref-type=""bibr"">14</xref>, <xref rid=""nlae022-B15"" ref-type=""bibr"">15</xref>). The neostriatum is divided into matrix and striosomes, the latter being discrete territories embedded serpentine-like within the matrix (<xref rid=""nlae022-B16"" ref-type=""bibr"">16</xref>). Matrix and striosomes can be distinguished in brain sections by their molecular characteristics most often by low levels of the calcium-binding protein calbindin or of the",7_9,Postmortem neuropathology in early Huntington disease,5 2024,,Huntington_Disease
"the calcium-binding protein calbindin or of the protein acetylcholinesterase in the striosomes, versus high levels in the matrix (<xref rid=""nlae022-B15"" ref-type=""bibr"">15</xref>, <xref rid=""nlae022-B17"" ref-type=""bibr"">17–19</xref>). Striosome and matrix neurons have different afferent and efferent connections (<xref rid=""nlae022-B17"" ref-type=""bibr"">17–21</xref>). This difference in connections between striosome and matrix SPNs implies a difference in function, with striosomes in general having more",7_10,Postmortem neuropathology in early Huntington disease,5 2024,,Huntington_Disease
"function, with striosomes in general having more limbic afferent associations and sending axons especially to the SNc, whereas matrix neurons, in general, have more motor and sensory connections, and send axons mainly to the GP and SNr. Another division of SPNs is into so-called indirect pathway SPNs (positive for D2 receptors and for enkephalin, targeting mainly the external pallidal segment [GPe]), and direct pathway SPNs (positive for D1 receptors, substance P, and targeting mainly the internal pallidal",7_11,Postmortem neuropathology in early Huntington disease,5 2024,,Huntington_Disease
"P, and targeting mainly the internal pallidal segment [GPi]). In addition, D1/substance P-positive SPNs target both segments of the SN (<xref rid=""nlae022-B8"" ref-type=""bibr"">8</xref>, <xref rid=""nlae022-B15"" ref-type=""bibr"">15</xref>, <xref rid=""nlae022-B21"" ref-type=""bibr"">21–23</xref>). Direct and indirect pathway SPN types occur in both striosomes and matrix. Immunolabeling of indirect pathway neurons is lost early in HD, possibly reflecting neuron loss, whereas direct pathway neurons are lost much",7_12,Postmortem neuropathology in early Huntington disease,5 2024,,Huntington_Disease
"whereas direct pathway neurons are lost much later. How the concept of early loss of indirect pathway neurons (or at least their immunolabeling) can be integrated with the early loss of striosomal SPNs in relation to early HD symptomatology is just beginning to be understood (<xref rid=""nlae022-B24"" ref-type=""bibr"">24</xref>), and is addressed in the present study. Several studies have shown greater changes in striosomes than in matrix in early Vonsattel stage postmortem HD brains. These studies report",7_13,Postmortem neuropathology in early Huntington disease,5 2024,,Huntington_Disease
"stage postmortem HD brains. These studies report loss of the following in striosomes or striosome-like patches, or diminished numbers of neurons molecularly identified by striosome markers: Calcineurin and synaptophysin (<xref rid=""nlae022-B25"" ref-type=""bibr"">25</xref>, <xref rid=""nlae022-B26"" ref-type=""bibr"">26</xref>); NADPH diaphorase and complexin II (<xref rid=""nlae022-B27"" ref-type=""bibr"">27</xref>, <xref rid=""nlae022-B28"" ref-type=""bibr"">28</xref>); SPNs (<xref rid=""nlae022-B29""",7_14,Postmortem neuropathology in early Huntington disease,5 2024,,Huntington_Disease
"SPNs (<xref rid=""nlae022-B29"" ref-type=""bibr"">29</xref>); Enkephalin and substance P mRNA (<xref rid=""nlae022-B30"" ref-type=""bibr"">30</xref>); D1, D2 receptors, adenosine A2a receptors (<xref rid=""nlae022-B23"" ref-type=""bibr"">23</xref>); GABA-A receptors (<xref rid=""nlae022-B23"" ref-type=""bibr"">23</xref>, <xref rid=""nlae022-B31"" ref-type=""bibr"">31</xref>); and Striosomal D2 and D1 receptor-bearing SPNs (<xref rid=""nlae022-B24"" ref-type=""bibr"">24</xref>). In a previous study, we showed greater loss of",7_15,Postmortem neuropathology in early Huntington disease,5 2024,,Huntington_Disease
"In a previous study, we showed greater loss of striosome than matrix neurons in early HD, including in 2 brains at grade 0, and 3 brains at grade 1 (<xref rid=""nlae022-B29"" ref-type=""bibr"">29</xref>). In these brains, a significant increase in glial fibrillary acidic protein (GFAP) staining in distal astrocytic fine processes was seen in the striosomes but not in the matrix; the latter contained scattered fibrillary astrocytes (<xref rid=""nlae022-B29"" ref-type=""bibr"">29</xref>). Tippett et al found greater",7_16,Postmortem neuropathology in early Huntington disease,5 2024,,Huntington_Disease
"Tippett et al found greater striosome than matrix loss of GABA-A receptor immunopositivity (presumed to be on striatal neurons), in early cases, but also introduced the concept of cases with the opposite change, so-called “matrix-predominant” GABA-A loss at later stages (<xref rid=""nlae022-B31"" ref-type=""bibr"">31</xref>). Neuron loss was inferred from immunolabeling, not from direct cell counting. In the present report, hematoxylin-stained SPNs were counted in striosomes and surrounding matrix in 16 early",7_17,Postmortem neuropathology in early Huntington disease,5 2024,,Huntington_Disease
"in striosomes and surrounding matrix in 16 early grade brains, 8 grade 0 and 8 grade 1, along with 8 controls. Extending a search for matrix loss predominance, SPN numbers in striosomes and matrix in 2 grade 2 cases were also counted. The 1C2 antibody against expanded polyglutamine tracts is widely used in neuropathological evaluation of postmortem HD brains. Deposits in neuronal nuclei and/or cytoplasm positive with this antibody have been reported in HD in grades 2 through 4 in some neurons of the",7_18,Postmortem neuropathology in early Huntington disease,5 2024,,Huntington_Disease
"HD in grades 2 through 4 in some neurons of the neostriatum and cerebral cortex and elsewhere (<xref rid=""nlae022-B32"" ref-type=""bibr"">32</xref>, <xref rid=""nlae022-B33"" ref-type=""bibr"">33</xref>), and similar inclusions identified with other antibodies have been reported in grades 0 and 1 brains (<xref rid=""nlae022-B34"" ref-type=""bibr"">34–36</xref>). The 1C2 antibody is also positive in neostriatum and cerebral cortex in some other expanded CAG repeat disorders including several varieties of",7_19,Postmortem neuropathology in early Huntington disease,5 2024,,Huntington_Disease
"repeat disorders including several varieties of spinocerebellar ataxia, as well as in the HD clinical and pathological mimic termed HD-like-2 (HDL-2), so that uncertainties in postmortem pathological differential diagnosis can arise (<xref rid=""nlae022-B29"" ref-type=""bibr"">29</xref>, <xref rid=""nlae022-B36"" ref-type=""bibr"">36</xref>). In HDL-2, pontine nucleus neurons are reported to be negative with the 1C2 antibody (<xref rid=""nlae022-B37"" ref-type=""bibr"">37</xref>), whereas they are positive in HD",7_20,Postmortem neuropathology in early Huntington disease,5 2024,,Huntington_Disease
"whereas they are positive in HD (<xref rid=""nlae022-B33"" ref-type=""bibr"">33</xref>, <xref rid=""nlae022-B37"" ref-type=""bibr"">37</xref>). In the CAG-repeat spinocerebellar ataxias, there are characteristic patterns of neuron loss and 1C2-positive inclusions (<xref rid=""nlae022-B38"" ref-type=""bibr"">38</xref>), different from the patterns in HD (<xref rid=""nlae022-B33"" ref-type=""bibr"">33</xref>). In the present study, a characteristic HD pattern of 1C2 positivity in neostriatum and basal pons with largely",7_21,Postmortem neuropathology in early Huntington disease,5 2024,,Huntington_Disease
"in neostriatum and basal pons with largely intact and 1C2-negative Purkinje cells was searched for in early HD, including premanifest cases.",7_22,Postmortem neuropathology in early Huntington disease,5 2024,,Huntington_Disease
"Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease Neurodegenerative diseases have long become an increasing area of interest, particularly as the global population ages. Disease understanding, however, has had inherent limitations due to the accessibility problems of studying central nervous system (CNS) tissue. The retina shares embryonic origin with the brain, specifically at the embryonic diencephalon.<sup>[<xref rid=""B1"" ref-type=""bibr"">1</xref>]</sup> This allows the",8_0,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"ref-type=""bibr"">1</xref>]</sup> This allows the neuroretina to serve as a unique window to provide insight into deeper brain tissues as well. It has also long been believed that there is significant homology between retinal and cerebral microvasculature.<sup>[<xref rid=""B2"" ref-type=""bibr"">2</xref>,<xref rid=""B3"" ref-type=""bibr"">3</xref>]</sup> Thus, there has been growing focus on analyzing the vascular and neural changes of the retina and choroid in neurodegenerative brain diseases, especially with the",8_1,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"brain diseases, especially with the growth of new modalities such as optical coherence tomography angiography (OCTA).<sup>[<xref rid=""B4"" ref-type=""bibr"">4</xref>,<xref rid=""B5"" ref-type=""bibr"">5</xref>,<xref rid=""B6"" ref-type=""bibr"">6</xref>,<xref rid=""B7"" ref-type=""bibr"">7</xref>,<xref rid=""B8"" ref-type=""bibr"">8</xref>,<xref rid=""B9"" ref-type=""bibr"">9</xref>]</sup>",8_2,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"OCTA is a functional extension of optical coherence tomography (OCT) technology utilized to visualize the retinal and choroidal vasculature.<sup>[<xref rid=""B10"" ref-type=""bibr"">10</xref>]</sup> OCT uses an infrared laser to measure the amplitude and delay of reflection to measure the depth and reflectivity of structures. These measurements comprise an axial scan, which can be sequentially combined to generate a B-scan (or cross-sectional image). Multiple B-scans acquired sequentially provide volumetric",8_3,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"B-scans acquired sequentially provide volumetric information, and these images can be compared on a pixel-by-pixel basis such that the observed signal changes can be attributable to erythrocyte motion. Algorithms within the OCTA software are then utilized to create a full-thickness retinal angiogram with images segmented into superficial and deeper layers.<sup>[<xref rid=""B11"" ref-type=""bibr"">11</xref>,<xref rid=""B12"" ref-type=""bibr"">12</xref>]</sup>",8_4,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"Dark adaptation testing measures the rate at which the rod and cone system recover sensitivity in the dark following exposure to a bright light source. Although impairments have been seen with increased age, worsened visual acuity, and retinal diseases such as age-related macular degeneration, the effects of brain neurodegenerative diseases on dark adaptation are not completely elucidated.<sup>[<xref rid=""B13"" ref-type=""bibr"">13</xref>]</sup>",8_5,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"Huntington's Disease (HD) is a neurodegenerative disease with an autosomal dominant inheritance pattern related to a mutation in the HTT gene. It is fully penetrant and can lead to cognitive and motor disturbances.<sup>[<xref rid=""B14"" ref-type=""bibr"">14</xref>]</sup> Although changes in visuospatial processing and visual perception have been studied previously, few studies have utilized OCT technology to study structural changes in the retina in those with HD. Parameters such as temporal retinal nerve",8_6,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"HD. Parameters such as temporal retinal nerve fiber layer (RNFL) thickness, macular RNFL thickness, and ganglion cell layer (GCL) thickness have been found to be lower in those with HD compared to controls.<sup>[<xref rid=""B15"" ref-type=""bibr"">15</xref>,<xref rid=""B16"" ref-type=""bibr"">16</xref>,<xref rid=""B17"" ref-type=""bibr"">17</xref>]</sup>",8_7,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"To the best of our knowledge, no study to date has analyzed dark adaptometry testing in HD patients and a single study using OCT angiography was recently published that found no statistically significant difference between HD patients and controls for superficial capillary plexus density, deep capillary plexus density, and choriocapillaris density.<sup>[<xref rid=""B18"" ref-type=""bibr"">18</xref>]</sup>",8_8,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"Study participants were recruited from Washington University in St. Louis, specifically through the Huntington's Disease Society of America Center of Excellence. The study design was approved by the institutional review board of Washington University in St. Louis at the Human Research Protection Office and adhered to the tenets of the Declaration of Helsinki. Risks and benefits were discussed with each participant, and informed consent was obtained before beginning the ophthalmic examination and testing.",8_9,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"beginning the ophthalmic examination and testing. Data for this study were collected from November 2020 until February 2022. Inclusion criteria required a Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) and gene-positive testing for the <italic toggle=""yes"">HTT </italic>gene. The UHDRS-TMS rates various motor signs including eye movements, speech, chorea, dystonia, bradykinesia, and gait in order to provide a measure of motor symptom severity. Exclusion criteria included a known",8_10,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
severity. Exclusion criteria included a known history of previous retinal diseases including age-related macular degeneration and diabetic retinopathy or any retinal disease that may have required intraocular surgery; intraocular pressure of 22 mmHg or higher; and previous retinal laser therapy. Control data was acquired from individuals without known Huntington Disease who otherwise had the same exclusion criteria as those above. This control group has been reported on in a previous study.<sup>[<xref,8_11,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"been reported on in a previous study.<sup>[<xref rid=""B5"" ref-type=""bibr"">5</xref>]</sup>",8_12,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"All participants received an ophthalmic exam that consisted of Snellen visual acuity assessment, ocular motility testing, intraocular pressure measurements, and examination of the anterior segment and dilated fundus. OCTA imaging of the macula was performed using the Avanti Optovue OCTA system (Optovue, Visionix USA) as shown in Figure 1. Measurements were automated using the manufacture's software (Optovue RTVue) providing an objective manner of collection. Data outcomes collected into superficial vessel",8_13,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"Data outcomes collected into superficial vessel capillary density at the fovea, deep vessel capillary density at the fovea, and foveal avascular zone (FAZ). Additionally, dark adaptometry testing was performed using the Diagnosys Dark Adaptometry system to measure cone sensitivity, rod sensitivity, and the rod-cone break point as shown in Figure 2. Measurements were automated using the manufacture's software providing a plot of the results. A total of 24 eyes from 12 individuals with HD were included in",8_14,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"eyes from 12 individuals with HD were included in the study (mean age [SD], 52.5 [10.8]). Of these, 11 individuals were Caucasian and 1 was African American. Eight eyes were excluded based on abnormal motion artifact (due to underlying HD-related motor disease) when completing OCTA testing. All 12 individuals were included in dark adaptometry testing. Additionally, 31 control eyes were included for comparison of OCTA testing (mean age [SD], 75.4 [6.6] years). All control individuals were Caucasian. One of",8_15,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"All control individuals were Caucasian. One of the control eyes was excluded due to artifact obscuring the reliability of the measurements. In regard to OCTA testing, 16 eyes with HD and 31 control eyes completed the test. As shown in Figure 3, the HD eyes had a mean superficial foveal capillary density of 24.7% compared to the control eyes of 31.8% (<italic toggle=""yes"">P</italic> = 0.0014, SD = 5.01%). The mean deep foveal capillary density in the HD group was 42.4% compared to 31.7% in the control group",8_16,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"was 42.4% compared to 31.7% in the control group (<italic toggle=""yes"">P</italic> = 0.0002, SD = 5.17%). The foveal avascular zone was 0.252 mm<sup>2</sup> in the HD eyes compared to 0.316 mm<sup>2</sup> in the control eyes (<italic toggle=""yes"">P</italic>",8_17,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"<inline-formula>
<math xmlns=""http://www.w3.org/1998/Math/MathML""><mo xmlns=""http://www.w3.org/1998/Math/MathML"">></mo></math>",8_18,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"</inline-formula> 0.05, SD = 0.09 mm<sup>2</sup>). Regression analysis revealed that when accounting for age, individuals in the HD group still maintained a lower mean superficial foveal capillary density (<italic toggle=""yes"">P</italic> = 0.022) and a higher mean deep foveal capillary density (<italic toggle=""yes"">P</italic> = 0.033). This difference did not diverge with worsening HD severity measures–there was no statistically significant change in the superficial or deep foveal capillary density or the",8_19,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"or deep foveal capillary density or the foveal avascular zone with increased severity based on the UHDRS-TMS (<italic toggle=""yes"">P</italic>",8_20,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"<inline-formula>
<math xmlns=""http://www.w3.org/1998/Math/MathML""><mo xmlns=""http://www.w3.org/1998/Math/MathML"">></mo></math>",8_21,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"</inline-formula> 0.05). All 12 individuals with HD had dark adaptometry testing that was considered within the range of normal based on the machine-generated plot of cone sensitivity, rod sensitivity, and the rod-cone break point. This study demonstrated a significant difference between the superficial and deep foveal capillary densities in those with HD and control individuals using the OCTA. This remained significant after controlling for age in our analysis. There was no significant difference in OCTA",8_22,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"There was no significant difference in OCTA parameters with worsened disease severity (via the UHDRS-TMS score) and no significant difference in foveal avascular zone between the two groups. There has been only one other study analyzing retinal vasculature using OCTA in those with HD. In that study, there was no statistically significant difference between HD patients and controls for superficial capillary plexus density, deep capillary plexus density, and choriocapillaris density.<sup>[<xref rid=""B18""",8_23,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"choriocapillaris density.<sup>[<xref rid=""B18"" ref-type=""bibr"">18</xref>]</sup> Additionally, to the best of our knowledge, no other study has analyzed dark adaptometry in patients with HD; therefore, this was a unique aspect to the study. However, in our population, dark adaptometry testing was otherwise unremarkable in the HD patients. This may be for a number of different reasons. Firstly, it may take more significant disease severity to manifest changes in dark adaptation. Secondly, photoreceptor",8_24,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"in dark adaptation. Secondly, photoreceptor function may be generally spared in HD such that changes in dark adaptation are not seen. Thirdly, it may also be that the sample size of this study was too small to ascertain any change. Recent studies have shown that altered neurovascular structure may be a true biomarker of HD. Lin et al showed an increase in cerebral vasculature density in post-mortem human tissue and mouse models.<sup>[<xref rid=""B20"" ref-type=""bibr"">20</xref>]</sup> Drouin-Oullet et al",8_25,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"Drouin-Oullet et al reported similar findings in human tissue and mouse models as well and discussed that this may be a compensatory response to maintain proper oxygenation of tissues despite an overall decrease in the number of larger blood vessels.<sup>[<xref rid=""B21"" ref-type=""bibr"">21</xref>]</sup> Additionally, there has been some precursory evidence for retinal dysfunction in the setting of HD. For instance, Paulus et al conducted an electrophysiologic study showing that those with HD had cone",8_26,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"study showing that those with HD had cone dysfunction when compared to normal controls.<sup>[<xref rid=""B22"" ref-type=""bibr"">22</xref>]</sup> Two other recent ERG studies have demonstrated altered retinal responses in subjects with HD compared to controls.<sup>[<xref rid=""B23"" ref-type=""bibr"">23</xref>,<xref rid=""B24"" ref-type=""bibr"">24</xref>]</sup>",8_27,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"Interestingly in our study, the HD group had a lower mean superficial foveal capillary density and a high deep foveal capillary density. Similar to what was seen in post-mortem cerebral vasculature as discussed earlier, the increase in the deep foveal capillary density may be a compensatory response to hypoperfusion. The superficial foveal capillary density may on the other hand be a surrogate for true hypoperfusion at the level of the retina. Further, while retinal vasculature was the focus of this",8_28,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"while retinal vasculature was the focus of this study, the retinal vascular changes may also provide insight into the blood–brain barrier (BBB) dysfunction in HD individuals especially as these mechanisms have remained elusive given the lack of in vivo analysis. In this study, there was no significant change in these variables with changes in the UHDRS-TMS score, however, further study with a larger sample size and thus a higher range of UHDRS-TMS scores will be required to understand the relationships",8_29,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"will be required to understand the relationships between these variable and disease progression. There are important limitations to be acknowledged in this study. Our sample size was small, which makes it difficult to ascertain true differences in the results. Furthermore, while the understanding of retinal involvement is limited in HD, these findings (a lower mean age-adjusted superficial foveal capillary density and a higher mean deep foveal capillary density compared to control subjects) indicate the",8_30,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"compared to control subjects) indicate the need of further study to assess true retinal biomarkers of disease. Altogether, this study suggests that changes in retinal biomarkers may exist in patients with HD and that additional investigations using multimodal techniques are warranted. None. None.",8_31,Dark Adaptometry and Optical Coherence Tomography Angiography in Huntington Disease,Jan-Mar 2024,,Huntington_Disease
"Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease Huntington disease (HD) is caused by an expanded polyglutamine mutation in huntingtin (mHTT) that promotes prominent atrophy in the striatum and subsequent psychiatric, cognitive deficits, and choreiform movements. Multiple lines of evidence point to an association between HD and aberrant striatal mitochondrial functions; however, the present knowledge about whether (or",9_0,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"however, the present knowledge about whether (or how) mitochondrial mRNA translation is differentially regulated in HD remains unclear. We found that protein synthesis is diminished in HD mitochondria compared to healthy control striatal cell models. We utilized ribosome profiling (Ribo-Seq) to analyze detailed snapshots of ribosome occupancy of the mitochondrial mRNA transcripts in control and HD striatal cell models. The Ribo-Seq data revealed almost unaltered ribosome occupancy on the nuclear-encoded",9_1,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"ribosome occupancy on the nuclear-encoded mitochondrial transcripts involved in oxidative phosphorylation (SDHA, Ndufv1, Timm23, Tomm5, Mrps22) in HD cells. By contrast, ribosome occupancy was dramatically increased for mitochondrially encoded oxidative phosphorylation mRNAs (mt-Nd1, mt-Nd2, mt-Nd4, mt-Nd4l, mt-Nd5, mt-Nd6, mt-Co1, mt-Cytb, and mt-ATP8). We also applied tandem mass tag–based mass spectrometry identification of mitochondrial proteins to derive correlations between ribosome occupancy and",9_2,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"correlations between ribosome occupancy and actual mature mitochondrial protein products. We found many mitochondrial transcripts with comparable or higher ribosome occupancy, but diminished mitochondrial protein products, in HD. Thus, our study provides the first evidence of a widespread dichotomous effect on ribosome occupancy and protein abundance of mitochondria-related genes in HD.  <list list-type=""simple"" id=""ulist0010""><list-item id=""u0010""><label>•</label><p id=""p0010"">Decreased mitochondrial",9_3,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"id=""p0010"">Decreased mitochondrial protein synthesis in HD.</p></list-item><list-item id=""u0015""><label>•</label><p id=""p0015"">Enhanced ribosome occupancy in mitochondria-encoded mRNAs in HD.</p></list-item><list-item id=""u0020""><label>•</label><p id=""p0020"">TMT-based proteomics showed significant mitochondrial proteome changes in HD.</p></list-item><list-item id=""u0a020""><label>•</label><p id=""paa0020"">HD lowers mito protein synthesis and higher ribosome occupancy in mito-encoded OXPHOS",9_4,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"higher ribosome occupancy in mito-encoded OXPHOS mRNA.</p></list-item></list> Our data reveal a pervasive dichotomous impact on the ribosome occupancy level and the protein turnover rate in genes associated with mitochondria in HD.   The inquiry into whether alterations in protein levels are primarily attributed to variations in protein synthesis rate, mRNA abundance, or protein turnover has been a longstanding topic of investigation in biology. In yeast, the current notion is that the proportion of",9_5,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"the current notion is that the proportion of ribosome-bound mRNA molecules, which signifies actively translated species, is a more reliable indicator of protein abundance than mRNA levels in isolation (<xref rid=""bib52"" ref-type=""bibr"">52</xref>, <xref rid=""bib53"" ref-type=""bibr"">53</xref>, <xref rid=""bib54"" ref-type=""bibr"">54</xref>). Here, we integrated ribosome profiling and mass spectrometry-based protein discovery techniques to provide a comprehensive analysis of the proteome in mammalian",9_6,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"analysis of the proteome in mammalian mitochondria. Our findings offer novel insights into the relationship between ribosome occupancy and the protein levels of mitochondrial proteins in HD cells. Multiple aspects of mitochondrial dysfunction are linked to numerous brain diseases, particularly neurodegenerative diseases (<xref rid=""bib55"" ref-type=""bibr"">55</xref>, <xref rid=""bib56"" ref-type=""bibr"">56</xref>, <xref rid=""bib57"" ref-type=""bibr"">57</xref>, <xref rid=""bib58"" ref-type=""bibr"">58</xref>, <xref",9_7,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"rid=""bib58"" ref-type=""bibr"">58</xref>, <xref rid=""bib59"" ref-type=""bibr"">59</xref>, <xref rid=""bib60"" ref-type=""bibr"">60</xref>, <xref rid=""bib61"" ref-type=""bibr"">61</xref>, <xref rid=""bib62"" ref-type=""bibr"">62</xref>, <xref rid=""bib63"" ref-type=""bibr"">63</xref>, <xref rid=""bib64"" ref-type=""bibr"">64</xref>, <xref rid=""bib65"" ref-type=""bibr"">65</xref>). Perturbed mitochondrial functions and disrupted protein synthesis have been reported in HD (<xref rid=""bib3"" ref-type=""bibr"">3</xref>, <xref rid=""bib16""",9_8,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"ref-type=""bibr"">3</xref>, <xref rid=""bib16"" ref-type=""bibr"">16</xref>, <xref rid=""bib66"" ref-type=""bibr"">66</xref>, <xref rid=""bib67"" ref-type=""bibr"">67</xref>, <xref rid=""bib68"" ref-type=""bibr"">68</xref>, <xref rid=""bib69"" ref-type=""bibr"">69</xref>, <xref rid=""bib70"" ref-type=""bibr"">70</xref>, <xref rid=""bib71"" ref-type=""bibr"">71</xref>, <xref rid=""bib72"" ref-type=""bibr"">72</xref>, <xref rid=""bib73"" ref-type=""bibr"">73</xref>, <xref rid=""bib74"" ref-type=""bibr"">74</xref>), but a detailed molecular and",9_9,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"but a detailed molecular and biochemical understanding is lacking. This report presents compelling evidence for the existence of a distinct dichotomy in the expression patterns of proteins linked to mitochondria. We found defects in translational regulation involving the enhanced loading of ribosomes onto mitochondrially encoded mRNAs that control mitochondrial energy production, cell signaling, and cell death functions (<xref rid=""bib75"" ref-type=""bibr"">75</xref>, <xref rid=""bib76""",9_10,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"ref-type=""bibr"">75</xref>, <xref rid=""bib76"" ref-type=""bibr"">76</xref>). Notably, this regulation was absent from the most nuclear-encoded mitochondrial mRNAs, revealing an intriguing mechanistic dichotomy in the translational process operating between the cytoplasm and the mitochondria in the HD context. This dichotomy has the potential to contribute to the observed decrease in mRNA translation in HD mitochondria (<xref rid=""fig1"" ref-type=""fig"">Fig. 1</xref>). An enormous pressure appears to exist for",9_11,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"An enormous pressure appears to exist for mitochondria-encoded transcripts to increase translational efficiency; however, for unknown reasons, this pressure is not translated into protein production. As reported here, there is a general decrease in protein production in HD mitochondria and mitochondrial OXPHOS transcripts. The reason for this misregulated translation efficiency in HD is unclear. One possibility is that the ribosomal proteins that translate mitochondria-encoded OXPHOS transcripts are",9_12,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"mitochondria-encoded OXPHOS transcripts are present at suboptimal levels. Consistent with this notion, of the 38 mitochondrial ribosomal proteins found in our TMT-MS data, 11 were significantly downregulated in HD cells. However, whether this downregulation is the cause or a consequence of enhanced ribosome occupancy is unclear because the stalled ribosomes and mRNA may be subject to no-go degradation (<xref rid=""bib77"" ref-type=""bibr"">77</xref>), resulting in diminished mitochondrial ribosomal protein",9_13,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"in diminished mitochondrial ribosomal protein levels. Previous studies have indicated that both wtHTT and mHTT are localized in the mitochondria, but whether they reside in the mitochondrial intermembrane space or in the outer membrane remains controversial (<xref rid=""bib18"" ref-type=""bibr"">18</xref>, <xref rid=""bib23"" ref-type=""bibr"">23</xref>, <xref rid=""bib26"" ref-type=""bibr"">26</xref>, <xref rid=""bib27"" ref-type=""bibr"">27</xref>, <xref rid=""bib78"" ref-type=""bibr"">78</xref>, <xref rid=""bib79""",9_14,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"ref-type=""bibr"">78</xref>, <xref rid=""bib79"" ref-type=""bibr"">79</xref>). Our TMT-MS experiment revealed HTT interacting protein-1, but not the HTT protein itself, in the mitochondrial fractions. Even if this mitochondrial localization is transient, it raises the intriguing possibility that mHTT/wtHTT can induce cellular signaling from the inner or outer membrane surface to regulate ribosome occupancy and cotranslational events involving mitochondria encoded OXPHOS mRNA (<xref rid=""fig11""",9_15,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"encoded OXPHOS mRNA (<xref rid=""fig11"" ref-type=""fig"">Fig. 11</xref>). Alternatively, wtHTT/mHTT fragments might directly bind to the polysomes and ribosomal proteins in the cytoplasm, thereby impeding the speed of ribosome translocation and protein synthesis (<xref rid=""bib35"" ref-type=""bibr"">35</xref>).<fig id=""fig11""><label>Fig. 11</label><caption><p><bold>Model for mHTT-mediated ribosome stalling of mitochondrially</bold><bold>en</bold><bold>coded OXPHOS genes.</bold> We reported widespread ribosome",9_16,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"genes.</bold> We reported widespread ribosome stalling in HD cells (<xref rid=""bib35"" ref-type=""bibr"">35</xref>). Our model has predicted that HTT hinders the movement of ribosomes, while mHTT acquires this capability and further obstructs ribosome mobility, leading to the inhibition of protein synthesis. Here, we report an intriguing observation regarding the ribosome occupancy of OXPHOS mRNA transcripts in HD cells. Almost all mitochondrially encoded OXPHOS transcripts, but not the nuclear-encoded OXPHOS",9_17,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"transcripts, but not the nuclear-encoded OXPHOS transcripts, show a higher ribosome occupancy in HD cells compared to control cells. We hypothesize that the signaling mechanisms by which HTT or mHTT induce ribosome loading of mt OXPHOS transcripts may originate from either the cytoplasm or the inner or outer mitochondrial membrane. The underlying molecular process and its role in HD onset and progression remain unknown. HD, Huntington's disease; HTT, huntingtin; mHTT, mutant huntingtin; OXPHOS, oxidative",9_18,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"mHTT, mutant huntingtin; OXPHOS, oxidative phosphorylation.</p></caption><graphic http://www.w3.org/1999/xlink href=""gr11""></graphic></fig> As most (>95%) of the mitochondrial proteins are produced in the nucleus, one possibility is that HTT/mHTT may activate signals in the nucleus and cytoplasm, and these then communicate messages to the mitochondrion for its own mRNA translation (<xref rid=""fig11"" ref-type=""fig"">Fig. 11</xref>). Recent studies in yeast have shown that cytosolic translational regulators",9_19,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"shown that cytosolic translational regulators control mitochondrial OXPHOS mRNA translation (<xref rid=""bib80"" ref-type=""bibr"">80</xref>, <xref rid=""bib81"" ref-type=""bibr"">81</xref>). In particular, some evidence indicate that a nuclear-encoded protein involved in OXPHOS might impede the assembly process of the nascent chain complex of mitochondrial OXPHOS proteins (<xref rid=""bib82"" ref-type=""bibr"">82</xref>). These discoveries suggest the existence of a functional and physical connection involved in the",9_20,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"and physical connection involved in the assembly of mitochondrial proteins. Whether or how such mechanisms impacts HD remains to be discovered (<xref rid=""fig11"" ref-type=""fig"">Fig. 11</xref>). Identifying the molecular nature of the cellular signals and ribosome stalling mechanisms in HD cells will provide new insights that could help curtail mitochondrial translation defects for a potential therapeutic impact on HD. One important observation from this study is the differential influence of ribosome",9_21,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"study is the differential influence of ribosome occupancy on mitochondrially coded mRNA by one copy of mHTT (HD-het) <italic toggle=""yes"">versus</italic> two copies of mHTT (HD-homo). When compared to HD-homo cells, the HD-het cells display a significantly higher ribosome occupancy on the mt-OXPHOS genes, with a minority of nu-coded OXPHOS transcripts exhibiting diminished occupancy (<xref rid=""fig3"" ref-type=""fig"">Fig. 3</xref>, <xref rid=""fig4"" ref-type=""fig"">Fig. 4</xref>, <xref rid=""fig5""",9_22,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"ref-type=""fig"">Fig. 4</xref>, <xref rid=""fig5"" ref-type=""fig"">Fig. 5</xref>). This observation suggests that the combined presence of wtHTT and mHTT may lead to the emergence of an additive risk for translation regulatory phenotypes that readapt to ongoing HD-related cellular demands. In addition, as wtHTT plays a key role as a negative regulator of ribosome translocation (<xref rid=""bib83"" ref-type=""bibr"">83</xref>), the loss of normal HTT in HD-het may lead to enhanced loading of ribosomes on",9_23,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"may lead to enhanced loading of ribosomes on mitochondrial OXPHOS transcripts. Alternatively, mHTT may exert a gain of function, so that the presence of two copies of mHTT in HD-homo cells further enhances the degree of ribosome occupancy in mitochondrial OXPHOS transcripts, leading to the collision of ribosomes and eventual no-go degradation of the transcripts. This notion is supported by the significantly reduced amounts of mitochondrial mRNA transcripts in the HD-homo <italic",9_24,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"mRNA transcripts in the HD-homo <italic toggle=""yes"">versus</italic> the HD-het or control cells (<xref rid=""fig3"" ref-type=""fig"">Fig. 3</xref>, <xref rid=""fig4"" ref-type=""fig"">Fig. 4</xref>, <xref rid=""fig5"" ref-type=""fig"">Fig. 5</xref>). This type of process may also be responsible for the much greater diminishment of protein synthesis in HD-homo cells than in HD-het cells (<xref rid=""fig1"" ref-type=""fig"">Fig. 1</xref>, <italic toggle=""yes"">A</italic>–<italic toggle=""yes"">C</italic>). Future studies",9_25,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"toggle=""yes"">C</italic>). Future studies should investigate the poly-Q–dependent mechanisms of HTT that might induce a decay of ribosome-stalled mitochondrial transcripts and how this could lead to diminished protein synthesis in HD. A previous study using two-dimensional difference gel electrophoresis indicated reduced levels of nuclear-encoded matrix mitochondrial proteins in HD-homo cells (<xref rid=""bib27"" ref-type=""bibr"">27</xref>). Consistent with this previous report, we also observed a significant",9_26,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"previous report, we also observed a significant reduction in the Idh3a, Slc25a24, and Pck2 protein levels, while Clpp and Me2 showed a decreasing trend that did not reach statistical significance. Thus, independent studies have validated the occurrence of defective mitochondrial proteomes in HD. Nevertheless, our high-throughput methodology has now further advanced the characterization of mitochondrial transcript-specific changes to uncover dynamic translational modifications in HD. For simplicity, the",9_27,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"modifications in HD. For simplicity, the altered transcripts could be grouped into two broad categories comparing control <italic toggle=""yes"">versus</italic> HD cells: (1) transcripts that had high ribosome occupancy but a diminished or similar protein content (<italic toggle=""yes"">e.g.</italic>, mt-nd1 and prkl12a) and (2) transcripts that had similar ribosome occupancy but diminished or higher protein levels (<italic toggle=""yes"">e.g.</italic>, Cox7a2I, Cavin1, and plpp3). Taken together, our study",9_28,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"Cavin1, and plpp3). Taken together, our study findings demonstrate an unexpected dichotomy of ribosome occupancy and proteomes among nuclear and mitochondrially coded OXPHOS transcripts due to mHTT. Defining the underlying mechanisms that create this dichotomy of OXPHOS mRNA translation and proteome changes, and determining their influence on mitochondrial structure and function, will provide a new understanding of HD pathogenesis and identify new therapeutic targets. All the data are available in the main",9_29,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"targets. All the data are available in the main text or the <xref rid=""appsec1"" ref-type=""sec"">Supplementary materials</xref>. This article contains <xref rid=""appsec1"" ref-type=""sec"">supplemental data</xref>. Authors declare no competing interests.",9_30,Ribosome Profiling and Mass Spectrometry Reveal Widespread Mitochondrial Translation Defects in a Striatal Cell Model of Huntington Disease,05 3 2024,,Huntington_Disease
"Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease <bold>Objectives</bold>
 To evaluate the associations between sleep quality and serum levels of neurofilament light (NfL) protein in individuals with premanifest Huntington disease (HD).
 <bold>Materials and Methods</bold>",10_0,Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease,15 2 2024,,Huntington_Disease
"<bold>Materials and Methods</bold>
 We recruited 28 individuals with premanifest HD from a pre-existing database (of the Huntington's Environmental Research Optimisation Scheme, HEROs). The participants filled out the Pittsburgh Sleep Quality Index (PSQI), a subjective measure of sleep quality, and blood was collected via routine venepuncture to measure peripheral NfL levels.
 <bold>Results</bold>",10_1,Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease,15 2 2024,,Huntington_Disease
"<bold>Results</bold>
 The PSQI scores (median: 5.0; interquartile range: 4.0–7.5) indicated poor sleep quality. General linear modelling revealed no significant (
<italic toggle=""yes"">p</italic>
 = 0.242) association between PSQI scores and NfL levels. No significant differences were found between individuals with good and poor sleep quality for any demographic variable collected.
 <bold>Discussion</bold>",10_2,Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease,15 2 2024,,Huntington_Disease
"<bold>Discussion</bold>
 Contrary to studies on other neurological conditions, there was no association between sleep quality and NfL levels in individuals with premanifest HD. This was unexpected, given the influence of environmental factors (such as social network size) on neurodegeneration in individuals with premanifest HD.
 
Poor sleep quality is a common and debilitating aspect of Huntington disease (HD). A survey of the HD community in the United Kingdom",10_3,Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease,15 2 2024,,Huntington_Disease
"<xref rid=""JR1071-1"" ref-type=""bibr"">1</xref>
revealed that up to 90% of individuals experience poor sleep. Evidence suggests that sleep difficulties arise prior to a formal diagnosis and persist over the course of the disease,
<xref rid=""JR1071-2"" ref-type=""bibr"">2</xref>
<xref rid=""JR1071-3"" ref-type=""bibr"">3</xref>
<xref rid=""JR1071-4"" ref-type=""bibr"">4</xref>
<xref rid=""JR1071-5"" ref-type=""bibr"">5</xref>
<xref rid=""JR1071-6"" ref-type=""bibr"">6</xref>",10_4,Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease,15 2 2024,,Huntington_Disease
"<xref rid=""JR1071-6"" ref-type=""bibr"">6</xref>
which may exacerbate cognitive, motor, and mood disturbances. The extent to which poor sleep impacts neurodegeneration in HD has been poorly explored to date.
<xref rid=""JR1071-7"" ref-type=""bibr"">7</xref>
 
Poor sleep quality has been linked to worse neurological outcomes in individuals presenting with sleep disorders and other neurodegenerative conditions.
<xref rid=""JR1071-8"" ref-type=""bibr"">8</xref>
<xref rid=""JR1071-9"" ref-type=""bibr"">9</xref>",10_5,Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease,15 2 2024,,Huntington_Disease
"<xref rid=""JR1071-9"" ref-type=""bibr"">9</xref>
<xref rid=""JR1071-10"" ref-type=""bibr"">10</xref>
Neurofilament light (NfL) proteins are one of three neurofilament chains that contribute to the structure of neurons in the central nervous system.
<xref rid=""JR1071-10"" ref-type=""bibr"">10</xref>
Therefore, NfL is released into the cerebrospinal fluid and eventually the blood when neurons are damaged or die.
<xref rid=""JR1071-10"" ref-type=""bibr"">10</xref>",10_6,Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease,15 2 2024,,Huntington_Disease
"<xref rid=""JR1071-10"" ref-type=""bibr"">10</xref>
Elevated levels of serum NfL have been detected in individuals with chronic insomnia disorder.
<xref rid=""JR1071-10"" ref-type=""bibr"">10</xref>
In addition, higher NfL levels in the cerebrospinal fluid have been observed in individuals with mild to moderate Alzheimer disease with reduced sleep depth.
<xref rid=""JR1071-8"" ref-type=""bibr"">8</xref>",10_7,Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease,15 2 2024,,Huntington_Disease
"<xref rid=""JR1071-8"" ref-type=""bibr"">8</xref>
Poor sleep quality has also been associated with higher plasma NfL levels in individuals with mild traumatic brain injury.
<xref rid=""JR1071-9"" ref-type=""bibr"">9</xref>
Given these findings, there is a need to explore the associations between sleep quality outcomes and markers of neurodegeneration in individuals with HD.
 
To date, one study has explored associations between sleep and neuropathology in HD: Baker et al.",10_8,Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease,15 2 2024,,Huntington_Disease
"<xref rid=""JR1071-7"" ref-type=""bibr"">7</xref>
noted greater thalamic atrophy in individuals with poor sleep, indicating that poor sleep may hasten neurodegeneration in HD. While an important finding, this study
<xref rid=""JR1071-7"" ref-type=""bibr"">7</xref>
did not use a validated questionnaire to examine sleep, rather a sleep item from the Becks Depression Inventory, limiting the validity of the findings and emphasizing the need for additional studies.",10_9,Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease,15 2 2024,,Huntington_Disease
"The purpose of the present study was to evaluate the associations between sleep quality and serum NfL levels in individuals with HD. We hypothesized that poor sleep quality would be associated with elevated NfL levels in individuals with premanifest HD.  
The demographic data of the 28 individuals with premanifest HD, separated into those with good and poor sleep quality, are presented in
<xref rid=""TB1071-1"" ref-type=""table"">Table 1</xref>",10_10,Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease,15 2 2024,,Huntington_Disease
". Overall, the median and interquartile range of the PSQI scores were of 5.0 (4.0–7.5). Very few participants consumed alcohol or took medication in either group. No significant differences were observed between the two groups for any of the demographic variables; no significant (
<italic toggle=""yes"">p</italic>
 = 0.242) relationship was found between PSQI scores and NfL levels (
<xref rid=""FI1071-1"" ref-type=""fig"">Fig. 1</xref>
). Additionally, sex (
<italic toggle=""yes"">p</italic>
 = 0.331) and age (",10_11,Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease,15 2 2024,,Huntington_Disease
"= 0.331) and age (
<italic toggle=""yes"">p</italic>
 = 0.130) did not significantly influence NfL levels of individuals with premanifest HD. There was no significant (
<italic toggle=""yes"">p</italic>
 = 0.981) difference in the NfL levels of the patients in the two study groups (
<xref rid=""FI1071-2"" ref-type=""fig"">Fig. 2</xref>
).
 
Emerging evidence indicates that sleep disturbances exacerbate neuropathological changes in individuals living with neurological conditions, including HD.",10_12,Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease,15 2 2024,,Huntington_Disease
"<xref rid=""JR1071-7"" ref-type=""bibr"">7</xref>
However, the extent to which reduced sleep quality is associated with biological markers of neurological damage, particularly serum NfL, has not been investigated to date.
<xref rid=""JR1071-7"" ref-type=""bibr"">7</xref>",10_13,Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease,15 2 2024,,Huntington_Disease
"<xref rid=""JR1071-7"" ref-type=""bibr"">7</xref>
In the present study, we have explored, for the first time, associations between sleep quality and serum NfL levels in people living with premanifest HD. In contrast to previous findings in other neurological conditions and our expectations, we found no associations between sleep quality and NfL levels.",10_14,Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease,15 2 2024,,Huntington_Disease
"As previously stated, in the present study, no significant difference in NfL levels was observed between individuals with good and poor sleep quality, as indicated by established PSQI cutoff values.
<xref rid=""JR1071-7"" ref-type=""bibr"">7</xref>",10_15,Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease,15 2 2024,,Huntington_Disease
"<xref rid=""JR1071-7"" ref-type=""bibr"">7</xref>
We expected associations between sleep quality and NfL levels, since previous findings have shown that lifestyle factors, such as cognitive reserve, and social network size and diversity, are associated with NfL levels in individuals with premanifest HD. These results differ from findings in other neurological disorders, such as Alzheimer disease and traumatic brain injury, which have shown that NfL levels are negatively influenced by poor sleep.",10_16,Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease,15 2 2024,,Huntington_Disease
"<xref rid=""JR1071-8"" ref-type=""bibr"">8</xref>
<xref rid=""JR1071-9"" ref-type=""bibr"">9</xref>
The discrepancy in findings may be attributed to the varied methods of collecting NfL (such as in the cerebrospinal fluid, plasma, or serum). However, this is unlikely, particularly given that Werner et al.
<xref rid=""JR1071-9"" ref-type=""bibr"">9</xref>
used the same method to collect NfL as the present study.
 
Similar to previous investigations,
<xref rid=""JR1071-11"" ref-type=""bibr"">11</xref>",10_17,Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease,15 2 2024,,Huntington_Disease
"<xref rid=""JR1071-11"" ref-type=""bibr"">11</xref>
<xref rid=""JR1071-12"" ref-type=""bibr"">12</xref>
in the present study, the median PSQI values obtained from the premanifest HD group indicated poor sleep quality. However, it is noteworthy that only 16 out of the 28 (57%) individuals assessed had poor sleep quality according to the PSQI (score ≥ 5). This is markedly lower than what has been previously reported by Goodman et al.,
<xref rid=""JR1071-1"" ref-type=""bibr"">1</xref>",10_18,Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease,15 2 2024,,Huntington_Disease
"<xref rid=""JR1071-1"" ref-type=""bibr"">1</xref>
who found that up to 90% of people living with HD experience sleep issues. The discrepancy in findings may be attributed to the fact that Goodman et al.
<xref rid=""JR1071-1"" ref-type=""bibr"">1</xref>
sampled individuals at all stages of the disease, with sleep disturbances more prominent in manifest HD. It is also noteworthy that Goodman et al.
<xref rid=""JR1071-1"" ref-type=""bibr"">1</xref>",10_19,Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease,15 2 2024,,Huntington_Disease
"<xref rid=""JR1071-1"" ref-type=""bibr"">1</xref>
used an unvalidated sleep survey, which may have overestimated sleep issues in the cohort, compared with the PSQI, which was used in the present study.
 
The conflicting findings between our study and previous articles in the literature may result from the fact that subjective sleep quality is not as influential in premanifest HD as CAG repeats.
<xref rid=""JR1071-7"" ref-type=""bibr"">7</xref>",10_20,Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease,15 2 2024,,Huntington_Disease
"<xref rid=""JR1071-7"" ref-type=""bibr"">7</xref>
Future studies should investigate objective sleep measures, such as polysomnography (PSG), in relation to central NfL measures. Moreover, future studies should include larger samples of individuals with premanifest HD, as neurodegeneration in this population can be influenced by several variables other than sleep, such as medication use and alcohol consumption.
<xref rid=""JR1071-14"" ref-type=""bibr"">14</xref>",10_21,Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease,15 2 2024,,Huntington_Disease
"<xref rid=""JR1071-14"" ref-type=""bibr"">14</xref>
Larger sample sizes would also enable moderation analyses on the role of the CAG expansion on associations between NfL and sleep quality.",10_22,Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease,15 2 2024,,Huntington_Disease
"It is important to acknowledge the limitations of the present study when analyzing the results. One significant limitation is the absence of a control group, which makes it difficult to determine whether the relationship between sleep quality and NfL levels is unique to premanifest HD. It is important to note that the present study was designed as cross-sectional and did not collect longitudinal data. Therefore, the findings only reflect the correlation between sleep quality and NfL levels at the time of",10_23,Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease,15 2 2024,,Huntington_Disease
"sleep quality and NfL levels at the time of testing, and it is essential to acknowledge that this relationship may vary over time.",10_24,Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease,15 2 2024,,Huntington_Disease
"While sleep quality has been explored in premanifest HD, the present is the first study to explore the association between sleep quality and neurodegeneration. Contrary to the literature on other neurological disorders, in the present study, we found no association between sleep quality and NfL levels. However, despite using different measures of sleep and neurodegeneration, the findings agree with those made by Baker et al.,
<xref rid=""JR1071-7"" ref-type=""bibr"">7</xref>",10_25,Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease,15 2 2024,,Huntington_Disease
"<xref rid=""JR1071-7"" ref-type=""bibr"">7</xref>
who reported no association between sleep problems and overall brain volume in individuals with premanifest HD. Future studies with objective sleep measures are required to determine the influence of sleep on neurodegeneration in premanifest HD.",10_26,Associations between Sleep Quality and Serum Levels of Neurofilament Light in Individuals with Premanifest Huntington Disease,15 2 2024,,Huntington_Disease
"Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report Huntington disease (HD) is an autosomal dominant genetic neurodegenerative disorder with well-known motor and neuropsychiatric effects. The neuropsychiatric effects are an early manifestation of HD, beginning up to 20 years prior to the movement manifestations [<xref rid=""B1"" ref-type=""bibr"">1</xref>]. There is a high rate of",11_0,Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report,14 2 2024,,Huntington_Disease
"There is a high rate of depression, suicidality, and overall morbidity due to the mental health impacts of the disease [<xref rid=""B2"" ref-type=""bibr"">2</xref>]. The pathophysiology behind HD is still under discovery, but many of its effects are attributed to the aberrant misfolding and subsequent deposition of toxic mutated huntingtin protein in the brain [<xref rid=""B3"" ref-type=""bibr"">3</xref>]. Some proposed mechanisms of the toxicity are changes in the microenvironment resulting in imbalanced",11_1,Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report,14 2 2024,,Huntington_Disease
"in the microenvironment resulting in imbalanced neurotransmitters and excitotoxicity [<xref rid=""B4"" ref-type=""bibr"">4</xref>–<xref rid=""B7"" ref-type=""bibr"">7</xref>], increased free radicals and oxidative stress [<xref rid=""B6"" ref-type=""bibr"">6</xref>, <xref rid=""B7"" ref-type=""bibr"">7</xref>], and decreased neural plasticity [<xref rid=""B4"" ref-type=""bibr"">4</xref>]. With these changes, the homeostasis of the brain is disrupted resulting in an inhibited capacity for recovery, adaptation, and connection.",11_2,Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report,14 2 2024,,Huntington_Disease
"for recovery, adaptation, and connection. This, along with the deposition of huntingtin protein, causes the histological, neuropsychiatric, and physical exam features that are characteristic of the disease. The current first-line treatment for major depressive disorder (MDD) in HD is a selective serotonin reuptake inhibitor with one study showing a 21.23% remission rate with its use [<xref rid=""B8"" ref-type=""bibr"">8</xref>]. This leaves much to be desired in treating the long-standing neuropsychiatric",11_3,Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report,14 2 2024,,Huntington_Disease
"in treating the long-standing neuropsychiatric effects. Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive treatment modality that uses a magnetic coil over the scalp to stimulate the underlying brain. It has been shown to balance neurotransmitters [<xref rid=""B9"" ref-type=""bibr"">9</xref>–<xref rid=""B11"" ref-type=""bibr"">11</xref>], decrease oxidative stress and excitotoxicity [<xref rid=""B9"" ref-type=""bibr"">9</xref>], and enhance neuronal plasticity and synaptogenesis [<xref rid=""B11""",11_4,Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report,14 2 2024,,Huntington_Disease
"plasticity and synaptogenesis [<xref rid=""B11"" ref-type=""bibr"">11</xref>]. Today, rTMS is primarily used in patients with severe MDD, in conjunction with at least one antidepressant medication, who have failed to respond to two or more pharmacological treatments in the past. There is potential for this treatment modality to be effective in a far greater variety of conditions, including neurodegenerative conditions like HD. We present a case report of a 68-year-old female with recently diagnosed HD who",11_5,Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report,14 2 2024,,Huntington_Disease
"68-year-old female with recently diagnosed HD who reports a significant decrease in depression, anxiety, and chorea following treatment with rTMS. The patient had a past mental health history of MDD, generalized anxiety disorder (GAD), post-traumatic stress disorder, and borderline personality disorder. She was diagnosed with HD in January 2023 with genetic analysis showing a 39 CAG repeat in one gene and no known family history of HD. She originally presented for treatment with rTMS, prior to receiving",11_6,Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report,14 2 2024,,Huntington_Disease
"for treatment with rTMS, prior to receiving her HD diagnosis, in June 2021 with severe symptoms of major depression and anxiety. These symptoms had been present for many years with frequent suicidal ideation (SI) without a plan or intent. She tried over eight medications including selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, atypical antipsychotics, bupropion, and lithium but felt they were all ineffective with undesirable side effects. She was found to be a good",11_7,Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report,14 2 2024,,Huntington_Disease
"side effects. She was found to be a good candidate for rTMS for her MDD because she had failed to respond to multiple pharmacological treatments. Prior to starting rTMS, the patient noted having daily SI and a “brain fog” that made it hard to think clearly and manage her finances. Additionally, she reported having poor sleep, low motivation, and overall poor quality of life. It was noted during the first rTMS treatment that she had frequent unintended sporadic movements. Her gait was ataxic, and she was",11_8,Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report,14 2 2024,,Huntington_Disease
"movements. Her gait was ataxic, and she was unable to sit completely still with frequent movement in the arms, legs, trunk, face, and mouth. The patient started right-sided rTMS 5 times per week for 30 treatments followed by a three, two, and one treatment(s) per week taper. Treatment involved a B-60 figure eight coil on the dorsolateral prefrontal cortex found using the BEAM method. Her motor threshold was found and rechecked on treatments 10, 20, 24, and 34. She was treated at 110% of her motor threshold",11_9,Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report,14 2 2024,,Huntington_Disease
"She was treated at 110% of her motor threshold at an amplitude of 45 for 15 min with 900 pulse total and 1 pps repetition rate and an interval of 0.1 s. She completed 41 treatments of rTMS from June to July 2021. Her progress was assessed using PHQ9 and GAD7 with her initial score being 25 and 19, respectively, and a final score of 2 and 4, respectively. During her first round of rTMS, she had been and continued taking 20 mg citalopram, 60 mg duloxetine, and 30 mg of buspirone. In April 2023, she presented",11_10,Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report,14 2 2024,,Huntington_Disease
"30 mg of buspirone. In April 2023, she presented with recurrent symptoms of depression and anxiety that slowly redeveloped over the interval of 21 months. Prior to this, in January 2023, she was referred to a neurologist for abnormal movements and received a diagnosis of HD. Genetic testing showed a 39 CAG repeat on one allele and 20 CAG repeats on the other. She only became aware of her unintended movements in December 2022, although her daughter noticed them a few months prior. In her second intake for",11_11,Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report,14 2 2024,,Huntington_Disease
"them a few months prior. In her second intake for rTMS, she reported that her previous treatment remarkably improved her mood disorder along with lessening her chorea. She was again found to be a good candidate for rTMS with her previous improvement and continued lack of response to pharmacological treatments alone. She restarted treatment in April 2023 and completed 36 treatments in June 2023. The second round of rTMS focused on the left side because she was more impacted by anxiety than depression at",11_12,Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report,14 2 2024,,Huntington_Disease
"was more impacted by anxiety than depression at that time. She underwent 5 treatments per week for 30 treatments followed by three, two and one treatment(s) per week taper. A B-60 figure 8 coil was used on her left DLPRC, found using the BEAM method. She completed 36 treatments of TMS at a 120% motor threshold at an amplitude of 43. There were 75 pulse trains with 40 pulses, 10 pulses per second, and 11 s between trains. Her motor threshold was rechecked on treatment number 9 and 19 to maintain 120% motor",11_13,Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report,14 2 2024,,Huntington_Disease
"treatment number 9 and 19 to maintain 120% motor threshold. During this treatment, she took 30 mg of buspirone daily with no changes. She reported no side effects during or after her rTMS treatments. After completing her 36 treatments with a taper, she continued with a maintenance regimen of one rTMS treatment per week. Her progress was assessed using PHQ9, GAD7, and the Unified Huntington’s Disease Rating Scale (UHDRS<sup>®</sup>) [<xref rid=""B12"" ref-type=""bibr"">12</xref>]. The treatment team focused on",11_14,Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report,14 2 2024,,Huntington_Disease
"The treatment team focused on the motor, behavioral, and functional portion of the UDHRS<sup>®</sup> for this patient. Her PHQ9, GAD7, and UDHRS<sup>®</sup> scores throughout treatment are displayed in <xref rid=""T1"" ref-type=""table"">Tables 1</xref> and <xref rid=""T2"" ref-type=""table"">2</xref>. She completed four weeks of maintenance treatment at the last follow-up and, while still struggling with her social environment, felt that her rTMS treatments were successful. She was continued on a once per week",11_15,Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report,14 2 2024,,Huntington_Disease
"successful. She was continued on a once per week left-sided rTMS maintenance regimen as described above. The maintenance regimen was working well for her, and her chorea was even less noticeable than one month prior. She remains capable of living independently with minimal symptoms and an increased feeling of purpose in her life. She was adherent to the treatment plan and denied having any adverse side effects. From the patient’s perspective, both rounds of rTMS significantly improved her mood, cognition,",11_16,Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report,14 2 2024,,Huntington_Disease
"rTMS significantly improved her mood, cognition, and quality of life. The brain fog she described was particularly debilitating, but she noticed that it appeared to lift after just one treatment, giving her back her independence. Furthermore, she notes that rTMS improved her motivation and desire to engage in hobbies and allowed her to maintain her independence in a fulfilling way. She is now optimistic about her future, whereas before she felt hopeless. The rTMS treatment succeeded when all other",11_17,Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report,14 2 2024,,Huntington_Disease
The rTMS treatment succeeded when all other pharmacological treatments failed. The patient felt it important to add that she tried nine total treatments with Spravato in between her first and second rounds of rTMS that significantly reduced her SI. She discontinued the Spravato because she was unable to tolerate the effects during treatment and felt it had worked sufficiently to discontinue. HD is a progressive genetic disorder that causes significant morbidity prior to ultimately taking the person’s life.,11_18,Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report,14 2 2024,,Huntington_Disease
"prior to ultimately taking the person’s life. This case report adds to the growing literature indicating rTMS as a viable first-line treatment of the neuropsychiatric and possibly the movement disorder in HD. Some of the key pathophysiological processes in HD are potentially attenuated and even reversed by rTMS [<xref rid=""B13"" ref-type=""bibr"">13</xref>]. The processes that may have led to this patient’s successful response to rTMS are the metabolism and reduction of ROS [<xref rid=""B6""",11_19,Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report,14 2 2024,,Huntington_Disease
"metabolism and reduction of ROS [<xref rid=""B6"" ref-type=""bibr"">6</xref>, <xref rid=""B7"" ref-type=""bibr"">7</xref>, <xref rid=""B9"" ref-type=""bibr"">9</xref>], rebalancing of neurotransmitters [<xref rid=""B4"" ref-type=""bibr"">4</xref>–<xref rid=""B7"" ref-type=""bibr"">7</xref>, <xref rid=""B9"" ref-type=""bibr"">9</xref>, <xref rid=""B10"" ref-type=""bibr"">10</xref>], activation of the DLPC [<xref rid=""B5"" ref-type=""bibr"">5</xref>], and/or increased neuroplasticity [<xref rid=""B4"" ref-type=""bibr"">4</xref>, <xref",11_20,Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report,14 2 2024,,Huntington_Disease
"[<xref rid=""B4"" ref-type=""bibr"">4</xref>, <xref rid=""B11"" ref-type=""bibr"">11</xref>]. In HD, there is hypoactivation of the dorsal lateral prefrontal cortex [<xref rid=""B5"" ref-type=""bibr"">5</xref>], an area specifically targeted by rTMS for depression. The repetitive stimulation may work to rebalance the dysregulation in HD by strengthening healthy connections, creating new connections, and encouraging a more homeostatic microenvironment via cellular regulation and metabolism. This treatment modality is",11_21,Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report,14 2 2024,,Huntington_Disease
"and metabolism. This treatment modality is potentially an underutilized tool for HD, especially early in the disease process. Two other case reports have reported on the use of rTMS on a patient with HD. Both patients in these case reports showed alleviation of their neuropsychiatric symptoms with the latter showing potential reduction of their movement disorder [<xref rid=""B14"" ref-type=""bibr"">14</xref>, <xref rid=""B15"" ref-type=""bibr"">15</xref>]. rTMS provides a unique opportunity to be used as an early",11_22,Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report,14 2 2024,,Huntington_Disease
"a unique opportunity to be used as an early intervention in patients with HD with potentially far better success than exclusive pharmacological treatment. Certain medications may be used in adjunct to rTMS to enhance the neuroplasticity effects. Examples are medications that work on the N-methyl-D-aspartate and brain-derived neurotrophic factor receptor such as ketamine and fluoxetine. Additionally, combination treatment with psychotherapy and/or exercise therapy may further potentiate the effects of rTMS",11_23,Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report,14 2 2024,,Huntington_Disease
"may further potentiate the effects of rTMS by inducing functional and epigenetic changes that are conducive to neuroplasticity. Medications that may dampen the effects of rTMS by suppressing neuronal activity are alcohol, benzodiazepines, and opioids. More clinical research needs to be done to assess the efficacy of rTMS on both the neuropsychiatric and movement portions of HD at different stages of the disease. This case report was written using help from the CARE guidelines for case reports [<xref",11_24,Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report,14 2 2024,,Huntington_Disease
"from the CARE guidelines for case reports [<xref rid=""B16"" ref-type=""bibr"">16</xref>]. The CARE guideline checklist has been completed by the authors and attached as online supplementary material (for all online suppl. material, see <ext-link http://www.w3.org/1999/xlink href=""10.1159/000537750"" ext-link-type=""doi"">https://doi.org/10.1159/000537750</ext-link>). Written informed consent was obtained from the patient for publication of the details of their medical case and accompanying images. Ethical",11_25,Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report,14 2 2024,,Huntington_Disease
medical case and accompanying images. Ethical approval is not required for this case report in accordance with local guidelines. The authors have no conflicts of interest to declare. No funding was received for this project. Cheyenne Rahn and Kris Peterson were responsible for patient care. Cheyenne Rahn and Lizzie Lamb wrote the manuscript. All authors read and approved the final manuscript.,11_26,Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder in Huntington Disease Patient with Improvement in Neuropsychiatric and Movement Symptoms: A Case Report,14 2 2024,,Huntington_Disease
"CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress Huntington disease (HD) is a neurodegenerative disease caused by the abnormal expansion of a polyglutamine tract resulting from a mutation in the <italic toggle=""yes"">HTT</italic> gene. Oxidative stress has been identified as a significant contributing factor to the development of HD and other neurodegenerative diseases, and targeting anti-oxidative stress has emerged as a potential therapeutic",12_0,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"stress has emerged as a potential therapeutic approach. CHCHD2 is a mitochondria-related protein involved in regulating cell migration, anti-oxidative stress, and anti-apoptosis. Although CHCHD2 is highly expressed in HD cells, its specific role in the pathogenesis of HD remains uncertain. We postulate that the up-regulation of CHCHD2 in HD models represents a compensatory protective response against mitochondrial dysfunction and oxidative stress associated with HD. To investigate this hypothesis, we",12_1,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"with HD. To investigate this hypothesis, we employed HD mouse striatal cells and human induced pluripotent stem cells (hiPSCs) as models to examine the effects of CHCHD2 overexpression (CHCHD2-OE) or knockdown (CHCHD2-KD) on the HD phenotype. Our findings demonstrate that CHCHD2 is crucial for maintaining cell survival in both HD mouse striatal cells and hiPSCs-derived neurons. Our study demonstrates that CHCHD2 up-regulation in HD serves as a compensatory protective response against oxidative stress,",12_2,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"protective response against oxidative stress, suggesting a potential anti-oxidative strategy for the treatment of HD. Huntington disease (HD) is a genetic neurodegenerative disease caused by the abnormal expansion of the CAG repeats encoding polyglutamine in the <italic toggle=""yes"">HTT</italic> gene resulting in the mutant huntingtin protein [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. Currently, treatment options for HD are limited to symptom management, with no effective method to halt or delay disease",12_3,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"with no effective method to halt or delay disease progression. Research on HD pathogenesis holds great significance: the clear genetic basis of HD facilitates the establishment of animal and cellular models, providing a solid foundation for exploring underlying disease mechanisms and an opportunity to evaluate promising therapies in a well-defined patient population. Furthermore, HD shares clinical manifestations and molecular signaling pathway abnormalities with other neurodegenerative diseases like",12_4,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"with other neurodegenerative diseases like Alzheimer’s disease (AD) and Parkinson’s disease (PD), including specific subtypes of neuronal death and protein misfolding and deposition [<xref ref-type=""bibr"" rid=""CR2"">2</xref>]. Therefore, investigating HD pathogenesis can offer important insights and ideas for the study and treatment of other neurodegenerative diseases. The specific molecular mechanisms underlying HD pathogenesis remain incompletely understood, but previous studies have highlighted the",12_5,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"but previous studies have highlighted the involvement of oxidative stress in HD pathophysiology. For instance, increased oxidative stress has been observed in the peripheral blood of HD patients [<xref ref-type=""bibr"" rid=""CR3"">3</xref>] and HD animal models [<xref ref-type=""bibr"" rid=""CR4"">4</xref>]. Factors contributing to oxidative stress in HD include the aggregation of mutant huntingtin proteins, impaired antioxidant systems, elevated brain lipid content, high neuronal energy demands, mitochondrial",12_6,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"high neuronal energy demands, mitochondrial electron transport chain damage, and mitochondrial dysfunction. HD cell mitochondria demonstrate significant alterations in morphology, structure, and Ca2<sup>+</sup> homeostasis. These changes lead to reduced oxidative phosphorylation levels, inadequate ATP production, elevated levels of reactive oxygen species (ROS), and subsequent onset of oxidative stress. Excessive ROS levels are considered pathological markers of HD, inducing toxicity, contributing to",12_7,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"markers of HD, inducing toxicity, contributing to further mitochondrial damage and protein misfolding, and ultimately resulting in neuronal death [<xref ref-type=""bibr"" rid=""CR5"">5</xref>]. The nuclear factor NFE2-related factor 2-antioxidant response element (Nrf2-ARE) signaling pathway represents one of the most critical anti-oxidative stress pathways [<xref ref-type=""bibr"" rid=""CR6"">6</xref>]. Activation of this pathway leads to the activation of various downstream antioxidant genes, including NQO1,",12_8,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"downstream antioxidant genes, including NQO1, GCLC, GCLM, and HO-1. These antioxidant genes eliminate cellular oxidative stress and restore the balance between pro-oxidants and antioxidants to maintain normal cellular function [<xref ref-type=""bibr"" rid=""CR7"">7</xref>]. Importantly, Nrf2-ARE signaling activation has been identified in HD cells, potentially serving as a compensatory protective mechanism against oxidative stress in HD. CHCHD2, a mitochondrial protein encoded by nuclear genes, belongs to the",12_9,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"protein encoded by nuclear genes, belongs to the “CHCH” protein family. Its physiological functions are diverse, including regulation of cell migration, differentiation, oxidative phosphorylation, maintenance of mitochondrial structure, and anti-apoptosis [<xref ref-type=""bibr"" rid=""CR8"">8</xref>]. Under hypoxic conditions, CHCHD2 acts as a transcription factor, binding to the conserved Oxygen Response Element (ORE) within the COX4I2 gene, and transcriptionally activating genes such as COX4I2 and CHCHD2",12_10,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"activating genes such as COX4I2 and CHCHD2 itself [<xref ref-type=""bibr"" rid=""CR9"">9</xref>]. Knockout of the CHCHD2 gene in cells reduces COX activity, increases ROS levels, and leads to mitochondrial fragmentation and apoptosis [<xref ref-type=""bibr"" rid=""CR10"">10</xref>, <xref ref-type=""bibr"" rid=""CR11"">11</xref>]. Conversely, overexpression of CHCHD2 protein reduces ROS levels and inhibits apoptosis [<xref ref-type=""bibr"" rid=""CR12"">12</xref>], suggesting a potential role for CHCHD2 in anti-oxidative",12_11,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"a potential role for CHCHD2 in anti-oxidative stress. Although the physiological and pathological functions of the CHCHD family of proteins remain poorly understood, recent research has highlighted their close association with the development of neurodegenerative diseases [<xref ref-type=""bibr"" rid=""CR13"">13</xref>]. Genetic analysis and experimental evidence indicate a strong correlation between <italic toggle=""yes"">CHCHD2</italic> gene mutations and Parkinson’s disease (PD) [<xref ref-type=""bibr""",12_12,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"Parkinson’s disease (PD) [<xref ref-type=""bibr"" rid=""CR14"">14</xref>] and Lewy body disease (LBD) [<xref ref-type=""bibr"" rid=""CR15"">15</xref>]. <italic toggle=""yes"">CHCHD2</italic> mutations in Drosophila have been shown to result in motor dysfunction, degeneration of dopaminergic neurons, shortened lifespan, and mitochondrial dysfunction [<xref ref-type=""bibr"" rid=""CR16"">16</xref>]. Moreover, PD-associated <italic toggle=""yes"">CHCHD2</italic> mutations in human embryonic stem cells (hESCs) have been found",12_13,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"embryonic stem cells (hESCs) have been found to induce mitochondrial abnormalities, including hollow mitochondria with reduced cristae [<xref ref-type=""bibr"" rid=""CR17"">17</xref>]. CHCHD2 has been shown to be up-regulated in HD patient peripheral blood cells, hESCs, human induced pluripotent stem cells (hiPSCs), and hESCs/hiPSCs-derived neuronal cells [<xref ref-type=""bibr"" rid=""CR18"">18</xref>–<xref ref-type=""bibr"" rid=""CR22"">22</xref>]. However, the precise role of CHCHD2 in HD, particularly in",12_14,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"the precise role of CHCHD2 in HD, particularly in modulating HD phenotypes, remains unknown. Given its involvement in maintaining mitochondrial function and resisting oxidative stress, we hypothesize that the up-regulation of CHCHD2 expression may serve as a compensatory protective response to mitochondrial dysfunction and oxidative stress in HD. In addition, we propose that CHCHD2 exerts a neuroprotective effect through the Nrf2-ARE anti-oxidative stress signaling pathway. This study aims to test this",12_15,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"signaling pathway. This study aims to test this hypothesis by manipulating CHCHD2 expression through overexpression or inhibition in HD mouse cell lines and hiPSC models. Moreover, we aim to elucidate the molecular mechanisms underlying the up-regulation of CHCHD2 expression and its anti-oxidative stress effects in HD. The findings from this study have the potential to contribute to the development of biomarkers and therapeutic drug targets for HD and other neurodegenerative diseases.   Oxidative",12_16,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"and other neurodegenerative diseases.   Oxidative stress-mediated neuronal cell death has been implicated in various neurodegenerative disorders including PD, AD, amyotrophic lateral sclerosis (ALS), and HD [<xref ref-type=""bibr"" rid=""CR26"">26</xref>]. Oxidative stress plays a crucial role in the pathogenesis of HD, making it a key target for HD treatment [<xref ref-type=""bibr"" rid=""CR27"">27</xref>]. In this study, we observed high expression of CHCHD2 in HD striatal cells. Overexpression of CHCHD2 reduced",12_17,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"striatal cells. Overexpression of CHCHD2 reduced intracellular ROS levels, enhanced cell survival under oxidative stress, and exerted a neuroprotective effect associated with activation of the Nrf2-ARE pathway. These findings highlight the anti-oxidative stress function of CHCHD2 and provide new insights for HD treatment. The Nrf2/ARE pathway is a critical anti-oxidative stress pathway in neurodegenerative diseases. Activation of Nrf2 has been shown to protect cortical and striatal neurons, reduce motor",12_18,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"cortical and striatal neurons, reduce motor deficits, and extend lifespan in animal models of HD [<xref ref-type=""bibr"" rid=""CR28"">28</xref>]. Selective activation of Nrf2 signaling effectively inhibits the release of the pro-inflammatory factor interleukin-6 in primary microglia and astrocytes from HD and wild-type mice [<xref ref-type=""bibr"" rid=""CR29"">29</xref>]. Moreover, in primary monocytes from healthy individuals and HD patients, Nrf2 suppresses the expression of pro-inflammatory cytokines,",12_19,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"the expression of pro-inflammatory cytokines, including interleukin-1, interleukin-6, interleukin-8, and tumor necrosis factor alpha [<xref ref-type=""bibr"" rid=""CR29"">29</xref>]. These findings collectively support the protective potential of the Nrf2 signaling pathway in key cell types associated with HD pathology, making Nrf2 a potential molecular target for HD treatment. A recent study demonstrated increased expression of Nrf2 and its downstream targets NQO1, HO-1, and GCLM mRNA in an HD model using",12_20,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"NQO1, HO-1, and GCLM mRNA in an HD model using PC12 cells [<xref ref-type=""bibr"" rid=""CR30"">30</xref>]. Consistent with this, our experiments also confirmed elevated mRNA expression levels of Nrf2, NQO1, HO-1, GCLC, and GCLM in HD mouse cell lines, where Q111 cells exhibited significantly higher expression compared to Q7 (Supplemental Fig. <xref rid=""MOESM3"" ref-type=""media"">3</xref>), indicating activation of the Nrf2-ARE anti-oxidative defense system in HD cells. CHCHD2 has recently been identified as a",12_21,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"cells. CHCHD2 has recently been identified as a regulator of mitochondrial metabolism [<xref ref-type=""bibr"" rid=""CR10"">10</xref>, <xref ref-type=""bibr"" rid=""CR31"">31</xref>]. Aras et al. demonstrated that CHCHD2 plays a role in the mitochondrial intermembrane space by activating cytochrome c oxidase (COX) and in the nucleus by promoting the transcription of specific genes, including COX4I2 and itself, in response to hypoxia [<xref ref-type=""bibr"" rid=""CR9"">9</xref>]. Up-regulation of CHCHD2 has been",12_22,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"Up-regulation of CHCHD2 has been observed in HD hESCs, hiPSCs, NSCs and human HD peripheral blood cells [<xref ref-type=""bibr"" rid=""CR18"">18</xref>–<xref ref-type=""bibr"" rid=""CR20"">20</xref>, <xref ref-type=""bibr"" rid=""CR22"">22</xref>]. In our study, KD of CHCHD2 in HD neurons reduced neuronal survival under both normal and growth factor withdrawal conditions. This suggests that the upregulation of CHCHD2 in HD may serve as a compensatory response to mutant HTT, and CHCHD2 could potentially serve as a",12_23,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"HTT, and CHCHD2 could potentially serve as a novel molecular marker of HD pathology. Our findings in this study provide experimental evidence linking CHCHD2 to neuronal death in HD, and point to the potential of CHCHD2 as a prospective drug development target for HD. Considering the potential anti-oxidative effect of CHCHD2 upregulation, it is essential to further clarify the specific transcription factors and pathways regulating CHCHD2 expression and function. Ruan et al. showed that the mitochondrial",12_24,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"Ruan et al. showed that the mitochondrial proteases OMA1 and Yme1L, which have been shown to interact with CHCHD2, are responsible for its degradation under certain conditions [<xref ref-type=""bibr"" rid=""CR32"">32</xref>]. In addition, Wei et al. experimentally verified the interaction between CHCHD2 and p32/C1QBP, a multifunctional mitochondrial chaperone implicated in oxidative stress responses [<xref ref-type=""bibr"" rid=""CR33"">33</xref>, <xref ref-type=""bibr"" rid=""CR34"">34</xref>], highlighting its close",12_25,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"rid=""CR34"">34</xref>], highlighting its close association with the generation of ROS and the oxidative stress process [<xref ref-type=""bibr"" rid=""CR35"">35</xref>]. Furthermore, Liu et al. revealed that CHCHD2 plays a role in regulating the levels of Opa1, a key determinant of mitochondrial dynamics and energetics, by competing with Yme1L for p32/C1QBP binding [<xref ref-type=""bibr"" rid=""CR36"">36</xref>]. These observations suggest complex post-translational processes regulating CHCHD2 expression and",12_26,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"processes regulating CHCHD2 expression and function. However, less is known about the transcriptional mechanisms that influence CHCHD2 expression. Future investigations could explore the involvement of well-known oxidative stress-responsive transcription factors, such as <italic toggle=""yes"">Nrf2</italic> and <italic toggle=""yes"">HIF-1α</italic>, and signaling pathways, like MAPK and PI3K/AKT in this process. Such studies could help clarify the mechanisms underlying changes in CHCHD2 expression in HD and",12_27,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"underlying changes in CHCHD2 expression in HD and would contribute to a more comprehensive understanding of the role CHCHD2 in normal physiology and disease. The establishment of animal models has been instrumental in studying the pathogenesis of HD [<xref ref-type=""bibr"" rid=""CR37"">37</xref>]. However, there are inherent limitations due to differences between humans and animals in terms of anatomy, physiological functions, and the timing and progression of the disease. The emergence of hiPSCs has",12_28,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"of the disease. The emergence of hiPSCs has partially overcome the limitations of animal models [<xref ref-type=""bibr"" rid=""CR38"">38</xref>]. hiPSCs can be derived from the adult cells of HD patients, carrying endogenously expressed full-length mutated HTT proteins and sharing the exact same genetic background as the patients [<xref ref-type=""bibr"" rid=""CR39"">39</xref>]. In the HD hiPSC model, the most stringent control group consists of isogenic controls created using CRISPR technology. The use of",12_29,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"created using CRISPR technology. The use of isogenic controls ensures that the HD and control groups are derived from the same parental cell line and are otherwise identical except for the mutated HTT gene. In our study, we used such isogenic controls for the HD hiPSC lines [<xref ref-type=""bibr"" rid=""CR20"">20</xref>]. In this study, we observed increased ROS levels and cellular susceptibility to growth factor withdrawal in HD hiPSC-derived neuronal cells. Furthermore, overexpression of CHCHD2 protected HD",12_30,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"overexpression of CHCHD2 protected HD hiPSC-derived neurons against growth factor deprivation. In this study, we have demonstrated that both oxidative stress and CHCHD2 expression are increased in HD models. Furthermore, we have observed that CHCHD2 expression is highly induced by oxidative stress in both human and mouse neuronal cells. Through our experiments, we have confirmed that overexpression of CHCHD2 provides protection to neuronal cells against oxidative stress-induced damage. This protective",12_31,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"oxidative stress-induced damage. This protective effect of CHCHD2 is associated with the activation of the Nrf2-ARE signaling pathway, indicating that the up-regulation of CHCHD2 in HD serves as a compensatory response against oxidative stress. Our results suggest that positive modulation of CHCHD2-mediated protective mechanism against oxidative damage in neuronal cells may provide novel neuroprotective strategies for treatment of HD and other neurodegenerative diseases.",12_32,CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress,10 2 2024,,Huntington_Disease
"Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease In Huntington disease (HD) the prodromal phase has been increasingly investigated and is currently in focus for early interventional treatments. Also, the influence of sex on disease progression and severity in patients is under discussion, as a sex-specific impact has been reported in transgenic rodent models for HD. To this end, we have been studying these aspects in Sprague Dawley rats",13_0,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"studying these aspects in Sprague Dawley rats transgenic for HD. Here, we took up on the congenic F344tgHD rat model, expressing a fragmented <italic toggle=""yes"">Htt</italic> construct with 51 CAG repeats on an inbred F344 rat background and characterized potential sexual dimorphism and gene-dosage effects in rats during the pre-symptomatic phase (1–8 months of age). Our study comprises a longitudinal phenotyping of motor function, emotion and sensorimotor gating, as well as screening of metabolic",13_1,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"gating, as well as screening of metabolic parameters with classical and automated assays in combination with investigation of molecular HD hallmarks (striatal cell number and volume estimation, appearance of HTT aggregates). Differences between sexes became apparent during middle age, particularly in the motor and sensorimotor domains. Female individuals were generally more active, demonstrated different gait characteristics than males and less anxiolytic-like behavior. Alterations in both the time course",13_2,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"behavior. Alterations in both the time course and affected behavioral domains varied between male and female F344tgHD rats. First subtle behavioral anomalies were detected in transgenic F344tgHD rats prior to striatal MSN cell loss, revealing a prodromal-like phase in this model. Our findings demonstrate that the congenic F344tgHD rat model shows high face-validity, closely resembling the human disease’s temporal progression, while having a relatively low number of CAG repeats, a slowly progressing",13_3,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"low number of CAG repeats, a slowly progressing pathology with a prodromal-like phase and a comparatively subtle phenotype. By differentiating the sexes regarding HD-related changes and characterizing the prodromal-like phase in this model, these findings provide a foundation for future treatment studies. Huntington disease (HD) is an autosomal dominant, neurodegenerative disorder, which is genetically characterized by a pathologically expanded CAG repeat sequence (>39) in exon 1 of the <italic",13_4,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"repeat sequence (>39) in exon 1 of the <italic toggle=""yes"">IT15</italic> gene located on chromosome 4 with a strong correlation between the CAG repeat length and the age of disease onset (<xref rid=""B68"" ref-type=""bibr"">Snell et al., 1993</xref>; <xref rid=""B73"" ref-type=""bibr"">The Huntington’s Disease Collaborative Research Group, 1993</xref>). The expansion results in an elongated polyQ stretch near the N-terminus of the so-called mutant huntingtin protein (mHTT), which accumulates in neurons and forms",13_5,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"(mHTT), which accumulates in neurons and forms aggregates leading to degeneration of the affected cells (<xref rid=""B16"" ref-type=""bibr"">DiFiglia et al., 1997</xref>; <xref rid=""B63"" ref-type=""bibr"">Scherzinger et al., 1997</xref>; reviewed in: <xref rid=""B4"" ref-type=""bibr"">Bates, 2003</xref>). Atrophy is especially present in basal ganglia and the neocortex of HD patients due to predominant loss of striatal GABA-ergic medium spiny neurons (MSN) and cortical pyramidal neurons (<xref rid=""B30""",13_6,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"and cortical pyramidal neurons (<xref rid=""B30"" ref-type=""bibr"">Halliday et al., 1998</xref>; <xref rid=""B81"" ref-type=""bibr"">Waldvogel et al., 2014</xref>; <xref rid=""B32"" ref-type=""bibr"">Jiang et al., 2023</xref>). Clinically, patients suffer from a triad of slowly progressive symptoms, i.e., often early mood and mental disturbances, followed by a hyperkinetic movement disorder and late cognitive decline that vary in severity and time of onset. First subtle emotional and cognitive deficits are already",13_7,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"emotional and cognitive deficits are already detectable about 15 years prior to any motor symptoms during the so-called prodrome. Subsequently, the beginning of the symptomatic phase is characterized by minor motor impairments (e.g., clumsiness or unstable gait), emotional disturbances, (e.g., anxiety or depression) and first subtle cognitive difficulties (e.g., problems with time estimation, decision making). Later, motor impairment, particularly choreatic movements, as well as deterioration of gait,",13_8,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"movements, as well as deterioration of gait, speech and swallowing, and further decline of cognitive functions occur. In the final stage of the disease, patients display severe weight loss and chorea transitions into rigidity, bradykinesia and dystonia (<xref rid=""B62"" ref-type=""bibr"">Sanberg et al., 1981</xref>; <xref rid=""B33"" ref-type=""bibr"">Johnson et al., 2014</xref>). Despite ongoing efforts, therapy today pursues a mere symptomatic approach and patients usually die within 10–15 years after",13_9,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"and patients usually die within 10–15 years after occurrence of the first motor symptoms (<xref rid=""B15"" ref-type=""bibr"">Dickey and la Spada, 2018</xref>). Lately, more attention is given to the pre-symptomatic as well as the prodromal phase (<xref rid=""B6"" ref-type=""bibr"">Blockx et al., 2012</xref>; <xref rid=""B67"" ref-type=""bibr"">Siebzehnrübl et al., 2018</xref>; <xref rid=""B83"" ref-type=""bibr"">Wood, 2018</xref>). In the latter, first subtle changes are already detectable but motor impairment and",13_10,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"are already detectable but motor impairment and pathological damage are still widely absent. Therefore, this phase is considered ideal for early intervention studies (<xref rid=""B32"" ref-type=""bibr"">Jiang et al., 2023</xref>). Ongoing preclinical research should focus even more on early onset alterations in an attempt to specify the prodromal-like phase and being of special interest to open the change for early diagnosis and to facilitate therapy of this deadly disease. Similar to other neurodegenerative",13_11,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"disease. Similar to other neurodegenerative diseases, the clinical picture of HD appears to be influenced by the patient’s sex. The majority of studies describe a slower and milder progression with higher prevalence for emotional disturbances in women (<xref rid=""B23"" ref-type=""bibr"">Foroud et al., 1999</xref>; <xref rid=""B52"" ref-type=""bibr"">Pekmezovic et al., 2007</xref>; <xref rid=""B18"" ref-type=""bibr"">Epping and Paulsen, 2011</xref>; <xref rid=""B60"" ref-type=""bibr"">Reedeker et al., 2012</xref>; <xref",13_12,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"et al., 2012</xref>; <xref rid=""B45"" ref-type=""bibr"">McAllister et al., 2021</xref>). Contradictory reports, however, stating no influence of sex exist as well (<xref rid=""B84"" ref-type=""bibr"">Zielonka et al., 2013</xref>; <xref rid=""B12"" ref-type=""bibr"">Dale et al., 2016</xref>). Size and ethnicity of the study cohorts and the environmental factors taken into account seem to substantially influence whether significant sex differences become evident or not (<xref rid=""B55"" ref-type=""bibr"">Pringsheim et",13_13,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"(<xref rid=""B55"" ref-type=""bibr"">Pringsheim et al., 2012</xref>; <xref rid=""B47"" ref-type=""bibr"">Meoni et al., 2020</xref>). Based on current literature, it can be said that the role of patients’ sex is controversially discussed but yet poorly understood. It is most probably accountable for some of the variability observed between patients, but more investigation is needed to fully determine the role of sex as biological variable in HD patients. Animal models, which are normally more standardized and less",13_14,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"which are normally more standardized and less influenced by environmental factors than human individuals, reflecting HD pathology show clear differences between sexes on molecular and behavioral levels as well, apparently independent of the genetic construct, background or species. Similar to the human situation, a more severe phenotype is seemingly present in male animals (<xref rid=""B17"" ref-type=""bibr"">Dorner et al., 2007</xref>; <xref rid=""B8"" ref-type=""bibr"">Bode et al., 2008</xref>; <xref rid=""B42""",13_15,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"et al., 2008</xref>; <xref rid=""B42"" ref-type=""bibr"">Kuljis et al., 2016</xref>; <xref rid=""B51"" ref-type=""bibr"">Padovan-Neto et al., 2019</xref>). A common misconduct in neuroscientific studies is the omission of sex differentiation or bias toward usage of exclusively male animals, which prevents the possibility to refine studies in the sense of the 3R principle and more importantly leads to impaired translatability, constituting an unacceptable risk for any interventional study (<xref rid=""B66""",13_16,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"for any interventional study (<xref rid=""B66"" ref-type=""bibr"">Shansky and Woolley, 2016</xref>; <xref rid=""B82"" ref-type=""bibr"">Will et al., 2017</xref>). The F344/HanSvh-Tg (tmHTT51CAG) (F344tgHD) strain is one of the very few rat models for HD (reviewed: <xref rid=""B10"" ref-type=""bibr"">Carreira et al., 2013</xref>). It constitutes a backcrossed version of the thoroughly characterized SPRDtgHD model (<xref rid=""B80"" ref-type=""bibr"">von Hörsten et al., 2003</xref>) with a truncated <italic",13_17,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"et al., 2003</xref>) with a truncated <italic toggle=""yes"">Htt</italic> construct comprising 51 CAG repeat. Homozygous males have been shown to reflect major key symptoms of human HD pathology like striatal volume reduction at 21 months and an early behavioral phenotype (<xref rid=""B54"" ref-type=""bibr"">Plank et al., 2018</xref>). A comprehensive sex comparison of this model as well as in-depth analysis of potential gene-dosage (zygosity) effects and advanced investigations into motor deficits as well as",13_18,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"investigations into motor deficits as well as early, prodromal-like symptoms are still owing (<xref rid=""B54"" ref-type=""bibr"">Plank et al., 2018</xref>). Classical motor tasks as performed by <xref rid=""B54"" ref-type=""bibr"">Plank et al. (2018)</xref> so far failed to detect eventual early motor impairments. Therefore, this study presents a comprehensive, longitudinal phenotyping with classical as well as automated behavioral assays in combination with investigation of molecular HD hallmarks (striatal MSN",13_19,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"of molecular HD hallmarks (striatal MSN loss, striatal volume reduction, presence of HTT aggregates) in female and male F344tgHD rats aged 1–8 months. Our study describes a prodromal-like phase in F344tgHD rats, where subtle behavioral impairments are already detectable while significant striatal cell loss and volume reduction is still absent. Additionally, we observed clear sexual dimorphism especially in the motor and sensorimotor domains in all three genotypes, stressing the need to distinguish between",13_20,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"stressing the need to distinguish between sexes to refine future studies and thereby increase the translatability.  This study aimed at characterizing early behavioral and molecular alteration in transgenic F344tgHD animals with special emphasis on potential sex-dimorphism (see <xref rid=""F1"" ref-type=""fig"">Figure 1A</xref> for study design). It comprises a longitudinal behavioral analysis as well as stereological and molecular investigation of HD hallmarks. All investigated parameters showed a significant",13_21,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
All investigated parameters showed a significant age-effect not further indicated in the graphs for clearer illustration. This is the first comparison of behavioral and neuropathological changes in both sexes of the F344tgHD rat model of HD and the first study designed to directly evaluate a prodromal-like phase in this model. We found first subtle behavioral changes in F344tgHD rats already at young age and significant differences between sexes especially in the motor and sensorimotor domain associated,13_22,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"in the motor and sensorimotor domain associated with decreased numbers of DARP32<sup>±</sup>cells in tg animals compared to wt controls at 8 months of age. The F344tgHD model is one of only three available rat models for HD (SDtgHDCAG<sub><italic toggle=""yes"">n</italic>51<italic toggle=""yes"">trunc</italic></sub>; F344tgHDCAG<sub><italic toggle=""yes"">n</italic>51<italic toggle=""yes"">trunc</italic></sub>; BACHD<sub><italic toggle=""yes"">CAGCAAn</italic>98</sub>) and constitutes a congenic version of the",13_23,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"and constitutes a congenic version of the previous SPRDtgHD model. Higher reproducibility and reliability are ensured by inbreeding of the F344tgHD rats (<xref rid=""B21"" ref-type=""bibr"">Festing, 2010</xref>) and their smaller body size is advantageous for imaging techniques (<xref rid=""B77"" ref-type=""bibr"">Urbach et al., 2014</xref>; <xref rid=""B54"" ref-type=""bibr"">Plank et al., 2018</xref>). The F344 background further qualifies this model especially for research on stress-related neuroendocrinology and",13_24,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"research on stress-related neuroendocrinology and -inflammation (<xref rid=""B79"" ref-type=""bibr"">Vodička et al., 2020</xref>). Male representatives have been previously characterized at symptomatic age by our group demonstrating the major key aspects of the adult-onset form of HD (<xref rid=""B80"" ref-type=""bibr"">von Hörsten et al., 2003</xref>; <xref rid=""B54"" ref-type=""bibr"">Plank et al., 2018</xref>). A thorough characterization of the rat equivalent to the human prodromal phase, currently in focus for",13_25,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"the human prodromal phase, currently in focus for early interventional treatments, as well as investigation of zygosity effects and potential sex dimorphism, was missing so far. Hence, we performed a comprehensive, longitudinal, cross sectional, in-depth analysis of female and male 1–8 months old F344tgHD rats. We thereby aim at increasing the validity and translatability of future studies while simultaneously causing a decrease in the number of used animals in the sense of the 3R principle “refine.”",13_26,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"in the sense of the 3R principle “refine.” Taking into account the neuropathological status of the animals, where they present mHTT-containing aggregates and pronounced striatal cell loss with a gene-dosage effect at 8 months, male F344tgHD convincingly replicate a prodromal-like phase as seen in human HD patients with early emotional disturbances prior to an apparent motor phenotype and observable neuropathology. In females the correlation between behavioral phenotype and neuropathology seems to be more",13_27,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"phenotype and neuropathology seems to be more complex. Hom females showed an early hyperactive motor phenotype with choreiform head movements, while subtle emotional disturbances became overt later. In contrast, het F344tgHD females did neither show a motor phenotype, nor significant cell loss, but instead an increase in the number of DARPP32<sup>±</sup>cells. Hence, het F344tgHD females present an unexpected delay of onset of HD symptoms. In summary, our study shows that HD progression follows a",13_28,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"our study shows that HD progression follows a sex-dependent course in the F344tgHD rat model with a clear prodromal-like phase in hom males and a relatively stronger motor phenotype in hom females. This characterization increases the validity and translatability of the model, contributing to the 3R principle “refine.” The described differences between female and male rats emphasize the importance of including sex as biological variable in preclinical studies to avoid a gender data gap and increase the",13_29,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"to avoid a gender data gap and increase the translatability of animal models and the associated outcome of therapeutical studies thereon. The original contributions presented in the study are included in the article/<xref rid=""FS1"" ref-type=""supplementary-material"">Supplementary material</xref>, further inquiries can be directed to the corresponding author. The animal studies were approved by Government of Lower Franconia, Bavaria, Germany. The studies were conducted in accordance with the local",13_30,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"were conducted in accordance with the local legislation and institutional requirements. Written informed consent was obtained from the owners for the participation of their animals in this study. VR-W: Writing – original draft, Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Project administration, Visualization. JoH: Writing – review and editing. SM: Writing – review and editing. JuH: Data curation, Writing – review and editing. CS: Writing – review and editing. SH:",13_31,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"editing. CS: Writing – review and editing. SH: Supervision, Writing – review and editing, Conceptualization, Data curation, Funding acquisition, Project administration, Resources.",13_32,Gene-dosage- and sex-dependent differences in the prodromal-Like phase of the F344tgHD rat model for Huntington disease,07 2 2024,,Huntington_Disease
"Digital assessment of speech in Huntington disease Huntington disease (HD) is an inherited neurodegenerative disease characterized by complex motor, cognitive, and behavioral symptoms. The onset of HD features typically occurs in midlife and symptoms progressively worsen (<xref rid=""ref1"" ref-type=""bibr"">1</xref>). Prior to meeting criteria for clinical diagnosis of HD, individuals who carry the <italic toggle=""yes"">huntingtin</italic> gene can be classified as having Prodromal HD and may experience some",14_0,Digital assessment of speech in Huntington disease,23 1 2024,,Huntington_Disease
"as having Prodromal HD and may experience some symptoms of HD (<xref rid=""ref2"" ref-type=""bibr"">2</xref>). Presently, there are no disease-modifying therapies to halt or slow HD progression, and clinical care largely focuses on symptomatic management (<xref rid=""ref3"" ref-type=""bibr"">3</xref>). However, longitudinal studies found that HD develops over many years since the onset of neurodegeneration and that some symptoms may be present years before clinical diagnosis (<xref rid=""ref4""",14_1,Digital assessment of speech in Huntington disease,23 1 2024,,Huntington_Disease
"years before clinical diagnosis (<xref rid=""ref4"" ref-type=""bibr"">4</xref>, <xref rid=""ref5"" ref-type=""bibr"">5</xref>). Early intervention in disease progression may be critical in identifying disease modifying agents. Speech changes often occur early in HD progression and may be observed prior to other motor, cognitive, and psychiatric symptoms, and may also be detected during the prodromal HD stage (<xref rid=""ref6"" ref-type=""bibr"">6</xref>). Individuals with HD may exhibit alterations in speech clarity,",14_2,Digital assessment of speech in Huntington disease,23 1 2024,,Huntington_Disease
"HD may exhibit alterations in speech clarity, articulation, or phonation, and experience a decline in syntactic complexity and speech rate (<xref rid=""ref7"" ref-type=""bibr"">7</xref>, <xref rid=""ref8"" ref-type=""bibr"">8</xref>). HD can also disrupt the pitch, rhythm, and stress of speech (“prosodic features”) which can lead to abnormalities in the melody and timing of speech, causing irregular pausing and intensity patterns (<xref rid=""ref6"" ref-type=""bibr"">6</xref>, <xref rid=""ref9""",14_3,Digital assessment of speech in Huntington disease,23 1 2024,,Huntington_Disease
"ref-type=""bibr"">6</xref>, <xref rid=""ref9"" ref-type=""bibr"">9</xref>). Since speech symptoms can present early in HD, tracking changes in speech may be a valuable marker of early disease and disease progression (<xref rid=""ref6"" ref-type=""bibr"">6</xref>). Assessment of HD commonly uses standardized clinician-rated outcome measures that are often administered in a clinic setting. These rating scales are limited by high inter-observer variability, insensitivity, and episodic administration (<xref rid=""ref10""",14_4,Digital assessment of speech in Huntington disease,23 1 2024,,Huntington_Disease
"and episodic administration (<xref rid=""ref10"" ref-type=""bibr"">10</xref>). Digital measures can enable quantitative, remote, and passive assessment of various diseases and disease-specific features. Digital measures have become increasingly popular with a rise in the ubiquity of sensing technologies (<xref rid=""ref11"" ref-type=""bibr"">11</xref>). In HD research, smartwatches (<xref rid=""ref12"" ref-type=""bibr"">12</xref>), smartphone apps (<xref rid=""ref13"" ref-type=""bibr"">13</xref>), and wearable sensors",14_5,Digital assessment of speech in Huntington disease,23 1 2024,,Huntington_Disease
"ref-type=""bibr"">13</xref>), and wearable sensors (<xref rid=""ref14"" ref-type=""bibr"">14</xref>) have been leveraged to collect measurements of gait, finger tapping, chorea, and global activity (<xref rid=""ref15"" ref-type=""bibr"">15</xref>, <xref rid=""ref16"" ref-type=""bibr"">16</xref>). While digital measures have been most well studied to capture motor symptoms of HD (<xref rid=""ref17"" ref-type=""bibr"">17</xref>), digital measures for speech symptoms of HD are a promising area of research given the early",14_6,Digital assessment of speech in Huntington disease,23 1 2024,,Huntington_Disease
"are a promising area of research given the early presence of speech features in HD progression. Speech measurements are also easy to collect and can be recorded in clinic or remote settings using simple, accessible devices (<xref rid=""ref18"" ref-type=""bibr"">18</xref>). Different types of speech tasks can be performed to capture different features of speech, such as spontaneous free-flowing speech, passage reading, and syllable repetition (<xref rid=""ref19"" ref-type=""bibr"">19</xref>), and features derived",14_7,Digital assessment of speech in Huntington disease,23 1 2024,,Huntington_Disease
"ref-type=""bibr"">19</xref>), and features derived from phonetic, articulatory and prosodic characteristic of the speech can be used to detect and monitor neuromotor dysfunction (<xref rid=""ref20"" ref-type=""bibr"">20</xref>). To test the sensitivity of speech features in differentiating individuals with HD, prodromal HD (pHD), and control participants, and in capturing disease severity, three speech tasks were performed. Speech feature outcomes were used to test for group differences, correlations with",14_8,Digital assessment of speech in Huntington disease,23 1 2024,,Huntington_Disease
"to test for group differences, correlations with clinical scores, and to train machine learning models to classify groups and predict clinical scores.   The present study investigated the utility of speech-based measures for assessing neurodegenerative movement disorders, focusing on HD. The study demonstrated the clinical potential significance of speech features obtained during passage reading and counting tasks. These assessments can be administered remotely and very frequently, allowing for a fine",14_9,Digital assessment of speech in Huntington disease,23 1 2024,,Huntington_Disease
"remotely and very frequently, allowing for a fine graded assessment of disease progression. The results demonstrated significant group differences in passage reading features between HD, pHD, and control groups. In general, a pattern can be seen where individuals in the HD and control groups differ the most across the passage reading features, while those with pHD are in between the two groups. However, while HD showed pronounced variations compared to pHD and control, the pHD group displayed minimal",14_10,Digital assessment of speech in Huntington disease,23 1 2024,,Huntington_Disease
"pHD and control, the pHD group displayed minimal deviations from the control, likely attributable to their early disease stage’s subtle phenotypic shifts and perhaps their age, which was younger than the other groups. Additionally, correlations with clinical scores and successful machine learning models for group differentiation and prediction of clinical scores were observed. In the analysis of passage reading features, HD participants exhibited distinct speech patterns compared to pHD and control groups.",14_11,Digital assessment of speech in Huntington disease,23 1 2024,,Huntington_Disease
"patterns compared to pHD and control groups. Notably, the speech-to-pause ratio was significantly lower in the HD group, indicating a higher proportion of pauses or silence relative to speech. Moreover, total pause time and total signal time were significantly longer in the HD group, suggesting more frequent and prolonged pauses during speech production. These differences in speech features may be indicative of dysarthria, a common symptom in HD, affecting motor speech control and articulation, and are in",14_12,Digital assessment of speech in Huntington disease,23 1 2024,,Huntington_Disease
"motor speech control and articulation, and are in line with previous studies (<xref rid=""ref30"" ref-type=""bibr"">30</xref>–<xref rid=""ref32"" ref-type=""bibr"">32</xref>). However, features related to loudness, pitch, articulatory rate, and total voiced time did not demonstrate significant group differences. In the counting forwards task, there were minimal differences between groups in errors made while counting (See <xref rid=""SM1"" ref-type=""supplementary-material"">Supplementary Table S1</xref> of the <xref",14_13,Digital assessment of speech in Huntington disease,23 1 2024,,Huntington_Disease
"Table S1</xref> of the <xref rid=""SM1"" ref-type=""supplementary-material"">Supplementary materials</xref>). This is consistent with the results from our study in older adults with and without cognitive decline (<xref rid=""ref33"" ref-type=""bibr"">33</xref>), where no differences in counting errors were observed between the two groups. However, the HD group had significantly higher counting errors on the counting backwards task compared to the prodromal and control groups (See <xref rid=""SM1""",14_14,Digital assessment of speech in Huntington disease,23 1 2024,,Huntington_Disease
"prodromal and control groups (See <xref rid=""SM1"" ref-type=""supplementary-material"">Supplementary Table S2</xref> of the <xref rid=""SM1"" ref-type=""supplementary-material"">Supplementary materials</xref>). Correlation analyses further supported the significance of speech features as potential markers of disease severity. Several speech features showed significant moderate to strong correlations with clinical scores related to cognitive function, motor abilities, and dysarthria severity. Longer pause",14_15,Digital assessment of speech in Huntington disease,23 1 2024,,Huntington_Disease
"abilities, and dysarthria severity. Longer pause durations, increased disfluencies, and lower similarity to the original passage were associated with poorer clinical scores. Further research is needed to determine whether these specific speech measures could be used to monitor disease progression and assess functional decline. The application of machine learning models for group differentiation and prediction of clinical scores showed promising results. A random forest classifier achieved relatively high",14_16,Digital assessment of speech in Huntington disease,23 1 2024,,Huntington_Disease
"random forest classifier achieved relatively high recall values for HD and control groups based on passage reading features, however it was the least successful at classifying cases of pHD. The model’s performance was improved by incorporating counting tasks, suggesting that a combination of speech assessments could enhance the accuracy of group classification. However, the classification of dysarthria scores was challenging, especially distinguishing between scores of 1 and 2. This may be attributed to",14_17,Digital assessment of speech in Huntington disease,23 1 2024,,Huntington_Disease
"scores of 1 and 2. This may be attributed to the limited number of recordings with dysarthria scores greater than 1. Prediction of clinical scores also showed promising results, with motor UHDRS and dysarthria scores explained variance over 50%, albeit only 14% of the variance was captured from functional UHDRS, suggesting that the model is more sensitive to specific assessments. The findings of this study have important implications for the clinical application of remote monitoring systems and wearable",14_18,Digital assessment of speech in Huntington disease,23 1 2024,,Huntington_Disease
"of remote monitoring systems and wearable sensors in neurodegenerative movement disorders, particularly in HD. While speech measurements were collected in clinic in this study, there is the potential to collect speech data remotely. Remote collection of speech data would allow for a quantitative assessment from the comfort of a patient’s home environment, however it may pose additional challenges such as a poorer recording quality and sources of ambient noise. Future research will be needed to determine",14_19,Digital assessment of speech in Huntington disease,23 1 2024,,Huntington_Disease
"Future research will be needed to determine the use and feasibility of remote speech data assessments in the HD population. Despite its promising results, this study is not without its limitations. Among them is the low sample size, particularly in the prodromal HD group, which may limit the generalizability of the findings. With only seven participants and a lack of age and sex matching in the prodromal HD group, our study’s statistical power may be limited, potentially missing some subtle but clinically",14_20,Digital assessment of speech in Huntington disease,23 1 2024,,Huntington_Disease
"potentially missing some subtle but clinically relevant differences. Furthermore, while the study incorporated passage reading and counting as speech assessments, a more comprehensive array of speech evaluations and inclusion of spontaneous speech might have yielded nuanced insights into the specific speech deficits in HD and their evolution. There’s also the potential that the current speech tasks are better suited to capture motor-related speech impairment rather than cognitive-related speech impairment.",14_21,Digital assessment of speech in Huntington disease,23 1 2024,,Huntington_Disease
"rather than cognitive-related speech impairment. Future studies would benefit from a larger sample size, especially in prodromal HD, age matching, and the inclusion of more diverse speech assessments to capture a broader spectrum of speech and cognitive impairments in HD. In conclusion, this study demonstrates the potential of utilizing speech-based measures as tools for assessing disease progression and aiding in early detection and intervention strategies in HD. The significant group differences,",14_22,Digital assessment of speech in Huntington disease,23 1 2024,,Huntington_Disease
"in HD. The significant group differences, correlations with clinical scores, and successful machine learning models provide evidence for the efficacy of digital measures in capturing HD symptoms. The integration of speech assessments into routine clinical practice can offer a non-invasive and objective approach to monitor disease progression and improve patient care in neurodegenerative movement disorders. Furthermore, changes in speech may precede the onset of motor symptoms and therefore digital speech",14_23,Digital assessment of speech in Huntington disease,23 1 2024,,Huntington_Disease
of motor symptoms and therefore digital speech assessments may be valuable in clinical trials as a marker of clinical onset and disease progression. This is especially important since most therapeutics under development are targeting prodromal and early-stages of HD to slowdown the progression of the disease. Future research should focus on further validating the proposed speech-based measures in larger and more diverse populations. The raw data supporting the conclusions of this article will be made,14_24,Digital assessment of speech in Huntington disease,23 1 2024,,Huntington_Disease
"the conclusions of this article will be made available by the authors, without undue reservation. The studies involving humans were approved by Research Subjects Review Board (RSRB) at the University of Rochester. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. AN: Formal analysis, Writing – original draft, Writing – review & editing. MP: Writing – original draft. RM:",14_25,Digital assessment of speech in Huntington disease,23 1 2024,,Huntington_Disease
"& editing. MP: Writing – original draft. RM: Writing – original draft. EW: Writing – review & editing. MC: Writing – review & editing. CT: Writing – review & editing. RS: Writing – review & editing. ED: Writing – review & editing. AV: Funding acquisition, Methodology, Writing – original draft, Writing – review & editing. JA: Funding acquisition, Writing – review & editing.",14_26,Digital assessment of speech in Huntington disease,23 1 2024,,Huntington_Disease
"Huntington disease alters the actionable information in plasma extracellular vesicles A.N. acted as a consultant for Triplet Therapeutics, Inc. during the time of the study. In the past 2 years, through the offices of UCL Consultants Ltd., a wholly owned subsidiary of University College London. S.J.T. has undertaken consultancy services for Alnylam Pharmaceuticals Inc., Atalanta Pharmaceuticals, F. Hoffmann‐La Roche Ltd., Genentech, Guidepoint, Horama, Locanobio, LoQus23 Therapeutics Ltd., Novartis Pharma,",15_0,Huntington disease alters the actionable information in plasma extracellular vesicles,09 1 2024,,Huntington_Disease
"LoQus23 Therapeutics Ltd., Novartis Pharma, PTC Therapeutics, Sanofi, Spark Therapeutics, Takeda Pharmaceuticals Ltd., Triplet Therapeutics, University College Irvine and Vertex Pharmaceuticals Incorporated. G.B.L. has provided consulting services, advisory board functions, clinical trial services and/or lectures for Acadia Pharmaceuticals, Affiris, Allergan, Alnylam, Amarin, AOP Orphan Pharmaceuticals AG, Bayer Pharma AG, Boehringer‐Ingelheim, CHDI‐Foundation, Deutsche Huntington‐Hilfe, Desitin,",15_1,Huntington disease alters the actionable information in plasma extracellular vesicles,09 1 2024,,Huntington_Disease
"Deutsche Huntington‐Hilfe, Desitin, Genentech, Genzyme, GlaxoSmithKline, F. Hoffmann‐LaRoche, Ipsen, ISIS Pharma (IONIS), Lilly, Lundbeck, Medesis, Medivation, Medtronic, NeuraMetrix, Neurosearch Inc., Novartis, Pfizer, Prana Biotechnology, Prilenia, PTC Therapeutics, Raptor, Remix Therapeutics, Rhône‐Poulenc Rorer, Roche Pharma AG Deutschland, Sage Therapeutics, Sanofi‐Aventis, Sangamo/Shire, Siena Biotech, Takeda, Temmler Pharma GmbH, Teva, Triplet Therapeutics, Trophos, UniQure and Wave Life Sciences.",15_2,Huntington disease alters the actionable information in plasma extracellular vesicles,09 1 2024,,Huntington_Disease
"Trophos, UniQure and Wave Life Sciences. B.v.E. is a part‐time employee of NatIgGs GmbH. All other authors declare they have no conflicts of interest. The local ethics committees at Ulm University and University CollegeLondon approved collection and analysis of the specimens (Ulm: 265‐12; London:12/LO/1565), and written informed consent was obtained from each participant. All experimental methods comply with the Helsinki Declaration.",15_3,Huntington disease alters the actionable information in plasma extracellular vesicles,09 1 2024,,Huntington_Disease
"Gastrointestinal Hemorrhage and Diffuse Bowel Dilation in Huntington Disease Huntington disease (HD) is a neurodegenerative condition associated with pathologic involvement beyond the striatum including involvement of the autonomic nervous system. Bowel dysfunction is found in patients with HD, but the exact mechanism is poorly understood and not well reported. Patients may be affected with problems such as dysphagia, weight loss, nutritional deficiencies, esophagitis, and gastritis. Lower bowel symptoms",16_0,Gastrointestinal Hemorrhage and Diffuse Bowel Dilation in Huntington Disease,1 2024,,Huntington_Disease
"esophagitis, and gastritis. Lower bowel symptoms are more prevalent with longer disease course. We present a case of a patient with late-stage HD who presents with severe esophagitis causing gastrointestinal hemorrhage, significant dysmotility including chronic dysphagia requiring gastrostomy tube, and chronic small bowel and colonic ileus. Huntington disease (HD) is a progressive neurodegenerative condition inherited in the autosomal dominant pattern.<sup><xref rid=""R1"" ref-type=""bibr"">1</xref></sup> It",16_1,Gastrointestinal Hemorrhage and Diffuse Bowel Dilation in Huntington Disease,1 2024,,Huntington_Disease
"rid=""R1"" ref-type=""bibr"">1</xref></sup> It results from unstable trinucleotide (cytosine, adenine, guanine [CAG]) repeats within the <italic toggle=""yes"">huntingtin</italic> gene and often presents in middle adulthood, with increased length of CAG expansion strongly correlated with earlier age of clinical presentation.<sup><xref rid=""R2"" ref-type=""bibr"">2</xref>,<xref rid=""R3"" ref-type=""bibr"">3</xref></sup> HD is classically characterized by symptoms of involuntary movements and cognitive and behavioral",16_2,Gastrointestinal Hemorrhage and Diffuse Bowel Dilation in Huntington Disease,1 2024,,Huntington_Disease
"movements and cognitive and behavioral disturbances; however, HD may progress, resulting in dysphagia, dysarthria, slowed muscular movements, and dementia.<sup><xref rid=""R4"" ref-type=""bibr"">4</xref></sup> Individuals with HD also report bladder incontinence and gastrointestinal dysfunction, although the pathophysiology is not well defined or reported.<sup><xref rid=""R5"" ref-type=""bibr"">5</xref>,<xref rid=""R6"" ref-type=""bibr"">6</xref></sup> We present a case of upper gastrointestinal inflammation revealing",16_3,Gastrointestinal Hemorrhage and Diffuse Bowel Dilation in Huntington Disease,1 2024,,Huntington_Disease
"of upper gastrointestinal inflammation revealing marked bowel dilation in a patient with HD. A 61-year-old man with a history of HD with functional quadriplegia and dysphagia requiring a gastrojejunostomy tube, as well as diabetes insipidus, depression, gastroesophageal reflux disease, and hypertension, presented to the hospital with 1 day of melena. History was limited because the patient was nonverbal; however, his caretaker noted that he was having black-tarry stools and coffee-ground emesis. The",16_4,Gastrointestinal Hemorrhage and Diffuse Bowel Dilation in Huntington Disease,1 2024,,Huntington_Disease
"black-tarry stools and coffee-ground emesis. The patient was diagnosed with HD 15 years ago after experiencing sentinel symptoms of depression, followed by choreiform movements. A computed tomography (CT) of the head from 2010 demonstrated atrophy of the ventricles and sulci out of proportion to his age. This progressed to dysphagia, weight loss, and recurrent aspiration, diagnosed with barium swallow. He required gastrostomy tube placement in 2016, subsequently exchanged for a gastrojejunostomy tube",16_5,Gastrointestinal Hemorrhage and Diffuse Bowel Dilation in Huntington Disease,1 2024,,Huntington_Disease
"exchanged for a gastrojejunostomy tube because of high gastric residuals. By 2019, he experienced marked cognitive decline, complete quadriplegia, and was nonverbal because of muscular weakness. His disease course was complicated by intermittent constipation treated with polyethylene glycol and docusate and gastroesophageal reflux sporadically treated with proton pump inhibitors (PPI). Multiple previous abdominal imaging demonstrated colonic dilation, although this was never further investigated. The",16_6,Gastrointestinal Hemorrhage and Diffuse Bowel Dilation in Huntington Disease,1 2024,,Huntington_Disease
"although this was never further investigated. The patient first presented 2 weeks earlier with symptoms of diarrhea and coffee-ground emesis. CT of the abdomen/pelvis at this time showed a distended fluid-filled stomach and distal esophagus and significant fecal burden throughout the colon and rectum (Figures <xref rid=""F1"" ref-type=""fig"">1</xref> and <xref rid=""F2"" ref-type=""fig"">2</xref>). A nasogastric tube was placed for decompression, with minimal output, and he underwent fecal disimpaction. During",16_7,Gastrointestinal Hemorrhage and Diffuse Bowel Dilation in Huntington Disease,1 2024,,Huntington_Disease
"and he underwent fecal disimpaction. During this admission, he had a hemoglobin drop from 14.2 to 11.7 g/dL. He underwent esophagogastroduodenoscopy revealing grade C esophagitis, chronic gastritis, normal duodenum, and no active bleeding. <italic toggle=""yes"">Helicobacter pylori</italic> testing was negative. At the time of discharge, the patient's hemoglobin was 10 g/dL, and he had not received any blood transfusions during this admission. He had resolution of emesis, was having small brown stools, and",16_8,Gastrointestinal Hemorrhage and Diffuse Bowel Dilation in Huntington Disease,1 2024,,Huntington_Disease
"of emesis, was having small brown stools, and was discharged with a PPI. The patient returned 1 week later with melena and coffee-ground emesis. Initial evaluation on this admission showed a comfortable-appearing male who was afebrile, normotensive (104/59 mm Hg), and borderline tachycardic (97/min). He had normal bowel sounds, benign abdominal examination, and the patient's gastrostomy tube site appeared clean without surrounding erythema or discharge. On digital rectal examination, the patient had normal",16_9,Gastrointestinal Hemorrhage and Diffuse Bowel Dilation in Huntington Disease,1 2024,,Huntington_Disease
"rectal examination, the patient had normal rectal tone, small amount of brown stool, and no palpable lesions. Anal wink was not assessed, and the patient was not asked to bear down to assess pelvic floor descent, internal anal sphincter relaxation, and external anal sphincter squeeze. Laboratory studies were remarkable for a normocytic anemia (Hgb 5.2 g/dL and mean corpuscular volume 83.8 fL). He received a total of 4 units of packed red blood cells, was started on intravenous PPI therapy, and received",16_10,Gastrointestinal Hemorrhage and Diffuse Bowel Dilation in Huntington Disease,1 2024,,Huntington_Disease
"started on intravenous PPI therapy, and received intravenous fluids. He underwent repeat esophagogastroduodenoscopy revealing erosive esophagitis with minor bleeding on contact; the stomach and duodenum appeared normal (Figure <xref rid=""F3"" ref-type=""fig"">3</xref>). No aspirates or duodenal biopsies were obtained. The patient also underwent colonoscopy, which demonstrated marked dilation of the entire examined colon and ileum, liquid stool throughout the colon, scattered diverticula in the sigmoid colon,",16_11,Gastrointestinal Hemorrhage and Diffuse Bowel Dilation in Huntington Disease,1 2024,,Huntington_Disease
"scattered diverticula in the sigmoid colon, and no evidence of obstruction (Figures <xref rid=""F4"" ref-type=""fig"">4</xref> and <xref rid=""F5"" ref-type=""fig"">5</xref>). It was later identified that the patient was not receiving PPI therapy as prescribed, resulting in further bleeding and anemia. At the time of discharge, he had improvement of hemoglobin to 9.8 g/dL, with resolution of emesis and bleeding, and was discharged home with gastroenterology follow-up. This case highlights an individual with HD",16_12,Gastrointestinal Hemorrhage and Diffuse Bowel Dilation in Huntington Disease,1 2024,,Huntington_Disease
"This case highlights an individual with HD with multiple gastrointestinal manifestations such as dysphagia, erosive esophagitis resulting in hemorrhage, and a long-standing history of small bowel and colonic ileus resulting in severe constipation. HD often presents with cognitive, motor, and behavioral deficits, as well as gastrointestinal tract abnormalities, such as dysphagia, gut dysbiosis, gastritis, esophagitis, and lower bowel symptoms.<sup><xref rid=""R5"" ref-type=""bibr"">5</xref>–<xref rid=""R10""",16_13,Gastrointestinal Hemorrhage and Diffuse Bowel Dilation in Huntington Disease,1 2024,,Huntington_Disease
"rid=""R5"" ref-type=""bibr"">5</xref>–<xref rid=""R10"" ref-type=""bibr"">10</xref></sup> However, the pathophysiology of these manifestations is not well understood, and therefore, management options are limited. It is hypothesized that inclusions of mutant huntingtin protein within enteric nervous system (ENS) may be responsible for bowel dysfunction in HD patients.<sup><xref rid=""R7"" ref-type=""bibr"">7</xref>,<xref rid=""R9"" ref-type=""bibr"">9</xref></sup> Multiple mice models of HD have demonstrated huntingtin",16_14,Gastrointestinal Hemorrhage and Diffuse Bowel Dilation in Huntington Disease,1 2024,,Huntington_Disease
"mice models of HD have demonstrated huntingtin inclusions within the neurons and ganglion cells of the ENS.<sup><xref rid=""R7"" ref-type=""bibr"">7</xref>,<xref rid=""R11"" ref-type=""bibr"">11</xref>,<xref rid=""R12"" ref-type=""bibr"">12</xref></sup> One study identified significant loss of neuropeptide expressed in the gastric portion of the ENS, reduced mucosal thickness and villi length in the duodenum and colon, prolonged gut transit time, and impaired absorption in a transgenic mouse model of HD (R6/2),",16_15,Gastrointestinal Hemorrhage and Diffuse Bowel Dilation in Huntington Disease,1 2024,,Huntington_Disease
"in a transgenic mouse model of HD (R6/2), compared with wild-type mice.<sup><xref rid=""R7"" ref-type=""bibr"">7</xref></sup> Another study compared the colonic histopathology of a patient with HD and progressive gut motility failure requiring partial colonic resection, with colonic specimens obtained from R6/2 mice.<sup><xref rid=""R9"" ref-type=""bibr"">9</xref></sup> Reduced amounts of enteric neuropeptides and villous abnormalities were observed in the colonic specimens of the patient and HD-like mouse",16_16,Gastrointestinal Hemorrhage and Diffuse Bowel Dilation in Huntington Disease,1 2024,,Huntington_Disease
"specimens of the patient and HD-like mouse model.<sup><xref rid=""R9"" ref-type=""bibr"">9</xref></sup> Impairment in colonic motility can result in bowel dilation, as frequently observed in colonic pseudo-obstruction.<sup><xref rid=""R13"" ref-type=""bibr"">13</xref></sup> In this case, recurrent acute pseudo-obstruction is possible, given multiple previous CT scans demonstrating colonic dilation, along with episodes of constipation. We hypothesize that this patient's diffuse bowel dilation occurred as a",16_17,Gastrointestinal Hemorrhage and Diffuse Bowel Dilation in Huntington Disease,1 2024,,Huntington_Disease
"patient's diffuse bowel dilation occurred as a peripheral manifestation of HD through a mechanism of ENS dysfunction. The literature is sparse regarding the presence of esophagitis and gastritis in HD. One study identified a high prevalence of gastric and/or esophageal inflammation in patients with HD who did not report any symptoms.<sup><xref rid=""R6"" ref-type=""bibr"">6</xref></sup> The etiology for the absence of symptoms is unclear but may be due to abnormal sensory processing within the ENS and lack of",16_18,Gastrointestinal Hemorrhage and Diffuse Bowel Dilation in Huntington Disease,1 2024,,Huntington_Disease
"sensory processing within the ENS and lack of pain recognition or sensation of the disease process until progression to severe inflammation.<sup><xref rid=""R6"" ref-type=""bibr"">6</xref>,<xref rid=""R14"" ref-type=""bibr"">14</xref></sup> Furthermore, there may be a histologic etiology; evaluation of the gastric mucosa of HD-like mice identified abnormalities in the densities of chief cells and G cells, suggesting a predisposition of HD patients toward upper gastrointestinal inflammation.<sup><xref rid=""R15""",16_19,Gastrointestinal Hemorrhage and Diffuse Bowel Dilation in Huntington Disease,1 2024,,Huntington_Disease
"inflammation.<sup><xref rid=""R15"" ref-type=""bibr"">15</xref></sup> Gastrointestinal manifestations of HD are heterogenous and can reduce the quality of life of individuals with HD. In this report, we report a unique case of an individual with progressive HD with preexisting dysphagia who presented with gastrointestinal inflammation and found to have significant small and large bowel dilation. Further studies are required to elucidate the exact pathophysiology and appropriate therapeutic modalities. Author",16_20,Gastrointestinal Hemorrhage and Diffuse Bowel Dilation in Huntington Disease,1 2024,,Huntington_Disease
"and appropriate therapeutic modalities. Author contributions: S. Kolachana: literature review, drafting of the manuscript, and approved the final draft submitted. K. Motwani: literature review, drafting of the manuscript, and approved the final draft submitted. S. Sakiani: revising the manuscript and approved the final draft submitted. K. Motwani is the article guarantor. Financial disclosure: None to report. Informed consent was obtained for this case report.",16_21,Gastrointestinal Hemorrhage and Diffuse Bowel Dilation in Huntington Disease,1 2024,,Huntington_Disease
"Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research Huntington’s disease (HD) is a progressive, fatal neurodegenerative disease characterized by motor, cognitive, and psychiatric symptoms. The precise mechanisms of HD progression are poorly understood; however, it is known that there is an expansion of the trinucleotide cytosine-adenine-guanine (CAG) repeat in the Huntingtin gene. Important new strategies are of paramount importance to identify",17_0,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"are of paramount importance to identify early biomarkers with predictive value for intervening in disease progression at a stage when cellular dysfunction has not progressed irreversibly. Metabolomics is the study of global metabolite profiles in a system (cell, tissue, or organism) under certain conditions and is becoming an essential tool for the systemic characterization of metabolites to provide a snapshot of the functional and pathophysiological states of an organism and support disease diagnosis and",17_1,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"of an organism and support disease diagnosis and biomarker discovery. This review briefly highlights the historical progress of metabolomic methodologies, followed by a more detailed review of the use of metabolomics in HD research to enable a greater understanding of the pathogenesis, its early prediction, and finally the main technical platforms in the field of metabolomics. Huntington’s disease (HD) is a rare genetically inherited neurodegenerative disorder of the central nervous system characterized by",17_2,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"of the central nervous system characterized by unwanted choreatic movements, behavioral and psychiatric disturbances, and dementia [<xref rid=""B1-metabolites-13-01203"" ref-type=""bibr"">1</xref>] HD affects approximately 1 in 10,000 people [<xref rid=""B2-metabolites-13-01203"" ref-type=""bibr"">2</xref>]. In general, a child whose parent (either sex) has HD has a 50% chance of inheriting the disease. It is a lifelong condition for both the individual and family and progressively worsens without treatment.  The",17_3,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"and progressively worsens without treatment.  The proposed underlying mechanism of Huntington’s disease involves several key aspects such as mutant Huntington protein formation, protein aggregation, toxicity and neuronal dysfunction, impaired autophagy and proteasomal function, mitochondrial dysfunction, transcriptional dysregulation, and excitotoxicity. The expansion of trinucleotide repeats in the HTT gene is central to the pathogenesis of Huntington’s disease. As the CAG repeats expand, the length of",17_4,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"disease. As the CAG repeats expand, the length of the polyQ tract in the huntingtin protein increases. This expanded polyQ tract is a key factor in the abnormal folding and aggregation of the mutant protein. The exact molecular mechanisms by which mHTT induces toxicity and disrupts cellular functions are complex and multifaceted. The age of onset and severity of symptoms in HD are often correlated with the length of the CAG repeat expansion, with longer repeats generally leading to earlier and more severe",17_5,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"generally leading to earlier and more severe manifestations of the disease. Understanding these mechanisms at the molecular level is crucial for the development of targeted therapeutic strategies for Huntington’s disease [<xref rid=""B3-metabolites-13-01203"" ref-type=""bibr"">3</xref>,<xref rid=""B4-metabolites-13-01203"" ref-type=""bibr"">4</xref>]. HD appears to be more prevalent in people of European, North American, and Australian ancestry compared to those of Asian background [<xref",17_6,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"compared to those of Asian background [<xref rid=""B5-metabolites-13-01203"" ref-type=""bibr"">5</xref>].  To date, studies have mainly focused on alleviating symptoms rather than determining how to reverse the progression [<xref rid=""B3-metabolites-13-01203"" ref-type=""bibr"">3</xref>,<xref rid=""B6-metabolites-13-01203"" ref-type=""bibr"">6</xref>]. Although the mutant gene responsible for causing HD, htt, was discovered 30 years ago, there is still no cure for the disease. Drugs currently in clinical trials",17_7,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"the disease. Drugs currently in clinical trials mostly target symptom control [<xref rid=""B6-metabolites-13-01203"" ref-type=""bibr"">6</xref>,<xref rid=""B7-metabolites-13-01203"" ref-type=""bibr"">7</xref>]. One of these investigational modalities includes vesicular monoamine transporter type 2 (VMAT2) inhibitors that are now used to treat HD-associated chorea. A newer VMAT2 inhibitor, deutetrabenazine (AUSTEDO™), has an improved pharmacokinetic profile and was recently approved by the U.S. Food and Drug",17_8,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"was recently approved by the U.S. Food and Drug Administration (FDA). Deutetrabenazine has fewer side effects and a longer half-life than older VMAT2 inhibitors. Despite the emerging data indicating significant symptomatic improvement of HD chorea, its long-term benefits remain unknown, and large clinical trials are warranted [<xref rid=""B8-metabolites-13-01203"" ref-type=""bibr"">8</xref>]. An important limitation of VMAT2 inhibitors is their contraindication in patients with a history of depression and",17_9,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"in patients with a history of depression and suicidal ideation, which are common in HD patients.  HD is a monogenic Mendelian disorder. Therefore, the pathogenesis of the disease is molecular, not epidemiological. Family members are at higher risk of inheriting HD than the population at large. To confirm the molecular biomarkers, a careful study of the entire family, not just primary cases, is required. As in other neurodegenerative diseases, the traits in Huntington’s are complex. The mutation leads to",17_10,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"Huntington’s are complex. The mutation leads to multiple internal alterations with multiple external conditions across the lifespan. To characterize an HD biomarker accurately, it is necessary to accumulate an appropriate collection of data that will reveal the underlying mechanism of the disease. Thus, for biomedical researchers around the world, a major goal is to identify new biomarkers and revise existing biomarkers for HD. As a result, biomarker discovery will aid in early detection and help",17_11,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"discovery will aid in early detection and help physicians monitor the progression of the disease. For the past decade, advances in emerging technologies, such as high-resolution liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR) imaging, have made it possible to explore the disease-causing mechanisms of HD.  A significant obstacle in the realm of neurodegenerative diseases is the identification of biological signatures that correlate with disease progression or react to",17_12,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"correlate with disease progression or react to interventions. Underscoring the significance of early detection in Huntington’s disease is paramount, as it sets the stage for timely interventions and treatments, particularly during the crucial initial stages when their efficacy is expected to be most pronounced. Within the landscape of Huntington’s disease, evident disruptions in cellular metabolic processes become apparent. Unveiling the complexities of metabolic changes linked to Huntington’s disease,",17_13,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"metabolic changes linked to Huntington’s disease, metabolomics plays a key role in shaping personalized therapeutic approaches. This in-depth comprehension opens avenues for precise and individualized interventions, potentially enhancing the effectiveness of treatments and optimizing the overall care for those impacted by Huntington’s. Metabolomics emerges as a crucial field in precisely identifying distinct metabolic alterations linked to the disease [<xref rid=""B9-metabolites-13-01203""",17_14,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"the disease [<xref rid=""B9-metabolites-13-01203"" ref-type=""bibr"">9</xref>,<xref rid=""B10-metabolites-13-01203"" ref-type=""bibr"">10</xref>,<xref rid=""B11-metabolites-13-01203"" ref-type=""bibr"">11</xref>,<xref rid=""B12-metabolites-13-01203"" ref-type=""bibr"">12</xref>,<xref rid=""B13-metabolites-13-01203"" ref-type=""bibr"">13</xref>,<xref rid=""B14-metabolites-13-01203"" ref-type=""bibr"">14</xref>,<xref rid=""B15-metabolites-13-01203"" ref-type=""bibr"">15</xref>,<xref rid=""B16-metabolites-13-01203""",17_15,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"rid=""B16-metabolites-13-01203"" ref-type=""bibr"">16</xref>,<xref rid=""B17-metabolites-13-01203"" ref-type=""bibr"">17</xref>,<xref rid=""B18-metabolites-13-01203"" ref-type=""bibr"">18</xref>]. The aim of this review is to examine and summarize the published literature on metabolomic studies in humans, animals, and various biological fluids using existing analytical techniques for HD. The study of metabolomic phenomena not only serves as a reflection of genomics but also helps us better understand the functional",17_16,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"also helps us better understand the functional activity of proteins and other molecules. The field of metabolomics has been revolutionized in the past decades, so we highlight the development of metabolomics to date. Lastly, we highlight the differences between targeted and untargeted metabolomics, their challenges, and insights into the practical considerations of targeted and untargeted metabolomics. Evidence suggests that as far back as 2600 BCE, humans have had a thirst for health-related information.",17_17,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"have had a thirst for health-related information. Ancient Chinese cultures recognized the importance of different signs for detecting disease. For example, as early as 2000–1500 BCE, sweet-tasting urine was considered indicative of disease (now known as diabetes). Likewise, Ancient Greek history also affirms the idea that changes in tissue and biological fluids are tell-tale signs of disease [<xref rid=""B19-metabolites-13-01203"" ref-type=""bibr"">19</xref>]. Clinical testing during the Middle Ages also",17_18,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"Clinical testing during the Middle Ages also involved biofluid tasting (<xref rid=""metabolites-13-01203-f001"" ref-type=""fig"">Figure 1</xref>). During the 13th century (1213–1288), metabolism was described by the polymath Ibn al-Nafis, who stated that “the body and its parts are in a continuous state of dissolution and nourishment, so they are inevitably undergoing permanent change” [<xref rid=""B20-metabolites-13-01203"" ref-type=""bibr"">20</xref>,<xref rid=""B21-metabolites-13-01203""",17_19,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"rid=""B21-metabolites-13-01203"" ref-type=""bibr"">21</xref>]. Compared with other omics, metabolomics studies change in small-molecule metabolite concentrations, which help confirm an organism’s phenotype. Metabolites are, in general, low-molecular-weight molecules (<1500 Da). The metabolome reveals important changes in the genome, transcriptome, and proteome [<xref rid=""B23-metabolites-13-01203"" ref-type=""bibr"">23</xref>]. Over the past decade, there has been a spike in interest in this field. Recent studies",17_20,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"a spike in interest in this field. Recent studies demonstrate that metabolomics plays a central role in areas of biology, ecology, cancer, aging, and neurodegenerative disorders [<xref rid=""B24-metabolites-13-01203"" ref-type=""bibr"">24</xref>]. In general, fields such as genomics, transcriptomics, and proteomics help us determine what might have happened or predict what may happen. In contrast, metabolomics and lipidomics offer a continuous and up-to-date picture of the state of a biological system. Of all",17_21,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"of the state of a biological system. Of all the various omics approaches, to date, metabolomics offers the best potential for applications in biomarker discovery in systems biology [<xref rid=""B25-metabolites-13-01203"" ref-type=""bibr"">25</xref>,<xref rid=""B26-metabolites-13-01203"" ref-type=""bibr"">26</xref>]. Researchers have also shown that metabolomics holds promise for determining neuroactive small-molecule metabolites that are associated with communication between the gut microbiota and brain [<xref",17_22,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"between the gut microbiota and brain [<xref rid=""B27-metabolites-13-01203"" ref-type=""bibr"">27</xref>]. Great strides have been made in metabolomics applications to the field of neurology, including neural development and neurodegenerative disorders, such as Parkinson’s disease, Alzheimer’s disease, HD, and amyotrophic lateral sclerosis [<xref rid=""B28-metabolites-13-01203"" ref-type=""bibr"">28</xref>]. The naming of Huntington’s disease goes back to 1872 when George Huntington published his first and only",17_23,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"George Huntington published his first and only scientific paper on chorea. Although he was not the first to describe the disease, the advantage of his study was that it documented the inheritance of the disease through two older generations (father and grandfather) of Huntington. Thus, the disease became known as Huntington’s chorea. For a long time, no significant progress was made in further understanding Huntington’s chorea [<xref rid=""B29-metabolites-13-01203"" ref-type=""bibr"">29</xref>]. Modern",17_24,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"ref-type=""bibr"">29</xref>]. Modern interest in Huntington’s chorea began in the 1980s. After researchers revealed extensive non-motor symptoms and signs, the name was changed to Huntington’s disease (HD). A study in the early 1980s confirmed a linkage on chromosome 4. It took a decade to confirm the gene for HD, and after 1993, research on HD expanded significantly [<xref rid=""B29-metabolites-13-01203"" ref-type=""bibr"">29</xref>]. With the efforts of a collaborative research group consisting of six teams in",17_25,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"research group consisting of six teams in the United States and Great Britain, the htt gene was discovered. From the early 2000s to 2013, studies confirmed that the prevalence of HD varied around the world. The differences in the prevalence are largely due to higher cytosine-adenine-guanine [CAG] repeat sizes in normal alleles in European populations compared to Asian populations [<xref rid=""B30-metabolites-13-01203"" ref-type=""bibr"">30</xref>]. Hence, reports indicate very low rates of HD in Japan and",17_26,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"indicate very low rates of HD in Japan and South Africa and much higher rates in Europe (<xref rid=""metabolites-13-01203-f002"" ref-type=""fig"">Figure 2</xref>). It is assumed that the disease spread due to the migration of affected people from northwest Europe [<xref rid=""B31-metabolites-13-01203"" ref-type=""bibr"">31</xref>,<xref rid=""B32-metabolites-13-01203"" ref-type=""bibr"">32</xref>,<xref rid=""B33-metabolites-13-01203"" ref-type=""bibr"">33</xref>]. Previously unrecognized small populations with HD disease",17_27,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"unrecognized small populations with HD disease have been reclassified more recently. These include HD cases from Lake Maracaibo, Venezuela, which are thought to derive from a single ancestor [<xref rid=""B34-metabolites-13-01203"" ref-type=""bibr"">34</xref>]. This Venezuela project has become a landmark in the history of HD because it confirmed the mapping and isolation of the HD gene. Although the discovery of the HD gene has opened new research lines and led to new models to predict the disease, the",17_28,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"and led to new models to predict the disease, the mechanism of how htt acquires abnormal functioning and cell death remains elusive (<xref rid=""metabolites-13-01203-f002"" ref-type=""fig"">Figure 2</xref>). Despite ongoing efforts to find a possible cure for the disease, most drugs provide only palliative relief [<xref rid=""B7-metabolites-13-01203"" ref-type=""bibr"">7</xref>]. One advantage of studying a monogenic Mendelian neurodegenerative disorder is that pre-symptomatic biomarkers will help confirm the",17_29,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"pre-symptomatic biomarkers will help confirm the progression of the disease. Thus, it will be valuable for clinicians to address the disease state with a quantifiable biomarker rather than a behavioral phenotype. The history of the omics fields, including genomics, transcriptomics, proteomics, metabolomics, and lipidomics, began with the Human Genome Project, which took place from 1990 to 2003 [<xref rid=""B35-metabolites-13-01203"" ref-type=""bibr"">35</xref>]. After completing the Human Genome Project,",17_30,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"After completing the Human Genome Project, researchers around the world began to apply its methods to explore additional biological niches, such as the transcriptome, proteome, and metabolome. Thus, omics emerged as an interdisciplinary field consisting of genomics, transcriptomics, epigenomics, proteomics, metabolomics, and lipidomics. It provides insights into the profiling and pathological complexity of systems biology. For example, genomics is used to confirm the analysis of nucleotide sequences,",17_31,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"to confirm the analysis of nucleotide sequences, genome structure, and its composition. It also reveals genetic variants that can be used to confirm the disease state and the response to treatment. Genome-wide association studies (catalog: <uri http://www.w3.org/1999/xlink href=""https://www.ebi.ac.uk/gwas/home"">https://www.ebi.ac.uk/gwas/home</uri>, accessed on 21 July 2021) identify thousands of genetic variants associated with complex diseases in human populations [<xref rid=""B1-metabolites-13-01203""",17_32,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"populations [<xref rid=""B1-metabolites-13-01203"" ref-type=""bibr"">1</xref>,<xref rid=""B36-metabolites-13-01203"" ref-type=""bibr"">36</xref>]. Ribonucleic acid (RNA) is considered the primary functional readout of deoxyribonucleic acid (DNA). RNA performs an important function known as transcription and plays a vital role in translation, which is studied by proteomics. The ENCODE Consortium confirmed an integrated encyclopedia of DNA elements in the human genome. The ENCODE project confirmed that only ~3% of",17_33,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"The ENCODE project confirmed that only ~3% of the genome encodes proteins and that up to 80% of the genome is transcribed (Consortium, EP 2012) [<xref rid=""B35-metabolites-13-01203"" ref-type=""bibr"">35</xref>]. In the last decade, the study of metabolomics and lipidomics has become more widespread. The history of metabolomics profiling goes back to the early 1970s. Zlatkis and colleagues performed urine profiling of 140 subjects or more [<xref rid=""B37-metabolites-13-01203"" ref-type=""bibr"">37</xref>]. Two",17_34,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"ref-type=""bibr"">37</xref>]. Two years later, to improve the diagnosis of human disease, Thompson and Markey compared separation methods to profiling the urinary organic acids by GC-MS [<xref rid=""B38-metabolites-13-01203"" ref-type=""bibr"">38</xref>]. For over 40 years, researchers around the world accumulated publicly available libraries under the standardized conditions of 70-eV electron ionization energy. The most popular library is the U.S. National Institute of Standards and Technology (NIST) [<xref",17_35,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"of Standards and Technology (NIST) [<xref rid=""B39-metabolites-13-01203"" ref-type=""bibr"">39</xref>], but larger, less well-curated versions are also available (e.g., the Wiley registry [<xref rid=""B40-metabolites-13-01203"" ref-type=""bibr"">40</xref>], the open-access MassBank database [<xref rid=""B41-metabolites-13-01203"" ref-type=""bibr"">41</xref>], and the Golm repository) [<xref rid=""B42-metabolites-13-01203"" ref-type=""bibr"">42</xref>]. The NIST14 library accumulated 242,477 unique compounds, of which",17_36,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"accumulated 242,477 unique compounds, of which roughly one-third have recorded standardized retention times. enabling the use of two orthogonal parameters (mass spectral and retention index matching) to identify compounds [<xref rid=""B43-metabolites-13-01203"" ref-type=""bibr"">43</xref>]. Omics is now evolving to a multi-omics approach—a new area that deserves exploration and includes the integration of genomics, transcriptomics, proteomics, and metabolomics. The advantages and disadvantages of individual",17_37,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"The advantages and disadvantages of individual omics analysis have been reviewed [<xref rid=""B1-metabolites-13-01203"" ref-type=""bibr"">1</xref>,<xref rid=""B36-metabolites-13-01203"" ref-type=""bibr"">36</xref>,<xref rid=""B44-metabolites-13-01203"" ref-type=""bibr"">44</xref>] and are summarized in <xref rid=""metabolites-13-01203-f003"" ref-type=""fig"">Figure 3</xref>. The data integration of multi-omics analysis is complex. Thus, each laboratory needs to follow standardized multi-omics sample preparation, data",17_38,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"standardized multi-omics sample preparation, data acquisition, data handling, and data standardization protocols to avoid lab-to-lab variation, which can lead to biased results. The proteome contains many proteins with a wide range of physicochemical properties, such as size, charge, and hydrophobicity, which require different types of analytical techniques. Proteomics is as important as genomics and transcriptomics because it provides information about enzymes during metabolic processes. Nevertheless,",17_39,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"enzymes during metabolic processes. Nevertheless, proteomics studies also confirm rapid changes in cell proliferation and migration and can document not only the abundance of proteins but also dynamic protein–protein interactions [<xref rid=""B45-metabolites-13-01203"" ref-type=""bibr"">45</xref>].  Advanced analytical techniques, including nuclear magnetic resonance (NMR) spectroscopy, gas chromatography (GC), and liquid chromatography (LC) combined with mass spectrometry (MS) enable researchers to",17_40,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"with mass spectrometry (MS) enable researchers to characterize past and ongoing physiological changes and to map the composition and magnitude of those changes in the metabolome. LC/MS-based metabolomics and lipidomics have been revolutionized in the past decade in the fields of chronic disease, aging, neurological disorders, biomarker discovery, microbiology, metabolic disorder, drug discovery, and precision medicine. Compared with other analytical techniques, LC/MS has the advantages of high sensitivity,",17_41,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"LC/MS has the advantages of high sensitivity, selectivity, and the capability to identify known and unknown analytes of interest [<xref rid=""B120-metabolites-13-01203"" ref-type=""bibr"">120</xref>,<xref rid=""B121-metabolites-13-01203"" ref-type=""bibr"">121</xref>,<xref rid=""B122-metabolites-13-01203"" ref-type=""bibr"">122</xref>]. Nevertheless, the high reproducibility of NMR-based techniques is superior to that of MS (see <xref rid=""metabolites-13-01203-f004"" ref-type=""fig"">Figure 4</xref>). Due to certain",17_42,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"ref-type=""fig"">Figure 4</xref>). Due to certain advantages provided by NMR and MS, to date, most metabolomic studies of HD have utilized LC/MS or NMR. Therefore, we focus on exploring the principles of those analytical platforms. The study of Huntington’s disease (HD) through the lens of metabolomics has emerged as a critical avenue for unraveling the intricacies of this neurodegenerative disorder. Despite the discovery of the HD mutation in 1993, the absence of disease-modifying treatments underscores the",17_43,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"of disease-modifying treatments underscores the urgency in comprehending the molecular and cellular underpinnings of HD. Metabolomics, with its distinctive advantages, has played a pivotal role in advancing our understanding of the disease. The precision and sensitivity offered by targeted metabolomics have allowed for in-depth analyses of specific metabolites associated with HD. This focused approach not only aids in the identification of biomarkers but also contributes to our understanding of",17_44,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"but also contributes to our understanding of well-established metabolic pathways affected by the disease. On the other hand, untargeted metabolomics, with its capacity for comprehensive and unbiased exploration, has facilitated the discovery of novel biomarkers and provided a holistic view of the global metabolic alterations in HD. In the period from 2001 to 2023, many studies have signified a crucial timeline where metabolomic investigations have thrived, contributing valuable insights into HD. These",17_45,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"contributing valuable insights into HD. These insights, ranging from changes in the metabolome associated with HD to the identification of potential non-invasive biomarkers, hold significant promise for the development of diagnostic tools and prognosis assessments, as well as the monitoring of therapeutic efficacy. As we navigate the complex landscape of Huntington’s disease, metabolomics stands as a beacon, offering a nuanced understanding of the molecular signatures and metabolic shifts that define this",17_46,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"signatures and metabolic shifts that define this condition. It is through the integration of targeted and untargeted metabolomics approaches that we can harness the full spectrum of analytical capabilities, ultimately paving the way for the development of novel treatments and personalized therapeutic strategies for individuals affected by HD.",17_47,Metabolomics: An Emerging “Omics” Platform for Systems Biology and Its Implications for Huntington Disease Research,18 12 2023,,Huntington_Disease
"A Phenotypic Atlas for Huntington Disease Based on Data From the Enroll-HD Cohort Study Huntington disease (HD) is an inherited autosomal dominant neurodegenerative disease caused by an unstable expansion of CAG repeats in exon 1 of the huntingtin gene (<italic toggle=""yes"">HTT</italic>) on chromosome 4 that encodes the huntingtin protein (HTT). The variable CAG repeat expansion in the huntingtin gene and its inverse relationship to motor dysfunction onset and survival are fundamental features of the",18_0,A Phenotypic Atlas for Huntington Disease Based on Data From the Enroll-HD Cohort Study,12 2023,,Huntington_Disease
"and survival are fundamental features of the disease.<sup><xref rid=""R1"" ref-type=""bibr"">1</xref>,<xref rid=""R2"" ref-type=""bibr"">2</xref></sup> However, much of the literature addressing the influence of CAG length in HD has focused on the concepts of age at motor diagnosis<sup><xref rid=""R3"" ref-type=""bibr"">3</xref></sup> or age of motor onset,<sup><xref rid=""R4"" ref-type=""bibr"">4</xref></sup> and the wider phenotype (including non-motor features) at particular CAG lengths, ages, and functional levels is",18_1,A Phenotypic Atlas for Huntington Disease Based on Data From the Enroll-HD Cohort Study,12 2023,,Huntington_Disease
"CAG lengths, ages, and functional levels is less well-characterized. Enroll-HD is a clinical research platform and the world's largest observational study for families affected by HD.<sup><xref rid=""R5"" ref-type=""bibr"">5</xref></sup> Others have previously used this platform to develop a clinical dashboard that allows comparison of total motor score (TMS), total functional capacity, and symbol digit modality test (SDMT) score of an individual against a defined Enroll-HD cohort, controlling for age and CAG",18_2,A Phenotypic Atlas for Huntington Disease Based on Data From the Enroll-HD Cohort Study,12 2023,,Huntington_Disease
"Enroll-HD cohort, controlling for age and CAG repeat length.<sup><xref rid=""R6"" ref-type=""bibr"">6</xref></sup> We report here the development of a new Enroll-HD Phenotype Atlas (EHDPA) that expands upon this concept to allow similar comparisons for a wider range of motor, cognitive, and behavioral aspects of HD that have all been measured as part of the Enroll-HD study.<sup><xref rid=""R5"" ref-type=""bibr"">5</xref></sup> The online atlas has been developed to assist clinicians to better visualize (through",18_3,A Phenotypic Atlas for Huntington Disease Based on Data From the Enroll-HD Cohort Study,12 2023,,Huntington_Disease
"to assist clinicians to better visualize (through tables, charts, and/or illustrations) and understand the relationships between age; CAG repeat length in the <italic toggle=""yes"">HTT</italic> gene; and key markers of phenotypic onset, function, and progression in HD.   The EHDPA summarizes the spectrum and distribution of HD phenotypes, including outliers and possible clusters, in all domains of disease involvement for the range of CAG lengths, ages, and functional levels. Examination of the nature and",18_4,A Phenotypic Atlas for Huntington Disease Based on Data From the Enroll-HD Cohort Study,12 2023,,Huntington_Disease
"functional levels. Examination of the nature and frequency of outliers in these profiles may help identify phenotypic variation reflecting the effect of secondary genetic, comorbid, and environmental influences on disease progression. The atlas is available on the Enroll-HD website as a user-friendly tool for clinicians, researchers, and health care professionals. The data aid in understanding the age-dependent features of HD as CAG lengths vary. The EHDPA readily illustrates whether the typical range",18_5,A Phenotypic Atlas for Huntington Disease Based on Data From the Enroll-HD Cohort Study,12 2023,,Huntington_Disease
"readily illustrates whether the typical range varies widely or not for a given CAG length and age range, allowing judgment of the degree to which an individual's phenotype is atypical. The huge sample size allows detailed observational summaries by 5-year age range for each CAG length as well as enabling the development of descriptive plots relating specific measurements to age and CAG. There are some limitations in interpretation of the EHDPA that users should understand. To maximize the number of",18_6,A Phenotypic Atlas for Huntington Disease Based on Data From the Enroll-HD Cohort Study,12 2023,,Huntington_Disease
"should understand. To maximize the number of observations available, data from all available visits for every eligible participant were reported. There is, therefore, a degree of nonindependence between repeated annual observations from the same participants. Such nonindependence of observations would need to be accounted for in potential future hypothesis-driven testing and modeling of these data. Although it is based on the largest observational HD database ever collected, this database is not a random",18_7,A Phenotypic Atlas for Huntington Disease Based on Data From the Enroll-HD Cohort Study,12 2023,,Huntington_Disease
"ever collected, this database is not a random sample of the entire population at risk. For example, the EHDPA illustrates phenotypes and the degree of variation in the assessments for the incompletely penetrant CAG repeat lengths of 36–39; for this range, there is the important caveat that the available sample is, at best, representative of the population in this age range that comes to clinical attention, but because of the partial penetrance, the EHDPA probably does not represent typical patterns for the",18_8,A Phenotypic Atlas for Huntington Disease Based on Data From the Enroll-HD Cohort Study,12 2023,,Huntington_Disease
"does not represent typical patterns for the whole population of individuals who have these repeat lengths. Clinical features affecting participation in the Enroll-HD study may also bias the data, particularly at the severe end of the illness spectrum; for instance, the apparent stability of some features in advanced HD may instead be attributable to nonparticipation or drop-out among those with more severe illness. These potential biases may also distort these age-dependent cross-sectional patterns if we",18_9,A Phenotypic Atlas for Huntington Disease Based on Data From the Enroll-HD Cohort Study,12 2023,,Huntington_Disease
"age-dependent cross-sectional patterns if we interpret them as typical longitudinal progression for an individual. Unfortunately, substantial ideal data—repeated systematic measurements of the same people across several decades—simply do not exist, and the potential biases for nonparticipation may not be improved by increasing sample sizes unless the sources of study recruitment evolve substantially. As the Enroll-HD study continues, it will be important to use future periodic data sets to compare",18_10,A Phenotypic Atlas for Huntington Disease Based on Data From the Enroll-HD Cohort Study,12 2023,,Huntington_Disease
"to use future periodic data sets to compare longitudinal within-person data with the disease course suggested by the atlas. Future work could expand on the observable patterns in the atlas to produce a more formal multidomain characterization of motor, cognitive, and psychiatric progression and the relationship to functional decline and disease modifiers.<sup><xref rid=""R11"" ref-type=""bibr"">11</xref>,<xref rid=""R12"" ref-type=""bibr"">12</xref></sup> Inclusion of age-specific control data would help the",18_11,A Phenotypic Atlas for Huntington Disease Based on Data From the Enroll-HD Cohort Study,12 2023,,Huntington_Disease
"of age-specific control data would help the clinician to understand how PwHD are different from people without the HD CAG expansion. Relevant phenotype definition is critical to the success of gene-discovery studies. The atlas will facilitate definition of more detailed and possibly more sensitive CAG-adjusted phenotypes for such studies.<sup><xref rid=""R13"" ref-type=""bibr"">13</xref></sup> For example, variability not well-explained by age and CAG might be used as the phenotypic outcome measure in studies",18_12,A Phenotypic Atlas for Huntington Disease Based on Data From the Enroll-HD Cohort Study,12 2023,,Huntington_Disease
"used as the phenotypic outcome measure in studies searching for additional HD-modifying genes. The EHDPA may also be a useful tool in assessing whether future therapeutic agents have a differential effect on motor, cognitive, and psychiatric aspects of HD. Clinicians are often faced with the challenge of providing prognosis for an individual, which could help PwHD and families with their professional and financial plans as well as for future care needs. The EHDPA has been developed to provide a graphical",18_13,A Phenotypic Atlas for Huntington Disease Based on Data From the Enroll-HD Cohort Study,12 2023,,Huntington_Disease
EHDPA has been developed to provide a graphical multidimensional representation of the range of HD phenotypes and assist clinicians in tracking disease progression in an individual by identifying phenotypic features most associated with loss of function. It will also assist in determining whether a suspected deviation from the likely course is truly unusual. The work done to develop this atlas has potential as a prototype for initiatives in other trinucleotide repeat disorders if large databases like,18_14,A Phenotypic Atlas for Huntington Disease Based on Data From the Enroll-HD Cohort Study,12 2023,,Huntington_Disease
repeat disorders if large databases like Enroll-HD can be created.,18_15,A Phenotypic Atlas for Huntington Disease Based on Data From the Enroll-HD Cohort Study,12 2023,,Huntington_Disease
"A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease Huntington disease (HD) is a degenerative brain disease caused by the expansion of CAG (cytosine-adenine-guanine) repeats, which is inherited as a dominant trait and progressively worsens over time possessing threat. Although HD is monogenetic, the specific pathophysiology and biomarkers are yet unknown specifically, also, complex to diagnose at an early stage, and identification is",19_0,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"diagnose at an early stage, and identification is restricted in accuracy and precision. This study combined bioinformatics analysis and network-based system biology approaches to discover the biomarker, pathways, and drug targets related to molecular mechanism of HD etiology. The gene expression profile data sets GSE64810 and GSE95343 were analyzed to predict the molecular markers in HD where 162 mutual differentially expressed genes (DEGs) were detected. Ten hub genes among them (<italic",19_1,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"were detected. Ten hub genes among them (<italic toggle=""yes"">DUSP1, NKX2-5, GLI1, KLF4, SCNN1B, NPHS1, SGK2, PITX2, S100A4</italic>, and <italic toggle=""yes"">MSX1</italic>) were identified from protein-protein interaction (PPI) network which were mostly expressed as down-regulated. Following that, transcription factors (TFs)-DEGs interactions (FOXC1, GATA2, etc), TF-microRNA (miRNA) interactions (hsa-miR-340, hsa-miR-34a, etc), protein-drug interactions, and disorders associated with DEGs were predicted.",19_2,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"disorders associated with DEGs were predicted. Furthermore, we used gene set enrichment analysis (GSEA) to emphasize relevant gene ontology terms (eg, TF activity, sequence-specific DNA binding) linked to DEGs in HD. Disease interactions revealed the diseases that are linked to HD, and the prospective small drug molecules like cytarabine and arsenite was predicted against HD. This study reveals molecular biomarkers at the RNA and protein levels that may be beneficial to improve the understanding of",19_3,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"may be beneficial to improve the understanding of molecular mechanisms, early diagnosis, as well as prospective pharmacologic targets for designing beneficial HD treatment. Huntington disease (HD) can be defined as a completely penetrant degenerative brain disease resulting from CAG (cytosine-adenine-guanine) repeat expansion that is inherited as a dominant trait in IT15 (“interesting transcript 15”) gene also defined as huntingtin (<italic toggle=""yes"">HTT)</italic> gene.<sup><xref",19_4,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"toggle=""yes"">HTT)</italic> gene.<sup><xref rid=""bibr1-11779322231210098"" ref-type=""bibr"">1</xref>,<xref rid=""bibr2-11779322231210098"" ref-type=""bibr"">2</xref></sup> Huntingtin is translated into such an excessively massive polyglutamine domain around the N-terminus of the Huntington protein.<sup>",19_5,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"<xref rid=""bibr3-11779322231210098"" ref-type=""bibr"">3</xref>",19_6,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"</sup> Mutant huntingtin (mHTT) becomes particularly unstable due to the enlargement of the CAG region and allows to a combination of proteins of the same type and/or other types resulting in clumps that may lead to discontinued neurotransmission.<sup><xref rid=""bibr4-11779322231210098"" ref-type=""bibr"">4</xref>,<xref rid=""bibr5-11779322231210098"" ref-type=""bibr"">5</xref></sup> Huntington disease is caused by a complicated interaction of environmental and genetic factors, resulting in succeeding generations",19_7,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"factors, resulting in succeeding generations to live in increasingly deplorable social conditions. Autosomal recessive inheritance is often seen in mid-life diagnosis and continuous progressive motor including intellectual and mental symptoms across 15 to 20 years.<sup><xref rid=""bibr6-11779322231210098"" ref-type=""bibr"">6</xref>,<xref rid=""bibr7-11779322231210098"" ref-type=""bibr"">7</xref></sup> It commonly starts in middle age, between the 21 and 50 years, including an average starting age of",19_8,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"50 years, including an average starting age of 41 years.<sup><xref rid=""bibr6-11779322231210098"" ref-type=""bibr"">6</xref>,<xref rid=""bibr8-11779322231210098"" ref-type=""bibr"">8</xref></sup> Fine motor function deterioration, cerebellar abnormalities, gait abnormalities, dysarthria, cognitive difficulties, and stiffness are all prevalent symptoms and indicators.<sup>",19_9,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"<xref rid=""bibr9-11779322231210098"" ref-type=""bibr"">9</xref>",19_10,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"</sup> It produces substantial physical and cognitive deficiencies such as memory loss, depression, mood fluctuations clumsiness as well as some other psychological problems and disorders.<sup><xref rid=""bibr4-11779322231210098"" ref-type=""bibr"">4</xref>,<xref rid=""bibr10-11779322231210098"" ref-type=""bibr"">10</xref></sup> Clinical diagnosis to identify HD is conducted when there are strong sets of evidence of a motor disorder, particularly chorea involving iatrogenic conditions and general internal",19_11,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
iatrogenic conditions and general internal disorders.<sup>,19_12,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"<xref rid=""bibr9-11779322231210098"" ref-type=""bibr"">9</xref>",19_13,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"</sup> Degenerative mutations and cellular damage can be found throughout the cortex and external areas of the central nervous system, specifically across the striatum; there are various symptomatic therapies and medication available, but there is no permanent remedy for this devastating brain disorder presently.<sup><xref rid=""bibr10-11779322231210098"" ref-type=""bibr"">10</xref>,<xref rid=""bibr11-11779322231210098"" ref-type=""bibr"">11</xref></sup> There are currently no medications available to delay",19_14,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"are currently no medications available to delay symptoms and disease development; however, there are numerous effective post management (ie, medication and nonpharmacologic approaches available).<sup>",19_15,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"<xref rid=""bibr12-11779322231210098"" ref-type=""bibr"">12</xref>
</sup> As the disease was first diagnosed, especially after Davenport and Munceyat 1916 pointed out a large collection of information on households in the New England area of America, individual family surveys on HD have been conducted.<sup>
<xref rid=""bibr13-11779322231210098"" ref-type=""bibr"">13</xref>",19_16,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"</sup> Most European nations, including Northern and Southern, have a quite high prevalence, ie, 4 to 8 in every 100 000 individuals, and the disease may also be common in India side by side in some areas of Central Asia, according to the findings.<sup>
<xref rid=""bibr14-11779322231210098"" ref-type=""bibr"">14</xref>
</sup> The prevalence of HD worldwide appears to vary by region.<sup>
<xref rid=""bibr15-11779322231210098"" ref-type=""bibr"">15</xref>",19_17,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"</sup> In South Africa and Zimbabwe, prevalence rates were determined to be extremely low.<sup>
<xref rid=""bibr16-11779322231210098"" ref-type=""bibr"">16</xref>
</sup> Since 1995, the prevalence rate (average) in Asian countries (South Korea, Hong Kong, Taiwan, and Japan) has been low (0.42 per 100 000 individuals) compared with the rate among white populations (North America, Australia, the United Kingdom and Western Europe) where the rate was 9.71 per 100 000 individuals.<sup>",19_18,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"<xref rid=""bibr15-11779322231210098"" ref-type=""bibr"">15</xref>
</sup> Following the emergence of genetic testing, the frequency of HD has increased in several populations.<sup>
<xref rid=""bibr17-11779322231210098"" ref-type=""bibr"">17</xref>",19_19,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"</sup> Although several studies have already identified histone modifications, protein hubs identification, transcription factor (TF) impairments, and abnormal microRNA (miRNA) expression, HD is difficult to diagnose at an early stage and identification is restricted in accuracy and precision, as well as expensive.<sup><xref rid=""bibr18-11779322231210098"" ref-type=""bibr"">18</xref>,<xref rid=""bibr19-11779322231210098"" ref-type=""bibr"">19</xref></sup> Also, contradictions between researchers were found about",19_20,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"between researchers were found about the conclusion of differential expressed genes. As a result, using brain cell analysis to predict HD could enhance disease’s early detection and treatment. In 1993, the faulty gene that triggers HD was first discovered and a genetic test for diagnosis is available now.<sup>",19_21,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"<xref rid=""bibr20-11779322231210098"" ref-type=""bibr"">20</xref>",19_22,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"</sup> The test can identify the malfunctioning gene for HTT protein as well as discover the genetic defect in individuals who already haven’t shown any symptoms but has the possibility to obtain the disease but this is a slow process and can only be diagnosed after mid-age.<sup><xref rid=""bibr20-11779322231210098"" ref-type=""bibr"">20</xref>,<xref rid=""bibr21-11779322231210098"" ref-type=""bibr"">21</xref></sup> This condition is caused by a CAG triplet repeat amplification in the <italic",19_23,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"a CAG triplet repeat amplification in the <italic toggle=""yes"">HTT</italic> gene.<sup><xref rid=""bibr20-11779322231210098"" ref-type=""bibr"">20</xref>,<xref rid=""bibr22-11779322231210098"" ref-type=""bibr"">22</xref></sup> Due to prolonged CAG repeat, HTT protein with an enlarged polyglutamine tract is produced, resulting in pathogenic HTT protein residues that are immune to the protein cycle, leading to cellular toxicity.<sup><xref rid=""bibr23-11779322231210098"" ref-type=""bibr"">23</xref>,<xref",19_24,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"ref-type=""bibr"">23</xref>,<xref rid=""bibr24-11779322231210098"" ref-type=""bibr"">24</xref></sup> Most HD patients have motor-involved problems, a small percentage (15%) establish clinically relevant psychological disease first and hence have a mental diagnosis before the start of movement disorder.<sup><xref rid=""bibr20-11779322231210098"" ref-type=""bibr"">20</xref>,<xref rid=""bibr25-11779322231210098"" ref-type=""bibr"">25</xref></sup> Huntington disease is associated with extremely selective deterioration of",19_25,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
with extremely selective deterioration of the corpus striatum which is a brain region with no noticeable abnormalities in peripheral tissues. Huntington and mHTT are prevalently distributed across the brain also including peripheral tissues.<sup>,19_26,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"<xref rid=""bibr10-11779322231210098"" ref-type=""bibr"">10</xref>
</sup> Histone modifications, protein hubs identification, TF impairments, and abnormal miRNA expression are among the processes linked to this imbalance and identification of disease specification biomarkers is crucial for HD drug testing.<sup>
<xref rid=""bibr26-11779322231210098"" ref-type=""bibr"">26</xref>",19_27,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"</sup> Several studies have been conducted from different perspectives to identify molecular biomarkers with various brain and blood data. As HD is a completely penetrant degenerative brain disease, in this study brain-based data sets were obtained to progress further analyses. Generally, genetic factors in HD have primarily been examined in diseased brains comparing controlled individuals, as well as in cell and animal models.<sup><xref rid=""bibr23-11779322231210098"" ref-type=""bibr"">23</xref>,<xref",19_28,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"ref-type=""bibr"">23</xref>,<xref rid=""bibr27-11779322231210098"" ref-type=""bibr"">27</xref></sup> Hundreds of research teams have spent the past 3 decades trying to figure out what causes HD based on cellular and molecular compounds.<sup><xref rid=""bibr18-11779322231210098"" ref-type=""bibr"">18</xref>,<xref rid=""bibr19-11779322231210098"" ref-type=""bibr"">19</xref>,<xref rid=""bibr27-11779322231210098"" ref-type=""bibr"">27</xref></sup> The goal of this research is to find molecular biomarkers that represent the",19_29,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"to find molecular biomarkers that represent the brain expression alignments of associative factors connected to HD development. The main objective of this study is to identify the differentially expressed genes (DEGs) and common genes using genomic information for HD. Second, we aimed to identify molecular biomarkers to diagnose early detection of HD and progression by identifying transcriptional and post-transcriptional level; side by side another objective was to identify potential interacting components",19_30,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"was to identify potential interacting components that are prominent in the gene list which can be used to find valuable medicines or drug targets. The rest of this article is organized as materials and methodology, results, discussion, and conclusions section. The materials and methodology section contains data acquisition, determination of DEGs and common genes, gene set enrichment analysis (GSEA), construction of protein-protein interaction (PPI) network for hub protein identification, transcriptomic",19_31,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"for hub protein identification, transcriptomic marker identification, prediction of small drug molecules, and finally, validation of the predicted molecular markers.   Huntington disease is a hereditary neurodegenerative condition which impacts in early forties and fifties.<sup><xref rid=""bibr24-11779322231210098"" ref-type=""bibr"">24</xref>,<xref rid=""bibr79-11779322231210098"" ref-type=""bibr"">79</xref></sup> Dysregulation of possible biomarkers has recently been found to be linked with neurological and",19_32,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"been found to be linked with neurological and neurodegenerative diseases,<sup><xref rid=""bibr80-11779322231210098"" ref-type=""bibr"">80</xref>,<xref rid=""bibr81-11779322231210098"" ref-type=""bibr"">81</xref></sup> and several studies have looked into the implications of biomolecular activities in patients with HD.<sup>",19_33,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"<xref rid=""bibr27-11779322231210098"" ref-type=""bibr"">27</xref>",19_34,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"</sup>,<sup><xref rid=""bibr82-11779322231210098"" ref-type=""bibr"">82</xref><xref rid=""bibr83-11779322231210098"" ref-type=""bibr""></xref><xref rid=""bibr84-11779322231210098"" ref-type=""bibr""></xref>-<xref rid=""bibr85-11779322231210098"" ref-type=""bibr"">85</xref></sup> Omics-based approaches are currently being used more often in biomedicine and systemic biology studies, and they have proven to be a helpful resource for deciphering disease pathogenesis, discovering molecular pathways, and determining biomarkers",19_35,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"molecular pathways, and determining biomarkers for various diseases.<sup>",19_36,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"<xref rid=""bibr31-11779322231210098"" ref-type=""bibr"">31</xref>",19_37,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"</sup> Gene expression is perhaps modulated at multiple stages of RNA processing, post-translational modification (PTM) of proteins, translation, or other genomic changes, according to previous researches.<sup><xref rid=""bibr86-11779322231210098"" ref-type=""bibr"">86</xref>,<xref rid=""bibr87-11779322231210098"" ref-type=""bibr"">87</xref></sup> Determining the biochemical pathway of an exact disease and identifying the impact of fundamental mechanisms involved in a certain phenotype require defining the",19_38,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"in a certain phenotype require defining the activity target proteins in bioactive molecules.<sup><xref rid=""bibr31-11779322231210098"" ref-type=""bibr"">31</xref>,<xref rid=""bibr88-11779322231210098"" ref-type=""bibr"">88</xref></sup> The functional characteristics of hub proteins are of special intrigue, and PPI can be characterized as persistent or transient, depending on how long they last and what they do.<sup>",19_39,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"<xref rid=""bibr89-11779322231210098"" ref-type=""bibr"">89</xref>
</sup> The networks based on PPI are considered scale-free where the connectivity between components follows generally a Poisson distribution.<sup>
<xref rid=""bibr90-11779322231210098"" ref-type=""bibr"">90</xref>",19_40,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"</sup> Adapting a network-based technique to genomic data aids in the discovery of connections between diverse biological activities and processes, resulting in new pathways, interaction networks, as well as other disease-related signals that result in identifying biomarkers and treatment targets.<sup>
<xref rid=""bibr91-11779322231210098"" ref-type=""bibr"">91</xref>",19_41,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"</sup> Although several studies identified miRNA expression of cellular and mouse structure,<sup><xref rid=""bibr85-11779322231210098"" ref-type=""bibr"">85</xref>,<xref rid=""bibr92-11779322231210098"" ref-type=""bibr"">92</xref></sup> common gene expression of HD patient,<sup>
<xref rid=""bibr82-11779322231210098"" ref-type=""bibr"">82</xref>
</sup> and DNA methylation in HD,<sup>
<xref rid=""bibr27-11779322231210098"" ref-type=""bibr"">27</xref>",19_42,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"</sup> a bioinformatics study regarding the identification of molecular signatures and pathways of healthy controls and HD patients has yet not been conducted comprehensively in a framework comparing all these methods at same time. We used a comprehensive bioinformatics strategy to identify molecular signatures and key pathways for HD in this study and emphasized an overall overview. The key word ‘Huntington’s Disease’ was used to explore the GEO database, and data sets featuring <italic toggle=""yes"">Homo",19_43,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"and data sets featuring <italic toggle=""yes"">Homo sapiens</italic> mRNA and array expression profiles were sorted containing control and diseased groups after reviewing some literatures.<sup>",19_44,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"<xref rid=""bibr28-11779322231210098"" ref-type=""bibr"">28</xref>",19_45,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"</sup> A bioinformatics approach was used to assess DEGs between the control and diseased groups where the HD patients revealed significant variations in gene expression compared with neurologically healthy controls. The selected databases (GSE64810 and GSE95343) showed total 162 common genes among them 106 genes were found up-regulated and 56 genes were found down-regulated by systematic and statistical approaches. The data set GSE95343 has not been studied yet in the view of comprehensive bioinformatics,",19_46,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"yet in the view of comprehensive bioinformatics, and it was found that GSE64810 was studied separately in a study where 1612 DEGs had been determined.<sup>",19_47,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"<xref rid=""bibr83-11779322231210098"" ref-type=""bibr"">83</xref>",19_48,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"</sup> The GO analysis was used to evaluate the biological relevance of HD regarding 162 common DEGs found. These important genes are identified to generate proteins with various molecular functions linked with important biological processes such as skeletal system development, collagen fibril organization, embryonic forelimb morphogenesis, proteolysis, and positive regulation of tumor necrosis factor–mediated signaling pathway matrix as well. However, GO term signal transduction in Biological",19_49,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"GO term signal transduction in Biological Process<sup><xref rid=""bibr83-11779322231210098"" ref-type=""bibr"">83</xref>,<xref rid=""bibr84-11779322231210098"" ref-type=""bibr"">84</xref></sup> and plasma membrane in Cellular Component<sup>",19_50,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"<xref rid=""bibr93-11779322231210098"" ref-type=""bibr"">93</xref>
</sup> were found in some other related researches. In our study, TF activity and sequence-specific DNA binding was found in molecular function enriched by gene ontologies, whereas TF activity in molecular function<sup>
<xref rid=""bibr3-11779322231210098"" ref-type=""bibr"">3</xref>",19_51,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"</sup> was found to be relevant to HD in a study. Combining earlier study findings, the current analysis may give new treatment targets or probable pathogenesis to be investigated further. In our study, the hub genes we identified were <italic toggle=""yes"">DUSP1, NKX2-5, GLI1, KLF4, SCNN1B, NPHS1, SGK2, PITX2, S100A4</italic>, and <italic toggle=""yes"">MSX1</italic> reflecting as the potential biomarkers for HD. These hub proteins are thought to be important particle in the disease-causing pathways.<sup>",19_52,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"<xref rid=""bibr94-11779322231210098"" ref-type=""bibr"">94</xref>
</sup> As a result, we recreated the protein interaction network with a focus on DEGs to find relevant hub proteins. These proteins could play a role in the development and progression of HD. In HD, sodium butyrate has previously been shown to be neuroprotective, and this is correlated with an increased affirmation of mitogen-activated protein kinase phosphatase 1 (DUSP1/MKP1).<sup>
<xref rid=""bibr53-11779322231210098"" ref-type=""bibr"">53</xref>",19_53,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"</sup> In some diseases, such as HD, low DUSP1 (also known as MKP-1) expression may contribute to MAPK hyperactivation, whereas increased MKP activity may be neuroprotective.<sup><xref rid=""bibr53-11779322231210098"" ref-type=""bibr"">53</xref><xref rid=""bibr54-11779322231210098"" ref-type=""bibr""></xref>-<xref rid=""bibr55-11779322231210098"" ref-type=""bibr"">55</xref></sup> GLI1 has also been identified as a contributing hub protein gene in HD, which has been linked to a number of other studies.<sup><xref",19_54,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"linked to a number of other studies.<sup><xref rid=""bibr58-11779322231210098"" ref-type=""bibr"">58</xref><xref rid=""bibr59-11779322231210098"" ref-type=""bibr""></xref><xref rid=""bibr60-11779322231210098"" ref-type=""bibr""></xref><xref rid=""bibr61-11779322231210098"" ref-type=""bibr""></xref><xref rid=""bibr62-11779322231210098"" ref-type=""bibr""></xref>-<xref rid=""bibr63-11779322231210098"" ref-type=""bibr"">63</xref></sup> In a study, NKX2-5 was discovered to be associated with protein synthesis in HD along with AGG and",19_55,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
with protein synthesis in HD along with AGG and GATA-4.<sup>,19_56,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"<xref rid=""bibr56-11779322231210098"" ref-type=""bibr"">56</xref>
</sup> NKX2-5 was also found as one of the significantly <inline-formula id=""inline-formula54-11779322231210098"">",19_57,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"<math xmlns=""http://www.w3.org/1998/Math/MathML""><mrow xmlns=""http://www.w3.org/1998/Math/MathML""><mo xmlns=""http://www.w3.org/1998/Math/MathML"">(</mo><mi xmlns=""http://www.w3.org/1998/Math/MathML"">P</mi><mo xmlns=""http://www.w3.org/1998/Math/MathML""><</mo><mo xmlns=""http://www.w3.org/1998/Math/MathML"">.</mo><mn xmlns=""http://www.w3.org/1998/Math/MathML"">05</mn><mo xmlns=""http://www.w3.org/1998/Math/MathML"">)</mo></mrow></math>
</inline-formula> up-regulated genes.<sup>",19_58,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"</inline-formula> up-regulated genes.<sup>
<xref rid=""bibr57-11779322231210098"" ref-type=""bibr"">57</xref>",19_59,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"</sup> Previous research has suggested KLF4 as a possible biomarker for HD, which is supported by our findings.<sup><xref rid=""bibr64-11779322231210098"" ref-type=""bibr"">64</xref><xref rid=""bibr65-11779322231210098"" ref-type=""bibr""></xref><xref rid=""bibr66-11779322231210098"" ref-type=""bibr""></xref><xref rid=""bibr67-11779322231210098"" ref-type=""bibr""></xref>-<xref rid=""bibr68-11779322231210098"" ref-type=""bibr"">68</xref></sup> Histones and nephrin (NPHS1) levels in the neuronal cytoplasmic pool were found to",19_60,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"in the neuronal cytoplasmic pool were found to be higher in HD and Alzheimer disease brains in a previous study. Increased NPHS1 expression has been linked to HD in a study, which backs up our findings.<sup>",19_61,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"<xref rid=""bibr71-11779322231210098"" ref-type=""bibr"">71</xref>
</sup> SCNN1Bs were identified as a molecular biomarker in HD which was also demonstrated in 2 earlier studies.<sup><xref rid=""bibr69-11779322231210098"" ref-type=""bibr"">69</xref>,<xref rid=""bibr70-11779322231210098"" ref-type=""bibr"">70</xref></sup> Decreased AKT signaling has been linked to the pathophysiology of HD in a previous study, and the SGK family has gained a lot of interest because of its high similarity to AKT.<sup>",19_62,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"<xref rid=""bibr72-11779322231210098"" ref-type=""bibr"">72</xref>
</sup> A study identified that in mammalian genomes, 3 genes encode the SGK family (SGK1, SGK2, and SGK3).<sup>
<xref rid=""bibr72-11779322231210098"" ref-type=""bibr"">72</xref>",19_63,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"</sup> In our research, we discovered that SGK2 is a possible protein hub in HD which is relevant to this previous study. Loss of PITX2 in HD does not affect the initial formation of striatal neurons composing the pathways directly and indirectly, according to recent studies although over-expressed PITX2 affects neurons.<sup><xref rid=""bibr73-11779322231210098"" ref-type=""bibr"">73</xref>,<xref rid=""bibr74-11779322231210098"" ref-type=""bibr"">74</xref></sup> In mice models of HD, <italic",19_64,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"In mice models of HD, <italic toggle=""yes"">S100A4</italic> genes were found to be considerably up-regulated within early-symptomatic R6/2 as well as pre-symptomatic HdhQ150 hearts, according to a study,<sup>",19_65,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"<xref rid=""bibr76-11779322231210098"" ref-type=""bibr"">76</xref>
</sup> and it was also identified as up-regulated in another research.<sup>
<xref rid=""bibr75-11779322231210098"" ref-type=""bibr"">75</xref>",19_66,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"</sup> Directory biomolecules are being explored more and more as potential biomarkers for serious illnesses like neurodegenerative disorders.<sup><xref rid=""bibr26-11779322231210098"" ref-type=""bibr"">26</xref>,<xref rid=""bibr31-11779322231210098"" ref-type=""bibr"">31</xref>,<xref rid=""bibr95-11779322231210098"" ref-type=""bibr"">95</xref>,<xref rid=""bibr96-11779322231210098"" ref-type=""bibr"">96</xref></sup> Keeping this in consideration, we investigated the involvement of TFs and miRNAs in DEG regulation via",19_67,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"of TFs and miRNAs in DEG regulation via TF-miRNA coregulatory networks. MicroRNAs have a crucial role in the regulation of gene expression, and there is growing evidence that they could be used as biomarkers for HD and other disorders.<sup><xref rid=""bibr83-11779322231210098"" ref-type=""bibr"">83</xref>,<xref rid=""bibr92-11779322231210098"" ref-type=""bibr"">92</xref></sup> Many miRNAs are expected to have a role in the pathogenic problem that introduces HD.<sup><xref rid=""bibr2-11779322231210098""",19_68,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"HD.<sup><xref rid=""bibr2-11779322231210098"" ref-type=""bibr"">2</xref>,<xref rid=""bibr94-11779322231210098"" ref-type=""bibr"">94</xref></sup> Our study disclosed top significant transcriptomic factors (TFs), ie, FOXC1, GATA2, PRRX2, YY1, TFAP2A, FOXL1, PPARG, HINFP, STAT3, MEF2A, and NFKB1 and top significant miRNAs, ie, hsa-miR-340, hsa-miR-34a, hsa-miR-495, hsa-miR-1, hsa-miR-124, hsa-miR-29a, hsa-miR-29b, hsa-miR-30e, hsa-miR-16, hsa-miR-206, hsa-miR-30a, hsa-miR-30c, and hsa-miR-944 as regulatory",19_69,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"hsa-miR-30c, and hsa-miR-944 as regulatory biomarkers for HD. FOXC1, GATA2, YY1, FOXL1, and PPARG, which were revealed to be engaged as regulatory TFs in another neurodegenerative disease (Alzheimer disease, Parkinson disease, and some other neurodegenerative diseases also), were among the TFs we detected.<sup><xref rid=""bibr81-11779322231210098"" ref-type=""bibr"">81</xref>,<xref rid=""bibr95-11779322231210098"" ref-type=""bibr"">95</xref>,<xref rid=""bibr96-11779322231210098"" ref-type=""bibr"">96</xref></sup> In a",19_70,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"ref-type=""bibr"">96</xref></sup> In a study, researchers discovered an increase in the concentration of TFAP2A nucleoid signals from various micropattern colonies in HD.<sup>",19_71,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"<xref rid=""bibr97-11779322231210098"" ref-type=""bibr"">97</xref>
</sup> Some relevant studies showed similar result as our findings resulting the TFs PPARG, STAT3, MEF2A, and NFKB1 be found in HD side by side other TFs.<sup>
<xref rid=""bibr22-11779322231210098"" ref-type=""bibr"">22</xref>",19_72,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"</sup>,<sup><xref rid=""bibr98-11779322231210098"" ref-type=""bibr"">98</xref><xref rid=""bibr99-11779322231210098"" ref-type=""bibr""></xref>-<xref rid=""bibr100-11779322231210098"" ref-type=""bibr"">100</xref></sup> It has been found that hsa-miR-340, hsa-miR-34a, hsa-miR-495, hsa-miR-30e, hsa-miR-206, and hsa-miR-30a have contribution to as a down-regulated miRNA;<sup>
<xref rid=""bibr96-11779322231210098"" ref-type=""bibr"">96</xref>",19_73,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"</sup>,<sup><xref rid=""bibr101-11779322231210098"" ref-type=""bibr"">101</xref><xref rid=""bibr103-11779322231210098"" ref-type=""bibr""></xref><xref rid=""bibr104-11779322231210098"" ref-type=""bibr""></xref>-<xref rid=""bibr104-11779322231210098"" ref-type=""bibr"">104</xref></sup> on the contrary, hsa-miR-1 was found to have potentiality in Schizophrenia.<sup>
<xref rid=""bibr105-11779322231210098"" ref-type=""bibr"">105</xref>",19_74,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"</sup> Huntington disease, Alzheimer disease, Hypoxic Ischemic Encephalopathy, Parkinson disease, and ischemic stroke have all been identified to have aberrant miR-124 expression.<sup><xref rid=""bibr106-11779322231210098"" ref-type=""bibr"">106</xref>,<xref rid=""bibr107-11779322231210098"" ref-type=""bibr"">107</xref></sup> Our findings revealed that decreased expression of miR-29a and hsa-miR-29b is a prevalent occurrence in many neurodegenerative disorders, including HD<sup>",19_75,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"<xref rid=""bibr85-11779322231210098"" ref-type=""bibr"">85</xref>
</sup> and Alzheimer disease<sup>
<xref rid=""bibr108-11779322231210098"" ref-type=""bibr"">108</xref>
</sup> and hsa-miR-16 is also a potential miRNA for HD.<sup>
<xref rid=""bibr109-11779322231210098"" ref-type=""bibr"">109</xref>",19_76,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"</sup> Differentially expressed genes were then investigated further to understand more about the prospective interactions using minor candidate drugs that could cure HD. Finally, we predicted drugs/compounds to produce drug repositioning hypothesis in HD based on the probability that revealed biomarkers (ie, hub proteins and TFs) could be potential therapeutic targets.<sup>
<xref rid=""bibr110-11779322231210098"" ref-type=""bibr"">110</xref>
</sup>-<sup>",19_77,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"</sup>-<sup>
<xref rid=""bibr112-11779322231210098"" ref-type=""bibr"">112</xref>
</sup> As a result, connections between identified HD biomarkers and medicines have been established, suggesting that they may impact critical pathways in disease development<sup>
<xref rid=""bibr113-11779322231210098"" ref-type=""bibr"">113</xref>",19_78,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"</sup>; nevertheless, more research is needed to assess the ramifications of proposed biomarker blocking. The successful implementation of disease-modifying therapies in HD progression will require the detection of potential biomarkers and their pathways. This research provided a summary of network-based approaches for identifying biochemical mechanisms underlying HD progression. From 2 transcriptomic data sets of HD, 162 DEGs were identified using a comprehensive bioinformatics analysis to build a PPI",19_79,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"bioinformatics analysis to build a PPI network, and the top most significant hub genes from the PPI network were identified as potential novel biomarkers in HD diagnosis. Following that, several TFs, ie, FOXC1, GATA2, PRRX2, etc and miRNAs such as, hsa-miR-340, hsa-miR-34a, hsa-miR-495, hsa-miR-1, etc were identified from the common genes linked to HD. However, more research is needed to confirm the anticipated drugs. We anticipate that all these biomarkers will allow quicker and more affordable detection",19_80,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"will allow quicker and more affordable detection of brain samples for the identification of HD. This method of identifying biomarkers can be used in obtainable tissue from brain to assess their presence and activity in inaccessible tissue, and it could be used to solve other therapeutic difficulties. We therefore suggest a more thorough validation of this framework and the possible biomarker transcripts we detected through clinical studies.",19_81,A Comprehensive Bioinformatics Approach to Identify Molecular Signatures and Key Pathways for the Huntington Disease,27 11 2023,,Huntington_Disease
"Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation Huntington disease (HD) is a neurodegenerative disorder caused by a mutation in the <italic toggle=""yes"">HTT</italic> gene. The expansion of CAG triplets leads to the appearance of misfolded HTT (huntingtin) forming aggregates and leading to impairment of neuronal functions. Here we demonstrate that stimulation of macroautophagy/autophagy by genistein (4′,5,7-trihydroxyisoflavone or",20_0,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"by genistein (4′,5,7-trihydroxyisoflavone or 5,7-dihydroxy-3-(4-hydroxyphenyl)-4 H-1-benzopyran-4-one) caused a reduction of levels of mutated HTT in brains of HD mice and correction of their behavior as assessed in a battery of cognitive, anxiety and motor tests, even if the compound was administered after symptoms had developed in the animals. Biochemical and immunological parameters were also improved in HD mice. Studies on molecular mechanisms of genistein-mediated stimulation of autophagy in HD cells",20_1,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"stimulation of autophagy in HD cells indicated the involvement of the FOXO3-related pathway. In conclusion, treatment with genistein stimulates the autophagy process in the brains of HD mice, leading to correction of symptoms of HD, suggesting that it might be considered as a potential drug for this disease. Combined with a very recently published report indicating that impaired autophagy may be a major cause of neurodegenerative changes, these results may indicate the way to the development of effective",20_2,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"indicate the way to the development of effective therapeutic approaches for different neurodegenerative diseases by testing compounds (or possibly combinations of compounds) capable of stimulating autophagy and/or unblocking this process. <bold>Abbreviations</bold>: CNS: central nervous system; EPM: elevated plus-maze; GOT1/ASPAT: glutamic-oxaloacetic transaminase 1, soluble; GPT/ALAT/ALT: glutamic pyruvic transaminase, soluble; HD: Huntington disease; HTT: huntingtin; IL: interleukin; mHTT: mutant",20_3,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"HTT: huntingtin; IL: interleukin; mHTT: mutant huntingtin; NOR: novel object recognition; MWM: Morris water maze; OF: open field; ROS: reactive oxygen species; TNF: tumor necrosis factor Huntington disease (HD) is a genetically transmitted, progressive neurodegenerative disease, inherited in an autosomal dominant manner [<xref rid=""cit0001"" ref-type=""bibr"">1</xref>]. It is caused by a mutation resulting in the expansion of CAG nucleotide triplets in exon 1 of the <italic toggle=""yes"">HTT/IT15</italic>",20_4,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"1 of the <italic toggle=""yes"">HTT/IT15</italic> (huntingtin) gene. The mutation results in the appearance of a long tract of glutamine residues in the HTT protein which impairs its proper folding. Thus, mutant HTT (mHTT) accumulates in cells, including neurons, as insoluble and hardly removable aggregates which impair the functions of these cells. Apart from mHTT aggregates, unproper secondary structures of mRNA molecules derived from the mutant <italic toggle=""yes"">HTT</italic> gene may disturb crucial",20_5,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"gene may disturb crucial cellular processes, like RNA splicing [<xref rid=""cit0002"" ref-type=""bibr"">2</xref>]. Then, both protein aggregates and faulty splicing can make an expression of many genes dysregulated [<xref rid=""cit0003"" ref-type=""bibr"">3</xref>], causing severe pathogenic effects in cells. These include dysfunction of lysosomes, impaired biogenesis of mitochondria, disrupted functions of organelles and improper protein transport, induction of inflammation, and enhanced oxidative stress [<xref",20_6,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"and enhanced oxidative stress [<xref rid=""cit0001"" ref-type=""bibr"">1</xref>]. At the organismal level, such pathological changes result in psycho-motoric dysfunctions, like changed behavior and impaired cognitive abilities. The quality of life of patients deteriorates over time, and they become dependent on their caregivers. Death usually occurs between 15 and 20 years after diagnosis [<xref rid=""cit0001"" ref-type=""bibr"">1</xref>]. Despite many attempts, no cure is still available for HD. Among therapeutic",20_7,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"cure is still available for HD. Among therapeutic strategies considered to date, those based on either silencing the expression of the mutant gene or elimination of mHTT aggregates appear the most promising [<xref rid=""cit0004"" ref-type=""bibr"">4–6</xref>]. However, there are serious challenges in both these strategies. First, it is difficult to deliver therapeutic inhibitors of gene expression, such as anti-sense RNAs, into cells of the central nervous system (CNS), and then, it is problematic to silence",20_8,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"(CNS), and then, it is problematic to silence only the mutant <italic toggle=""yes"">HTT</italic> allele while leaving the functional allele fully active. Second, the elimination of insoluble protein aggregates from the cells, especially neurons, is a complicated task, especially as too effective activation of protein-degrading cellular systems might result in severe adverse effects [<xref rid=""cit0007"" ref-type=""bibr"">7</xref>]. In light of the latter option, it is worth noting that impairment of the",20_9,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"option, it is worth noting that impairment of the macroautophagy/autophagy process, which is responsible for the decay of improper and unwanted molecules or structures and damaged or dysfunctional organelles, has been demonstrated in HD [<xref rid=""cit0008"" ref-type=""bibr"">8–14</xref>]. Therefore, one might propose that stimulation of autophagy might be considered a therapeutic strategy for HD, and perhaps also other neurodegenerative diseases caused by the accumulation of misfolded and aggregated",20_10,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"by the accumulation of misfolded and aggregated proteins. Indeed, such proposals have been published previously [<xref rid=""cit0007"" ref-type=""bibr"">7</xref>,<xref rid=""cit0015"" ref-type=""bibr"">15</xref>,<xref rid=""cit0016"" ref-type=""bibr"">16</xref>]. However, the major problem in such an approach is that the potential drug should have several properties. Namely, (i) it should effectively induce autophagy but at the same time it should not overstimulate this process, to avoid auto-destruction of cellular",20_11,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"process, to avoid auto-destruction of cellular components, especially in the process of autophagy-dependent apoptosis; (ii) it should effectively cross the blood-brain-barrier to be easily delivered to CNS following oral (preferably) or intravenous administration; (iii) it should be safe and reveal little or no adverse effects in a long-time treatment, as such therapy of any genetic and/or neurodegenerative disease is expected to be lifelong [<xref rid=""cit0007"" ref-type=""bibr"">7</xref>]. In addition, in",20_12,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"ref-type=""bibr"">7</xref>]. In addition, in the case of HD, a disease in which enhanced oxidative stress and induction of inflammation are important secondary mechanisms leading to neurodegeneration [<xref rid=""cit0001"" ref-type=""bibr"">1</xref>], a therapeutic compound should ideally also reveal antioxidant and anti-inflammatory properties. Although reduction of mHTT accumulation in animal and cellular models of HD in response to autophagy stimulation was first demonstrated some two decades ago [<xref",20_13,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"first demonstrated some two decades ago [<xref rid=""cit0017"" ref-type=""bibr"">17</xref>,<xref rid=""cit0018"" ref-type=""bibr"">18</xref>], compounds like rapamycin (a strong autophagy inducer), express serious adverse effects when used for a longer time (despite they are registered as drugs for a short-time use in different purposes), including thrombocytopenia, anemia and leukopenia. Therefore, we were looking for compounds that are effective but gentle and safe autophagy stimulators, being also antioxidants",20_14,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"autophagy stimulators, being also antioxidants and anti-inflammatory compounds. Our preliminary experiments suggested that genistein (4′,5,7-trihydroxyisoflavone or 5,7-dihydroxy-3-(4-hydroxyphenyl)-4 H–1-benzopyran-4-one) might be such a molecule. This isoflavone has already been known for acting as an antioxidant and an anti-inflammatory agent [<xref rid=""cit0019"" ref-type=""bibr"">19</xref>], however, we have demonstrated that it also activated autophagy in a cellular HD model, leading to the",20_15,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"autophagy in a cellular HD model, leading to the disappearance of mHTT aggregates [<xref rid=""cit0020"" ref-type=""bibr"">20</xref>]. These results were confirmed in experiments with the cells (fibroblast lines) derived from HD patients [<xref rid=""cit0021"" ref-type=""bibr"">21</xref>]. Moreover, genistein has been demonstrated to be safe for patients even at doses as high as 150 mg/kg/day administered orally for 1–2 years [<xref rid=""cit0022"" ref-type=""bibr"">22</xref>]. Therefore, in this study, we aimed to",20_16,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"Therefore, in this study, we aimed to test the efficacy of genistein in the mouse model of HD (the R6/1 mice) by assessing the efficacy of this compound in the correction of behavioral (cognitive, anxiety, and memory) changes, biochemical abnormalities, oxidative stress enhancement, and induced inflammation. Unlike most other studies on the therapeutic effects of potential anti-HD drugs, we tested the effects when genistein was started to be administered after the appearance of serious symptoms in the",20_17,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"after the appearance of serious symptoms in the animals to assess therapeutic rather than prophylactic efficacy. Moreover, molecular studies were performed (using both animal and cellular models) to learn abound principles of the mechanisms by which genistein stimulates autophagy in HD cells. To our knowledge, this is the first study demonstrating in a comprehensive manner that genistein stimulates autophagy through the FOXO3-related mechanism, thus, reducing levels of mHTT in the brains and correcting",20_18,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"levels of mHTT in the brains and correcting behavior of the HD mice as assessed in a battery of cognitive, anxious and motoric tests, even if administered after the animals have developed symptoms, and at the same time abolishing oxidative stress, inflammation, and stress responses. Therefore, we suggest that genistein can be considered as a putative drug for HD and that further studies in this direction are substantiated.  The severity of HD and the lack of effective treatment have led to efforts to",20_19,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"of effective treatment have led to efforts to develop an effective therapy for this disease substantiated, important and urgent [<xref rid=""cit0001"" ref-type=""bibr"">1</xref>,<xref rid=""cit0004"" ref-type=""bibr"">4–6</xref>]. As a genetic, neurodegenerative disease, it is, however, especially difficult to treat. Since the major problem in HD pathogenesis is the formation of insoluble aggregates of the product of the mutated <italic toggle=""yes"">HTT</italic> gene, one of the potential therapeutic options is to",20_20,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"one of the potential therapeutic options is to decrease the levels of the toxic protein [<xref rid=""cit0004"" ref-type=""bibr"">4–7</xref>]. To achieve this, it is necessary to activate a cellular process capable of degrading protein aggregates, and autophagy meets such a requirement. Therefore, autophagy stimulation was proposed as a therapeutic option for HD [<xref rid=""cit0007"" ref-type=""bibr"">7</xref>,<xref rid=""cit0015"" ref-type=""bibr"">15</xref>]. On the other hand, a candidate for an anti-HD drug should",20_21,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"hand, a candidate for an anti-HD drug should not only activate the autophagy process effectively, but at the same time, it should be safe (not causing significant adverse effects) in a lifelong treatment, cross the blood-brain-barrier, and optimally also act as an antioxidant and anti-inflammatory agent to diminish secondary, though still important pathological mechanisms of the disease [<xref rid=""cit0001"" ref-type=""bibr"">1</xref>,<xref rid=""cit0007"" ref-type=""bibr"">7</xref>]. Our previous preliminary",20_22,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"Our previous preliminary studies suggested that genistein, one of the isoflavones, may meet all these features [<xref rid=""cit0020"" ref-type=""bibr"">20</xref>,<xref rid=""cit0021"" ref-type=""bibr"">21</xref>]. Indeed, this compound, apart from the stimulation of the autophagy process, reveals many biological activities, including anti-inflammatory, antioxidant, anti-angiogenic, anti-obesity, anti-cancer, cardioprotective, and anti-diabetic properties [<xref rid=""cit0019"" ref-type=""bibr"">19</xref>]. Therefore,",20_23,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"ref-type=""bibr"">19</xref>]. Therefore, in this study, we aimed to perform a comprehensive study on the effects of this compound administration in the HD mouse model. Unlike many other studies on searching for anti-HD therapy, the onset of administration of the tested compound was after the development of the disease symptoms rather than before such a disease stage. This allowed us to determine whether genistein treatment can correct the already disturbed functions of the organism, not only to prevent or",20_24,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"functions of the organism, not only to prevent or delay the appearance of the specific symptoms. The presented results demonstrate that treatment with genistein at the dose of 150 mg/kg/day not only improved the behavior of HD mice, but even corrected most of the tested parameters to levels undistinguishable from the control (healthy) animals. Since a battery of tests measuring cognitive functions and anxiety was employed, and in all types of assays the significant improvement in HD animals was evident, it",20_25,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"improvement in HD animals was evident, it can be concluded that genistein corrects behavior in this model. Moreover, motoric functions which are severely impaired in HD (also in the R6/1 mouse model of HD) could be corrected by daily oral genistein administration. Importantly, various biochemical and hematological parameters of the blood of HD mice were considerably changed relative to control animals, whereas genistein treatment corrected these abnormalities. Similar to them, levels of oxidative stress in",20_26,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"Similar to them, levels of oxidative stress in muscles normalized, as did levels of pro- and anti-inflammatory interleukins in the blood of HD animals. All these results suggest that the efficacy of genistein in the correction of so many HD symptoms, even when the administration of this compound was started after the appearance of the abnormalities in animals, may be due to several biological activities and complex action of this isoflavone. One should note that while the neurodegenerative aspects of HD",20_27,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"that while the neurodegenerative aspects of HD are crucial in this disorder, other changes play also a significant role in the development of various symptoms. Although the nature of IL6 (pro-inflammatory or anti-inflammatory) is constantly discussed in the literature, it plays an important role in HD. It has a role not only in the immune system response but, due to its central expression, also in the course of cognitive processes. Changes in IL6 levels in HD patients are the earliest described markers of",20_28,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"HD patients are the earliest described markers of impaired immune response, appearing up to 16 years before the onset of motor dysfunction [<xref rid=""cit0023"" ref-type=""bibr"">23</xref>]. It was demonstrated that in the R6/2 HD mouse model with IL6 deficiency, there was a dysregulation of many genes related to synaptic function, as well as the BDNF receptor NTRK2 and disruption of the behavioral pattern [<xref rid=""cit0023"" ref-type=""bibr"">23</xref>]. Moreover, at early stages of HD, elevated IL6 levels",20_29,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"at early stages of HD, elevated IL6 levels are thought to have protective effects, similar to those in animal models of traumatic brain injury, Parkinson and Alzheimer diseases. However, as the disease progresses, when the number of mHTT deposits increases, resulting in serious abnormalities in the functioning of the immune system, there is a decrease in IL6 levels, not only in peripheral blood but also in its central expression, which translates into the severity of various categories of pathological",20_30,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"severity of various categories of pathological disturbances. Elevated levels of anti-inflammatory cytokines, such as IL4 and IL10, were observed in the plasma of HD patients only at the pre-symptomatic stage of the disease or when the symptoms were still mild. IL10 plays an important role in the course of many different diseases, being responsible primarily for supporting the repair processes of tissues whose structure has been damaged as a result of infection or inflammation, as well as for suppressing",20_31,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"or inflammation, as well as for suppressing the pro-inflammatory reaction, which ultimately leads to the above-mentioned damage. At the advanced stage of Huntington disease, decreased levels are observed not only in the blood plasma but also in the central nervous system, indicating impaired inflammation-suppressing processes, as well as weakening of repair mechanisms [<xref rid=""cit0024"" ref-type=""bibr"">24</xref>]. In this light, the normalization of levels of factors involved in the immune response by",20_32,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"of factors involved in the immune response by treatment with genistein indicates that this isoflavone might efficiently control not only the primary but also secondary pathomechanisms of HD. The above conclusion can be corroborated by the improvement of various biochemical parameters in HD mice by genistein, including activities of GPT/ALAT (glutamic pyruvic transaminase, soluble) and GOT1/ASPAT (glutamic-oxaloacetic transaminase 1, soluble), and levels of bilirubin, CK (creatine kinase), TNN (troponin I),",20_33,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"CK (creatine kinase), TNN (troponin I), and ROS. These biochemical markers were determined in view of monitoring changes in the functioning of organs, such as the liver, kidneys, and heart, whose gradual dysfunction is observed in HD [<xref rid=""cit0025"" ref-type=""bibr"">25</xref>]. Despite other genistein biological activities, autophagy stimulation appears to be the major one in its anti-HD effectivity. We have proven that this stimulation is effective in both HD mouse models and human cells. Activated",20_34,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"both HD mouse models and human cells. Activated autophagy could lead to the efficient degradation of already accumulated mHTT, and a significant reduction of levels of this mutant protein in both mouse brains and human fibroblasts. Therefore, we have asked what the molecular mechanism of genistein-mediated activation of autophagy is. Previous studies indicated that genistein stimulated TFEB, which is the master regulator of lysosomal biogenesis [<xref rid=""cit0026"" ref-type=""bibr"">26</xref>]. Nevertheless,",20_35,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"ref-type=""bibr"">26</xref>]. Nevertheless, there are at least 7 pathways of autophagy stimulation, thus, it was important to learn more details about the genistein’s activity in this process. Especially important is also the fact that one of the recent reports indicated that mHTT co-aggregates with TFEB [<xref rid=""cit0027"" ref-type=""bibr"">27</xref>], making the attempts to stimulate autophagy solely through activation of this transcription factor doubtful. In this study we demonstrate that genistein, apart",20_36,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"this study we demonstrate that genistein, apart from influencing levels and modifications of known general autophagy markers, significantly modulated both levels and phosphorylation of FOXO3, resulting in the translocation of this transcription factor to the nucleus. Importantly, silencing of the <italic toggle=""yes"">FOXO3</italic> gene expression impaired the effect of genistein on the reduction of the mHTT levels, supporting the proposal that genistein-mediated stimulation of autophagy, which is",20_37,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"stimulation of autophagy, which is responsible for the effective removal of mHTT aggregates, requires FOXO3. Indeed, recent studies by others have shown that FOXO3 positively regulates the expression of genes involved in autophagy, stimulating this process effectively [<xref rid=""cit0028"" ref-type=""bibr"">28</xref>,<xref rid=""cit0029"" ref-type=""bibr"">29</xref>]. One might speculate that such a regulation could positively influence the course of neurodegenerative disease. Although the role of this",20_38,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"disease. Although the role of this transcription regulator in various neurodegenerative diseases has been discussed recently, it was rather considered a factor implicated in the control of aging and longevity [<xref rid=""cit0030"" ref-type=""bibr"">30</xref>]. However, since FOXO3 may activate the expression of autophagy-related genes [<xref rid=""cit0028"" ref-type=""bibr"">28</xref>,<xref rid=""cit0029"" ref-type=""bibr"">29</xref>], it could also prevent neurodegeneration through the reduction of toxic aggregates",20_39,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"through the reduction of toxic aggregates in cells. Our results corroborate such suggestions while showing for the first time that genistein is a stimulator of FOXO3. Previous attempts to stimulate autophagy in order to reduce the levels of mHTT involved the use of various compounds. The earliest works were based on the treatment with rapamycin, a strong inhibitor of MTOR [<xref rid=""cit0017"" ref-type=""bibr"">17</xref>,<xref rid=""cit0018"" ref-type=""bibr"">18</xref>]. However, this compound, although",20_40,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"However, this compound, although registered now as a drug, reveals serious adverse effects when used for a longer period. Felodipine, a calcium channel blocker, used currently as an anti-hypertensive drug, was shown to stimulate autophagy which prevented the accumulation of misfolded proteins [<xref rid=""cit0031"" ref-type=""bibr"">31</xref>], though its ability to reduce already accumulated aggregates remains unknown. In another study, autophagy was stimulated by overexpression of the gene coding for either",20_41,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"by overexpression of the gene coding for either TFEB or Beclin-1, but the effects on mHTT aggregates were limited [<xref rid=""cit0032"" ref-type=""bibr"">32</xref>]. CGAS (cyclic GMP-AMP synthase) was shown to activate both inflammatory and autophagy responses [<xref rid=""cit0033"" ref-type=""bibr"">33</xref>] which was an interesting discovery, however, it would have perhaps limited applications in searching for a potential anti-HD drug as inflammation stimulation would not be desirable in this case. Some",20_42,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"would not be desirable in this case. Some authors proposed that the MTOR-RPS6KB-EIF4EBP signal transduction pathway might be a target for an anti-HD drug based on autophagy stimulation [<xref rid=""cit0034"" ref-type=""bibr"">34</xref>], though further studies are required to demonstrate the efficacy of such a potential therapeutic option, and the role of AMPK in autophagy induction cannot be underestimated in this case [<xref rid=""cit0035"" ref-type=""bibr"">35</xref>]. The GSK3 protein is another regulator of",20_43,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"The GSK3 protein is another regulator of autophagy, and the use of a selective inhibitor of GSK3, called L807mts, resulted in a decrease in the amounts of mHTT aggregates in HD cells [<xref rid=""cit0036"" ref-type=""bibr"">36</xref>]. Treatment of the R6/2 mouse model with L807mts indicated the neuroprotective effect and improvement of symptoms, though total correction could not be demonstrated [<xref rid=""cit0036"" ref-type=""bibr"">36</xref>]. Deletion of the SUMO1 was suggested as a possible target for",20_44,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"the SUMO1 was suggested as a possible target for anti-HD drugs as deletion of the corresponding gene in the mouse model, as well as the use of a SUMOylation inhibitor in cell cultures, resulted in the autophagy stimulation and lower levels of mHTT [<xref rid=""cit0037"" ref-type=""bibr"">37</xref>]. Erythropoietin was then shown to modulate the PI3K-AKT-MTOR-RPS6KB pathway of autophagy stimulation and improvement in the rat model of HD induced by 3-nitropropionic acid [<xref rid=""cit0038""",20_45,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"by 3-nitropropionic acid [<xref rid=""cit0038"" ref-type=""bibr"">38</xref>]. However, in this model, only symptoms resemble those occurring in humans suffering from HD, while no HTT aggregates occur, therefore, it is difficult to estimate the effects of such a therapy when used in patients. It is also worth noting that regulation through microRNA was proposed to be important in autophagy stimulation in HD cells [<xref rid=""cit0039"" ref-type=""bibr"">39</xref>]. Finally, a recent report demonstrated that an",20_46,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"Finally, a recent report demonstrated that an artificial compound, called J3, stimulated autophagy, and when administered to HD mice showed a slight improvement in the motor functions in the open-field test, balance beam test, and rotarod tests [<xref rid=""cit0040"" ref-type=""bibr"">40</xref>]. Interestingly, in the same tests (open-field and rotarod) performed with HD mice treated with genistein in this work, total correction rather than slight improvement of symptoms was noted. These results might suggest",20_47,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"symptoms was noted. These results might suggest a higher efficacy of genistein than J3 in the normalization of pathological changes caused by HD. Normal HTT is required for basal autophagy, and defects in this process in HD cells were reported previously [<xref rid=""cit0006"" ref-type=""bibr"">6</xref>]. In this light, it is interesting that in the brains of R6/1 mice which express both transgenic human <italic toggle=""yes"">HTT</italic> exon 1 with multiple CAG repeats and the wild-type mouse <italic",20_48,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"CAG repeats and the wild-type mouse <italic toggle=""yes"">HTT</italic> gene, the level of soluble HTT protein was significantly decreased. After treatment with genistein, soluble HTT became significantly more abundant, and occurred at a level similar to that found in wild-type mice which received genistein (this level was significantly, though not dramatically, lower than in non-treated control animals). This may suggest that normal HTT can be trapped by mHTT aggregates, thus being inactivated, and –",20_49,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"by mHTT aggregates, thus being inactivated, and – between others – unable to stimulate autophagy. Such a scenario would mean a positive feedback regulation loop, leading to the formation of more and more aggregates. Genistein, through independent stimulation of the autophagy process, might restore the cellular machinery degrading macromolecular complexes, and thus, rescue the ability of cells to remove toxic aggregates. Importantly, a very recent report demonstrated that the blockage of the autophagy",20_50,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"demonstrated that the blockage of the autophagy process through stimulation of the MTOR activity, mediated by the activation of the CCR5 receptor (C-C motif chemokine receptor 5), might be a major cause of neurodegeneration [<xref rid=""cit0041"" ref-type=""bibr"">41</xref>]. These pathological processes may occur even before the appearance of disease symptoms, as demonstrated with the mouse model of HD [<xref rid=""cit0038"" ref-type=""bibr"">38</xref>]. A promising result was the finding that pharmacological",20_51,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"result was the finding that pharmacological inhibition of CCR5 improves the neuropathology in HD and tauopathy by unblocking the autophagy process, thus causing the removal of toxic aggregates [<xref rid=""cit0041"" ref-type=""bibr"">41</xref>]. That important work, together with results presented in this report, strongly suggested that either stimulating or unblocking autophagy might be a putative way to either prevent neurodegeneration or correct this pathological process or both. This may shed new light on",20_52,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"process or both. This may shed new light on the development of novel therapeutical strategies for neurodegenerative diseases. In summary, treatment with genistein stimulates the autophagy process in the brains of HD mice, acting through the FOXO3 pathway. This leads to the correction of behavioral symptoms of HD. Moreover, oxidative stress and inflammatory processes are normalized. These results suggest that genistein might be considered a drug for HD. Considering these results, together with very recently",20_53,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"these results, together with very recently published studies, showing that inhibition of the CCR5 receptor may unblock the impairment of autophagy [<xref rid=""cit0041"" ref-type=""bibr"">41</xref>], it is tempting to propose that activation of this process might be crucial in developing effective therapies for HD and some other neurodegenerative diseases. This might be achieved by optimization of the autophagy stimulation through an effective and safe compound (like genistein) or by direct activation of FOXO3",20_54,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"(like genistein) or by direct activation of FOXO3 (overcoming the problem of a relatively low genistein bioavailability) or by using improved CCR5 inhibitors. A combination of the above-mentioned strategies of autophagy stimulation might also be considered. There are some limitations of this study. First, the R6/1 mouse model of HD consists of transgenic mice which express the exon 1 of the human <italic toggle=""yes"">HTT</italic> gene with extension of the CAG repeats, together with the native mouse",20_55,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"the CAG repeats, together with the native mouse <italic toggle=""yes"">HTT</italic> variant [<xref rid=""cit0042"" ref-type=""bibr"">42</xref>,<xref rid=""cit0043"" ref-type=""bibr"">43</xref>]. Although this model is useful in laboratory studies, and represents an accelerated form of the disease, it differs from the genetic configuration of human patients where one normal and one mutant (but bearing all exons and introns) variants of the <italic toggle=""yes"">HTT</italic> gene are expressed. Therefore, one should",20_56,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"gene are expressed. Therefore, one should avoid to simply extrapolate putative effects of genistein in HD patients from the results presented in this report. Second, only males of the R6/1 model were investigated in this work, due to previously reported differences in the disease course between R6/1 males and females [<xref rid=""cit0044"" ref-type=""bibr"">44</xref>], and potential difficulties with interpretation of the results in the case of the latter group. However, HD occurs in humans with equal",20_57,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"group. However, HD occurs in humans with equal frequency in both males and females. Therefore, further studies employing mice of both sexes are necessary to fully understand effects of genistein on the disease and to estimate efficacy of this isoflavone in treatment of males and females.",20_58,Correction of symptoms of Huntington disease by genistein through FOXO3-mediated autophagy stimulation,22 11 2023,,Huntington_Disease
"GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study Huntington disease (HD) is one of nine autosomal dominant, rare, neurodegenerative, polyglutamine (polyQ) disorders characterised by pathological expansions of a trinucleotide CAG repeat region encoding polyQ. In HD, the CAG region is located in the <italic toggle=""yes"">HTT</italic> gene, which encodes the polyQ region in the huntingtin protein.<xref rid=""bib1""",21_0,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"region in the huntingtin protein.<xref rid=""bib1"" ref-type=""bibr""><sup>1</sup></xref> HD typically manifests between 30 and 40 years of age with a movement disorder (typically chorea), cognitive dysfunction (e.g., abnormal executive functions) and behavioural changes, which are associated with an early progressive neurodegeneration of the cortex and striatum.<xref rid=""bib2"" ref-type=""bibr""><sup>2</sup></xref> Normal CAG repeat lengths are usually stably inherited, whereas mutant expansions (>36 repeats)",21_1,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"whereas mutant expansions (>36 repeats) can show instability when transmitted to subsequent generations. A mutant CAG repeat further increases the risk of somatic CAG expansion and can lead to earlier disease onset, at a juvenile age (i.e., <20 years). Highly expanded (HE) mutations (i.e., >80 CAG repeats) cause paediatric onset of disease (i.e., during the first decade of life).<xref rid=""bib3"" ref-type=""bibr""><sup>3</sup></xref> Patients with HE paediatric HD (HE-PHD) often exhibit neurodevelopmental",21_2,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"HD (HE-PHD) often exhibit neurodevelopmental delay or regression and a particularly severe phenotype, resulting in a shorter lifespan when compared to juvenile-onset HD (JOHD), which has relatively shorter CAG repeat lengths (i.e., <73),<xref rid=""bib3"" ref-type=""bibr""><sup>3</sup></xref> or adult-onset Huntington disease (AOHD).<xref rid=""bib3"" ref-type=""bibr""><sup>3</sup></xref> HE-PHD is also associated with a high rate of infantile epilepsy,<xref rid=""bib3""",21_3,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"high rate of infantile epilepsy,<xref rid=""bib3"" ref-type=""bibr""><sup>3</sup></xref><sup>,</sup><xref rid=""bib4"" ref-type=""bibr""><sup>4</sup></xref> liver steatosis,<xref rid=""bib5"" ref-type=""bibr""><sup>5</sup></xref> striatal volume loss with preserved brain cortex,<xref rid=""bib3"" ref-type=""bibr""><sup>3</sup></xref><sup>,</sup><xref rid=""bib6"" ref-type=""bibr""><sup>6</sup></xref> and severe striatal glucose hypometabolism.<xref rid=""bib7"" ref-type=""bibr""><sup>7</sup></xref> Abnormal glucose metabolism is",21_4,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"Abnormal glucose metabolism is a hallmark of several neurodegenerative diseases and is due, at least in part, to altered expression of glucose transporters (GLUTs),<xref rid=""bib8"" ref-type=""bibr""><sup>8</sup></xref> which control glucose uptake into the brain. GLUT-1 and 3 are the major transporters of glucose across the blood–brain barrier and into neurons.<xref rid=""bib9"" ref-type=""bibr""><sup>9</sup></xref> GLUT-1 deficiency syndrome is a rare genetic neurometabolic disorder caused by mutations in the",21_5,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"disorder caused by mutations in the <italic toggle=""yes"">SCL2A1</italic> gene, which results in impaired glucose transport into the brain.<xref rid=""bib10"" ref-type=""bibr""><sup>10</sup></xref> Clinically, GLUT-1 deficiency syndrome manifests with neurodevelopmental delay, microcephaly, a high rate of infantile epilepsy, cognitive impairment and varying degrees of spasticity, ataxia, and dystonia<xref rid=""bib11"" ref-type=""bibr""><sup>11</sup></xref> – a spectrum of symptoms that shares several similarities",21_6,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"of symptoms that shares several similarities with HE-PHD.<xref rid=""bib3"" ref-type=""bibr""><sup>3</sup></xref><sup>,</sup><xref rid=""bib12"" ref-type=""bibr""><sup>12</sup></xref><sup>,</sup><xref rid=""bib13"" ref-type=""bibr""><sup>13</sup></xref> We hypothesised that expression of GLUT-1 and GLUT-3 may underlie HE-PHD pathology and differ from AOHD. We therefore compared GLUT-1 and GLUT-3 expression in the brain and peripheral tissues of patients with HE-PHD, JOHD and AOHD, and control subjects. Furthermore, we",21_7,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"and AOHD, and control subjects. Furthermore, we postulated that defects in glucose uptake are associated with impaired brain energy metabolism in patients with HD. Thus, we evaluated expression of mitochondrial complexes and hexokinase-II (HK-II) in the brains of the same four populations.   Neurodegenerative conditions, such as Alzheimer, Huntington, and Parkinson diseases, are associated with brain glucose hypometabolism, which is contributed to by impaired GLUT-1 and GLUT-3 glucose transporters.<xref",21_8,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"GLUT-1 and GLUT-3 glucose transporters.<xref rid=""bib8"" ref-type=""bibr""><sup>8</sup></xref> Interestingly, dysregulation in GLUT transporters has also been observed in aberrant brain neurodevelopment,<xref rid=""bib18"" ref-type=""bibr""><sup>18</sup></xref> micromalformations<xref rid=""bib19"" ref-type=""bibr""><sup>19</sup></xref> and epilepsy, all conditions that have been associated with HD.<xref rid=""bib3"" ref-type=""bibr""><sup>3</sup></xref><sup>,</sup><xref rid=""bib4""",21_9,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"rid=""bib4"" ref-type=""bibr""><sup>4</sup></xref><sup>,</sup><xref rid=""bib20"" ref-type=""bibr""><sup>20</sup></xref><sup>,</sup><xref rid=""bib21"" ref-type=""bibr""><sup>21</sup></xref> Patients with HE-PHD manifest signs and symptoms that are uncommon to AOHD, including high frequency of epileptic seizures, early onset hypokinetic-rigid syndrome/dystonia and developmental delay.<xref rid=""bib3"" ref-type=""bibr""><sup>3</sup></xref><sup>,</sup><xref rid=""bib4"" ref-type=""bibr""><sup>4</sup></xref> Interestingly,",21_10,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"Interestingly, certain HE-PHD clinical features, such as epilepsy, are also observed in patients with GLUT-1 deficiency syndrome, where genetic defects in this transporter result in a chronic shortage of glucose in the brain.<xref rid=""bib22"" ref-type=""bibr""><sup>22</sup></xref> This suggests that alterations in glucose transport or metabolism may also occur in HE-PHD and could explain some of its unique symptoms, compared to AOHD. In the context of HD, this study demonstrates reduced protein expression of",21_11,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"study demonstrates reduced protein expression of GLUT-1 and GLUT-3 in the frontal cortex and striatum of brains from patients with HE-PHD, compared to brains from patients affected since adulthood, including JOHD, and from controls. Our results are partly in line with others, who have reported significantly lower GLUT-1 and GLUT-3 protein expression in the striatum of late-stage AOHD (classified as neuropathological Vonsattel grade 3), compared to earlier-stage AOHD (neuropathological Vonsattel grades 1",21_12,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"AOHD (neuropathological Vonsattel grades 1 and 2).<xref rid=""bib20"" ref-type=""bibr""><sup>20</sup></xref> However, they found no evidence of reduced GLUT-1 and GLUT-3 expression in AOHD cortex,<xref rid=""bib23"" ref-type=""bibr""><sup>23</sup></xref> whereas in our frontal cortex samples we found statistically significantly lower GLUT-1 expression in patients with HE-PHD versus controls, and statistically significantly lower GLUT-3 expression in all cohorts (HE-PHD, JOHD and AOHD) versus controls. Furthermore,",21_13,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"JOHD and AOHD) versus controls. Furthermore, we identified reduced protein levels of Rab11-A in HE-PHD frontal cortex. Rab11-A is a small GTPase that has a critical role in regulating the trafficking of GLUT-3 to the neuronal cell surface,<xref rid=""bib24"" ref-type=""bibr""><sup>24</sup></xref> experiments in HD cell models have shown reduced neuronal GLUT-3<xref rid=""bib25"" ref-type=""bibr""><sup>25</sup></xref> and Rab11-A expression levels and highlights the relevance of altered glucose transportation in",21_14,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"relevance of altered glucose transportation in models with HE mutations. In HE-PHD brain samples, low levels of GLUT-1 and GLUT-3 were observed alongside low levels of mitochondrial complexes involved in energy metabolism. In the frontal cortex, significant differences versus controls and versus AOHD were seen for complexes II and III and versus JOHD for complex I. Results from <italic toggle=""yes"">in vitro</italic> studies have revealed calcium abnormalities in mitochondria from patients and transgenic",21_15,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"in mitochondria from patients and transgenic mice with HD, and that these defects are a direct effect of HE polyQ.<xref rid=""bib26"" ref-type=""bibr""><sup>26</sup></xref> Our findings in brain tissues affected by HE <italic toggle=""yes"">HTT</italic> mutations, therefore, corroborate these <italic toggle=""yes"">in vitro</italic> observations. Furthermore, we also observed significantly lower levels of HK-II in HE-PHD but not AOHD brains compared to control. Hexokinases catalyse the first committed step of",21_16,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"Hexokinases catalyse the first committed step of glucose metabolism, by phosphorylating glucose to glucose-6-phosphate.<xref rid=""bib27"" ref-type=""bibr""><sup>27</sup></xref> HK-II also protects cells from death during hypoxia and functions as a sensor of glucose availability, inducing apoptosis in response to glucose depletion.<xref rid=""bib28"" ref-type=""bibr""><sup>28</sup></xref> Our finding, that expression levels of GLUT-1, GLUT-3, mitochondrial complexes and HK-II were significantly and selectively",21_17,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"and HK-II were significantly and selectively lower in HE-PHD frontal cortex and striatum, shows that a disease-relevant biological dysfunction (i.e., hypometabolic state) occurs without any substantial neuronal loss in the frontal cortex of these patients. Relatively preserved brain cortex has been observed previously in HE-PHD by magnetic resonance imaging (MRI), magnetic resonance spectroscopy and neuropathological studies,<xref rid=""bib3"" ref-type=""bibr""><sup>3</sup></xref> and is in line with findings",21_18,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"and is in line with findings from ongoing studies using volumetric MRI in paediatric-onset patients (Sabatini, personal communication). Nevertheless, the disease pathophysiology of patients with HE <italic toggle=""yes"">HTT</italic> mutations, concurs with a more severe disease and worse prognosis. To validate the findings from our study on brain tissues of patients with HE-PHD, we conducted an analysis of metabolic profiles in fibroblasts obtained from patients with HE-PHD. Our results revealed",21_19,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"from patients with HE-PHD. Our results revealed significantly reduced levels of GLUT-1 in both gene and protein expression, and a somewhat less pronounced decrease in GLUT-3 protein expression. However, no significant differences were observed in gene expression when compared to the healthy control. This discrepancy between findings in the brain tissues versus fibroblasts is likely explained by the fact that GLUT-3 is not the main transporter of glucose in peripheral cells such as fibroblasts.<xref",21_20,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"in peripheral cells such as fibroblasts.<xref rid=""bib29"" ref-type=""bibr""><sup>29</sup></xref> While our data emphasize that the primary pathology in HE-PHD is found in the brain, they also highlight the probable existence of a peripheral component to the disease, as also suggested by our recent study which identified liver steatosis in patients with HE-PHD.<xref rid=""bib5"" ref-type=""bibr""><sup>5</sup></xref> The evidence of peripheral biological abnormalities may represent an important observation",21_21,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"may represent an important observation considering currently ongoing experimental therapies aimed at lowering mutated <italic toggle=""yes"">HTT</italic> in both the brain and periphery.<xref rid=""bib30"" ref-type=""bibr""><sup>30</sup></xref> Since a direct relationship between GLUT function, neurodegeneration and neurodevelopment is still poorly understood, additional studies in HD and other neurodegenerative diseases are therefore needed due to its potential role in HD pathogenesis<xref rid=""bib20""",21_22,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"role in HD pathogenesis<xref rid=""bib20"" ref-type=""bibr""><sup>20</sup></xref> and therapy perspectives.<xref rid=""bib31"" ref-type=""bibr""><sup>31</sup></xref> In fact, growing evidence suggests an important modulatory role for glucose transport in the HD mitochondrial deregulation, emphasizing that abnormal energy metabolism could interfere with brain neurodevelopment and may represent a critical therapeutic target for HD, as also suggested for adulthood disease.<xref rid=""bib32""",21_23,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"suggested for adulthood disease.<xref rid=""bib32"" ref-type=""bibr""><sup>32</sup></xref> For instance, the GLUT-1 role in HE-PHD pathology suggests that a ketogenic diet could be beneficial for patients with HE-PHD when initiated in the early stages of the disease.<xref rid=""bib11"" ref-type=""bibr""><sup>11</sup></xref> The high-fat ketogenic diet may result in permanent ketosis and provide the brain with an alternative energy source. The beneficial effects of the ketogenic, normocaloric, with low carbohydrate",21_24,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"ketogenic, normocaloric, with low carbohydrate intake diet, currently used in epilepsy and movement disorders, are well documented in children with GLUT-1 deficiency and may offer new therapeutic approaches to HE-PHD. This is especially important given that there is no validated experimental protocol so far to at least address any disease-modifying treatment against HE-PHD. We are aware that our study has a number of limitations, the main one being that our HE-PHD brain donor cohort is limited to only two",21_25,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"HE-PHD brain donor cohort is limited to only two patients. This is due to the extremely rare occurrence of this variant. HD itself is a rare disease and only a small proportion of about 6% patients have juvenile-onset disease,<xref rid=""bib14"" ref-type=""bibr""><sup>14</sup></xref> and an even smaller proportion have HE-PHD. Thus, the opportunity to acquire a donor brain from a patient with HE-PHD is exceptionally rare. Likewise, owing to a general lack of donor brains from healthy controls, especially child",21_26,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"brains from healthy controls, especially child donors, it was not possible to age-match our healthy control donor brain cohort to our HE-PHD cohort. It is therefore possible that some of the differences we observed between patients with HE-PHD and controls may have been due to differences in age rather than pathophysiology. Another limitation is due to the analysis of frontal cortex only, while an extensive study of several parts of brain and cortical regions might have offered additional insights.",21_27,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"regions might have offered additional insights. Unfortunately, we cannot provide a fine stratification of brain areas in our current context. This argues again that more cases and more extensive examination of the cerebral cortex are required to draw any firm conclusions. An additional limitation is due to the clinical stratification of our adult cohort, specifically concerning the retrospective reconstruction of the approximate age of onset of JOHD. To limit such a bias, we included in the JOHD cohort",21_28,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"limit such a bias, we included in the JOHD cohort only those patients with mutation size >55 CAG repeats, a mutation size which is widely believed to be associated with JOHD.<xref rid=""bib14"" ref-type=""bibr""><sup>14</sup></xref> Notwithstanding these limitations, our findings shed light on the pathology of this devastating disease variant and highlight differences in potential biological mechanisms underlying HE-PHD and AOHD. Such differentiation may be important not only from a therapeutic perspective but",21_29,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"not only from a therapeutic perspective but also to ensure appropriate inclusion of paediatric patients into Huntington disease clinical trials.<xref rid=""bib14"" ref-type=""bibr""><sup>14</sup></xref> Finally, our study highlighted a difference in GLUT-1 expression between HE-PHD and JOHD. Such a biological difference, in addition to the CAG mutation length, suggests there may be a need to reconsider the old classification of HD variants and abandon the terminology “juvenile-onset”, which currently includes",21_30,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"“juvenile-onset”, which currently includes some adult-onset patients and instead replace this with the term “paediatric-onset” HD, to represent the category of patients that appears clinically and biologically different from adulthood HD. AT contributed to conceptualization, methodology, formal analysis, validation and editing; HB contributed to methodology, formal analysis, investigation and editing; FP contributed to methodology, project administration, data curation and editing. AT, HB and FP",21_31,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"data curation and editing. AT, HB and FP contributed equally to this work. MDN contributed to methodology, data curation, editing. TM contributed to methodology, formal analysis, software and editing. MPA contributed to methodology, data curation, editing. MZ and SP contributed to methodology, investigation, editing. RC, SdB, MP, and WvR-M contributed to conceptualization, data curation, supervision, editing and had direct access to the data and verified the data. FS contributed to conceptualization,",21_32,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"the data. FS contributed to conceptualization, funding acquisition, resources, supervision, writing, and editing and had direct access to the data and verified the data. All authors reviewed and approved the final version of the manuscript. The data that support the findings of this study are available from the corresponding author, upon reasonable request. We will consider data requests from qualified scientific or medical researchers conducting legitimate scientific research. Data will be made available",21_33,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"scientific research. Data will be made available to researchers whose proposal has been approved by an independent review committee. We will share anonymized individual patient level data collected during the study, as well as associated study documents, including the clinical study protocol, statistical analysis plan and informed consent forms. Requests for such data can be made immediately upon publication (no end date). Data will be shared by email to <email>ferdinando.squitieri@lirh.it</email>. FS",21_34,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"<email>ferdinando.squitieri@lirh.it</email>. FS received remuneration as member of the scientific advisory board of PTC Therapeutics and Prilenia. Leiden University Medical Center (LUMC) receives grants from the European Huntington’s Disease Network (EHDN) and Cure HD Initiative (CHDI), participates in an EU Horizon 2020 project: Innovative Medicines Initiative (IMI) 2 (IDEA_FAST), and participates in clinical trials sponsored by PRILENIA, PTC Therapeutics, WAVE and VICO Therapeutics. The aforementioned",21_35,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"WAVE and VICO Therapeutics. The aforementioned sponsors had no role in the design, execution, interpretation, or writing of this manuscript. S.T. de Bot is a board member of the scientific advisory board of the Vereniging van Huntington (HD patient association); unpaid. W.v.R.M. declares to have patents on exon skipping approaches for neurological disorders. In the past, some of these patents have been licensed to ProQR therapeutics. W.v.R.M. further discloses being ad hoc consultant for Accure",21_36,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"discloses being ad hoc consultant for Accure Therapeutics and Herbert Smith Freehills. Remuneration for these activities is paid to the LUMC. She is on the scientific advisory board of the European Huntington Disease Network, the Dutch Brain Foundation, the Dutch Ataxia Foundation. She is co-director of the Dutch Centre of RNA Therapeutics, board member of the 1 Mutation 1 Medicine network and core member of the Ataxia Advisory Committee for Therapeutics.",21_37,GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study,26 10 2023,,Huntington_Disease
"HD-DRUM, a Tablet-Based Drumming Training App Intervention for People With Huntington Disease: App Development Study",22_0,"HD-DRUM, a Tablet-Based Drumming Training App Intervention for People With Huntington Disease: App Development Study",2023,,Huntington_Disease
"Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia Chorea associated with Huntington disease (HD) and tardive dyskinesia (TD) are hyperkinetic movement disorders, characterized by excessive abnormal involuntary movements, that can greatly diminish patient QoL.<xref rid=""i2168-9709-13-5-207-b01"" ref-type=""bibr"">1</xref> Patient surveys have shown that in chorea associated with HD, overall QoL is known to decline as the severity of chorea",23_0,Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia,10 2023,,Huntington_Disease
"QoL is known to decline as the severity of chorea increases; chorea has also been shown to negatively impact daily functioning.<xref rid=""i2168-9709-13-5-207-b02"" ref-type=""bibr"">2</xref>,<xref rid=""i2168-9709-13-5-207-b03"" ref-type=""bibr"">3</xref> Similarly, individuals with severe TD have significantly worse QoL and social withdrawal compared with those with less severe TD and those without TD.<xref rid=""i2168-9709-13-5-207-b04"" ref-type=""bibr"">4</xref>",23_1,Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia,10 2023,,Huntington_Disease
"Vesicular monoamine-transporter 2 (VMAT2) inhibitors are the only class of drugs approved by the United States (US) FDA for treatment of chorea associated with HD and TD. Deutetrabenazine, a selective VMAT2 inhibitor, was approved by the US FDA in 2017<sup>5-7</sup> based on phase 3 clinical trials for treatment of chorea associated with HD<xref rid=""i2168-9709-13-5-207-b08"" ref-type=""bibr"">8</xref> and treatment of TD.<xref rid=""i2168-9709-13-5-207-b09"" ref-type=""bibr"">9</xref>,<xref",23_2,Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia,10 2023,,Huntington_Disease
"ref-type=""bibr"">9</xref>,<xref rid=""i2168-9709-13-5-207-b10"" ref-type=""bibr"">10</xref> Treatment with deutetrabenazine significantly reduced abnormal involuntary movements and improved patient QoL.<xref rid=""i2168-9709-13-5-207-b11"" ref-type=""bibr"">11</xref>-<xref rid=""i2168-9709-13-5-207-b13"" ref-type=""bibr"">13</xref>",23_3,Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia,10 2023,,Huntington_Disease
"Despite this, in a study of real-world adherence patterns in patients with TD receiving VMAT2 inhibitors, approximately 50% of patients were found to be nonadherent to treatment.<xref rid=""i2168-9709-13-5-207-b14"" ref-type=""bibr"">14</xref> In a second study of adherence and discontinuation rates among patients with chorea associated with HD, patients receiving deutetrabenazine had greater adherence and lower discontinuation rates compared with patients treated with tetrabenazine.<xref",23_4,Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia,10 2023,,Huntington_Disease
"with patients treated with tetrabenazine.<xref rid=""i2168-9709-13-5-207-b15"" ref-type=""bibr"">15</xref> Given the demonstrated positive effects of deutetrabenazine on QoL,<xref rid=""i2168-9709-13-5-207-b13"" ref-type=""bibr"">13</xref> treatment discontinuation and/or nonadherence may be associated with declines in patient QoL. An understanding of which characteristics (eg, demographics, comorbidities, concomitant medication, insurance type) correlate to treatment patterns and behaviors has the potential to",23_5,Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia,10 2023,,Huntington_Disease
"patterns and behaviors has the potential to allow for the identification of patients at high risk of discontinuation and nonadherence and subsequent intervention. However, data on predictors of real-world adherence to deutetrabenazine in patients with chorea associated with HD and TD are limited. This retrospective study was designed to identify patient and treatment characteristics associated with deutetrabenazine persistence and adherence among patients with chorea associated with HD or TD, as well as to",23_6,Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia,10 2023,,Huntington_Disease
"chorea associated with HD or TD, as well as to develop and validate prediction models of persistence and adherence based on the identified characteristics.  The outcome for persistence analyses was time to discontinuation of deutetrabenazine, defined as a gap in index treatment use of >30 days from the end of the last observed deutetrabenazine fill and the end of data. Outcomes for the adherence analyses included proportion of days covered (PDC) and adherence rate, defined as the proportion of patients",23_7,Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia,10 2023,,Huntington_Disease
"rate, defined as the proportion of patients with PDC >80%. All outcomes were assessed during the 6-month study period. Kaplan-Meyer analyses were used to characterize the proportions of patients who discontinued deutetrabenazine. Means, medians, SDs, and ranges were used to describe the distribution of PDC within each cohort. For patient characteristics, means and SDs were calculated for continuous variables, while counts and proportions were calculated for categorical variables. For cohorts 2 and 4,",23_8,Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia,10 2023,,Huntington_Disease
"for categorical variables. For cohorts 2 and 4, patient characteristics were compared between those who were adherent (PDC >80%) versus nonadherent (PDC ≤80%). Wilcoxon rank-sum tests were used to compare continuous variables and Fisher exact tests were used to compare categorical variables between the 2 groups. Multivariable models adjusted for baseline patient characteristics were developed—2 Cox proportional hazards models to identify predictors of persistence for each disease cohort separately (cohort",23_9,Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia,10 2023,,Huntington_Disease
"for each disease cohort separately (cohort 1 and cohort 3) and 2 logistic regression models to identify predictors of adherence for each disease cohort separately (cohort 2 and cohort 4)—using the modeling set. HRs and ORs and the corresponding 95% CIs and <italic toggle=""yes"">P</italic> values were reported to identify predictors of persistence and adherence, respectively, based on effect size and significance. Grønnesby and Borgan tests and Hosmer—Lemeshow tests were used to evaluate goodness of fit for",23_10,Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia,10 2023,,Huntington_Disease
"tests were used to evaluate goodness of fit for the persistence and adherence models, respectively. The in-sample predictive performances of the final persistence models were evaluated using the mean of Chambless and Diao's estimates of cumulative or dynamic AUC generated using 10-fold cross validation. The in-sample predictive performances of the final adherence models were evaluated using AUC of receiver operating characteristics curves generated using 5-fold or 10-fold cross-validation, depending on the",23_11,Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia,10 2023,,Huntington_Disease
"or 10-fold cross-validation, depending on the size of the modeling set. Each of the 4 models was validated using the data in the corresponding validation sets. The predictive performance was assessed using AUC for all models; AUC ≥0.8 was considered an excellent prediction, AUC ≥0.70 to <0.80 a good prediction, AUC ≥0.60 to <0.70 a fair prediction, and AUC ≥0.50 to <0.60 a poor prediction.<xref rid=""i2168-9709-13-5-207-b18"" ref-type=""bibr"">18</xref>",23_12,Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia,10 2023,,Huntington_Disease
"This retrospective study used claims data to characterize and identify predictors of real-world persistence and adherence patterns with deutetrabenazine among patients with HD or TD in the United States. In patients with HD (cohort 1), four predictors of persistence were found to be statistically significant (<italic toggle=""yes"">P</italic> < .05). Patients using Medicaid were more likely to be persistent with deutetrabenazine compared with those using Medicare; similarly, patients using anticonvulsants",23_13,Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia,10 2023,,Huntington_Disease
"similarly, patients using anticonvulsants or lipid-lowering agents were more likely to be persistent with deutetrabenazine compared with patients not on those treatments. In contrast, patients with an anxiety disorder were more likely to discontinue deutetrabenazine than those without an anxiety disorder diagnosis. For adherence (cohort 2), patients with HD using Medicaid were less likely to be adherent to deutetrabenazine compared with those using Medicare, and patients using ≤2 treatments for chronic",23_14,Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia,10 2023,,Huntington_Disease
"and patients using ≤2 treatments for chronic diseases also had lower odds of adherence. These results are consistent with the observation that patients with multimorbidity may require more frequent visits with physicians and have better access to health care resources and services, which might be associated with better persistence and adherence to treatment in general.<xref rid=""i2168-9709-13-5-207-b19"" ref-type=""bibr"">19</xref>",23_15,Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia,10 2023,,Huntington_Disease
"In TD (cohort 3), 3 predictors of persistence were found to be statistically significant (<italic toggle=""yes"">P</italic> < .05). Patients treated with lipid-lowering agents were more likely to be persistent with deutetrabenazine therapy, whereas patients with schizoaffective disorder, schizophrenia, or a sleep-wake disorder were more likely to discontinue deutetrabenazine. In cohort 4, patients with schizoaffective disorder or schizophrenia diagnosis were significantly less likely to be adherent to",23_16,Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia,10 2023,,Huntington_Disease
"were significantly less likely to be adherent to deutetrabenazine. Nonadherence to antipsychotic agents is a common problem in schizophrenia management.<xref rid=""i2168-9709-13-5-207-b20"" ref-type=""bibr"">20</xref>,<xref rid=""i2168-9709-13-5-207-b21"" ref-type=""bibr"">21</xref> Lack of patient insight, which manifests as lack of awareness of their own illness and need for treatment, is one factor associated with intentional nonadherence<xref rid=""i2168-9709-13-5-207-b22"" ref-type=""bibr"">22</xref> and might",23_17,Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia,10 2023,,Huntington_Disease
"ref-type=""bibr"">22</xref> and might precipitate nonadherence to deutetrabenazine. Whereas both models of persistence demonstrated strong predictive performance, both models of adherence had limited predictive performance. Poor predictive performance could have been driven by the limited sample size of the adherence modeling sets (HD, n = 85; TD, n = 120). Statistically significant predictors of deutetrabenazine persistence, such as the use of lipid-lowering agents and the presence of comorbid conditions,",23_18,Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia,10 2023,,Huntington_Disease
"agents and the presence of comorbid conditions, may reflect more frequent physician visits and/or better access to health care services. Further studies are needed to better understand the reasons for associations between certain variables and treatment persistence or adherence and to investigate the potential association of other variables, such as social determinants of health (eg, educational level, financial status) and health care provider characteristics, with treatment behaviors. There are a few",23_19,Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia,10 2023,,Huntington_Disease
"with treatment behaviors. There are a few limitations to this study. Presence of TD, HD, and comorbidities present at baseline were identified by ICD-10-CM codes used for administrative billing purposes and may be underestimated because of lack of coding completeness. This analysis did not capture comorbidities present after treatment initiation, so no conclusions can be drawn regarding treatment side effects. In addition, the SHS Integrated Dataverse does not capture reasons for treatment discontinuation.",23_20,Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia,10 2023,,Huntington_Disease
"capture reasons for treatment discontinuation. Continuous health plan enrollment was inferred using medical and pharmacy claims activity, as the SHS Integrated Dataverse database does not include eligibility records. Because the SHS Integrated Dataverse database is based on a large convenience sample, results of this observational study may be confounded by unmeasured characteristics. Additionally, claims that took place outside of the SHS Integrated Dataverse were not captured. Importantly, patient",23_21,Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia,10 2023,,Huntington_Disease
"Dataverse were not captured. Importantly, patient adherence may have been overestimated, as claims for prescription fills may not capture actual use. Moreover, patient sampling did not exclude those who switched from valbenazine or tetrabenazine to deutetrabenazine, which could introduce confounding effects. As deutetrabenazine was only approved by the FDA for use in chorea associated with HD and TD in 2017, sample sizes for patients taking deutetrabenazine were limited. Future studies may benefit from",23_22,Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia,10 2023,,Huntington_Disease
"were limited. Future studies may benefit from larger sample sizes or a time frame beyond 6 months, which could elucidate additional predictors of persistence and adherence among patients with HD and TD. In addition, future research investigating real-world reasons for treatment discontinuation and side effects is warranted. In conclusion, these results suggest that underlying psychiatric comorbidities may negatively affect treatment persistence in some patients. Pharmacists and health care providers can",23_23,Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia,10 2023,,Huntington_Disease
"Pharmacists and health care providers can leverage these findings to better understand and aid patient populations at the greatest risk for negative treatment use outcomes, as well as implement targeted interventions to maximize adherence to treatment. As deutetrabenazine is often dispensed in a specialty pharmacy setting, there is potential for pharmacists to serve as key personnel in the identification of patients at risk for discontinuation and/or nonadherence, perhaps facilitated by the development of",23_24,Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia,10 2023,,Huntington_Disease
"perhaps facilitated by the development of software that flags patients with a risk factor for adverse treatment behavior. Such patients can then be redirected to health care providers, who can provide personalized support designed to improve treatment persistence and adherence.",23_25,Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia,10 2023,,Huntington_Disease
"In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease 
<fig position=""float"" id=""absf1"" fig-type=""featured""><graphic http://www.w3.org/1999/xlink href=""jnumed.123.265569absf1"" position=""float""></graphic></fig>",24_0,In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease,10 2023,,Huntington_Disease
"Huntington disease (HD) is a neurodegenerative disorder caused by an expanded polyglutamine (CAG) trinucleotide expansion in the huntingtin (<italic toggle=""yes"">HTT</italic>) gene that encodes the mutant huntingtin protein (mHTT). Visualization and quantification of cerebral mHTT will provide a proxy for target engagement and a means to evaluate therapeutic interventions aimed at lowering mHTT in the brain. Here, we validated the novel radioligand <sup>11</sup>C-labeled",24_1,In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease,10 2023,,Huntington_Disease
"the novel radioligand <sup>11</sup>C-labeled 6-(5-((5-methoxypyridin-2-yl)methoxy)benzo[d]oxazol-2-yl)-2-methylpyridazin-3(2H)-one (<sup>11</sup>C-CHDI-180R) using PET imaging to quantify cerebral mHTT aggregates in a macaque model of HD. <bold>Methods:</bold> Rhesus macaques received MRI-guided intrastriatal delivery of a mixture of AAV2 and AAV2.retro viral vectors expressing an HTT fragment bearing 85 CAG repeats (85Q, <italic toggle=""yes"">n</italic> = 5), a control HTT fragment bearing 10 CAG repeats",24_2,In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease,10 2023,,Huntington_Disease
"5), a control HTT fragment bearing 10 CAG repeats (10Q, <italic toggle=""yes"">n</italic> = 4), or vector diluent only (phosphate-buffered saline, <italic toggle=""yes"">n</italic> = 5). Thirty months after surgery, 90-min dynamic PET/CT imaging was used to investigate <sup>11</sup>C-CHDI-180R brain kinetics, along with serial blood sampling to measure input function and stability of the radioligand. The total volume of distribution was calculated using a 2-tissue-compartment model as well as Logan graphical",24_3,In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease,10 2023,,Huntington_Disease
model as well as Logan graphical analysis for regional quantification. Immunostaining for mHTT was performed to corroborate the in vivo findings. <bold>Results:</bold>,24_4,In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease,10 2023,,Huntington_Disease
"<sup>11</sup>C-CHDI-180R displayed good metabolic stability (51.4% ± 4.0% parent in plasma at 60 min after injection). Regional time–activity curves displayed rapid uptake and reversible binding, which were described by a 2-tissue-compartment model. Logan graphical analysis was associated with the 2-tissue-compartment model (<italic toggle=""yes"">r</italic><sup>2</sup> = 0.96, <italic toggle=""yes"">P</italic> < 0.0001) and used to generate parametric volume of distribution maps. Compared with controls,",24_5,In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease,10 2023,,Huntington_Disease
"of distribution maps. Compared with controls, animals administered the 85Q fragment exhibited significantly increased <sup>11</sup>C-CHDI-180R binding in several cortical and subcortical brain regions (group effect, <italic toggle=""yes"">P</italic> < 0.0001). No difference in <sup>11</sup>C-CHDI-180R binding was observed between buffer and 10Q animals. The presence of mHTT aggregates in the 85Q animals was confirmed histologically. <bold>Conclusion:</bold> We validated <sup>11</sup>C-CHDI-180R as a",24_6,In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease,10 2023,,Huntington_Disease
"We validated <sup>11</sup>C-CHDI-180R as a radioligand to visualize and quantify mHTT aggregated species in a HD macaque model. These findings corroborate our previous work in rodent HD models and show that <sup>11</sup>C-CHDI-180R is a promising tool to assess the mHTT aggregate load and the efficacy of therapeutic strategies.   Various new therapeutic approaches for HD focus on the modulation of mHTT levels (<xref rid=""bib9"" ref-type=""bibr"">9</xref>,<xref rid=""bib11"" ref-type=""bibr"">11</xref>,<xref",24_7,In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease,10 2023,,Huntington_Disease
"rid=""bib11"" ref-type=""bibr"">11</xref>,<xref rid=""bib21"" ref-type=""bibr"">21</xref>). To determine whether these approaches are achieving target engagement in the relevant brain structures, and whether they are leading to lowering mHTT levels in vivo, the development of noninvasive quantification of mHTT is needed (<xref rid=""bib12"" ref-type=""bibr"">12</xref>–<xref rid=""bib14"" ref-type=""bibr"">14</xref>,<xref rid=""bib22"" ref-type=""bibr"">22</xref>,<xref rid=""bib23"" ref-type=""bibr"">23</xref>). We recently",24_8,In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease,10 2023,,Huntington_Disease
"ref-type=""bibr"">23</xref>). We recently demonstrated that <sup>11</sup>C-CHDI-180R PET imaging is able to quantify mHTT aggregates in HD mouse models (<xref rid=""bib15"" ref-type=""bibr"">15</xref>). Here, we offer evidence that <sup>11</sup>C-CHDI-180R is applicable in a large NHP model of HD bearing mHTT aggregates and behavioral phenotypes (<xref rid=""bib16"" ref-type=""bibr"">16</xref>,<xref rid=""bib17"" ref-type=""bibr"">17</xref>). In contrast to previous preclinical mouse studies (<xref rid=""bib15""",24_9,In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease,10 2023,,Huntington_Disease
"preclinical mouse studies (<xref rid=""bib15"" ref-type=""bibr"">15</xref>), analysis of the plasma profile of NHPs revealed the formation of at least one radiometabolite more polar than <sup>11</sup>C-CHDI-180R. This radiometabolite polarity, together with the measured brain time–activity curves, suggested no evidence of brain-penetrant radiometabolite species. This is important validation for the use of this ligand in humans and lays the foundation for future studies to use this NHP model to test the",24_10,In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease,10 2023,,Huntington_Disease
"future studies to use this NHP model to test the efficacy of therapeutic interventions designed to lower mHTT in the brain. The results of both regional and voxelwise quantification of <sup>11</sup>C-CHDI-180R revealed significantly increased binding in several brain regions in the 85Q group compared with the buffer and 10Q control groups, suggesting specific binding to mHTT aggregates. It was previously demonstrated that the intrastriatal delivery of a mixture of AAV2 and AAV2.retro leads to transduction",24_11,In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease,10 2023,,Huntington_Disease
"of AAV2 and AAV2.retro leads to transduction in the caudate and putamen as well as several cortical structures (as a result of the retrograde transport capability of AAV2.retro), forming detectable mHTT aggregates in all of these regions (<xref rid=""bib16"" ref-type=""bibr"">16</xref>,<xref rid=""bib17"" ref-type=""bibr"">17</xref>). This distribution profile is closely recapitulated by the binding pattern of <sup>11</sup>C-CHDI-180R PET imaging, with the putamen, anterior cingulate cortex, and supplemental motor",24_12,In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease,10 2023,,Huntington_Disease
"anterior cingulate cortex, and supplemental motor cortex representing the most affected gray matter structures in this model (<xref rid=""bib16"" ref-type=""bibr"">16</xref>,<xref rid=""bib17"" ref-type=""bibr"">17</xref>). Importantly, we found an association between the increased binding pattern of <sup>11</sup>C-CHDI-180R PET imaging and the behavioral assessments of motor and cognitive function in the 85Q group. Compared with genetically engineered animal models of HD, in which mHTT expression tends to be",24_13,In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease,10 2023,,Huntington_Disease
"of HD, in which mHTT expression tends to be uniform throughout the brain, viral vector-based models often result in mHTT expression in specific targeted brain regions or subregions. Accordingly, voxel-based analyses in the AAV2:AAV2retro-based macaque HD model identified significant <sup>11</sup>C-CHDI-180R binding in subregions of several brain structures, some of which were not identified using the region-of-interest-based approach. This finding suggests that voxel-based analyses may also be useful in",24_14,In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease,10 2023,,Huntington_Disease
"that voxel-based analyses may also be useful in human HD studies, in which mHTT aggregates are more concentrated in subregions of certain structures, such as the lateral putamen and in deeper layers of the cerebral cortex (<xref rid=""bib5"" ref-type=""bibr"">5</xref>,<xref rid=""bib24"" ref-type=""bibr"">24</xref>). Additionally, should PET imaging be used in future studies to demonstrate target engagement of HTT-lowering therapeutics, voxel-based analysis may be able to discern HTT changes when therapeutic",24_15,In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease,10 2023,,Huntington_Disease
"be able to discern HTT changes when therapeutic constructs reach only subregions of brain structures after delivery. We performed a postmortem histologic investigation to confirm the formation of 2B4-positive mHTT aggregates in brain regions that showed significantly increased <sup>11</sup>C-CHDI-180R <italic toggle=""yes"">V</italic><sub>T</sub>. However, an important limitation of such a comparison is that this radioligand does not bind to large mHTT species, as detected by the common antibodies used for",24_16,In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease,10 2023,,Huntington_Disease
"as detected by the common antibodies used for histologic assessment, such as EM48 and 2B4. We have previously demonstrated binding to mHTT-derived fibrils and to mHTT aggregates expressed in mouse HD models and human HD samples, whose precise state has yet to be defined (<xref rid=""bib12"" ref-type=""bibr"">12</xref>,<xref rid=""bib13"" ref-type=""bibr"">13</xref>,<xref rid=""bib15"" ref-type=""bibr"">15</xref>). Given that radioligand and antibodies do not recognize the same mHTT species, a direct association",24_17,In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease,10 2023,,Huntington_Disease
"the same mHTT species, a direct association between readouts is not possible. Therefore, histologic analysis was performed to confirm the presence of mHTT aggregates in relevant brain regions. Accordingly, in 85Q animals, 2B4-positive aggregates were detected in the regions of injection (caudate and putamen) and in several cortical gray matter structures that send afferent projections to the striatum. The anterior-to-posterior cortical gradient observed on immunostaining aligns with a similar distribution",24_18,In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease,10 2023,,Huntington_Disease
"immunostaining aligns with a similar distribution observed with PET imaging and recapitulates the previously described distribution of the AAV2:AAV2.retro viral vector mixture (<xref rid=""bib16"" ref-type=""bibr"">16</xref>). We also detected increased <sup>11</sup>C-CHDI-180R binding in the white matter of 85Q-treated animals, a finding that was not anticipated given the lack of white matter binding observed during in vitro <sup>3</sup>H-CHDI-180 autoradiography studies in mouse models and human postmortem",24_19,In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease,10 2023,,Huntington_Disease
"studies in mouse models and human postmortem tissue (<xref rid=""bib12"" ref-type=""bibr"">12</xref>,<xref rid=""bib13"" ref-type=""bibr"">13</xref>,<xref rid=""bib15"" ref-type=""bibr"">15</xref>). Histologic evaluation shows 2B4-positive mHTT aggregates in white matter tracts in, and near, visible needle tracts. This finding is not surprising, given that the infusion pump was run while the needle was lowered into the caudate and putamen to maintain positive pressure, prevent infusate backflow, and prevent tissue",24_20,In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease,10 2023,,Huntington_Disease
"prevent infusate backflow, and prevent tissue damage. Autoradiography has been used in genetic mouse models and human HD brain tissue samples, in combination with immunohistochemistry, to confirm regional and subregional binding of CHDI-180R. Although tissue was not available in the current study to perform autoradiography, pilot studies on 4 adult macaques injected with either AAV2retro-85Q (left hemisphere) and diluent (right hemisphere) or AAV2retro-10Q (left hemisphere) and diluent (right hemisphere)",24_21,In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease,10 2023,,Huntington_Disease
"(left hemisphere) and diluent (right hemisphere) used autoradiography to demonstrate specific binding in the putamen, globus pallidus, and cortex of 85Q-injected animals but not in 10Q- or diluent-injected controls. Our study demonstrated the validity of <sup>11</sup>C-CHDI-180R as a reliable radioligand to visualize and quantify the region-specific distribution of mHTT aggregated species in the HD macaque model with high spatial resolution. These findings corroborate our previous work in rodent HD models",24_22,In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease,10 2023,,Huntington_Disease
"corroborate our previous work in rodent HD models and further support ongoing investigation of <sup>11</sup>C-CHDI-180R as a pharmacodynamic biomarker in HD. Daniele Bertoglio was supported by the Research Foundation Flanders (FWO) (1229721N and K201222N) and the University of Antwerp (FFB210050). Daniele Bertoglio, Jeroen Verhaeghe, and Steven Staelens are members of the µNeuro Research Centre of Excellence at the University of Antwerp. Alison Weiss was supported by a postdoctoral fellowship (NIH/NIA",24_23,In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease,10 2023,,Huntington_Disease
"supported by a postdoctoral fellowship (NIH/NIA T32AG055378). Jodi McBride is supported by NIH grant P51OD011092, and the creation of the NHP model of HD used in this project was supported by NIH grant NS099136. Microscopy was supported in part by the Imaging and Morphology Core at the Oregon National Primate Research Center (S10OD025002-01). Radiolabeling was done using the Oregon Health and Science University Center for Radiochemistry Research Core Facility. This work was funded by the CHDI Foundation,",24_24,In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease,10 2023,,Huntington_Disease
"This work was funded by the CHDI Foundation, Inc. (<ext-link http://www.w3.org/1999/xlink href=""https://chdifoundation.org/"" ext-link-type=""uri"">https://chdifoundation.org/</ext-link>). Vinod Khetarpal, Longbin Liu, Celia Dominguez, Ignacio Munoz-Sanjuan, and Jonathan Bard are employed by CHDI Management, Inc., as advisors to CHDI Foundation, Inc., a privately funded nonprofit biomedical research organization dedicated exclusively to collaboratively developing therapeutics that improve the lives of those",24_25,In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease,10 2023,,Huntington_Disease
therapeutics that improve the lives of those affected by HD. No other potential conflict of interest relevant to this article was reported.,24_26,In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using <sup>11</sup>C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease,10 2023,,Huntington_Disease
"Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state Huntington disease (HD) is an incurable neurodegenerative disease characterized by neuronal loss and astrogliosis. One hallmark of HD is the selective neuronal vulnerability of striatal medium spiny neurons. To date, the underlying mechanisms of this selective vulnerability have not been fully defined. Here, we employed a multi-omic approach including single nucleus RNAseq (snRNAseq), bulk RNAseq, lipidomics, <italic",25_0,Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state,12 9 2023,,Huntington_Disease
"(snRNAseq), bulk RNAseq, lipidomics, <italic toggle=""yes"">HTT</italic> gene CAG repeat length measurements, and multiplexed immunofluorescence on post-mortem brain tissue from multiple brain regions of HD and control donors. We defined a signature of genes that is driven by CAG repeat length and found it enriched in astrocytic and microglial genes. Moreover, weighted gene correlation network analysis showed loss of connectivity of astrocytic and microglial modules in HD and identified modules that",25_1,Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state,12 9 2023,,Huntington_Disease
"modules in HD and identified modules that correlated with CAG-repeat length which further implicated inflammatory pathways and metabolism. We performed lipidomic analysis of HD and control brains and identified several lipid species that correlate with HD grade, including ceramides and very long chain fatty acids. Integration of lipidomics and bulk transcriptomics identified a consensus gene signature that correlates with HD grade and HD lipidomic abnormalities and implicated the unfolded protein response",25_2,Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state,12 9 2023,,Huntington_Disease
"and implicated the unfolded protein response pathway. Because astrocytes are critical for brain lipid metabolism and play important roles in regulating inflammation, we analyzed our snRNAseq dataset with an emphasis on astrocyte pathology. We found two main astrocyte types that spanned multiple brain regions; these types correspond to protoplasmic astrocytes, and fibrous-like - CD44-positive, astrocytes. HD pathology was differentially associated with these cell types in a region-specific manner. One",25_3,Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state,12 9 2023,,Huntington_Disease
"these cell types in a region-specific manner. One protoplasmic astrocyte cluster showed high expression of metallothionein genes, the depletion of this cluster positively correlated with the depletion of vulnerable medium spiny neurons in the caudate nucleus. We confirmed that metallothioneins were increased in cingulate HD astrocytes but were unchanged or even decreased in caudate astrocytes. We combined existing genome-wide association studies (GWAS) with a GWA study conducted on HD patients from the",25_4,Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state,12 9 2023,,Huntington_Disease
"a GWA study conducted on HD patients from the original Venezuelan cohort and identified a single-nucleotide polymorphism in the metallothionein gene locus associated with delayed age of onset. Functional studies found that metallothionein overexpressing astrocytes are better able to buffer glutamate and were neuroprotective of patient-derived directly reprogrammed HD MSNs as well as against rotenone-induced neuronal death <italic toggle=""yes"">in vitro</italic>. Finally, we found that",25_5,Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state,12 9 2023,,Huntington_Disease
"vitro</italic>. Finally, we found that metallothionein-overexpressing astrocytes increased the phagocytic activity of microglia <italic toggle=""yes"">in vitro</italic> and increased the expression of genes involved in fatty acid binding. Together, we identified an astrocytic phenotype that is regionally-enriched in less vulnerable brain regions that can be leveraged to protect neurons in HD. Huntington disease (HD) is an incurable neurodegenerative disease characterized by selective loss of specific",25_6,Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state,12 9 2023,,Huntington_Disease
"characterized by selective loss of specific neuronal populations leading to motor, cognitive and psychiatric impairment<sup><xref rid=""R1"" ref-type=""bibr"">1</xref>–<xref rid=""R7"" ref-type=""bibr"">7</xref></sup>. Although the disease-causing mutation is present in all brain cells, the severity of the disease varies across brain regions<sup><xref rid=""R5"" ref-type=""bibr"">5</xref>, <xref rid=""R6"" ref-type=""bibr"">6</xref></sup>. New evidence suggests that the CAG repeats in exon 1 of the Huntingtin gene",25_7,Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state,12 9 2023,,Huntington_Disease
"the CAG repeats in exon 1 of the Huntingtin gene (<italic toggle=""yes"">HTT</italic>) can expand during the lifetime of the organism, and in different cell types at different rates, which may contribute to disease progression<sup><xref rid=""R8"" ref-type=""bibr"">8</xref>–<xref rid=""R11"" ref-type=""bibr"">11</xref></sup>. Moreover, research implicates mutant <italic toggle=""yes"">HTT</italic> (mHTT) expression in cortical and striatal neurons as a necessary substrate for striatal neurodegeneration<sup><xref",25_8,Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state,12 9 2023,,Huntington_Disease
"for striatal neurodegeneration<sup><xref rid=""R12"" ref-type=""bibr"">12</xref></sup>. Furthermore, increased vulnerability of striatal neurons to deprivation of the cortical-derived, neuroprotective BDNF has shed light on striatal neuronal vulnerability in HD<sup><xref rid=""R13"" ref-type=""bibr"">13</xref>, <xref rid=""R14"" ref-type=""bibr"">14</xref></sup>. However, despite recent advances in our understanding of regional heterogeneity of neurodegeneration in HD, there is much to be learned about how astrocytic",25_9,Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state,12 9 2023,,Huntington_Disease
"there is much to be learned about how astrocytic heterogeneity contributes to this phenomenon. In addition to the expression of <italic toggle=""yes"">HTT</italic> in neuronal cells, previous work has established the role of glial changes in HD. HD affects oligodendrocytes, microglia, and astrocytes. We previously described oligodendrocytic pathology at the single nucleus level in HD<sup><xref rid=""R15"" ref-type=""bibr"">15</xref></sup>. Astrocytes, the subject of this study, have long been noted to be",25_10,Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state,12 9 2023,,Huntington_Disease
"subject of this study, have long been noted to be “reactive”, as judged by their enlargement and the increase in markers such as GFAP, present particularly in the severely affected areas like the striatum (Vonsattel et al. 2008<sup><xref rid=""R16"" ref-type=""bibr"">16</xref></sup> for review). Studies in human brain and in mouse models suggest a loss of function phenotype, including, for example, a decrease in the major glutamate transporter, EAAT2/GLT1 both in mouse striatum<sup><xref rid=""R17""",25_11,Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state,12 9 2023,,Huntington_Disease
"both in mouse striatum<sup><xref rid=""R17"" ref-type=""bibr"">17</xref>–<xref rid=""R19"" ref-type=""bibr"">19</xref></sup>, human striatum<sup><xref rid=""R20"" ref-type=""bibr"">20</xref></sup>, and in the cortex<sup><xref rid=""R20"" ref-type=""bibr"">20</xref>, <xref rid=""R21"" ref-type=""bibr"">21</xref></sup>. Astrocyte pathology is well-documented in HD. Studies of mHTT expressing astrocytes showed these cells can elicit and exacerbate HD pathology in murine models<sup><xref rid=""R22"" ref-type=""bibr"">22</xref>, <xref",25_12,Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state,12 9 2023,,Huntington_Disease
"rid=""R22"" ref-type=""bibr"">22</xref>, <xref rid=""R23"" ref-type=""bibr"">23</xref></sup>. mHTT can impair baseline astrocyte function<sup><xref rid=""R18"" ref-type=""bibr"">18</xref></sup> and may elicit inflammation<sup><xref rid=""R24"" ref-type=""bibr"">24</xref></sup>. Also, downregulating Htt in astrocytes can slow down disease progression in murine HD models<sup><xref rid=""R25"" ref-type=""bibr"">25</xref></sup>. Moreover, human fetal-derived astrocytes with mHTT displayed several transcriptionally abnormalities,",25_13,Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state,12 9 2023,,Huntington_Disease
"several transcriptionally abnormalities, including low levels of metallothionein-3 (MT3) and genes involved in fatty acid synthesis. Functional deficiency of astrocytes can recapitulate specific motor and behavioral phenotypes in HD<sup><xref rid=""R26"" ref-type=""bibr"">26</xref></sup>. HD pathology extends from function to morphology. In fact, HD astrocytes are structurally abnormal<sup><xref rid=""R27"" ref-type=""bibr"">27</xref>, <xref rid=""R28"" ref-type=""bibr"">28</xref></sup>, and astrocyte maturation",25_14,Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state,12 9 2023,,Huntington_Disease
"and astrocyte maturation defects have been described in HD iPSC models<sup><xref rid=""R28"" ref-type=""bibr"">28</xref></sup>. Thus, there is evidence for cell-autonomous astrocyte pathology that contributes to neuronal injury in HD. The interaction between astrocytes and neurons is central to HD pathology. In fact, the response of astrocytes to injury in HD appears most robust when both neurons and astrocytes express the mutant protein in murine models, suggesting that a large component of astrocyte",25_15,Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state,12 9 2023,,Huntington_Disease
"suggesting that a large component of astrocyte pathology in HD is “reactive” to neuronal injury in the setting of compromised basic astrocyte functions<sup><xref rid=""R29"" ref-type=""bibr"">29</xref></sup>. In addition, astrocytes with mHTT derived from human glial progenitor cells can recapitulate motor aspects of the HD phenotype when implanted into mice, while normal astrocytes can ameliorate HD pathology when implanted into HD mice<sup><xref rid=""R30"" ref-type=""bibr"">30</xref></sup>. Finally, genetically",25_16,Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state,12 9 2023,,Huntington_Disease
"Finally, genetically modified astrocytes can be leveraged to rescue HD symptoms<sup><xref rid=""R31"" ref-type=""bibr"">31</xref></sup> and impart neuroprotection in HD<sup><xref rid=""R32"" ref-type=""bibr"">32</xref>–<xref rid=""R34"" ref-type=""bibr"">34</xref></sup>. The goal of this study is to systematically map astrocyte pathology across different brain regions in human HD. Building on our previous results showing that mHTT protein aggregates in astrocytes, and that cingulate cortex astrocytes exhibit",25_17,Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state,12 9 2023,,Huntington_Disease
"and that cingulate cortex astrocytes exhibit phenotypic heterogeneity even within the same region<sup><xref rid=""R21"" ref-type=""bibr"">21</xref></sup>, we generated multimodal omics data and performed systematic analyses to define astrocytic phenotypic heterogeneity in HD and correlate this molecular heterogeneity to disease severity. We combined bulk level RNAseq from 76 samples from 20 patients across different HD grades and 10 controls, as well as patients with juvenile-onset HD, with associated",25_18,Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state,12 9 2023,,Huntington_Disease
"patients with juvenile-onset HD, with associated lipidomics from 27 cingulate cortex samples to extract disease severity signatures that correlate with CAG repeat length and HD grade. We also performed snRNAseq on samples from the severely affected caudate nucleus, and relatively less severely affected cingulate cortex and nucleus accumbens<sup><xref rid=""R35"" ref-type=""bibr"">35</xref></sup>, and analyzed astrocyte states and then correlated them to neuronal vulnerability across different brain regions. We",25_19,Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state,12 9 2023,,Huntington_Disease
"vulnerability across different brain regions. We found that protoplasmic astrocytes differed from fibrous-like CD44 positive astrocytes in their association with neurodegeneration and discovered further regional heterogeneity in protoplasmic astrocyte pathology across vulnerable and resilient brain regions. We discovered a gene signature characterized by increased metallothionein gene expression, which we posited is neuroprotective. We further analyzed existing GWAS data and identified a SNP in the",25_20,Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state,12 9 2023,,Huntington_Disease
"existing GWAS data and identified a SNP in the metallothionein gene locus, a key hallmark of this putative neuroprotective signature, that is associated with delayed disease onset. We then performed validation and functional experiments and mapped metallothionein protein expression <italic toggle=""yes"">in vivo</italic> and confirmed the neuroprotective function of metallothionein-3 in astrocytes in vitro. Finally, we discovered a novel function of metallothionein-3 expressed in astrocytes on microglial",25_21,Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state,12 9 2023,,Huntington_Disease
"expressed in astrocytes on microglial function and gene expression. Together, our results pave the way for astrocyte-centric therapeutic strategies to treat HD.  In this work, we used transcriptomic and lipidomic analyses of different brain regions in HD to extract HD-related disease severity gene signatures. We found that these involve upregulation of glial genes including astrocytic and immune genes and downregulation of genes related to neuronal function. Lipidomic analysis of HD cortex revealed that",25_22,Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state,12 9 2023,,Huntington_Disease
"Lipidomic analysis of HD cortex revealed that long chain fatty acids were increased in HD. Integration of lipidomic and transcriptomics in HD implicated unfolded protein response genes as being correlated with HD lipidomic pathology. The unfolded protein response has been previously incriminated in HD pathology<sup><xref rid=""R75"" ref-type=""bibr"">75</xref></sup>. snRNAseq of protoplasmic and fibrous-like astrocytes allowed us to uncover astrocytic states that vary across brain regions and exhibit",25_23,Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state,12 9 2023,,Huntington_Disease
"states that vary across brain regions and exhibit heterogeneous gene expression profiles. We identified a neuroprotective state of protoplasmic astrocytes which upregulated metallothioneins mainly in the cingulate cortex and nucleus accumbens, but was depleted in the caudate nucleus – where HD neurodegeneration was most severe. The depletion of the neuroprotective astrocytic state (protoplasmic cluster P1) was correlated with the depletion of vulnerable MSNs in the caudate nucleus. GWAS analysis",25_24,Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state,12 9 2023,,Huntington_Disease
"MSNs in the caudate nucleus. GWAS analysis incriminated a SNP, rs3812963, in the MT gene locus – which is associated with increased MT levels in the brain - to be associated with delayed disease age of onset. Functional experiments confirmed that metallothionein protein expression was neuroprotective, astroprotective, and induced increased expression of glutamate transporters, which increased glutamate buffering and lending further credence to the neuroprotective utility of metallothioneins in astrocytes.",25_25,Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state,12 9 2023,,Huntington_Disease
"utility of metallothioneins in astrocytes. Finally, we found that genes induced in microglia due to astrocytic MT3 upregulation, which included genes related to fatty acid metabolism and lipid transport, could only be identified in microglia of the cingulate cortex, where astrocytes upregulated MTs, and the MT-primed microglia exhibited increased phagocytic capacity.",25_26,Multi-OMIC analysis of Huntington disease reveals a neuroprotective astrocyte state,12 9 2023,,Huntington_Disease
Pearls & Oy-sters: Huntington Disease Presenting as Primary Progressive Aphasia We present a case of semantic variant primary progressive aphasia as the presenting feature in a patient with Huntington disease (HD). The patient initially developed progressive language impairment including impaired naming and object knowledge and single-word comprehension and then developed chorea and behavioral changes. An MRI of the brain showed left anterior temporal lobe and hippocampal atrophy. A neurologic FDG PET/CT,26_0,Pearls & Oy-sters: Huntington Disease Presenting as Primary Progressive Aphasia,29 8 2023,,Huntington_Disease
and hippocampal atrophy. A neurologic FDG PET/CT showed reduced metabolism in the head of the left caudate nucleus. Huntingtin gene testing revealed an expansion of 39 CAG repeats in 1 allele. This case outlines the substantial overlap between the clinical presentation of HD and frontotemporal lobar degeneration syndromes and provides commentary on the investigation of these neurodegenerative diseases. Full text not available in PMC,26_1,Pearls & Oy-sters: Huntington Disease Presenting as Primary Progressive Aphasia,29 8 2023,,Huntington_Disease
Factors Associated With the Place of Death in Huntington Disease: Analysis of Enroll-HD Full text not available in PMC,27_0,Factors Associated With the Place of Death in Huntington Disease: Analysis of Enroll-HD,01 7 2023 July 2023,,Huntington_Disease
Death Anxiety in Huntington Disease: Longitudinal Heath-Related Quality-of-Life Outcomes Full text not available in PMC,28_0,Death Anxiety in Huntington Disease: Longitudinal Heath-Related Quality-of-Life Outcomes,01 7 2023 July 2023,,Huntington_Disease
"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields Huntington disease (HD) is an inherited neurodegenerative disorder, arising from an unstable trinucleotide CAG repeat expansion in the <italic toggle=""yes"">huntingtin</italic> (Htt) gene. The typical diagnosis of HD is marked by the presence of choreiform movements in middle age, accompanied by an array of dysexecutive neurocognitive and behavioral",29_0,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"of dysexecutive neurocognitive and behavioral symptoms [<xref rid=""ene15918-bib-0001"" ref-type=""bibr"">1</xref>]. Although these clinical manifestations are commonly attributed to the frontostriatum, longitudinal studies have revealed widespread brain and cognitive changes that predate the motor onset, and that are not frontostriatally mediated [<xref rid=""ene15918-bib-0002"" ref-type=""bibr"">2</xref>, <xref rid=""ene15918-bib-0003"" ref-type=""bibr"">3</xref>]. In particular, a significant body of work has",29_1,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"In particular, a significant body of work has implicated hippocampal involvement in HD [<xref rid=""ene15918-bib-0004"" ref-type=""bibr"">4</xref>]. Many facets of hippocampal dysfunction are commonly observed in early HD [<xref rid=""ene15918-bib-0004"" ref-type=""bibr"">4</xref>, <xref rid=""ene15918-bib-0005"" ref-type=""bibr"">5</xref>, <xref rid=""ene15918-bib-0006"" ref-type=""bibr"">6</xref>, <xref rid=""ene15918-bib-0007"" ref-type=""bibr"">7</xref>]. Notably, successive studies both in human and mouse models have",29_2,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"studies both in human and mouse models have reported visuospatial memory deficit that is analogous and hippocampal‐mediated [<xref rid=""ene15918-bib-0004"" ref-type=""bibr"">4</xref>]. This cognitive correlate presents as a promising measure for translating findings from animal models to human in HD as it is also associated with motor onset and disease progression [<xref rid=""ene15918-bib-0006"" ref-type=""bibr"">6</xref>, <xref rid=""ene15918-bib-0008"" ref-type=""bibr"">8</xref>]. In contrast, whole hippocampal",29_3,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"In contrast, whole hippocampal atrophy has not been identified consistently in the early stages of HD, but it is apparent and accelerated in the middle to late symptomatic stages [<xref rid=""ene15918-bib-0004"" ref-type=""bibr"">4</xref>, <xref rid=""ene15918-bib-0005"" ref-type=""bibr"">5</xref>, <xref rid=""ene15918-bib-0009"" ref-type=""bibr"">9</xref>]. Given the discrepancy between the hippocampal impairment and structural involvement in early HD, hippocampal atrophy may be confined to certain subfields, and may",29_4,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"may be confined to certain subfields, and may not be apparent when measured as a whole. Several studies have evaluated the hippocampal subregions in HD [<xref rid=""ene15918-bib-0005"" ref-type=""bibr"">5</xref>, <xref rid=""ene15918-bib-0009"" ref-type=""bibr"">9</xref>, <xref rid=""ene15918-bib-0010"" ref-type=""bibr"">10</xref>]. In MRI surface analyses, atrophy of medial and posterior regions has been reported in early HD [<xref rid=""ene15918-bib-0005"" ref-type=""bibr"">5</xref>, <xref rid=""ene15918-bib-0009""",29_5,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"<xref rid=""ene15918-bib-0009"" ref-type=""bibr"">9</xref>]. Postmortem studies have shown neuronal loss in the subiculum and the body of cornu ammonis (CA) 1 [<xref rid=""ene15918-bib-0010"" ref-type=""bibr"">10</xref>, <xref rid=""ene15918-bib-0011"" ref-type=""bibr"">11</xref>]. Interpretation of these studies, however, is limited by the omission of key hippocampal subfields, specifically those that form the main hippocampal connection, the perforant‐pathway (Figure <xref rid=""ene15918-fig-0001""",29_6,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"(Figure <xref rid=""ene15918-fig-0001"" ref-type=""fig"">1</xref>) [<xref rid=""ene15918-bib-0012"" ref-type=""bibr"">12</xref>]. Moreover, the neural correlate of visuospatial memory implicates certain subfields in the perforant‐pathway. In a pioneering discovery by O'Keefe [<xref rid=""ene15918-bib-0013"" ref-type=""bibr"">13</xref>], the place cells, which specify the subject's location within an environment, have been described in the dentate gyrus (DG) and CA of the rat hippocampus. Successive studies have found",29_7,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"rat hippocampus. Successive studies have found other spatial learning cells, including head‐direction, spatial‐view, and grid cells, in the presubiculum [<xref rid=""ene15918-bib-0014"" ref-type=""bibr"">14</xref>, <xref rid=""ene15918-bib-0015"" ref-type=""bibr"">15</xref>, <xref rid=""ene15918-bib-0016"" ref-type=""bibr"">16</xref>]. Additionally, these cells are physiologically regulated by the inhibitory cells in the hippocampal molecular layer (ML). While these findings are derived largely from animal models",29_8,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"findings are derived largely from animal models during navigational tasks, virtual simulation of the same experimental conditions in humans have corroborated the involvement of the same subfields [<xref rid=""ene15918-bib-0017"" ref-type=""bibr"">17</xref>]. Likewise, several virtual simulation studies have reported poor navigational performance in pre‐motor symptomatic (pre‐HD) and early symptomatic HD (symp‐HD), which posits the selective vulnerability of hippocampal subfields that comprise spatial learning",29_9,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"subfields that comprise spatial learning cells to the neurodegenerative process in early HD [<xref rid=""ene15918-bib-0007"" ref-type=""bibr"">7</xref>, <xref rid=""ene15918-bib-0008"" ref-type=""bibr"">8</xref>]. Recent advances in MRI segmentation techniques have offered in vivo automated volumetric analysis of the hippocampal subfields. We obtained data from the IMAGE‐HD longitudinal study to compare the volumes of 12 hippocampal subfields and their annual rate of change among healthy individuals and compared",29_10,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"of change among healthy individuals and compared these volumes to pre‐HD and early symp‐HD individuals. In the combined HD group, we further clustered the hippocampal subfields by their volumetric changes, and also evaluated the subfield volumes for associations with HD genetic and clinical measures. We hypothesized that the subfields comprising the perforant‐pathway and involved in visuospatial memory will have significantly greater volume reductions than in other subfields and that these changes would",29_11,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"in other subfields and that these changes would correlate with the measures of clinical severity in HD.   This study evaluates discrete volumes of hippocampal subfields in pre‐HD and early symp‐HD, given prior evidence of hippocampal‐specific impairment in the early stages of HD. We report a selective reduction in subfield volumes in the symp‐HD group, compared with pre‐HD and controls, comprising tail, presubiculum, subiculum, DG, and right ML. Volumes of these subfields aggregate into a single principal",29_12,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"these subfields aggregate into a single principal component, which demonstrates an accelerated rate of volume loss during the early symptomatic stage and highlights the vulnerability of the afferent and subicular regions in the hippocampal perforant‐pathway. Clinically, these implicated subfields are associated with the CAG repeat length, DBS, and motor onset. Whole hippocampal atrophy in our early symp‐HD cohort is consistent with previous studies [<xref rid=""ene15918-bib-0004"" ref-type=""bibr"">4</xref>,",29_13,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"rid=""ene15918-bib-0004"" ref-type=""bibr"">4</xref>, <xref rid=""ene15918-bib-0009"" ref-type=""bibr"">9</xref>]. In contrast, we did not find any volume differences between the pre‐HD and matched healthy controls in the whole hippocampus or its subfields, which adds to the variable reports of hippocampal atrophy in the pre‐symptomatic stage [<xref rid=""ene15918-bib-0005"" ref-type=""bibr"">5</xref>, <xref rid=""ene15918-bib-0009"" ref-type=""bibr"">9</xref>]. The reduced subicular volume in symp‐HD compared to controls",29_14,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"subicular volume in symp‐HD compared to controls supports previous findings in a postmortem study by Braak et al. [<xref rid=""ene15918-bib-0010"" ref-type=""bibr"">10</xref>], who coincidingly postulate the involvement of the perforant‐pathway. Although there is a trend of subicular atrophy in symp‐HD when compared to pre‐HD group, greater volume differences in the presubiculum, ML, and tail may specify a vulnerability that is intrinsic to HD. The prominent presubiculum and tail atrophy in symp‐HD supports",29_15,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"presubiculum and tail atrophy in symp‐HD supports our hypothesis regarding the selective involvement of subfields that mediate visuospatial memory. Deficits in visuospatial memory in early HD have been shown in human studies and animal models under comparable testing conditions (e.g., the virtual Morris water maze) [<xref rid=""ene15918-bib-0007"" ref-type=""bibr"">7</xref>, <xref rid=""ene15918-bib-0008"" ref-type=""bibr"">8</xref>]. In animal models, these testing conditions elicit the physiological activation",29_16,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"conditions elicit the physiological activation of various hippocampal spatial learning cells, such as the spatial‐view, head‐direction, and grid cells. These cells are postulated to exist in the human presubiculum [<xref rid=""ene15918-bib-0016"" ref-type=""bibr"">16</xref>, <xref rid=""ene15918-bib-0026"" ref-type=""bibr"">26</xref>, <xref rid=""ene15918-bib-0027"" ref-type=""bibr"">27</xref>]. In the hippocampal tail, our findings of atrophy in symp‐HD is aligned with a previous study in early HD [<xref",29_17,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"aligned with a previous study in early HD [<xref rid=""ene15918-bib-0009"" ref-type=""bibr"">9</xref>]. The hippocampal tail is heterogeneous, containing the caudal extension of other subfields from the hippocampal body [<xref rid=""ene15918-bib-0027"" ref-type=""bibr"">27</xref>, <xref rid=""ene15918-bib-0028"" ref-type=""bibr"">28</xref>]. Differentiation of these subfields in the hippocampal tail is currently beyond the conventional MRI spatial resolution at clinically available field strengths such as 3 T.",29_18,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"clinically available field strengths such as 3 T. Nonetheless, the functional interconnectivity of the hippocampal tail, presubiculum, and occipitoparietal region has been demonstrated in humans and appears to be involved in the cognitive processes of visuospatial memory [<xref rid=""ene15918-bib-0017"" ref-type=""bibr"">17</xref>]. Molecular layer (ML) atrophy may further contribute to the impaired spatial memory in symp‐HD. This subfield is enriched with inhibitory interneurons that regulate theta rhythm,",29_19,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"interneurons that regulate theta rhythm, which heralds the online state of spatial learning cells during navigation [<xref rid=""ene15918-bib-0013"" ref-type=""bibr"">13</xref>, <xref rid=""ene15918-bib-0029"" ref-type=""bibr"">29</xref>]. In HD, aberrant theta activities have been detected in the hippocampus and temporal regions, as well as correlated with cognitive performance and CAG repeats [<xref rid=""ene15918-bib-0030"" ref-type=""bibr"">30</xref>, <xref rid=""ene15918-bib-0031"" ref-type=""bibr"">31</xref>].",29_20,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"ref-type=""bibr"">31</xref>]. Mutant <italic toggle=""yes"">Huntingtin</italic> (mHtt) aggregates, encoded by an elongated CAG repeat, appear readily detectable in ML [<xref rid=""ene15918-bib-0032"" ref-type=""bibr"">32</xref>]. Although the relationship between mHtt aggregates and ML interneuronal survival remains unclear, marked loss of inhibitory interneurons have been reported in the striatum and various cortices [<xref rid=""ene15918-bib-0033"" ref-type=""bibr"">33</xref>, <xref rid=""ene15918-bib-0034""",29_21,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"<xref rid=""ene15918-bib-0034"" ref-type=""bibr"">34</xref>]. Among the various classes of interneurons, striatal parvalbumin interneurons appear to be most affected in HD and share similar γ‐aminobutyric acid A (GABA<sub>A</sub>) binding profiles (i.e., benzodiazepine‐sensitive) to the parvalbumin interneurons in presubiculum and ML, where various spatial learning cells have been colocated [<xref rid=""ene15918-bib-0027"" ref-type=""bibr"">27</xref>, <xref rid=""ene15918-bib-0035"" ref-type=""bibr"">35</xref>, <xref",29_22,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"ref-type=""bibr"">35</xref>, <xref rid=""ene15918-bib-0036"" ref-type=""bibr"">36</xref>, <xref rid=""ene15918-bib-0037"" ref-type=""bibr"">37</xref>]. In early HD, mHtt dysregulates endocytosis and recycling of various membrane receptors, resulting in toxic gain of function and membrane receptors alterations [<xref rid=""ene15918-bib-0038"" ref-type=""bibr"">38</xref>]. Within the hippocampus, the presence of mHtt aggregates has been associated with reduced GABA<sub>A,</sub> muscarinic 2 (M<sub>2</sub>), serotonin 1",29_23,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"muscarinic 2 (M<sub>2</sub>), serotonin 1 (5‐HT<sub>1</sub>), and alpha‐adrenergic 2 (α<sub>2</sub>) receptor densities [<xref rid=""ene15918-bib-0039"" ref-type=""bibr"">39</xref>, <xref rid=""ene15918-bib-0040"" ref-type=""bibr"">40</xref>, <xref rid=""ene15918-bib-0041"" ref-type=""bibr"">41</xref>, <xref rid=""ene15918-bib-0042"" ref-type=""bibr"">42</xref>, <xref rid=""ene15918-bib-0043"" ref-type=""bibr"">43</xref>]. Topographically, these receptors show differential distribution among the subfields in the",29_24,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"distribution among the subfields in the neurologically healthy human hippocampi, including high GABA<sub>A</sub> and M<sub>2</sub> receptor affinities in presubiculum and ML, and 5‐HT<sub>1A</sub> and α<sub>2</sub> affinities in ML [<xref rid=""ene15918-bib-0037"" ref-type=""bibr"">37</xref>, <xref rid=""ene15918-bib-0044"" ref-type=""bibr"">44</xref>]. This receptor‐based topography conforms with the pattern of subfield atrophy in our symp‐HD individuals and lends support to the concept that there is a process of",29_25,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"support to the concept that there is a process of advancing pathophysiology of mHtt from membrane receptor alterations to neuronal death in the hippocampus. The DG has been evaluated discretely in HD for its role in spatial memory, its pathogenic vulnerability to mHtt, and its capacity for neurogenesis [<xref rid=""ene15918-bib-0004"" ref-type=""bibr"">4</xref>]. A viral transduction of mHtt into the DG of wild‐type adult mice is associated with altered gene expression in granule cells, and resulted in spatial",29_26,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"in granule cells, and resulted in spatial memory impairment [<xref rid=""ene15918-bib-0045"" ref-type=""bibr"">45</xref>]. Maturation of DG granule cells is also regulated by inhibitory interneurons in its molecular layer [<xref rid=""ene15918-bib-0046"" ref-type=""bibr"">46</xref>]. Thus, the atrophy of DG in symp‐HD may arise from its molecular layer and the granule cell layer. Collectively, the presubiculum, subiculum, tail, and right ML volume in our HD cohorts aggregate into a single component. This component",29_27,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"aggregate into a single component. This component corresponds to the subicular regions of the perforant‐pathway and contains the hippocampal afferent that stems from the entorhinal cortex, perforates through the presubiculum and subiculum, and synapses at the ML of CA1 and DG (Figure <xref rid=""ene15918-fig-0001"" ref-type=""fig"">1</xref>). Hippocampal output originating from the efferent region (CA pyramidal and DG granule layer) also projects out to the subiculum [<xref rid=""ene15918-bib-0012""",29_28,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"to the subiculum [<xref rid=""ene15918-bib-0012"" ref-type=""bibr"">12</xref>]. Thus, accelerated atrophy in the subicular regions of the perforant‐pathway in symp‐HD involves the main hippocampal connections and may result in global hippocampal impairment. Numerous postmortem studies in HD have reported the presence of pathogenic tau and neurofibrillary tangles in the medial temporal region [<xref rid=""ene15918-bib-0047"" ref-type=""bibr"">47</xref>]. The relatively older subject age in these studies compared to",29_29,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"older subject age in these studies compared to our cohort, however, suggests that tau may be involved in the later stages of the disease. The distribution of tau in the hippocampal subfields is unclear given the lack of systematic evaluation. A postmortem study has observed pathogenic tau staining in the CA pyramidal and DG granule cells [<xref rid=""ene15918-bib-0048"" ref-type=""bibr"">48</xref>]. Although the volume of the DG‐CA collateral component is significantly reduced in our HD cohorts, the more",29_30,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"significantly reduced in our HD cohorts, the more prominent atrophy in the subicular perforant‐pathway component may primarily diminish the connection and inhibition to the DG‐CA pyramidal region, leading to deafferentation and excessive excitotoxicity [<xref rid=""ene15918-bib-0010"" ref-type=""bibr"">10</xref>]. CAG repeat length, which predicts the age of motor onset and the rate of functional decline, is associated with whole hippocampal, presubiculum, ML, tail, and perforant‐pathway subfields volumes in",29_31,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"tail, and perforant‐pathway subfields volumes in our HD cohorts [<xref rid=""ene15918-bib-0049"" ref-type=""bibr"">49</xref>]. This association complements the pattern of hippocampal subfield atrophy in symp‐HD when compared to pre‐HD. Although the combination of CAG repeat and age in DBS has revealed widespread subfields associations, there is a relatively stronger relationship with the subiculum and ML, left presubiculum and tail, and subicular perforant‐pathway component than the other subfields and DG‐CA",29_32,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"component than the other subfields and DG‐CA component. These relationships with the CAG‐based measures further suggest that the hippocampal neurodegeneration in early HD may be mediated by mHtt and predominantly affect the presubiculum, subiculum, ML, tail, and subicular perforant‐pathway region. Consistent with earlier studies, we found significant associations between the posterior hippocampal region (i.e., left tail) and CAG repeat [<xref rid=""ene15918-bib-0004"" ref-type=""bibr"">4</xref>, <xref",29_33,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"ref-type=""bibr"">4</xref>, <xref rid=""ene15918-bib-0009"" ref-type=""bibr"">9</xref>]. Additionally, the left tail was associated with motor onset in our pre‐HD group. Mutant Htt may preferentially exert greater pathogenic effect posteriorly due to its dense myelination [<xref rid=""ene15918-bib-0025"" ref-type=""bibr"">25</xref>, <xref rid=""ene15918-bib-0050"" ref-type=""bibr"">50</xref>]. Moreover, SDMT and UHDRS motor score are not associated with the subfield volume. These measures may correlate predominantly",29_34,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"These measures may correlate predominantly with the frontostriatal and other cortical regions [<xref rid=""ene15918-bib-0002"" ref-type=""bibr"">2</xref>]. This study has several noteworthy limitations. First, the symp‐HD group does not include matched healthy controls, which limits our ability to examine the relationship between the subfield volumes and the independent effect of age in healthy individuals, as well as the effect of age–gene size interaction in symp‐HD. Secondly, the classification between",29_35,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"in symp‐HD. Secondly, the classification between pre‐HD and symp‐HD group is clinically reliant on motor symptoms. We did not find any associations between the hippocampal subfields and UHDRS motor score. Further evaluation using standardized measures that integrate MRI data and measures of motor and other neurocognitive symptoms may offer more homogenous comparisons of hippocampal subfields across different studies in the future. Nevertheless, our post‐hoc analyses using a novel HD integrated staging",29_36,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"analyses using a novel HD integrated staging system have revealed comparable results to the IMAGE‐HD group classification (Figure <xref rid=""ene15918-supitem-0001"" ref-type=""supplementary-material"">S1</xref>, Tables S<xref rid=""ene15918-supitem-0001"" ref-type=""supplementary-material"">5</xref>, and S<xref rid=""ene15918-supitem-0001"" ref-type=""supplementary-material"">6</xref>). Finally, there is a significant gap in translating the structural findings in our study as measures of visuospatial memory are not",29_37,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"study as measures of visuospatial memory are not available. In conclusion, the differential pattern of hippocampal subfield atrophy seen in our early motor symptomatic group is consistent with the known cellular pathophysiology in HD, specifically the effect of mutant <italic toggle=""yes"">Huntingtin</italic> on vulnerable regions in the hippocampus. Functionally, atrophy in these structures may contribute to hippocampal dysfunction, including visuospatial memory impairment, in early HD. Further cognitive",29_38,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"memory impairment, in early HD. Further cognitive and pathological evaluations of the hippocampal subfields are critical for confirming our findings. Nonetheless, automated MRI hippocampal segmentation can be readily implemented and provide a practical approach for translating the functional and structural findings from HD experimental animal models to humans, and represent a potential tool for monitoring outcomes of disease‐modifying treatments. NG‐K is the principal investigator of the IMAGE‐HD study.",29_39,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
"the principal investigator of the IMAGE‐HD study. IMAGE‐HD data and image processing was conducted by PW. Statistical analyses were completed by PW and CBM. First manuscript draft was written by PW, MW, CBM, DV, and NG‐K. All authors were involved in the study design, reviewing the statistical analyses, and editing of the final version of the manuscript. No funding was received towards this work. No financial disclosure/competing interests to declare.",29_40,"Selective perforant‐pathway atrophy in Huntington disease: <styled-content style=""fixed-case"" toggle=""no"">MRI</styled-content> analysis of hippocampal subfields",23 6 2023,,Huntington_Disease
